

Vol.25, NO.01 January, 2014

ISSN 1029 - 385 X



MEDICAL FORUM MONTHLY

APNS
Member

CPNE
Member

ABC
Certified

RECOGNIZED BY PMDC

Journal of all Specialities

Electronic Copy

“Medical Forum Monthly” Indexed by WHO Index Medicus (IMEMR) for EMRO Region Since 1997, Recognized by Pakistan Medical and Dental Council Islamabad Since 1998, Extra Med is Covered by EXCERPTA MEDICA, Netherlands Since 2000, CAB abstract and Global Health of UK, is Registered with international serials data system of France bearing ISSN No. 1029-385X. Medical Forum is also indexed in Medlip of CPSP Karachi and Pakmedinet Islamabad Pakistan.

MEDICAL FORUM MONTHLY

ISSN 1029 - 385 X

APNS
Member

CPNE
Member

ABC
Certified

Recognized by PMDC
(Reg.No.IP/0048)

Recognized by Higher Education Commission, Isd.
Recognized by the Information Dept. Govt. of Pak. Isd.
(Press Reg. No.1212 Copr)

Journal of all specialities
Indexed by: WHO (EMRO) Egypt,
Excerpta Medica (Netherlands),
Scopus Database, Pakmedinet, Isd.
CPSP Medlip Karahi.

Editorial Executives

Editor-in-Chief

Dr. Azhar Masud Bhatti
Public Health Specialist & Nutritionist

Co-Editors

Tahir Masud Jan (Canada)
Dr. Tahir Abbas (Canada)
Dr. Shahid I. Khan (USA)
Dr. Iftikhar A. Zahid (Pak)

Editor

Mohsin Masud Jan

Managing Editor

Dr. Nasreen Azhar
Senior Consultant Gynaecologist

Patron-in-Chief

Mahmood Ali Malik
Ex-Principal & Prof. of
Medicine, KEMC, Lahore

Editorial Board

Abdul Hamid
Prof. of Forensic Medicine,
FMC, Abbottabad

Abdullah Jan Jaffar
Prof. & Chief Executive,
Children Hospital, Quetta.

Abdul Khaliq Naveed
Maj. Gen. & Prof. of Bio, AMC
& Dean Med, NUST, Rwp.

Aftab Mohsin
Principal & Prof. of Medicine,
GMC, Gujranwala

Akbar Ch.
Principal & Prof. of Medicine,
Azra Naheed MC, Lahore.

Akmal Liaque
Prof. of Paed. Medicine KEMU,
Lahore

Amanullah Khan
Prof. of Community Medicine,
FMMC, Lahore

Anjum Habib Vohra
Principal & Prof. of Neuro-Surgery
PGMI, Lahore

Asad Aslam Khan
Prof. of Ophthalmology,
KEMU, Lahore

Aamir Ali Khan,
Assoc. Prof. of Pathology NMC,MTN

Bashir Ahmad Ch.
Ex-Principal & Prof. of Neuro-
Surgery, KEMC, Lahore

Dur-e-Sabih
Director MINAR, NMC, Multan

Faisal Masood
Vice Chancellor & Prof. of
Medicine, KEMU, Lahore

Ghazanfar Ali Sheikh
Prof. (Retd) of Paed. Medicine
KEMU, Lahore

Ghulam Murtaza Cheema
Prof. of Orthopaedics AIMC,
Lahore

Haroon Khurshid Pasha
Principal & Prof. of Paed. Surgery,
QAMC, Bahawalpur

Jafar Hussain Jaffari
Prof. (Retd.) of Surgery AIMC,
Lahore

Javed Akram
Ex-Principal & Prof. of Medicine
AIMC, Lahore

Jawad Zaheer
Prof. of Medicine, PGMI, Lahore

Kh. M. Azeem
Prof. of Surgery KEMU, Lahore

Khalid Masood Gondal
Prof. of Surgery, KEMU, Lahore

Khalid Jamil Akhtar
Head of Physical Medicine &
Rehabilitation, KEMU, Lahore

Lamees Shahid
Prof. of Dermatology
AIMC, Lahore

M. Afzal Sheikh
Prof. of Paed. Surgery ICH, Lahore

M. Amjad
Prof. of ENT, SIMS, Lahore

M. Amjad Amin.
Prof. of Surgery NMC, Multan

M. Iqbal Mughal
Prof. of Forensic Medicine,
Central Park MC, Lahore

Mahmood Nasir Malik
Assoc. Prof. of Medicine, AIMC,
Lahore

Majeed Ahmad Ch.
Principal & Prof. of Surgery, LMDC,
Lahore

Mian Rasheed
Principal & Prof. of Forensic
Medicine, Mohtrema Benazir
Bhutto MC, AJK

Misbah-ul-Islam Khan
Principal Research Cell, FJMC,
Lahore

M.A. Sufi
Ex-Principal & Prof. of Dental Public
Health, IPH, Lahore

Muhammad Ali
Prof. of Medicine NMC, Multan

Munawar Zaheen Ashraf
Ex-Principal & Prof. of Gynae & Obs.
NMC, Multan

Muneer ul Haq
Prof. (Retd.) Ophthalmology KEMC,
Lahore

M. Mohsin Khan
Assoc. Prof. of Community Medicine,
Amna Inayat MC, Lahore

Naseer M. Akhtar
Ex-Principal & Prof. of Orthopaedics,
KEMC, Lahore

Naseeb R. Awan
Prof. (Retd.) of Forensic Medicine,
KEMC, Lahore

Nazim H. Bokhari
Prof. of Chest Diseases SKBZ, MC,
Lahore

Nazir Ahmad Asif
Prof. (Retd.) of Ophthalmology,
KEMC, Lahore

Numan Ahmad
Prof. of Anaesthesia, SKBZ, MC,
Lahore

Pervez Akhtar Rana
Prof. of Forensic Medicine
CMH, LMC, Lahore

Rashid Latif Khan
Principal & Prof. of Gynae & Obs.
Rashid Latif MC, Lahore

Rehana Mahmood Malik
Prof. of Gynae & Obs.
Shalimar Medical College, Lahore

Rukhsana Majeed
Prof. of Community Medicine
BMC, Quetta

Safdar Ali Shah
Assoc. Prof. of Urology, SZMC,
R. Y. Khan

Saleema Qaisera
Prof. (Rtd) of Medicine, FJMC,
Lahore

Salma Aslam Kundi
Prof. of Physiology, AMC, Abbotabad

Sardar Fareed Zafar
Prof. of Gynae & Obs. FJMC, Lahore

Sardar Fakhar Imam
Principal & Prof. of Medicine, FJMC,
Lahore

Saulat Ullah Khan
Prof. of Chest Diseases, PGMI Lahore

Shahryar A. Sheikh
Ex-Dean & Prof. of Cardiology, PIC,
Lahore

Shabbir A. Naroo
Prof. (Retd.) of Surgery, KEMC,
Lahore

Shabbir A. Nasir
Principal & Prof. of Medicine,
MMC, Multan

Shahid Hameed
Assoc. Prof. of Cardiology, PIC,
Lahore

Shamim Ahmad Khan
Ex-Chief & Prof. of Surgery, PGMI,
Lahore

Shamshad Rasool Awan
Prof of Chest Diseases, SMDC,
Lahore

Syed Atif Kazmi
Prof. of Dermatology KEMU, Lahore

Syed M. Awais
Prof. of Orthopaedics, KEMU, Lahore

Syed Mudassar Hussain
Assoc. Prof. of Forensic Medicine,
KEMU, Lahore

Syed Sibtul Hasnain
Ex-Principal & Prof. of Medicine
AIMC, Lahore

Taeed Butt

Prof. of Paed. Medicine ICH,
Lahore

Tahseen Sahi

Prof. of Ophthalmology, KEMU,
Lahore

Tahir Masood

Ex-Dean & Prof. of Paed. Medicine,
ICH, Lahore

Tahir Saeed Haroon

Prof. (Retd.) of Dermatology, KEMC,
Lahore

Tariq Iqbal Bhutta

Ex- Principal & Prof. of Paed.
Medicine, NMC, Multan

Wajid Ali Khan

Dy. Dean & Assoc. Prof. of
Ophthalmology Al-Shifa MC,
Rawalpindi

Yasmin Rashid

Prof. (Retd.) of Gynae & Obs KEMU,
Lahore

Zafarullah Ch.

Prof. (Retd.) of Surgery
KEMC, Lahore

Business Manager

Nayyar Zia Ch.

Legal Advisors

Jan Muhammad Bhatti, Ibraaz Masud Jan Bhatti, Kh. Ejaz Feroz (Barrister),
Kh. Mazhar Hassan & Fardous Ayub Ch.

Published By

Dr. Nasreen Azhar

15-A, Abbot Road, Behind PS, Qila Gujar Singh, Lahore – Pakistan

Ph: 92-42-36361436

Cell: 0331-6361436

E-mail: med_forum@hotmail.com

Website: www.medforum.pk

Printed By

Syed Ajmal Hussain

Naqvi Brothers Printing Press, Darbar Market, Lahore

Rate per Copy

Rs.1200.00

Subscription Rates

Annually

Pakistan

Rs.9000.00

USA & Canada

US\$ 350.00

China & Japan

US\$ 300.00

United Kingdom

US\$ 300.00

Middle East

US\$ 250.00

Recognized by PMDC

CONTENTS

Recognized by HEC

Editorial

1. **Mortality may be Reduced after Hip or Knee Replacement – A New Study** _____ 1
Mohsin Masud Jan

Original Articles

2. **Hepatoprotective Effects of Curcuma Longa against Carbon Tetrachloride Induced Liver Injury in Rats** _____ 2-5
1. Zaheer Ahmed Memon 2. Muhammad Bachal Pandhiani 3. Aftab Ahmed Shaikh
4. Haji Khan Khoharo
3. **Proportion of Urinary Symptoms in Pre and Post-Menopausal Women with Uterovaginal Prolapse** _____ 6-9
1. Samina 2. Deebea Kalim 3. Amjad Zahoor 4. Israr Ahmed Akhund 5. Muhammad Ishaq
4. **A Randomized Controlled Trial on Prevention of Postpartum Haemorrhage with Sublingual Misoprostol or Oxytocin** _____ 10-12
1. Kulsoom Bhatti 2. Tahmina Mahar 3. Rubeena Hafeez 4. Shoaib-u-Nisa
5. **Causes and Management Out Come of Peritonitis** _____ 13-17
1. Muhammad Ali Sohail 2. Rafique Ahmed Sahito 3. Feroze Ahmed Mahar
6. **Beneficial Effect and Safety of 5% Permethrin Cream in Scabies Patients** _____ 18-21
1. Farah Asad 2. Fatima Rizvi 3. Jawed Iqbal
7. **Alterations in Mitochondria of Kidney Tubules by Different Doses of Diclofenac Sodium in Rabbits** _____ 22-26
1. Talat Yasmeen 2. Irfan Ashraf Siddiqui 3. Zaheer Amjad 4. Amir Ali Shoro 5. Talat Mirza
8. **Efficacy of Platelet Rich Plasma Application in Comparison to Conventional Dressing Therapy in Partial Thickness Burn Wound** _____ 27-30
1. Ehmer-Al-Ibran 2. Masood Hussain Rao 3. Maria Khan 4. Farrukh Hasan 5. Raaziyah Abdul Khaliq
6. Syeda Zehra
9. **Prediction of Large Esophageal Varices in Patients with Decompensated Cirrhosis by Child-Pugh Score, in Medical Unit-II, Chandka Medical College Hospital, Larkana** _____ 31-35
1. Muhammad Aslam Soomro 2. Imdad Ali Ansari 3. Ghulam Yasin Abro 4. Sayed Aftab Ahmed Shah 5. Sayed Shafiq Rahman Shah
10. **Cognition-Enhancing Effect of Oral Therapeutic Doses of Methylphenidate in Rats** _____ 36-39
1. Nausheen Alam 2. Rahila Najan
11. **EPI Status under One Year Children and their Mothers attending Paediatric Department Sheikh Zayed Medical College & Hospital, Rahim Yar Khan** _____ 40-43
1. Jamal Anwer 2. M.I. Babar 3. Kifayat Niazi 4. Zahid Mahmood
12. **Functional Outcome of Cemented Versus Uncemented Hemiarthroplasty for Intracapsular Hip Fractures** _____ 44-48
1. Manqoosh ur Rehman 2. Muhammad Imran 3. Tanveer Ahmad Kang
13. **Efficacy of Intra Articular Injections in Different Grades of Osteoarthritis of Knee** _____ 49-52
1. Muhammad Imran 2. Manqoosh ur Rehman 3. Tanveer Ahmad Kang
14. **Effect of Thiamine on Glycemic Control in Induced Diabetic Rat Model** _____ 53-56
1. Muhammad Bachal Pandhiani 2. Maria Kazi 3. Saif-ur-Rehman 4. Navaid Kazmi 5. Salman Ahmad Farsi Kazi 6. Haji Khan Khoharo
15. **Pentoxifylline Protects against Carbon Tetrachloride Induced Liver Injury in Adult Male Wistar Rat Model** _____ 57-61
1. Maria Kazi 2. Muhammad Bachal Pandhiani 3. Salman Ahmad Farsi Kazi 4. Saif-ur-Rehman 5. Haji Kjan Khoharo
16. **Validity of Pleural Fluid Protein in Differentiating Tuberculouse from Malignant Pleural Effusion** _____ 62-65
1. Ghulam Nabi Khokhar 2. Muhammad Ashfaq 3. Ikram Ullah Khan 4. Muhammad Ishaq
5. Israr Ahmed

17. **To Assess the In vitro Genotoxicity of Metformin and Aspartame alone & In Combination** ____ 66-70
 1. Amna Nazar 2. Rafique Ahmed 3. Sajida Bano 4. Muhammad Ashraf 5. Imran Altaf
 6. Aqeel Javeed
18. **Study of Type 2 Diabetes Mellitus and its Correalation with Blood Groups** _____ 71-75
 1. Shamsul Arfin Qasmi 2. Aftab Ahmed Khan 3. Hasan Askari 4. Rabiya Pirzada
19. **The Effects of Monosodium Glutamate on the Histology of Fallopian Tube in Female Rats** ____ 76-79
 1. Aftab Ahmed Shaikh 2. Muhammad Bachal Pandhiani 3. Zaheer Ahmed Memon
 4. Haji Khan Khoharo
20. **Incidence of Malignant Lymphomas in Balochistan** _____ 80-84
 1. Zahid Mehmood 2. M.Hanif Mengal 3. Haroon ur Rasheed 4. Hafiz Khush Naseeb Ahmed
21. **Adjuvant Therapy for Old Age Glioblastoma Patients** _____ 85-89
 Salman A. Jaffery
22. **Comparative Study on Neem Leaf Extract and Nimolicin (NC) on Gastric Mucosa of Albino Rats** _____ 90-94
 1. Qamar Aziz Siddiqui 2. Syed Ijaz Hussain Zaidi 3. Asghar Hussain 4. Muhammad Omar Shamim
 5. Nazar Hussain 6. Syed Naimul Hassan Naqvi 7. Mohammed Arshad 8. Rajput Muhammad Tariq
 9. Mazhar Hijazi

Subject Index

23. **Subjects Index January to December 2013** _____ 95-103
 Azhar Masud Bhatti

Author Index

24. **Authors Index January to December 2013** _____ 104-107
 Azhar Masud Bhatti

Electronic Copy

Editorial

Mortality may be Reduced after Hip or Knee Replacement – A New Study

Mohsin Masud Jan

Editor

The risk of death from hip or knee replacement surgery as dropped substantially in recent years. Dutch researchers found that since the early 1990s, death rates have fallen by almost two-thirds among Danish adults having the procedures. The length of patients' hospital stays also dropped — from more than two weeks, on average, to about one week.

The study did not dig into the reasons for the improvements, but it's likely that changes in post-surgical care have had a big impact, said lead researcher Arief Lalmohamed, of the Utrecht Institute of Pharmaceutical Sciences in the Netherlands.

Those changes, he said, include new blood-thinning medications that help prevent patients from developing potentially dangerous blood clots after surgery. Clots can, in some cases, lead to a heart attack, stroke or pulmonary embolism. In the United States, more than 1 million people have a hip or knee replacement each year, according to the U.S. National Institutes of Health. The surgery often is prompted by severe wear and tear on the joints due to arthritis.

The findings, reported recently in the *Journal Arthritis & Rheumatology*, are based on data from only one country. But Lalmohamed said he would expect to see a similar pattern in other countries that made the same changes in medical care over the years. Dr. Richard Lorio, chief of adult reconstruction at NYU Langone Medical Center in New York City, agreed that the trend would be similar in the United States. Lorio, who was not involved in the study, named a number of advances that have been made over the years to make joint-replacement surgery safer and better. Changes in the procedures and anesthesia techniques have been key, Lorio said. And patients start physical rehab much faster than they did in years past. "We get people out of bed

and moving on the first day after — or the day of — surgery," Lorio said. That mobility is important, he said, because it lowers patients' risk of developing blood clots. Lorio said doctors have also gotten better at managing chronic health conditions that many patients have. That, in turn, lowers the risk of complications.

For the study, Lalmohamed's team turned to Denmark's system of national health registries. The researchers found information on more than 112,000 people who had a hip or knee replacement between 1989 and 2007. Overall, the rate of death in the two months after surgery fell over time, from about 3.4 percent each year between 1989 and 1991 to 1.4 percent per year between 2003 and 2007, Lalmohamed said. Deaths from heart attack, stroke and pneumonia all dropped, despite the fact that heart and lung disease was more common in patients who had surgery in recent years.

Lalmohamed said there's still a need for similar studies in other countries. But he also said candidates for joint replacements can be reassured by his team's findings.

Lorio agreed, "Clearly, patients can take heart," he said. "This operation is safer than it was 20 years ago, and it's very effective."

However, some surgeons and hospitals are better than others. In general, surgeons and centers with the most experience in hip and knee replacements have better results than those who do fewer procedures.

And, of course, each patient is different, Lorio said. An individual's overall health — rather than age alone — is vital. But, he added, it's also possible to manage some of the health issues that can increase the risks of joint-replacement surgery. Patients can quit smoking or lose excess weight, for example.

Hepatoprotective Effects of Curcuma Longa against Carbon Tetrachloride Induced Liver Injury in Rats

1. Zaheer Ahmed Memon 2. Muhammad Bachal Pandhiani 3. Aftab Ahmed Shaikh
4. Haji Khan Khoharo

1. Asstt. Prof. of Anatomy, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad
2. Asstt. Prof. of Anatomy, Al-Tibri Medical College, Karachi 3. Asstt. Prof. of Pharmacology, Faculty of Medicine
and Allied Medical Sciences, Isra University, Hyderabad 4. Asstt. Prof. of Physiology/Medicine, Faculty of
Medicine and Allied Medical Sciences, Isra University, Hyderabad

ABSTRACT

Objective: To investigate the protective effect of Curcuma longa (CL) against carbon tetrachloride (CCl₄) induced liver injury in adult male Wistar rat model.

Study Design: Experimental/Analytical study

Place and Duration of Study: Animal House, Isra University Hyderabad from March to December 2013.

Subjects and Methods: Forty five adult male Wistar rats were divided into three groups; Group 1. controls received 0.9% isotonic saline, Group 2. received CCl₄ orally (1.9mg/kg) mixed in olive oil, and Group 3. received the CCl₄+CL (250mg/kg) Blood samples were collected for liver biochemical assays. The animals were sacrificed, liver tissue, after fixation in 4% formaldehyde, was embedded in paraffin. Tissue sections of 5μ thickness were subjected to haematoxylin and eosin staining and were assessed by light microscopy. The data was analyzed on SPSS 21.0 using one-way ANOVA, Fischer's LSD and Chi-square tests. A p-value of ≤ 0.05 was taken statistically significant.

Results: The liver biochemical and histological findings reveal statistically significant differences among the controls, CCl₄ and CCl₄+CL groups (p=0.0001). Liver enzymes and histology were deranged significantly in CCl₄ group compared to controls and CCl₄+CL group (p=0.0001). The CCl₄+CL group showed less elevation of liver enzymes and derangement in liver histology compared to CCl₄ group (p=0.001). The histological findings of congestion, inflammatory cell infiltrate, vacuolar degeneration and necrosis are found prominent in CCl₄ group.

Conclusion: The Curcuma longa protects against oxidative damages caused by carbon tetrachloride induced liver injury in rat model.

Key Words: Curcuma longa, Carbon Tetrachloride, Liver injury.

INTRODUCTION

Curcuma longa (CL) is a rhizomatous perennial herb that belongs to the family Zingiberaceae, native to South Asia and is commonly known as turmeric.¹ In Sindhi, it is commonly known as "Hade". The turmeric plant is a popular ingredient for preparing culinary dishes. In addition, it is used as herbal remedy due to the prevalent belief that the plant has medical properties. In folk medicine, the rhizome juice from C. longa is used in the treatment of many diseases such as anthelmintic, asthma, gonorrhoea and urinary, and its essential oil is used in the treatment of carminative, stomachic and tonic.² In traditional medicine, several plants and herbs have been used experimentally to treat liver disorders, including liver cirrhosis.^{3,4} C. longa possesses antioxidant⁵, anti-tumor⁶, antimicrobial⁷, anti-inflammatory⁸, wound healing⁹, and gastroprotective activities.¹⁰

Carbon tetrachloride (CCl₄) is a hepatotoxic compound. The CCl₄ has been used extensively in laboratory animals for induction of liver injury, elucidate the underlying mechanism of liver injury and hepatoprotective effects of various therapeutic agents.¹¹

One of the postulated mechanism of CCl₄ induced liver injury is the formation of ROS. The ROS disrupts the hepatocyte at cell membrane level through the lipid peroxidation^{11, 12} causing anatomical disruption of liver architecture and physiological disturbances.¹³ The hepatocyte injury causes leakage of cytoplasmic and mitochondrial enzymes in the blood streams.¹⁴

The cytoplasm and mitochondrial enzymes of hepatocytes are clinically used as markers of liver injury, and for monitoring and treating the liver diseases. The liver enzymes which appear in the blood as a result of liver injury include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) are important enzymes that are often employed in assessing liver injury.^{11,15}

The previous studies have shown that the aqueous extract of C. longa has hepatoprotective activity against carbon tetrachloride toxicity¹⁹. The present study aims to investigate the possible hepatoprotective effects of the ethanolic extract of Curcuma longa rhizomes against Carbon tetrachloride (CCl₄)-induced hepatotoxicity in adult male Wistar rat model.

MATERIALS AND METHODS

The present original study was conducted at the animal house of Isra University from March to December 2013. Adult male Wistar rats of 250-300 grams were included while female rats and rats weighing <250 grams or >300 grams were excluded from the study protocol. The animal's house is well equipped with essential facilities like an optimal room temperature with 55-60% humidity and exposure to 12 hour light-dark cycles. The fresh alfalfa and clean water are provided freely. The rats were divided into three groups;

Group 1. Control Group (n=15) Rats received 0.9% isotonic saline orally on alternate day for three successive weeks and served as control group,

Group 2. Carbon tetrachloride Group (n=15) Rats were given CCl₄ orally mixed in olive oil on alternate day for three successive weeks and

Group 3. Experimental Group (n=15) Rats received Curcuma longa (250 mg/kg) and CCl₄ on alternate days for three successive weeks

Experimental Details: The CL was purchased from Medical store of Isra University Hospital. The Curcuma longa was administered in a dose of 250 mg/kg orally.¹⁶ Carbon tetrachloride was purchased from scientific drug store at Hyderabad City. The CCl₄ dissolved in olive oil as vehicle (1:1 Ratio) at a dose level of 1.9 ml/kg orally on alternate day for three successive weeks and sacrificed at the end of their respective period of time.¹⁵ The animals were sacrificed using standard method as described by Nayak et al. (2006)¹⁷ In order to examine the liver tissue, the liver of the sacrificed animals was removed promptly and preserved in formaldehyde.

Blood sampling: The blood samples were collected from tail at twenty four hours of experimental period. Sera were separated by centrifugation at 300xs for ten minutes. Serum samples were used to estimate liver enzymes.

Biochemical assay: Liver enzyme assays were determined for alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) using commercially available diagnostic kits.

Histological studies: After fixation in 4% formaldehyde, samples were embedded in paraffin. Sections of 5μ thickness were subjected to haematoxylin and eosin Hepatic morphology was assessed by light microscopy. A total of five sections for each liver tissue sample were observed under light microscope.

In H & E staining, damaged hepatocytes graded as 0= normal, += mild damage (swollen and pale cytoplasm), ++= moderate damage (vacuolated cytoplasm), +++= severe damage and ++++= very severe damage (pyknotic nucleus and eosinophil cytoplasm).¹⁸

The data was analyzed on SPSS version 21.0 (IBM corporation). The continuous variables were presented as mean±SD using one-way ANOVA and Fischer's LSD test. Chi-square test was used for categorical variables. A p-value of ≤ 0.5 was taken statistically significant.

RESULTS

The present study observes major differences in liver injury among groups as indicated by blood enzyme levels in animal groups. The serum LDH, ALP, and ALT, AST of Rats treated with carbon tetrachloride were found elevated compared with control group after three weeks, with a highly significant p-value (p=0.001).

The CCl₄+ Curcuma longa (CL) group shows a significant reduction in the liver enzymes compared with the CCl₄ group (p=0.001) and control group (p=0.001). The animals CCl₄+CL group shows significant reduction in the liver enzyme elevation compared to CCl₄ group alone (p=0.001). The finding shows significant hepatoprotection by the CL in CCl₄ induced injury. The liver enzyme assays among different groups are shown in table.1.

Table 1. Biochemical liver parameters in controls, *CCl₄ and CCl₄+ Curcuma longa (CL) groups (n=45)

Groups	ALT (IU/L)	AST (IU/L)	LDH (IU/L)	ALP (IU/L)
Group. 1 (Controls)	48.9± 3.19	91.3± 15.1	712.4± 41.7	83.6± 8.71
Group. 2 (*CCl ₄)	189.6± 11.91	479.7 ± 19.9	2278.8± 117.6	165.1± 8.02
Group. 3 (*CCl ₄ + CL)	87.7± 17.92	181.3± 18.3	1938.6± 141.3	135.7± 18.1

*Carbon tetrachloride

Table 2. Histology of liver injury of controls, *CCl₄ and Curcuma longa (CL) groups (n=45)

Groups	Inflammatory cell	Congestion	Vacuolar degeneration	Necrosis
Group. 1 (Controls)	0	0	0	0
Group. 2 (*CCl ₄)	++++	++++	+++	++++
Group. 3 (*CCl ₄ + CL)	+++	++	++	++

*Carbon tetrachloride

Different parameters of histological score of liver injury are shown in Table. 2. The Liver sections of the control group animals show intact central venules and hepatocytes arranged in compact cords. Normal looking hepatocytes with prominent nucleus, nucleolus and well preserved cytoplasm were seen in control group. On the contrary, the CCl₄ group shows derangement of hepatocytes cords, hydropic changes with congestion of central venules and sinusoids, and abundant

inflammatory cell infiltration. The centrilobular hepatocytes show hydropic changes and necrosis, while midzonal and peripheral hepatocytes show vacuolar degeneration and fatty changes in CCl₄ group. In CCl₄+CL animals, liver tissue sections reveal less significant derangement of hepatocytes cords, hepatocytes damage and necrosis was limited compared with CCl₄ group.

DISCUSSION

The present study is an original research work, which investigates the effect of Curcuma longa (CL) on carbon tetrachloride (CCl₄) induced liver injury in adult male Wistar rats. The Null hypothesis is rejected because the study observes hepatoprotective effects of CL as evidenced by biochemical and histological marker of liver injury.

Curcumin, the most common antioxidant constituent of Curcuma longa rhizome extract, was reported to enhance apoptosis of damaged hepatocytes which might be the protective mechanism whereby curcumin down-regulated inflammatory effects and fibrogenesis of the liver.¹⁹

The present study shows liver damage caused by the carbon tetrachloride as indicated by serum levels of liver enzymes compared to control group in rat model. The carbon tetrachloride induced liver injury with release of liver enzymes is comparable finding to reported previously by Hurkkeri et al.²⁰ The Hurkkeri et al.²⁰ reported elevated hepatocyte enzyme of liver as a consequence of CCl₄ induced liver injury in animal model. The release of large quantities of cytoplasmic and mitochondrial enzymes of liver is a chemical indicator of hepatocyte cell membrane damage and rupture sufficient to produces change in enzyme levels in blood.²¹

The ethanolic extract of C. longa rhizomes showed a significant hepatoprotective effect when orally administrated in doses of 250 mg/kg. The main constituents of CL extract are the flavonoid curcumin and various volatile oils, including tumerone, atlantone, and zingiberene.¹ The hepatoprotective effects of turmeric and curcumin might be due to direct antioxidant and free radical scavenging mechanisms, as well as the ability to indirectly augment glutathione levels, thereby aiding in hepatic detoxification.²² The volatile oils and curcumin of C. longa exhibit potent anti-inflammatory effects.²³

The present study shows that the damage of liver caused by CCl₄ is evident by the rise in serum enzymes levels beside the histological changes in liver tissue. Administration of CCl₄ significantly increases the serum levels of liver enzymes; LDH, ALP, ALT and AST, which are indices of hepatocyte damage and leakage of enzymes from cells.^{24,25}

The histological examination of present research study correlates in parallel to disturbance in biochemical

markers of liver injury. The histology of liver tissue shows disruption of liver architecture, hepatocytes, hepatic lobules and arrangement of hepatocytes in cords. The hepatocytes show findings of cellular injury with marked cytoplasmic vacuolization. The injured hepatocytes show pyknotic nuclei with lymphocyte infiltrations. The pyknotic nuclei are a sign of severe cellular injury caused by a toxin like carbon tetrachloride. The histological and biochemical findings of present study are comparable to those mentioned previously.^{26,27} The carbon tetrachloride is metabolized to free radical during its metabolism and detoxification in smooth endoplasmic reticulum by the cytochrome P450.²⁸ The findings of present study are highly comparable to a recent study of Salma et al.¹ The Salma et al¹ reported hepatoprotective effects of CL in thiacetamide induced liver cirrhosis in rat models. The present study concludes that the Curcuma longa decreases the carbon tetrachloride induced oxidative stress and liver damage.

CONCLUSION

The Curcuma longa protects against oxidative damages caused by carbon tetrachloride induced liver injury in rat model. The Curcuma longa may be used as an effective protector against chemical induced liver damages; however, further studies are warranted.

REFERENCES

1. Salma SM, Abdulla MA, AlRashdi AS, Ismail S, Alkiyumi SS, Gulbabapour S. Hepatoprotective effect of ethanolic extract of Curcuma long on thiacetamide induced liver cirrhosis in rats. BMC Compl Alt Med 2013;13:56.
2. Phansawan B, Pongbangpho S. Antioxidant capacities of Pueraria mirifica, Stevia rebaudiana Bertoni, Curcuma longa Linn. Andrographis paniculata (Burm. f.) Nees. and Cassia alata Linn. for the development of dietary supplement. Kasetsart J 2007;41(3):407-413.
3. Alshawsh MA, Abdulla MA, Ismail S, Amin ZA. Hepatoprotective Effects of Orthosiphon stamineus Extract on Thioacetamide-Induced Liver Cirrhosis in Rats. Evid Based Complement Alternat Med 2011;2011:1-6.
4. Kadir FA, Othman F, Abdulla MA, Hussan F, Hassandarvish P. Effect of Tinospora crispa on thioacetamide-induced liver cirrhosis in rats. Indian J Pharmacol 2011;43(1):64.
5. Maizura M, Aminah A, Wan Aida W. Total phenolic content and antioxidant activity of kesum (Polygonum minus), ginger (Zingiber officinale) and turmeric (Curcuma longa) extract. Int Food Res J 2011;18:526-531.
6. Kunnumakkara AB, Guha S, Krishnan S, Diagaradjane P, Gelovani J, Aggarwal BB. Curcumin Potentiates Antitumor Activity of

- Gemcitabine in an Orthotopic Model of Pancreatic Cancer through Suppression of Proliferation, Angiogenesis, and Inhibition of Nuclear Factor- κ B-Regulated Gene Products. *Cancer Res* 2007; 67(8):3853.
7. Kim KJ, Yu HH, Cha JD, Seo SJ, Choi NY, You YO. Antibacterial activity of *Curcuma longa* L. against methicillin-resistant *Staphylococcus aureus*. *Phytother Res* 2005;19(7):599–604.
 8. Kohli K, Ali J, Ansari M, Raheman Z. Curcumin: a natural anti-inflammatory agent. *Indian J Pharmacol* 2005;37(3):141–147.
 9. Panchatcharam M, Miriyala S, Gayathri VS, Suguna L. Curcumin improves wound healing by modulating collagen and decreasing reactive oxygen species. *Mol Cell Biochem* 2006; 290(1):87–96.
 10. Miriyala S, Panchatcharam M, Rengarajulu P. Cardioprotective effects of curcumin. The molecular targets and therapeutic uses of curcumin in health and disease 2007;595:359–377.
 11. Obi FO, Omogbal LA, Orlafo OS, Ovat OD. Effect of a Short Time Post Carbon Tetrachloride Treatment Interval on Rat Plasma Enzyme Levels and Percentage Mortality. *J Applied Sci Environ Mgt* 2001;5:5-8.
 12. Muriel P, Albo N, Perez-Alvarez VM. Kupffer cells inhibition prevents hepatic lipid peroxidation and damage induced by carbon tetrachloride. *Comp Biochem Physiol C Toxicol Pharmacol* 2001;130: 219-26.
 13. Rasha SA, Ashraf AA and Aly R. Carbon tetrachloride-induced liver disease in rats: the potential effect of supplement oils with vitamins E and C on the nutritional status. *German Med Sci* 2009;7:1612-3174.
 14. Rost DA, Welker DA, Welker J, Millonig G, Berger I, Autschbach F, et al. Liver-homing of purified glucose oxidase: A novel in vivo model of physiological hepatic oxidative stress (H_2O_2). *J Hepatol* 2007;46: 482-91.
 15. Essawy AE, Abdel-Moneim AM, Khayyat LI and Elzergy AA. *Nigella sativa* seeds protect against hepatotoxicity and dyslipidemia induced by carbon tetrachloride in mice. *J Appl Pharm Sci* 2012;2 (10):021-5.
 16. Movssaghi S, Sharifi ZN, Mohammadzadeh F, Soleimani M. Pentoxifylline protects the rat liver against fibrosis and apoptosis induced by acute administration of 3,4-Methyleneoxy methamphetamine (MDMA or Ecstasy). *Ir J Basic Med Sci* 2013; 16: 922-27.
 17. Nayak S, Nalabothu P, Sandiford S, Bhogadi V, Adogwa A. Evaluation of wound healing activity of *Allamanda cathartica* L. and *Laurus nobilis* L. Extracts on rats. *BMC Compl Alt Med* 2006; 6: 12.
 18. Murat-Bilgin H, Atmaca M, Deniz-Obay B, Ozekinci S, Taşdemir E, Ketani A. Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats. *Exp Toxicol Pathol*. 2011; 63(4): 325-30.
 19. Wang ME, Chen YC, Chen IS, Hsieh SC, Chen SS, Chiu CH. Curcumin protects against thioacetamide-induced hepatic fibrosis by attenuating the inflammatory response and inducing apoptosis of damaged hepatocytes. *J Nutr Biochem* 2012;11:120-8.
 20. Hurkkeri VI, Jaiparkash B, Lavhale RV, Karadi RV, Kuppast IJ. Hepatoprotective activity of *Anthus Excelsa* Roxb leaf extract on experimental liver damage in rats. *J Pharmacogn* 2002;11: 120-28.
 21. Shaarawy SM, Tohamy AA, Elgendy SM, Elmageed ZY, Bahnasy A, Mohamed MS, et al. Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. *Int J Biol Sci* 2009;5(6):549-57.
 22. Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh P, Pradhan SC. Hepatoprotective activity of picrosily, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. *Fundam Clin Pharmacol* 2009;23(6):735–45.
 23. Organization WH. WHO monographs on selected medicinal plants-Vol. 1. Geneva: World Health Organization 2002.
 24. Rajesh M, Latha M. Preliminary evaluation of anti-hepatotoxic activity of Kamilari, a polyherbal formulation. *J Ethnopharmacol* 2004; 91: 99-104.
 25. Bashandy S, Al-Wasel S. Carbon tetrachloride-induced hepatotoxicity and nephrotoxicity in rats: Protective role of vitamin C. *J Pharm Toxicol* 2001; 16(30): 283-92.
 26. Trivedi P, Mowat A. Carbon tetrachloride-induced hepatic fibrosis and cirrhosis in the developing rat: an experimental model of cirrhosis in childhood. *Br J Exp Pathol* 1983; 64(1): 25–33.
 27. Berman E, House D, Allis J, Simmons J. Hepatotoxic interactions of ethanol with allyl alcohol or carbon tetrachloride in rats. *J Toxicol Environ Health* 1992; 37(1): 161–76.
 28. Brandao C, Ferreira H, Piovesana H, Polimeno N, Ferraz J, de-Nucci G. Developmental model of liver cirrhosis in rabbits. *Clin Exp Pharma Physiol* 2000; 27: (12): 987-90.

Address for Corresponding Author:

Dr. Haji Khan Koharo,
Assistant Professor of Physiology/Medicine
Faculty of Medicine and Allied Medical Sciences
Isra University, Hyderabad.
Cell No.: 0331-2662500.

Proportion of Urinary Symptoms in Pre and Post-Menopausal Women with Uterovaginal Prolapse

1. Samina 2. Deeba Kalim 3. Amjad Zahoor 4. Israr Ahmed Akhund 5. Muhammad Ishaq

1. Asstt. Prof. of Obst. & Gynae 2. Asstt. Prof. of Obst. & Gynae 3. Assoc. Prof. of Pediatrics 4. Prof. of Physiology
5. Prof. of Surgery, Jinnah Medical College, Peshawar

ABSTRACT

Objective: To compare the proportion of urinary symptoms in pre and postmenopausal women with uterovaginal prolapse.

Study Design: Comparative Study.

Place and Duration of Study: The study was carried out at the Department of Obstetrics & Gynecology Unit II, Dow University of Health Sciences and Civil Hospital Karachi from July 2005 to January 2006.

Materials and Methods: Sixty consecutive patients (30 premenopausal and 30 postmenopausal) were included in the study through structured Proforma from the out patient ward or emergency. Informed consent was obtained. A detailed history and related examinations and investigations were done. These include urine DR, Urine C/S and Urodynamic like Cystometry in selected patients.

Results: In this study the difference of urinary symptoms in pre and postmenopausal women of Uterovaginal prolapse were statistically found insignificant like frequency of urine (26.7% versus 33.3%), Urgency (20% vs 26.7%), Nocturia (26.7% vs 13.3%), Dysuria (40% vs 26.7%), Voiding problems (40% vs 46.7%), Urge incontinence (40% vs 20%). Stress incontinence was slightly higher in postmenopausal group than premenopausal (53.3% vs 46.7%) but this difference was found insignificant, while parity status between these two groups had significant difference like parity 2-5 was higher in pre-menopause group than postmenopause (66.7% vs 36.7%) and parity 6-10 was higher in postmenopause group than pre-menopause (63.3% vs 26.7%).

Conclusion: Significant difference in parity was found between pre and post-menopausal women with uterovaginal prolapse but the difference of urinary symptoms in pre and postmenopausal group was found significant. Uterovaginal prolapse associated with different urinary symptoms especially incontinence and voiding problems. These urinary symptoms effect over quality of life of women. This warrants greater attention for Gynecological health needs in our country by safe family planning practices.

Key Word: Uterovaginal Prolapse, Pre-Menopausal, Post-Menopausal

INTRODUCTION

Uterovaginal prolapse is the descent of vagina and uterus due to the loss of integrity of structures that support the contents of female pelvis¹. The exact incidence of uterovaginal prolapse is difficult to determine. It has been estimated that a 50% of parous women lose pelvic floor support, resulting in prolapse and about 10-20% of them seek medical care². A WHO multicentre collaborative study carried out in Pakistan identified at least 22% women with uterovaginal prolapse who attended health care facility³. The chance of a woman having a prolapse increases with age. Therefore the incidence of prolapse will rise as life expectancy increases⁴. Uterovaginal prolapse is usually the result of childbirth, menopause (due to deficiency of estrogen), increase intra abdominal pressure, injury to sacral nerves S1-S4 or diabetic neuropathy. Congenital weakness of pelvic support causes prolapse in young nulliparous women, prolapse of vagina may occur after hysterectomy⁵. Prolapse is often asymptomatic. The usual presenting symptoms in patients with uterovaginal prolapse are something coming down of

vagina, lump in vagina and backache which is aggravated by standing and eased by lying down⁶. Prolapse is frequently associated with urinary complains like increase frequency, urgency, nocturia, hesitancy, urinary incontinence or incomplete emptying. In severe cases of incomplete bladder emptying, retention of urine may occur. Voiding dysfunction may result in increase frequency of urinary tract infections and occasionally, overflow incontinence. Due to the kinking of the urethra, stress incontinence and even intrinsic sphincter deficiency may be over looked⁷. The world wide prevalence of urinary symptoms in association with prolapse varies ranging from 5 to 39%. In Pakistan, hospital based study on urinary incontinence reported the frequency of urinary incontinence as 20.5%. According to one study conducted by community health centre of Agha Khan University Hospital (AKUH) from November 1st to 30th, 2002 stress incontinence was the highest reported complaint (38.4%) followed by burning (34.4%), frequency (26%), painful micturition (20.4%), urge incontinence (18.8%), incomplete emptying of bladder (14.4%) and poor stream (8.4%)⁸.

Urogynecology as a subspecialty has not been introduced in Pakistan and we believe the extent of significant lower urinary tract symptoms has been hugely underestimated⁹. The severity of these symptoms is more in postmenopausal women¹⁰. The rationale for conducting this study is based on the hypothesis that the proportion of urinary symptoms will be significantly different in the pre and postmenopausal women with uterovaginal prolapse. The aim of our study is to compare the proportion of urinary symptoms in pre and postmenopausal women with uterovaginal prolapse.

MATERIALS AND METHODS

The study was carried out in the department of Obstetrics & Gynecology unit II, Dow University of Health Sciences and Civil Hospital Karachi, Pakistan. This was a cross sectional comparative study from July 2005 to January 2006. Sixty consecutive patients (30 premenopausal and 30 postmenopausal) were included in the study through structured Proforma by purposive sampling technique from the outpatient, ward or emergency. Informed consent was obtained. The inclusion criteria were patients with all degree of uterovaginal prolapse, both pre and postmenopausal and married and unmarried women. Exclusion criteria were women who were pregnant with uterovaginal prolapse, patients with diagnosed renal pathology, recurrent urinary tract infection, and medical disorder such as diabetes mellitus or sclerosis. A detailed history and related examination and investigations were done. These include urine D/R, Urine C/S and urodynamic like Cystometry in selected patients. Frequency was defined as the passage of urine every 2 hrs or more than seven times a day. Nocturia was defined as interruption of sleep more than once each night of need to micturate. Urgency was a strong sudden desire to void while Dysuria defined as urethral pain during micturition. Retention of urine means failure to empty the bladder totally, bladder pressure being unable to overcome urethral resistance. Voiding problems include hesitancy, a poor stream, straining to void, incomplete bladder emptying and also frequency, urgency and dysuria. Stress incontinence was defined as the involuntary loss of urine when the intravesical pressure exceeds the maximum urethral closing pressure. While urge incontinence was defined as urinary leakage associated with the sensation of urgency. Data analysis was performed through SPSS Version 10. Age was presented by Mean \bar{x} standard deviation and its histogram was also presented in premenopause and postmenopause group because Means were not comparable. Frequencies and percentages were computed to present all categorical variables including .menstrual status, parity status, urinary complains and symptoms. Chi-square test was applied to compare parity status, urinary symptoms including frequent

urine passing, urgent urine passing, dysuria urine passing, incontinence and retention urine passing while Fisher's exact test was applied to compare nocturia urine passing, retention urine passing between two groups. Statistical significance was taken at $P < 0.05$.

RESULTS

Average age of premenopause group was computed (35.57 \pm 5.04 years, range=25-40) and postmenopause group was (58.77 \pm 9.97 years, range 40-80). There were only two patients were either nulliparous or single parous and both these patients were found in premenopause group. Parity 2-5 was significantly higher in premenopause than postmenopause group (66.7%vs36.7%), while parity 6-10 was significantly higher in postmenopause group than premenopause group (63.3%vs26.7%).This data revealed a significant difference ($X^2=9.09$, $P=0.011$) of parity status between two groups. (Table1). A symptom of frequent urine passing was reported by 8 (26.7%) patients of premenopause group and 10(33.3%) patients of postmenopause group. There was insignificant difference($X^2=0.317$, $P=0.573$) of proportion of frequency of urine between two groups. Urgency in passing urine was reported by 6 (20%) patients of premenopause group and 8(26.7%) patients of postmenopause group and had insignificant difference($x^2=0.373$, $P=0.542$) between two groups (Fig 1).8(26.7%) patients of pre and 4(13.3%) patients of postmenopause group complained nocturia.

Table No. 1: Comparison of Parity Status between Pre & Most Menopausal Patients

Parity Status	Pre-Menopause (N=30)	Post-Menopause (N=30)	Total
Para 0 – 1	2 (6.7%)	0 (0%)	2
Para 2 – 5	20 (66.7%)	11 (36.7%)	31
Para 6 – 10	8 (26.7%)	19 (63.3%)*	27

*Significantly high proportion ($X^2 = 9.09$, $p=0.011$) at $p < 0.05$

Table No. 2: Comparison of Incontinence Symptom between two Groups

Incontinence	Pre-Menopause (N=30)	Post-Menopause (N=30)	Total
Urge	Yes	12 (40%)	$X^2 = 2.86$ $P = 0.091$
	No	18 (60%)	
Stress	Yes	14 (46.7%)	$X^2 = 0.27$ $P = 0.606$
	No	16 (53.3%)	

An insignificant difference ($P=0.333$) of proportion was observed in 4 (13.3%) of pre and 6 (20%) patients of postmenopause group. Statistically insignificant difference ($P=0.731$) of proportion was observed

between two groups (fig 6). Greater number of patients of premenopause than postmenopause group were found with dysuria (40% vs 26.7%, $P=0.273$). However this difference of proportion was insignificant statistically (fig7). Urge type incontinence was reported by 12(40%) patients of pre and 6(20%) patients of postmenopause group, however this difference of proportion was insignificant ($P=0.091$). Stress incontinence was slightly higher in postmenopause than premenopause group (53.3% vs 46.7%, $P=0.606$) but this difference was insignificant (table2). Proportion of voiding problem in premenopause group was 40% and postmenopause group was 46.7%, this difference of proportion was statistically insignificant ($\chi^2=0.271, P=0.602$) (Table 2).

DISCUSSION

Women with uterovaginal prolapse may present with a plethora of lower urinary tract symptoms including urine frequency, urgency, nocturia, hesitancy, incomplete emptying and incontinence. These symptoms may or may not be related to the uterovaginal prolapse, but with careful clinical and urodynamic investigations it is usually possible to determine the underlying pathophysiology¹¹. There is study conducted by weber AM, Waltar MD Schova LR, Mitchinson A, they found that women with prolapse were older than those without prolapse (mean age 58.2 vs 49.2 years respectively)¹². In this study we used a comparison group of pre and postmenopausal women with uterovaginal prolapse to determine the frequency and proportion of associated urinary symptoms. In this study we found that the average age of premenopausal group was 35.57 yrs (range 25-40 yrs) while the average age of postmenopausal women was 58.77 (range 40-61 yrs). A multi country collaborative study in Pakistan found that women with multiparity were more likely to have prolapse¹. In our study only two patients in premenopause group were either nulliparous or single parous. Other patients in premenopause group had parity 2-5 which was significantly higher than postmenopausal group (66.7% vs, 36.7%), while parity 6-10 was significantly higher in postmenopause group than premenopause (63.3% vs, 26.7%). So the parity status between these two groups had significant difference ($\chi^2=9.09, P=0.001$). As this study was carried out on the basis of hypothesis that there is a likely to be significant difference in urinary symptoms between pre and postmenopausal group with uterovaginal prolapse, the result of our study was found against this hypothesis that differences were insignificant. In our study urge incontinence was reported by 40% patients of premenopause and 20% patients of postmenopause group, however this difference of proportion was insignificant ($P=0.091$) while stress incontinence was slightly higher in postmenopause group (53.3% vs 46.7%, $P=0.606$) but

this difference was insignificant and was not support the hypothesis on which our study based. (Risk factors for urge and stress incontinence were different). The major predictors of urge incontinence were increasing age, UTI and diabetes. Other large population based studies have reported age as an important risk factor for urge incontinence¹³. According to one study the major predictors of stress urinary incontinence were white race, higher basal metabolic index and higher waist to hip ratio¹⁴. In our study the urinary frequency, urgency and voiding difficulties were found more in postmenopausal group as compare to premenopausal group (33.3% vs 26.7%, 26.7% vs 20% and 46.7% vs 40% respectively) but statistically these differences were insignificant. There is one study conducted by Bun gay et al who reported that frequency and urgency are 20% and 15% respectively and these figures increases only slightly with age¹⁵. In our study greater number of patients of premenopause group than postmenopause were found with dysuria (40% vs 26.7%, $P=0.273$) but this difference is insignificant. According to survey conducted in Chinese population in Hong Kong the prevalence of dysuria reported by 166 of 819 women (20%). According to one study conducted by Schatzl and colleagues in 2000 only 3.1% of women younger than 30 experienced nocturia greater than twice per night, where as 26.7% of those aged 60 and older did. But in our study group nocturia found to be higher in premenopause group than postmenopause (26.7% vs 13.3%). However this difference was found to be insignificant ($P=0.333$). Similarly retention of urine was observed higher in postmenopause group (20%) than premenopause (13.3%) but again this difference was found insignificant. Despite thorough evaluation, the source of voiding dysfunction will not be discovered in many women with lower urinary tract symptoms. Age alone correlates with its development; regardless of existing risk factor. This may be caused by a number of processes such as occult Supratentorial central nervous system lesion, neurogenic or myogenic dysfunction at the level of the bladder and changes in extracellular matrix composition at the level of the bladder and urethra¹⁶.

CONCLUSION

Uterovaginal prolapse is associated with different urinary symptoms commonly incontinence and voiding problems. These symptoms are usually affected with age and parity. In our study significant difference in parity was found between pre and postmenopausal group but the difference of proportion of urinary symptoms was found insignificant. All urinary symptoms need to be investigated before performing any vaginal surgery to exclude coexistent pathology such as detrusor instability. These urinary symptoms effect over quality of life of women. This warrants greater attention for gynecological health needs in our

country by safe family planning practices, strengthened with health education of women for delayed age at marriage, to reduce the risk of uterovaginal prolapse and associated urinary symptoms. Further studies are required in the community to study the natural history of the development of urinary symptoms and the relationship to prolapse.

REFERENCES

- Mehboob R, Ahmad N. Uncomplicated pathology at vaginal hysterectomy for genital prolapse. Pak J Med Res 2002;41(4):142-4.
- Thakar R, Stanton S. Management of genital prolapse. BMJ 2003;324:1258-62.
- Bhurt AW, Fikree FF, Bhurt AM, Bozdar NM, Bhurt A, Bhurt R. Uterovaginal prolapse in a rural community of Sindh, Pakistan. J Coll Physician & Surg Pak 2001;11:42-6.
- Olsen AL, Smith VJ, Bergstrom JO, Colling JE, Clark AL. Epidemiology of Surgically managed pelvic organ prolapse and urinary incontinence. Obstet Gynaecol 1997;89:501-6.
- Tayyab S, Hussain N. Incidence and surgical management of genital prolapse in periurban based teaching hospital. Medical channel 1999;5(3):9-12.
- Jones DL. Uterovaginal displacements, damage and prolapse. In: Oates J, Abraham S, editors. Fundamentals of obstetrics and gynaecology. Edinburgh: Elsevier Mosby;2005.p.311-6.
- Adam RA. Enterocele and massive vaginal eversion. e medicine 2002;1-18. Available at website www.emedicine.com.
- Andrades M, Paul R, Ambreen A, Dodani S, Dhanani RH, Qidwai W. Distribution of lower urinary tract symptoms in adult women. J Coll Physician Surg Pak 2004;14:132-5.
- Rizvi RM, Nazim MH. Frequency of urinary symptoms in women attending gynaecology clinics at the AKUH, Pakistan. JPMA 2005;55(11): 489 – 492.
- Versi E, Harvey M, Cardoz L. Urogenital prolapse and atrophy at menopause: a prevalence study. Int Urogynaecol J 2001;12:107-10.
- Balmforth J. Assessment of lower urinary tract function. In: Lussely DM, Baker PN, editors, obstetrics and gynaecology. London: Arnold; 2004.p.619-33.
- Tayrac RD, Chebalier N, Chauveaud lambling A, Gervaise A, Fernandoze H. Risk of urge and stress in continence at long term follow up after vaginal hysterectomy. Am J of Obstet and Gynecol 2004; 191:90-4.
- Barranger E, Fritel X, Pigne A. Abdominal sacrohysteropexy in young women with uterovaginal prolapse: Long term follow-up. Am J Obst and Gynaecol 2003;189:1245-50.
- Jones DL. The urinary tract and its relationship to gynaecology. In: Oats J, Abraham S. Fundamental of obstetrics and gynaecology, Edinburgh: Elsevier Mosby;2005.p.317-22.
- Dolan LM, Hilton P. Deciding on the appropriate surgery for stress incontinence. In: Bonnar J, editors. Recent advances in obstetrics and Gynaecology, 23rd ed. London: Royal society of medicine press limited;2005.p.133-45.
- Charlton RG, Morley AR, chambers P, Gillespie JL. Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. B J Urol Int 1999;84 (9):953-60.

Address for Corresponding Author:

Prof. Dr. Muhammad Ishaq

Chairman & Founder

Jinnah Medical College

Warsak Road Peshawar

Cell: +92-333-9152060

Email: Ishaq@Jmcp.Edu.Pk

Faizimrd@Gmail.Com

A Randomized Controlled Trial on Prevention of Postpartum Haemorrhage with Sublingual Misoprostol or Oxytocin

1. Kulsoom Bhatti 2. Tahmina Mahar 3. Rubeena Hafeez 4. Shoaib-u-Nisa

1. Asstt. Prof., 2, 3, 4. Senior Registrars, Department of Obstetrics & Gynecology, Ghulam Muhammad Mahar Medical College Sukkur.

ABSTRACT

Introduction: Failure of the uterus to contract adequately after child birth (a tonicity) is the most common cause of postpartum hemorrhage and misoprostol produces a rapid peak concentration, and is more effective than oral administration.

Objective: We compared the postpartum blood loss with 400µg sublingual misoprostol and after standard care using 10 iu intramuscular oxytocin.

Study Design: Randomized controlled trial.

Place and Duration of Study: This study was conducted in a Department of Obstetrics and Gynecology Ghulam Muhammad Mahar Medical College Teaching Hospital Khairpur Sindh during 2011.

Materials and Methods: 60 women for each group were assigned to receive the study medications with in 1 minute of clamping and cutting the cord. Chi-square and studentt-test were used to test categorical and continuous outcomes. Mean postpartum blood loss and PPH (>500ml), >10% pre- to postpartum decline in hemoglobin and reported side effects.

Results: The mean estimated blood loss with sublingual misoprostol was 200 ± 125 ml (n=60) and 360 ± 136 ml with oxytocin (n=60) P-value ≤ 0.001 . The incidence of PPH was 3.3% with misoprostol and 6.6% with oxytocin group. No women lost >1000 ml of blood. Hemoglobin decline of > 10% observed that 11.6% and 45.0% in women after receiving misoprostol and oxytocin (P ≤ 0.001). Side effects were significantly greater in the misoprostol group than in the oxytocin group.

Conclusion: In this trial we found sublingual misoprostol more effective than intramuscular oxytocin reducing PPH, with only transient side effects.

Key Words: Hemoglobin, misoprostol, oxytocin, Postpartum hemorrhage, sublingual.

INTRODUCTION

Postpartum hemorrhage (PPH), defined as a blood loss of > 500 ml after delivery, is the most common complication of the 3rd stage of labor and is the leading cause of maternal death in Africa and Asia.¹

Although most women experiencing a blood loss of 500ml do not require additional treatment,² PPH can also exacerbate anemia and its consequences.³

The usefulness of misoprostol a synthetic prostaglandin E1 analog marketed for the prevention and/or treatment of peptic ulcer, also used in the active management of third stage of labor (AMTSL) in developing countries was first reported by EL-Rafaey.⁴ Because of its uterotonic effects, misoprostol has been demonstrated to be effective for both the prevention and treatment of PPH.⁵ With its ease of administration and storage, there has been increasing evaluation and promotion of misoprostol in developing countries.⁶

Compared with other routes of administration, sublingual and oral misoprostol have the shortest time to reach peak concentration (20 minutes), which is approximately one-third of the time of the vaginal route. Sublingual misoprostol also has the highest peak concentration and greatest bioavailability, 400µg

administered sublingually approaches nearly twice the peak concentration of oral administration.⁷ The avoidance of first-pass metabolism via the liver achieves a higher peak concentration by sublingual administration than by oral administration. Sublingual misoprostol more suitable than other routes of administration for clinical applications requiring a rapid onset of action, such as that required for the prevention of PPH.⁸

Oxytocin, long considered the gold standard of uterotonics, remains an efficient uterotonic, with a slightly more rapid onset of action, but has a shorter half-life than misoprostol.⁹

A study was conducted in India showed women receiving 600 and 400µg sublingual misoprostol had lower mean blood loss (96 and 26ml) than those receiving oxytocin (126ml).¹⁰

Our study's aim was to compare the effectiveness of a relatively low dose, 400µg of sublingual misoprostol with the standard care of 10 iu I/M oxytocin on measured postpartum blood loss.

MATERIALS AND METHODS

Women with a singleton pregnancy at >37 weeks of gestation, with cephalic presentation, anticipating a

normal spontaneous vaginal delivery and with hemoglobin > 10 g/dl at the time of presentation, who were admitted to the labor room of Obstetric Department of Ghulam Muhammad Mahar Medical College Teaching Hospital Khairpur Sindh during year of 2011 were included in the study.

Women with postdates pregnancy, medical disorders, instrumental deliveries, multiple gestation and still births were excluded from the study.

Subjects were assigned to treatment with 1:1 ratio using simple randomization.

During one year of study period 120 women were included in the study. Sixty women for each group. One group received 2 tablets (400µg) misoprostol sublingual and other group received 10 iu I/M oxytocin within 1 minute of clamping and cutting the cord. Clinicians continued to monitor the patients.

As part of the standard of care, controlled card traction and uterine massage were provided to both groups.

Visual assessment of blood loss was measured for 2 hours after delivery, women's vital sign and side effects (nausea, vomiting, diarrhea, abdominal pain and fever) were monitored for 6 hours after delivery. A blood sample for hemoglobin and hematocrit estimation was obtained between 12 and 48 hours after delivery.

The primary outcomes are mean blood loss and postpartum hemorrhage. Secondary outcomes include side effects and > 10% postpartum decline in hemoglobin, which is directly associated with blood loss.

SPSS version 15 was used for data analysis. Student's t-test and Chi-square test were used for analysis of the study results.

RESULTS

A total of 120 women were eligible during the study period. Of these, 60 were randomly assigned to the misoprostol group and 60 were randomly for the oxytocin group.

The characteristics of the study subjects and the birth weights of the newborns were comparable (Table: 1). On average all women were aged <25 years and delivered between 38-39 weeks of gestation.

Women receiving oxytocin were slightly younger (22±3.0 years old) and more had first pregnancy (53.3%) compared with women receiving misoprostol (23±3.2 years old and 55% were parity more than one). Unbooked women were equally more in both groups of study population. More women in the misoprostol group received antenatal iron supplementation (41.6%) compared with those receiving oxytocin (33.3%), P=0.06. The average birth weight of newborn in both groups was nearly identical (Table: 1).

Regarding complications and blood loss in third stage of labor, estimated mean blood loss was 200±125 ml in women receiving misoprostol compared with 360ml ±136 ml in women receiving 10 iu intramuscular

oxytocin (P<0.001) shown in (Table: 2). Only 2(3.33%) of women experienced PPH in misoprostol group, compared with 5(8.33%) in women who receiving oxytocin (P=0.002). There was no blood loss of >1000ml or maternal death occurred in both study groups (Table: 2).

Table No.1: Characteristics of study population

variable	Misoprostol N=60 %	Oxytocin N=60 %
-Age	23±3.2	22±3.0
-Parity		
-Nulliparous	27 45%	32 53.3%
-Multiparous<5	33 55%	28 46.6%
-Gestation at delivery	38.6 weeks	38.5 weeks
-Received antenatal care	20 33.3%	18 30%
-Un booked women	40 66.6%	42 70%
-Received antenatal iron	25 41.6%	20 33.3%
-Duration of 1st stage labor	9-10 hours	8-9 hours
-Duration of 2 nd stage labor	20-45 minutes	35-50 minutes
-Episiotomy	32 53.3%	30 50.0%
-Birth weight (kg)	2.6-2.9 kg	2.8-3.1 kg

Table No. 2 Blood loss, Hb changes and side effects

Variables	Misoprostol N:60	Oxytocin N:60	P-value
Mean blood loss (ml)	200±125ml	360±136ml	< 0.001
PPH	2(3.33%)	5(8.33%)	<0.002
Hb decline >10%	7(11.6%)	27(45%)	<0.001
Duration of 3 rd stage	10-22 minutes	10-25 minutes	<0.05
Nausea	4(6.66%)	-	-
Vomiting	3(5.0%)	1(1.6%)	<0.02
Shivering	32(53.3%)	3(5.0%)	<0.001
Fever (>38°C)	2(3.33%)	-	-
Additional uterotonic	1(1.6%)	3(5.0%)	<0.02
Blood transfusion	1(1.6%)	1(1.6%)	<0.98
Maternal death	-	-	-

Women receiving misoprostol and oxytocin had a similar duration of third stage of labor.

More than 10% decline of postpartum hemoglobin in women receiving misoprostol and oxytocin, 11.6% and 45% respectively.

Minor type of side effects like nausea, vomiting and fever was more seen in misoprostol group as compared to oxytocin group. Shivering was more seen in misoprostol group 32(53.3%) as compared to 3(5.6%) in oxytocin receiving women. In more cases additional utero-tonic required in oxytocin group 3(5.0%) as

compared to 1(1.6%) in misoprostol group. One woman in each group required a blood transfusion.

DISCUSSION

The WHO recommends oxytocin as the preferred treatment for managing PPH due to uterine atony but oxytocin has a slower onset of action,¹¹ or in situation where skilled health worker are not able to provide AMTSL, WHO recommends either oxytocin or misoprostol for prevention of PPH.¹²

In 2011, the WHO added misoprostol (600µg) orally to its Model list of essential Medicines for the prevention of PPH.

This study found 400µg sublingual misoprostol, with more rapid bioavailability than oral misoprostol, to be significantly superior to 10 iu intramuscular oxytocin in reducing mean postpartum blood loss. The Cochrane review found virtually no difference in mean blood loss in its comparisons of sublingual misoprostol and injectable uterotonic.¹³

Women receiving oxytocin required additional uterotonic than sublingual misoprostol for PPH treatment in our study, consistent with Vimala et al.¹⁴

The incidence of PPH in this study is higher in those receiving oxytocin I/M (8.33%) where as those receiving sublingual misoprostol had a PPH rate (3.33%), it is correlate with study of Vimala et al.¹⁴

Consistent with studies comparing 600µg oral misoprostol or 400µg sublingual misoprostol with injectable oxytocin, the incidence of side effects in women receiving 600µg oral misoprostol or 400µg sublingual misoprostol is similar and may be attributable to the group and sustained bioavailability of sublingual misoprostol.^{13,14} In those studies, more women receiving misoprostol experienced side effects, although, as in this study, transient shivering has often been the side effects with substantially greater incidence than that associated with oxytocin 32(53.3%), 3(5.6%) women who experienced shivering and other side effects in misoprostol group cure with simple supportive measures, all side effects, including fever, were short lived and required no medical interventions.

CONCLUSION

The transient and self-resolving nature of the side effects associated with misoprostol and the effectiveness and ease of the administration of sublingual misoprostol particularly useful in busy and low resource setting labor room.

This trial found sublingual misoprostol more effective than intramuscular oxytocin in reducing PPH, with only minor and transient side effects.

REFERENCES

1. Khan KS, Wojdyla D, Say L, Gulmezogly AV, Van Look PF. WHO analysis of causes of maternal death: a systematic review. *Lancet* 2006;367:1066-74.
2. Slon NL, Durocher J, Aldrich T, et al. What measured blood loss tells us about postpartum bleeding: a systematic review? *BJ Obstet Gynecol* 2010;117:788-80.
3. Brab in BJ, Hakim M, Pelletire D. An analysis of anemia and pregnancy-related maternal mortality. *J Nutr* 2001;131:604-14.
4. EL-Refaei H, O'Brien P, Morafa W. et al. Misoprostol for the third stage of labor. *Lancet* 1996;347:1257.
5. Winikoff B, Dabash R, Durocher J, et al. Treatment of postpartum hemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomized, non-inferiority trial. *Lancet* 2010;16:375.
6. Walley RL, Wilson JB, Crane JM, et al. A double-blind placebo controlled randomized trial of misoprostol and oxytocin in the management of the third stage of labor. *BJOG* 2000;107:111-5.
7. Tang OS, Ho PC. The pharmacokinetics and different regimens of misoprostol in early first-trimester medical abortion. *Contraception* 2006;74:26-30.
8. Tang Osschweer H Seyberth HW. Pharmacokinetics of different routes of administration of misoprostol. *Hum Reprod* 2002; 17: 332-336s.
9. Paker KL, Schimmer BP. Pituitary hormones and their hypothalamic releasing hormones. In: Brunton LL, Lazo JS, Parker KL, editors. *Goodman and Gilman: The pharmacologic basis of therapeutics* 11th ed. New York: McGraw- Hill; 2006.p.1489-1510.
10. Singh G, Radhakrishnan G, Guleria K. Comparison of sublingual misoprostol, intravenous oxytocin and intravenous methylergometrine in active management of third stage of labor. *Int J Gynecol Obstet* 2009;107:130-4.
11. Gulmezoglu AM, Villar J, Ngoc NTN, et al. WHO multicenter recognized trial of misoprostol in the management of third stage of labor. *Lancet* 2001; 358: 689-95.
12. The WHO is updating its guidelines on the prevention and treatment of PPH in March 2012.
13. Gulmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for preventing postpartum hemorrhage, *Cochrane Database Syst Rev* 2007;3.
14. Vimala N, Nittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. *Int J Gynecol Obstet* 2006;106-10.

Electronic Copy

Causes and Management Outcome of Peritonitis

1. Muhammad Ali Sohail 2. Rafique Ahmed Sahito 3. Feroze Ahmed Mahar

1. Assoc. Prof. of Urology 2. Assoc. Prof. of Surgery 3. PGR of Urology,
Peoples University of Medical and Health Science for Women, Nawabshah, SAB

ABSTRACT

Objective: This retrospective study was conducted to study the different causes of peritonitis and to determine the surgical outcome.

Study Design: Retrospective study

Place and Duration of Study: This study was carried out at the Department of Surgery Peoples Medical College Hospital Nawabshah from 1st January 2001 to 31st December 2001.

Materials and Methods: In this study of 51 patients of peritonitis admitted, out of them, 16 cases of typhoid ileal perforation, 8 cases of perforated duodenal Ulcer, 7 cases of tuberculosis of those 2 cases were of jejunal perforation and 5 cases of ileal perforation, 4 cases of perforated appendix, 4 cases of ruptured liver abscess, 2 cases of perforated neoplasms of those 1 case each with multiple ileal/ jejunal perforation due to lymphoma, malignant caecal perforation, gastric perforation, jejunal perforation obstructive/strangulated, infective caecal perforation each, 2 cases of post operative peritonitis, 3 cases trauma, 2 cases of blunt abdominal trauma each developed peritonitis due to ileal and jejunal perforation, 1 case of gunshot injury causing peritonitis due to colon perforation, 2 cases of ruptured ovarian cyst associated with appendicitis.

Results: In our study, male to female ratio is 4:1. Maximum frequency was observed in 20-30 years age, whereas most of the patients ranged between 13 to 40 years.

Conclusion: Surgical outcome of the peritonitis resulted poor in those cases who came late with hugely contaminated peritoneal cavity when operated. They developed post operative complications i.e. wound infection, septicemia, fecal fistula & longer hospital stays. 22 patient's outcome was poor and out of them 8 patients expired. The mean hospital stay was 23.0 ± 17.7 days and the range was 67(3-110 days).

Key Words: Peritonitis, Causes & Management

INTRODUCTION

Generalized peritonitis is one of the most common emergencies in general surgery. It is an inflammation of peritoneum, can be aseptic or septic, bacterial or viral, primary or secondary, can be acute or chronic^{1,2}.

Intestinal perforations are a common cause of generalized peritonitis. It is often severe because of fecal contamination and overwhelming sepsis resulting in high morbidity and mortality^{2,3,4,5,7,8,9,10} even after treatment with all conventional means^{2,3}. A better survival can be achieved by early diagnosis, fluid resuscitation, appropriate parental antibiotics, and prompt surgical intervention with thorough peritoneal lavage. All are often valuable adjuncts on reducing mortality and morbidity from these common conditions^{2,5,6}.

MATERIALS AND METHODS

This retrospective study was carried out in one year at Department of surgery Peoples Medical College Hospital Nawabshah from 1st January 2001 to 31st December 2001, a total of 51 cases with peritonitis were treated. All the cases had clinically established generalized peritonitis confirmed by clinical examination, radiological, ultrasonography, X ray abdomen erect/supine and operative findings, in order

to assess the underlying etiology, a detailed history was taken in each case inquiring especially about the mode of onset and original site of pain before becoming generalized, duration, prodromal symptoms, associated symptoms and past-history. A comprehensive general physical examination and systemic examination were performed in order to assess the association of co-existing abnormalities and complications. Emphasis was laid on symptoms and signs of abdominal pain, pyrexia, guarding, rigidity, distension, generalized and rebound abdominal tenderness, absent bowel sounds, free fluid and obliteration of hepatic dullness. Complete blood count (CBC), erythrocyte sedimentation rate, random blood glucose level, blood urea nitrogen (BUN), serum electrolytes and urine analysis and cross match blood with grouping were performed in all cases.

X-ray chest, (P.A), view was also performed in all the patients and in those suspected of suffering from tuberculosis or chest complications suggested by history and physical examination. An electrocardiogram (ECG) was also obtained in all the cases of above 40 years of age.

On arrival, all the patients were resuscitated, nasogastric suction was commenced, urinary catheter was inserted and broad spectrum parenteral antibiotic. The anemic patients were given blood transfusion.

Patients in septicemia state were given appropriate circulatory support as required in addition to intravenous fluids and antibiotics in high doses. The antibiotics used were Metronidazole, Gentamycin, Ampicillin and third generation cephalosporins and in patients with impaired renal function, replacing gentamycin and additionally ciprofloxacin in infusion form in typhoid enteric perforation. The antibiotics were continued routinely for 7-10 days. Patients suffering from intestinal tuberculosis confirmed by AFB staining, operative findings and histopathology were registered for antituberculous therapy for 9 months orally. Patients suspected of peptic ulcer perforation on history and physical and examination, were administered H₂- receptor blockers. All the operations were performed as emergency under general anaesthesia after resuscitation and clinical evaluation.

Abdominal cavity explored through a grid iron / midline incisions, the quality and quantity of intra-abdominal exudates were measured. Pus and intestinal contents were removed. Then abdominal cavity washed. A definitive diagnosis was made during the operation. Samples of pus for culture were obtained in cases of obscure etiology/surgical finding and were not routinely taken in the presence of fecal peritonitis. Biopsy specimens comprising of excised tissues/resected segments and mesenteric lymph nodes were taken for histopathology wherever applicable. Outcome of surgical management was determined by intra operative complications, post-operative complications i.e. wound infection, septicemia and fecal fistulas.

On the basis of operative findings, patients were classified into 5 etiological categories as follows (graph 2& 3):

1. **Intrinsic diseases of gastrointestinal tract:** This category was used to classify all inflammatory, ischemic and neoplastic diseases of gastrointestinal tract from stomach to rectum, leading to perforation and intrinsic contamination of peritoneal cavity.
2. **Hepatobiliary category:** Cases of peritonitis from gangrenous perforating cholecystitis and ruptured liver abscess were classified under this category.
3. **Genitourinary category:** This category was exclusively used to classify cases of peritonitis resulting from urologic or female genital origin.
4. **Post-operative category:** Cases operated for abdominal problems other than peritonitis and developing peritonitis post-operatively due to dehiscence of surgical repair/anastomosis were classified under this category.
5. **Traumatic category:** This category was used to classify all those cases developing peritonitis as a result of contamination caused by blunt and penetrating abdominal trauma.

Data collection is done by Questionnaire filled at the time of admission and postoperatively. Data analysis was done on SPSS Version 11.0.

Inclusion Criteria: Patients above 12 years age of either sex. All cases proved as peritonitis based on history, examination, clinical features, X-ray abdomen, ultrasound and C.T scan (if required) appearances included in the study.

Exclusion Criteria: All other causes of acute abdominal conditions without peritonitis like Gastritis, Renal Colic, Pancreatitis, and Gastroenteritis.

RESULTS

A total of 51 cases treated, out of them, there were 40 males and 11 females ranging from 13 years to 80 years in age (mean age = 31.2 + 13.6 years). They were classified into 5 etiological categories on the basis of operative findings (Table 10) as follows:

- a. **Intrinsic Diseases of Gastrointestinal Tract:** 40 cases (32 males and 8 females) were included in this category. There were 16 cases of typhoid ileal perforation alone accounting for 31.4% of the total. Besides these, there were 4 appendicular perforations (7.8%) with generalized peritonitis. 7 cases of tuberculosis out of 7. 2 cases were of jejunal perforation and 5 (9.8%) of ileal perforation. 2 cases of perforated neoplasms 1 (2%) of those with multiple perforations in ileum and jejunum due to lymphoma other was 2% of caecal perforation due to carcinoma rectum 8 cases (15.7%) duodenal ulcer perforations, 1 case 2% of gastric ulcer perforation, 1 case 2% of jejunal perforation due to intestinal obstruction caused by strangulated incisional hernia, 1 case 2% of caecal perforation due to amoebic colitis.
- b. **Hepatobiliary:** Total 4 (7.8%) cases of ruptured liver abscess leading to generalized peritonitis included in the study.
- c. **Post operative:** 2 Cases 3.9% were included both were of jejunal perforation who developed peritonitis few days post operatively.
- d. **Traumatic:** 3 cases (5.8%) of trauma out of those 2 cases were of blunt abdominal trauma each developed peritonitis due to ileal and jejunal perforation 1 case (2%) of gunshot injury causing peritonitis due to perforation in colon.
- e. **Genitourinary:** Only 2 (3.9%) case of Ruptured ovarian cyst associated with appendicitis who developed generalized peritonitis.

Sign & Symptoms: Acute generalized pain was present in all cases. 90.19% with fever, 66.66% with vomiting. Constipation 68.62%. 15.68% complained of coffee ground vomiting (duodenal perforation), and 1 case of typhoid ileal perforation attributed to stress ulceration. 9.80% patients reported Melina and 1.96% fresh bleeding per rectum. On examination, all had generalized abdominal tenderness, while rebound

tenderness was (90.19%) of cases. Abdominal rigidity (82.35%), dehydration (86.27%), abdominal distention (84.31%), absent gut sound (66.66%). Shifting dullness was elicited in (64.70%) of cases and jaundice in (1.96%) of cases.

Management Outcome: The patients of poor outcome developed post operative complications like wound infection, septicemia and faecal fistula & longer hospital stay, 8 (15.6%) patients were expired out of 22(43.4%). Patients of good outcome got smooth recovery with hospital stay was shorter, few of them developed mild wound infection which was cured. The mean hospital was 23.0 ± 17.7 and the range was 67(3-110 days) (Table No.3).

Investigations: In all causes of perforation like Typhoid ileal perforation, Appendicular Perforation, Perforated Neoplasm, Perforated intestinal obstruction Upright abdominal X-rays showed gas under the diaphragm. Abdominal ultrasonography revealed the presence of free fluid in the peritoneal cavity. Serum revealed electrolytes imbalance

Perforated Neoplasm: Abdominal X-rays showed pneumo-peritoneum and ground glass abdomen with dilated loops of bowel and fluid in peritoneal cavity in these cases. Histopathology reports revealed small T cell lymphoma and Carcinoma rectum. Para colic nodes were positive for malignant also.

Table No.1: Hospital Stay (four groups)

Days	Cases	Percentage
Up to 10 days	13	25.5%
Up to 11-20 days	17	33.3%
Up to 21-30 days	12	23.5%
More than 30 days	9	17.4%

Mean Stay was 23.0 ± 17.7 and Range was 107 (3-110)

Table No.2: Biopsy

	Frequency	Percent
CGI TB	7	13.7
Appendices	6	11.8
SC Lymphoma	1	2.0
Widal +	14	27.5
CA Rectum	1	2.0
Nil	21	41.2
Amoebic Perforation	1	2.0
Total	51	100.0

Table No.3: Post Operative Complications

	Frequency	Percent
WI+SEP+FF	10	19.6
WI	20	39.2
WI+SEP	5	9.8
SEP	2	3.9
Nil	14	27.5
Total	51	100

- WI- WOUND INFECTION
- FF- FAECAL FISTULA
- SEP-SEPTICEMIA

Table No.4: Outcome

Outcome	Frequency	Percentage
Good	29	56.6%
Poor	22	43.5%
Total	51	100%

Table No.5: Etiological Classification on the basis of Operative Finding

Category	Total	%age
I. Intrinsic		
Gastrointestinal tract		
A. Typhoid ileal perforation	16	31.4%
B. Perorated appendix	4	7.8%
C. (i) perforated ileocaecal tuberculosis	5	9.8%
(ii) jejunal perforation (tuberculosis)	2	3.9%
D. Perforated duodenal ulcer	8	15.7%
E. Perforated intestinal obstruction	1	2%
F. Perforated neoplasm's	1	2%
(i) Caecal perforation		
(ii) Multiple perforations (ileum, jejunum)	1	2%
G. Caecal perforation (amoebic)	1	2%
H. Gastric ulcer perforation	1	2%
II. Hepatobiliary		
Ruptured liver abscess	4	7.8%
III. Post-Operative		
Jejunal Perforation	2	3.9%
IV. Traumatic		
A. ASC. Trans. Colon Perf. (Gunshot)	1	2%
B. Iliac Perf. (Blunt ABD. Trauma)	1	2%
C. Jujenal Perforation (Blunt ABD. Trauma)	1	2%
V. Genitourinary		
1. Ruptured Ovarian Cyst + Appendicitis	2	3.9%
Total	51	100%

DISCUSSION

Acute generalized peritonitis is a challenging surgical condition that requires prompt attention and appropriate surgical treatment. Despite advances in surgical techniques, good antimicrobial therapy and intensive care support, it carries high morbidity and mortality while its management remains difficult and complex¹¹. Peritonitis, if not treated promptly, can lead to multisystem organ failure and death^{12,13}. Worldwide there is a predominance of males presenting with this life-threatening disease^{14,15} our series also shows a similar trend, with a male to female ratio of 4:1. Maximum frequency was observed in the 20-30 years

age group (52.94%) whereas most of the patients ranged between 13 to 40 years in age (84.31%).

Many etiological factors have been implicated in the pathogenesis of this generalized intra-abdominal sepsis. The objective of this research exercise is to study the different causes of generalized peritonitis (secondary peritonitis) and to determine the surgical outcome

Abdominal pain was the most common symptom and tenderness the commonest sign observed in 100 percent cases. Rebound tenderness was noted in 90% cases attributable to a possible masking effect of altered conscious level in toxemia. Findings of pneumoperitoneum in 56.9 percent patients and elicitation of shifting dullness in (64.70%) is comparable with similar studies. Coffee ground vomiting in (15.68%) patients reflects the diverse nature of clinical presentation that can be observed in generalized peritonitis. These included patients with typhoid ileal perforation and 8 cases with duodenal perforation and was attributed to stressful effects of toxemia on stomach in cases of typhoid leading to stress ulceration. Similarly, Melina was observed in 9.80% cases, 8 of those 9 cases had a perforated duodenal ulcer and 1 had typhoid ileal perforation.

Investigations irrespective of etiology revealed anaemia, varying degrees of electrolyte imbalance, raised blood urea nitrogen. Metabolic acidosis & predominance of polymorph nuclear leukocytes in the differential count which was not markedly elevated and even below normal in some cases. Cause of this functional neutropenia has been described to be a massive shift of leukocytes along with the inflammatory exudates into the peritoneal cavity so that their number falls in circulating blood usually observed in the reactive toxic stage of peritonitis with multiple organ failure. Delayed treatment associated with other factors such as malnourishment and impaired immunity are the major reasons for high mortality and morbidity. Kaur N et al., in their study also attribute delay seeking surgical treatment as an important cause for high morbidity¹⁶.

Almost (31.4%) of the cases were due to typhoid ileal perforation alone and the second most common cause of peritonitis was perforated duodenal ulcer and than ileocaecal tuberculosis perforation and perforated appendicitis. Quereshi AM¹⁷ & Dorairajan LN¹¹ who report majority of perforations involving distal gastrointestinal tract such as ileum. Chatterjee H too reported typhoid as the commonest cause of perforations in two separate studies^{18,19}.

Similarly, 4 cases of ruptured liver abscess and 2 cases of perforated neoplasms were observed. No case of colonic diverticular perforation was observed which was fairly common cause of generalized peritonitis in the West.

Incidence of post-operative peritonitis was also very low and only 2 cases developed peritonitis post-

operatively. In our study perforated appendix 7.8% and peptic ulcer 15.7%. Dandpat MC studied 340 cases of gastrointestinal perforations and found that 22(6.4%) patients developed secondary peritonitis secondary to perforated appendix²⁰. Primary intestinal tuberculosis is uncommon in the west²¹ but is still common in developing countries like Pakistan²². In our study perforated tuberculosis ileocaecal perforation was 9.8% and tuberculosis jejunal perforation 3.9%.

Blunt abdominal trauma ignored earlier by the patients was seen to be associated with serious intra-abdominal injuries leading to peritoneal contamination and generalized peritonitis. Those patients sought medical help upon development of abdominal pain and distention 24 hours to 5 days (average 2 days) after sustaining abdominal trauma. Intestinal obstruction leading to peritonitis was observed in 2 cases. Perforation was found in both cases. 2 cases of malignancy were found in our study one involved the large bowel 2%, while one showed involvement of small bowel 2%.

This etiological pattern observed reflected the effects of a poor socioeconomic background and lack of hygienic conditions. Ignorance and delay in seeking medical advice was observed leading to typhoid ileal perforation whereas incomplete and inadequate anti tuberculous treatment was seen in cases of open pulmonary tuberculosis leading to gastrointestinal complications. While long history of epigastric pain found in patients of perforated duodenal ulcer which developed due to inappropriate treatment of acid peptic disease.

The patients of poor outcome developed post operative complications & longer hospital stay, 8 (15.6%) patients were expired out of 22(43.4%). postoperative complication in secondary peritonitis reported by Jhobta RS²³ are respiratory tract infections (28%), wound infection (25%), septicaemia (18%) and electrolyte imbalance (17%). Kim et al.²⁴ in their study report mortality rate of 9.9%. Patients of good outcome got smooth recovery with hospital stay was shorter, few of them developed mild wound infection which was cured. The mean hospital was 23.0±17.7 and the range was 67(3-110 days)

CONCLUSION

The diagnosis of acute generalized peritonitis was largely clinical and the radiological evidence of perforation was conclusive in only 57.9 percent of the cases. Majority of cases belonged to the intrinsic diseases of gastrointestinal category with the following etiological distribution; typhoid ileal perforation 31.4%, appendicular perforation 7.8%, perforated intestinal tuberculosis 13.7%, perforated duodenal ulcer 15.7%, perforated intestinal obstruction 2%, perforated carcinoma 3.9%. Ruptured ovarian cyst 3.9%, Ruptured liver abscess 7%. Majority of cases had faecal peritonitis

and rest of the cases had suppurative peritonitis. Surgical outcome of the peritonitis resulted poor in those cases who came late & they developed post operative complications with longer hospital stay. Surgical outcome of patients whose arrival was early and there was less contamination of peritoneum, outcome was good with smooth recovery and there hospital stay was shorter.

REFERENCES

- Richard H. Turnage. Abdominal wall, umbilicus, peritoneum, mesenteries omentum and retroperitoneum. In: Sabiston DC, JR eds. Textbook of Surgery. The biological basis of modern surgical practice. 17th ed. Philadelphia: WB Saunders Co; 2004: 1137-97.
- Miyano G, Okazaki T, Kato Y, Marusasa T, Takahashi T, Lane GJ, et al. Open versus laparoscopic treatment for pan-peritonitis secondary to perforated appendicitis in children: a prospective analysis. *J Laparoendosc Adv Surg Tech A* 2010;20(7):655-7.
- Adesunkanmi ARK, Badmus TA, Ogundoyin O. Causes and determinants of outcome of intestinal perforations in a semiurban African Community. *Ann Coll Surg HK* 2003;7:116-23.
- Wani RA, Parry FQ, Bhat NA, Wani MA, Bhat TH, Farzana F. Non traumatic terminal ileal perforation. *World J Emerg Surg* 2006; 1:7.
- Aziz M, Qadir A, Aziz M, Faizullah. Prognostic factors in typhoid perforation. *J Coll Physicians Surg Pak* 2005;15:704-7.
- White SI, Frenkiel B, Martin PJ. A ten-year audit of perforated sigmoid diverticulitis: highlighting the outcomes of laparoscopic lavage. *Dis Colon Rectum* 2010;53(11):1537-41.
- Haider W, Abdul Majid, Khanum A, Bhutta A. The prognostic factors in typhoid ileal perforations. *Pak Postgrad Med J* 2002;13:1-3.
- Trenti L, Biondo S, Golda T, Monica M, Kreisler E, Fraccalvieri D, et al. Generalized peritonitis due to perforated diverticulitis: Hartmann's procedure or primary anastomosis? *Int J Colorectal Dis* 2010;15.
- Miller SV, Vinnik IuS, Tepliakova OV. The results of the practical use of the destructive peritonitis' standartized treatment. *Khirurgiia (Mosk)* 2012; (5):24-30.
- Qureshi JN, Qureshi ZA, Ahuja P, Memon A. Gunshot perforation of gut and associated injuries. *J Surg Pak* 2001;6:21-3.
- Dorairajan LN, Gupta S, Deo SV, Chumber S, Sharma L: Peritonitis in India-a decade's experience. *Trop Gastroenterol* 1995;16(1):33-38.
- Gupta S, Kaushik R: Peritonitis--the Eastern experience. *World J Emerg Surg* 2006;1:13.
- Eid HO, Hefny AF, Joshi S, Abu-Zidan FM: Non-traumatic perforation of the small bowel. *Afr Health Sci* 2008;8(1):36-39.
- Jhobta RS, Attri AK, Kaushik R, Sharma R, Jhobta A. Spectrum of perforation peritonitis in India-review of 504 consecutive cases. *World J Emerg Surg* 2006;1:26.
- Wani RA, Parry FQ, Bhat NA, Wani MA, Bhat TH, Farzana F. Nontraumatic terminal ileal perforation. *World J Emerg Surg* 2006;1:7.
- Kaur N, Gupta MK, Minocha VR: Early enteral feeding by nasoenteric tubes in patients with perforation peritonitis. *World J Surg* 2005; 29(8):1023-1027.
- Qureshi AM, Zafar A, Saeed K, Quddus A. Predictive power of Mannheim Peritonitis Index. *J Coll Physicians Surg Pak* 2005;15(11):693-696.
- Chatterjee H, Jagdish S, Pai D, Satish N, Jayadev D, Reddy PS. Changing trends in outcome of typhoid ileal perforations over three decades in Pondicherry. *Trop Gastroenterol* 2001;22(3): 155-158.
- Chatterjee H, Pai D, Jagdish S, Satish N, Jayadev D, Srikanthreddy P. Pattern of nontyphoid ileal perforation over three decades in Pondicherry. *Trop Gastroenterol* 2003, 24(3):144-147
- Dandapat MC, Mukherjee LM, Mishra SB, Howlader PC. Gastrointestinal perforations. *Ind J Surg* 1991;53:189-193.
- Michalopoulos A, Papadopoulos VN, Panidis S, Papavramidis TS, Chiotis A, Basdanis G. Cecal obstruction due to primary intestinal tuberculosis: a case series. *J Med Case Reports* 2011;5:128.
- Jamal S, Khan Z, Ahmed I, Shabbir S, Khaliq T. Presentation and Outcome of Abdominal Tuberculosis in a Tertiary Care Unit. *Ann Pak Inst Med Sci* 2011;7(1):33-36.
- Langell JT, Mulvihill SJ: Gastrointestinal perforation and the acute abdomen. *Med Clin North Am* 2008;92(3):599-625.
- Kim JP, Oh SK, Jarrett F: Management of ileal perforation due to typhoid fever. *Ann Surg* 1975; 181(1):88-91.

Address for Corresponding Author:

Dr. Muhammad Ali Suhail

Email:talktouroman@yahoo.com

Cell No.: 03002654334

Beneficial Effect and Safety of 5% Permethrin Cream in Scabies Patients

1. Farah Asad 2. Fatima Rizvi 3. Jawed Iqbal

1,2. Asstt. Profs. of Pharmacology & Therapeutic, JM&DC, Karachi

3. M.Phil Student, Dept. of Pathology, BMSI, JPMC, Karachi

ABSTRACT

Objective: To evaluate the efficacy and safety of 5% permethrin in scabies patients

Background: Scabies is a contagious, itchy ectoparasitic infection. It is a common public health problem with an estimated global prevalence of 300 to 400 million cases. They increases day by day. 5% permethrin is one of the effective treatment of scabies, it is highly effective, well tolerated, poorly absorbed and rapidly metabolized by skin.

Study Design: Open label clinical trial

Place and Duration of Study: This study conducted in Basic Medical Sciences Institute with collaboration of Dermatology Department from ____.

Materials and Methods: This study sample involved 65 clinically diagnosed scabies patients one was lost from follow up, the duration of study was 90 days. They were treated with 5% permethrin cream, clinical data was collected by using questionnaire. Patients were divided into three age groups and given two applications of permethrin cream on first and 15 day. Follow up was done on Day 3, Day 15, Day 30 and Day 90

Results: It was found that efficacy and safety of permethrin cream in scabies patients was highly significant which clinically improved the symptoms of patients.

Conclusion: Scabies patients should advised 5% Permethrin cream with conventional therapy which improves symptoms significantly following proper local.

Key Words: Scabies, 5% Permethrin Cream, Efficacy And Safety.

INTRODUCTION

Scabies is a common ectoparasitic infection caused by the mite *Sarcoptes scabiei* variety *hominis*, an arthropod of order Acarina.¹

The world wide prevalence has been estimated at about 300 million cases yearly, although it is common disease of children but occur in both sexes, in all ethnic groups and at all socioeconomic levels.² A scabies infestation symptom includes rash and intense pruritus that is often worse at night. The lesion begins as tiny erythematous papules.³ The diagnostic signs of scabies are the burrows.⁴

Permethrin is a synthetic pyrethroid and considered as a gold standard of topical scabiecidic.⁵ It acts on voltage dependent sodium channels by extended channel opening causing increased sodium current, depolarization is prolonged leading repetitive filling of nerve.⁶ It is well tolerated, poorly absorbed through skin and rapidly metabolized by skin esterase. Local skin irritation, such as pruritus, burning sensation or tingling has occasionally been reported but all are short duration.^{7,8}

MATERIALS AND METHODS

This was open label clinical trial approved by ethical Committee of Jinnah Postgraduate Medical Centre, Karachi conducted in Basic Medical Sciences Institute with collaboration of Dermatology Department. Cases diagnosed by consultant dermatologist were enrolled to participate in trial. Detailed questionnaire was

completed and inform written consent was taken from patients and their relatives. Patients willing to participate were screened by applying the inclusion and exclusion criteria. Patients were divided into 3 groups according to age. Inclusion criteria are night itching, diagnosed cases of scabies either gender, age above 5 years and below 70 years, demonstration of burrows or presence of scabies lesion at the classical sites, history of similar illness in the family. Three or more criteria mentioned above made the patient eligible to include the study. Exclusion criteria are pregnant women, lactating women, crusted scabies, patient who had received treatment during last 1 month, diabetic and patients with hepatic impairment or with dermatological, cardiovascular and neurological diseases. Eligible subjects were assigned to apply 5% permethrin cream over night (over 14 hours) and then repeated the application on day 15. The duration of study was 90 days with 5 follow up visits. Total 65 scabies patients enrolled in this trial and divided into 2 groups which were further sub-divided according to age into 3 groups. Clinical efficacy assessed by appearance of new skin lesion and pruritus which was evaluate by visual analogue scales, it has both static and dynamic component. Dynamic component was scored on a scale 0-6.

Statistical Analysis: Data were analyzed using SPSS software Ver. 11.0, mean±SEM.

RESULTS

Table No.1: Visual Analogue Scale In Scabies Treated Patients on Day-0 to Day-90 of Permethrin Group

Follow up available		Permethrin Cream Group (n=65) (n=64)
Visual analogue scale (VAS)		Mean ± SEM
Day – 0		6.00 ± 0.00
Day – 30		3.67 ± 0.08
Day – 15		2.33 ± 0.10
Day – 30		0.94 ± 0.15
Day – 60		0.48 ± 0.18
Day – 90		0.87 ± 0.26**
Visual analogue scale (VAS) according to age groups		
5-25 years	Day – 0	6.00 ± 0.00
	Day – 3	3.46 ± 0.15
	Day – 15	2.08 ± 0.18
	Day – 30	0.71 ± 0.24
	Day – 60	0.21 ± 0.21
	Day – 90	1.00 ± 0.47**
26-45 years	Day – 0	6.00 ± 0.00
	Day – 3	3.75 ± 0.09
	Day – 15	2.35 ± 0.15
	Day – 30	1.00 ± 0.24
	Day – 60	0.55 ± 0.34
	Day – 90	0.75 ± 0.41**
46-70 years	Day – 0	6.00 ± 0.00
	Day – 3	3.85 ± 0.15
	Day – 15	2.60 ± 0.18
	Day – 30	1.15 ± 0.30
	Day – 60	0.70 ± 0.38
	Day – 90	0.80 ± 0.44**

**=Highly significant.

Total mean VAS scoring for pruritus in all scabies patients at day 0 was 6.00±0.00, at day 3 the mean VAS scoring was decreased to 3.67±0.08, at day 15 the mean VAS scoring was improved to 2.33±0.10, at day 30 the mean VAS scoring was decreased to 0.94±0.15, at day 60 the mean VAS scoring was 0.48±0.18 and at day 90 the mean VAS scoring was increased to 0.84±0.26 this increased may be due to recurrence in patients. When day 0 compared with day 90 the outcome was highly significant. According to age groups in all ages the baseline mean VAS scoring of scabies patients compared with the outcome was highly significant, as depicted in table 1. The Total percentage of new lesion in scabies patients at day 15 was 1.6%(1), at day 30 the percentage of new lesion was 9.4%(6), at day 60 the percentage was changed to 10.9% (7) and at day 90 the percentage was increased to 15.6% (10) which was non

significant. In all age groups the appearance of new lesion was also non-significant. As depicted in table 2.

Table No.2: Appearance of new lesion in scabies treated patients permethrin group

Follow-up available		Permethrin Cream Group (n=65)	
		n = 64	P-value
Appearance of new lesion			
Day – 3		-	0.052
Day – 15		1 (1.6%)	
Day – 30		6 (9.4%)	
Day – 60		7 (10.9%)	
Day – 90		10 (15.6%)	
Appearance of new lesion according to age groups			
5-25 years (n=24)	Day – 3	-	0.265
	Day – 15	-	
	Day – 30	1 (1.6%)	
	Day – 60	1 (1.6%)	
	Day – 90	4 (6.2%)	
26-45 years (n=20)	Day – 3	-	0.741
	Day – 15	1 (1.6%)	
	Day – 30	3 (4.7%)	
	Day – 60	3 (4.7%)	
	Day – 90	3 (4.7%)	
46-70 years (n=20)	Day – 3	-	1.000
	Day – 15	-	
	Day – 30	2 (3.1%)	
	Day – 60	3 (4.7%)	
	Day – 90	3 (4.7%)	




Figure No.1: Cure rate in scabies treated patients on day-30 to day-90 permethrin group

Cure rate of 64 (98.5%) Permethrin treated scabies patients at day 30 was 92.1% (59 patients), at day 60 the percentages was changed to 89.1% (57 patients) and at day 90 the percentage was decreased to 84.4% (54 patients). This reduction may be due to recurrence when day 0 compared to day 90 the cure rate was highly significant and same in all age groups. As depicted in fig 1. The safety profile clinically was

assessed by complaint of adverse effects in treated patients during the drug study period. The major adverse effects were not observed except mild burning, the percentage was 1.6 % (1), as depicted in figure 2.




Figure No.2: Clinically safety profile assessed by adverse effects in scabies treated patients

DISCUSSION

Scabies is widely spread in our community and conventional scabiecidal therapies are difficult to instill and hard to implant. This often results in higher failure rates because of non-compliance or reinfestation.⁹ The reported incidence of scabies in Karachi is 22.7% which is more than other infection and shown alarming prevalence indicating a lack of awareness about this common skin problem.¹⁰ Absolute confirmation can be made by the discovery of burrows and microscopical examination.^{11,12} Treatment of scabies is as important as making a correct diagnosis. Patient should be properly instructed about the method of using scabicide.¹³

The cure rate in this study was 84.4% and only one patient gave complain of mild burning. The results of our study are in accordance with other study that compared the 5% Permethrin with Ivermectin and found better results with permethrin cream.¹⁴ In present study cure rate was assessed by the presence of new lesions. The participants who did not have any new lesion were considered as cured. Every participant was asked about pruritus which was quoted as 0/25/50/75/100% on visual analogue scale (VAS) at day 0, the pruritus was considered as 100%. Our results matched with other study who declared that permethrin act against all emerging stages of mites.¹⁵ In the present study these participants who showed new lesions and gave complain of pruritus that had developed resistance and recurrence because of poor compliance¹⁶. Improper application of medicine may be the main factor of drug resistance in study, to decrease the drug resistance of scabies patients advised the repeated prescription of scabiecidal medicines. This highly contagious nature of

disease requires that all other household members be treated simultaneously whether they have no symptoms¹⁸. This study shows that permethrin was safe in adults, children and pregnant and lactating women¹⁹. For achieving good control, increased awareness and education, hygiene improvement and massive treatment campaign should be integrated²⁰.

CONCLUSION

5% Permethrin cream is effective and safe, but advice with conventional therapy.

REFERENCES

- Downs AMR, Harvey I, Kennedy CTC. The epidemiology of head lice and scabies in the UK. *Epidemiol Infect* 1999;122:471-477.
- Walton SF, Currie BJ. Problems in diagnosing scabies, a Global disease in Human and animal populations. *Clin Microbiol Rev* 2007;20(2): 268-279.
- Khan I, Yasmin R. Ivermectin in the treatment of scabies. *J Pak Assoc Dermatologists* 2007;17: 78-83.
- Wende K, Rompalo A. Scabies and pediculosis pubis: An update of treatment regimens and general review. *CID* 2002; 35(Suppl 2):S147-S151.
- Ammed EF, Abdol-Wawad MM, Moustafa YM. Oral ivermectin versus topical permethrin in the treatment of uncomplicated human scabies. *Egypt J Dermatol* 2001; 21:53-58.
- Chansirpornchai P, Chansirpornchai N. Effects of permethrin at a prophylactic dose for ectoparasite infection on cholinesterase activity in dogs. *Thai J Vet Med* 2009;39(4):343-347.
- Schultz MW, Gomez M, Hansen RC, Mills J, Menter A, Rodgers H, et al. Comparative study of 5% permethrin cream and 1% lindane lotion for the treatment of scabies. *Arch Dermatol* 1990; 126(2): 167-170.
- Albakri U, Goldman RD. Permethrin for scabies in children. *Child Health Update* 2010; 54:100529.
- Akhtar SJ, Mann MA, Iqbal J, Kapadia N. Treatment of scabies simplified. *J Pak Assoc Dermatologists* 2007;17:240-249.
- Rathi SK, Rathi HSK, Lakhani H and Hansotia MF. Awareness about scabies among general medical practitioners (GPs) of Karachi, Pakistan. *J Pak Med Assoc* 2001; 51:370-375.
- Rook's Mites (Acari) In: Burns T, Breathnach S, Cox N, Griffiths C, editors *Rook's Textbook of Dermatology*. 7th ed. Wiley-Blackwell; 2004.p. 33.37-33.48.
- Burns T, Breathnach S, Cox N, Griffiths C, editors. *Rook's Morphology and biology of the scabies mite*. *Rook's Textbook of Dermatology*. 7th ed. Wiley-Blackwell; 2010.p.38.36-38.47.

13. Karthikeyan K. Treatment of scabies: newer perspectives. Postgrad Med J 2005; 81:7-11.
14. Usha V, Nair TVG. A comparative study of oral ivermectin and topical permethrin cream in the treatment of scabies. J Am Acad Dermatol 2000; 42:236-240.
15. Kenawi MZ, Morsy TA, Abdalla KF, el Hady HM. Treatment of human scabies by sulfur and permethrin. J Egypt Soc Parasitol 1993;23(3): 691-696.
16. Raza N, Qadir SNR, Agha H. Risk factors for scabies among male soldiers in Pakistan: case control study. Eastern Mediterranean J 2009; 15(5): 1105-1110.
17. Rizvi SDA, Uddin R, Syed TM. Impact of demonstration of extracted sarcoptes scabiei Pak Armed Forces Med J 2009; 2:1-5.
18. Banez JA, Nazareno RC, Medel RB. Clinical trial on the effectiveness of Gliricidia sepium (Kakawati) in treating patients with scabies in the Antipolo CBHP. Phil J Microbiol Infect Dis 1999; 28(4):147-153.
19. Hamm H, Beiteke U, Hoger PH, Seitz CS, Thaci D, Sunderkotter C. Treatment of scabies with 5% permethrin cream: results of a German multicenter study. J Der Deutschen Dermatologischen Gassellschaft 2006; 4(5):407-413.
20. Ursani NM, Baloch GH. Scabies epidemic at Tando Muhammad Khan, Sindh. J pak Assoc Dermatologists 2009; 19:86-89.

Address for Corresponding Author:

Dr. Farah Asad,

Assistant Prof.

Department of Pharmacology and Therapeutic,
Jinnah Medical and Dental College, Karachi.

Electronic Copy

Alterations in Mitochondria of Kidney Tubules by Different Doses of Diclofenac Sodium in Rabbits

1. Talat Yasmeen 2. Irfan Ashraf Siddiqui 3. Zaheer Amjad 4. Amir Ali Shoro 5. Talat Mirza

1. Prof. of Anatomy, JSMU, Karachi 2. Asstt. Prof. of Anatomy, JSMU, Karachi 3. Senior Demonstrator Anatomy, DUHS, Karachi 4. Prof. of Anatomy, LPMC, Karachi 5. Prof. of Pathology, DUHS, Karachi

ABSTRACT

Introduction: Diclofenac sodium, a Non-Steroidal anti-inflammatory agent (NSAIDs), is being prescribed since many decades for the treatment of rheumatic diseases as well as for the relief of pain and fever. It is the inhibitor of enzyme cyclooxygenase. Unfortunately its use is often accompanied by gastro-intestinal renal and hepatic side effects. Renal dysfunction is characterized from acute renal failure to chronic injury. We herein report the damaging effect of diclofenac sodium on the ultrastructure of PCT of rabbit kidney by increasing the doses above the recommended.

Study Design: Experimental Study

Place and Duration of Study: This study was conducted at the Institute of Basic Medical Sciences (IBMS), Dow University of Health Sciences from March 2009 to March 2010.

Material and methods: In this study 88 male albino rats were selected, they were divided into 4 groups group A received normal saline 2 ml/kg, group B diclofenac sodium 2mg/kg body weight group C 4 mg/kg and group D 6 mg/kg for two weeks. At the end of experiment animals were sacrificed, dissected, kidneys were identified, fixed in 4% gluteraldehyde than 1% osmium tetroxide and passed through graded alcohols, infiltrated and embedded in resins. Semithin 3~4 μ m sections were stained with toluidine, ultrathin (1 μ m) with uranyl acetate. Tissue sections were observed under transmission electron microscope. Tissue changes were graded as 0, +, ++ and +++, no change, mild moderate and severe changes respectively. The results were then analyzed statistically.

Results: There were non-significant changes in the cell organelles of PCT in group A and B, while significant changes were observed in group C and highly significant in group D.

Conclusion: Diclofenac sodium has damaging effect on the mitochondria of PCT cells far before the light microscopic changes. So its use should be restricted only in very painful conditions. Secondly in case of prolong treatment follow up with regular renal function test should be carried out.

Key Words: Diclofenac sodium, kidney, ultrastructure.

INTRODUCTION

NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are very commonly prescribed drugs. During the past thirty years there has been a substantial increase in the number of NSAIDs, but their availability varies markedly between countries¹. These drugs when grouped by generic categories they are the most widely prescribed of all medications². As large population is exposed to these compounds their adverse effects are also rapidly expanding.

Diclofenac sodium, a commonly prescribed analgesic also belongs to the group non-steroidal anti-inflammatory drugs (NSAID). It is a non-selective COX inhibitor³ and probably one of the most common non-steroidal compounds with analgesic, anti-inflammatory, anti-rheumatic and antipyretic properties with inhibitory effect on prostaglandin synthesis⁴.

Its potency is substantially greater than that of indomethacin, naproxen and several other agents⁵. Chief clinical application of Diclofenac sodium is an anti-inflammatory agent in the treatment of musculoskeletal disorders such as rheumatoid arthritis,

osteoarthritis, ankylosing spondylitis, and in dysmenorrhoea. It is also found effective for the control of postoperative pain when used preoperatively⁶, pre-operative rectal diclofenac is found to delay the onset of post-operative pain and is adequate as an analgesic for early post-operative period⁷. It has also been used in neonates to close the ductus arteriosus when it has remained patent⁸.

The gastrointestinal toxicities are well known, while kidney is also an important site for untoward effects. In fact these agents have been known to produce a wide array of untoward renal effects that may be divided into several distinct nephrologic syndromes, including acute renal failure⁹, chronic renal injury, nephrotic syndrome¹⁰, interstitial nephritis, abnormalities of water metabolism, and abnormalities of sodium and potassium homeostasis. Renal papillary necrosis and nephritic syndrome have been reported in many patients taking Diclofenac sodium⁹. Experimental studies have also shown damage to kidney tubules at ultrastructural level¹¹. Hepatotoxicity though uncommon but when occurs it is lethal.

MATERIALS AND METHODS

For this experimental study 88 male rabbits were taken from the Institute of Basic Medical Sciences (IBMS), Dow University of Health Sciences. They were about three months of age and 900-1000 gm. in weight. They were divided into four groups A, B, C, and D each comprising of 22 animals.

The animals were weighed on single pan triple beam balance on day-1 and day-14 of the experimental period. Group A served as control receiving normal saline 2ml intraperitoneally/daily, group B received diclofenac sodium (injection Voren) in the dose of 2 mg/kg body weight daily, group C received diclofenac sodium in the dose of 4mg/kg body weight daily (double the therapeutic dose), and the group D received diclofenac sodium 6 mg/kg/daily (three times the therapeutic dose), given intraperitoneally. These injections were given for 14 days. On day 15 the animals were sacrificed by a blow on head.

The kidneys were dissected out and divided into small pieces with the help of a sharp knife, and were fixed in 4% gluteraldehyde for electron microscopy¹².

Tissue Processing for Electron Microscopy

All the tissue processing was done under a fume hood. Pieces of kidney were then chopped to 1 mm³ pieces again transferred to the same fixative for further 24 hours for proper infiltration of the fixative.

- The tissue pieces were washed with Sorensen phosphate buffer for ten minutes then post-fixed in osmium tetra oxide at 4 °C for one hour. They were dehydrated in alcohols and infiltrated with hard resin and half acetone at 37 °C for one hour and embedded in full resin.
- Semi-thin sections 3~4 µm were cut and stained with toluidine blue for general orientation of the tissue. After areas of interest were identified thin sections 1 µm (100 nm) stained with uranyl acetate and lead citrate were examined under transmission electron microscope (TEM Leica, Germany).
- Tissue changes were graded as 0 no change, +, ++, and +++ as mild, moderate and sever changes respectively. The results were then analyzed statistically. P value less than 0.05 was taken as statistically significant. SPSS version 17 was used or the analysis of data.

RESULTS

The gross examination of the kidney in the group A, B, C, and D showed normal appearance. The kidney in group A appeared oval in shape, dark red in colour, soft in consistency with smooth shiny surface having delicate fibrous capsule that stripped off with ease. The kidneys of animals in groups B, C, and D were appeared normal, somewhat oval in shape with smooth

looking contour, extra soft in consistency and capsule stripped with ease. The cut surface showed normal thickness of the cortex.

Electron Microscopic Observation: The kidney sections from animals of all four groups which were processed for electron microscopy and were mounted on grids; were examined under E/M. The following observations were recorded.

Group A: In group A animals the ultrastructure of kidney tubules revealed normal morphology. The plasmalemma at the microvillar brush border showed normal hazy appearance. In the cytoplasm the cell organelles appeared normal.

The mitochondria were elongated and rod shape, they were scattered all over the cell but gathered more near the base of the cell. Here they were arranged parallel to the long axis of cell in the basal infolding of plasmalemma. Both the inner and outer mitochondrial membranes were distinctly visible with densities in matrix; while most of the cristae were arranged transversely (Fig-1). The mean value of changes in this group was 0.14 ± 0.34 (Table-1).

Table A.1: Changes in Mitochondria of PCTs

Animal No.	Group A	Group B	Group C	Group D
1	0	0	0	1
2	0	0	0	0
3	1	0	1	2
4	0	0	0	0
5	0	0	2	3
6	0	0	0	0
7	0	1	0	2
8	0	0	0	0
9	0	0	0	1
10	0	0	1	0
11	0	0	0	0
12	1	0	0	1
13	0	0	0	0
14	0	0	2	3
15	0	1	0	1
16	0	0	0	1
17	0	0	2	0
18	1	0	0	0
19	0	0	0	0
20	0	1	0	1
21	0	0	0	2
22	0	0	2	0
Mean	0.14	0.14	0.45	0.82
Std Dev	0.34	0.34	0.78	0.98

Table A.2: Post Hoc Tests – Changes in Mitochondria of PCTs – Multiple Comparisons

	Group B	Group C	Group D
Group A	1.000	0.695	0.033
Group B		0.695	0.033
Group C			0.615





Figure 1: Electron micrograph of the rabbit kidney treated with normal saline (group A) showing a PCT cell with normal brush border, nucleus and other cell organelles x 6000




Figure 2: Electron micrograph of the rabbit kidney treated with Diclofenac sodium 6 mg/kg (group D) showing damaged mitochondria and brush border in a PCT cell x 6000

Group B: In group B animals the proximal tubular cells were almost normal under E/M. in cellular details the plasma membrane was intact and clearly visible, the cytoplasmic organelles were also studied and they showed mild to moderate change.

Most of the mitochondria were elongated they were very well visualized along the basal part of the cells. They were arranged parallel within the basal infolding of plasmalemma of proximal tubular cells. Some of the mitochondria were swollen and in these mitochondria the outer membrane was not properly visualized. Mean value of the changes in group B was 0.14 ± 0.34 .

Group C: The cells in proximal convoluted tubules showed many degenerative changes. Although the plasma membrane was normal bilaminar; the changes were clearly observable in other cell organelles. Mitochondria were swollen in many of the proximal tubular cells. Inner membrane was indistinct, and the cristae were short. In some of the mitochondria cristae structure was lost and it appeared as if mitochondria are filled with flocculent densities. Mean value of the changes in group C was 0.45 ± 0.78 .

Group D: The tubular lining cells showed significant ultrastructural changes. However the proximal convoluted tubules were more affected. Plasmalemma at the basal surface of the cells was almost normal while the apical surface i.e. the brush border revealed some loss.

There was marked swelling of the mitochondria in many of the proximal convoluted tubular cells. In some of the mitochondria the outer membrane was ruptured, there was loss of the cristae in inner membrane while increased densities inside the matrix were noted (Fig-2).

Mean value of the changes in group D was 0.82 ± 0.98 (Table-1).

Statistically non-significant changes were observed in the mitochondria of cells in PCT in group A animals, while in groups B and C these changes were significant. Statistically highly significant changes were observed in group D ($p < 0.05$).

DISCUSSION

There are numerous reports describing various morphological and biochemical changes that occur in the kidney following administration of diclofenac sodium^{12,13,14,15}. In this report an attempt has been made to study injury to cell organelle specially mitochondria of PCT under the influence of diclofenac sodium. We have tried to correlate the extent of injury with the dose of the drug. The extent of injury with the dose of the drug was also calculated statistically. An attempt has also been made to understand the mechanism of nephrotoxicity.

Rabbits treated with 2 mg/kg diclofenac sodium showed no any remarkable change in the mitochondria of cells in PCT. While those treated with higher doses i.e. 4mg/kg and 6 mg/kg body weight showed mild to severe changes. Nephrotoxicity was statistically significant in rabbits getting the diclofenac sodium 6 mg/kg.

The swelling and rupture of mitochondrial membrane is due to a phenomenon called mitochondrial permeability transition (MPT). In this phenomenon the permeability of mitochondrial membrane is increased to solutes of molecular weight less than 1500 Da. This MPT is formed at the contact sites between the inner and outer mitochondrial membrane. It results in depolarization and there is equilibrium of solutes between cytoplasm and mitochondrial matrix. This ultimately leads to the rupture of mitochondrial membranes.

Many researchers have identified the ability of diclofenac sodium to induce apoptosis and it was found that mitochondria play an important role in this mechanism^{16,17}. At therapeutic dose it causes swelling of mitochondria but as the dose is increased there is rupture of mitochondrial membrane. The changes in this study are comparable with that found by Kretz Romel and Boelsterli¹⁸. They suggested that changes in mitochondria are dose dependent.

The E/M observations are essentially in agreement with those of Hickey EJ¹⁹ also who proved that Diclofenac targets the mitochondria of renal proximal tubules. But he proposes the mechanism in which there is oxidative stress and massive DNA fragmentation.

The present results may have both toxicological and bioenergetic implications. First they show the potential of diclofenac sodium for toxicity in renal PCT mitochondria and secondly this drug is potential inducer of MMPT prevention. In this regard studies are necessary to evaluate the sensitivity to MMPT following diclofenac sodium exposure *in vivo*²⁰.

CONCLUSION

Diclofenac sodium has damaging effect on the mitochondria of PCT cells far before the light microscopic changes. So its use should be restricted only in very painful conditions. Secondly in case of prolong treatment follow up with regular renal function test should be carried out.

REFERENCES

1. Hayat MA. "Principles and techniques of electron microscopy" USA: Cambridge; 2000.p.124-129
2. Purcell P, Henry D, Melville G. Diclofenac hepatitis. *Gut* 1991;32:1381-1385.
3. Aydin G, Gokeimen A, Oncu M, Cieck E, Karahan N, Gokalp O. Histopathological changes in liver and renal tissues induced by different doses of Diclofenac sodium in rats. *Turk J Vet Sci* 2003; (27): 1131-1140.
4. Katzung BG. Basic and clinical pharmacology, 10th ed. Connecticut; Appleton and Lange: 2007.p. 580.
5. Lippincott's illustrated reviews: Pharmacology. 3rd ed. Philadelphia: Lippincott's Williams and Wilkins; 2006.p.503.

6. Wuolijki E, Oikarinen VJ, Ylipaavalniemi P, Hampf G, Tolynen M. Effective postoperative pain control by preoperative injection of diclofenac. *Eur J Clin Pharmacol* 1987;32:249-252.
7. Alijanpour E, et al. Suppository diclofenac instead of intravenous meperidine for postoperative management. *Caspaian J Intern Med* 2012;3(3): 506-507.
8. Clyman RI, Hardy P, Waleh N, Chen YQ, Mauray F, Fouran JC, et al. Cyclooxygenase-2 plays a significant role in regulating the tone of foetal lamb ductus arteriosus. *Am Physiol* 1999;276:R913-R921.
9. Irit K, Roxana C, Bella E, Miriam D. Acute renal failure, associated with non-steroidal anti-inflammatory drugs in healthy children. *Paediatric Nephrol* 2005;20(9):1295-1298.
10. Yinnon AM, Mores JS, Slotki IN. Nephrotic syndrome associated with Diclofenac sodium. *Br Med J (Clin Res Ed)* 1987;295:556.
11. Kusuhara H, Matsuyuki H, Matsuura M, Imayoshi T, Okumoto T, Matsui H. Induction of apoptotic DNA fragmentation by nonsteroidal anti-inflammatory drugs in cultured rat gastric mucosal cells. *Eur J Pharmacol* 1998;360(2-3):273-280.
12. Ng LE, Halliwell B, Wong KP. Nephrotoxic cell death by diclofenac and meloxicam. *Biochemical and biophysical research communications* 2008; (369):873-877.
13. Ng LE, Vincent AS, Halliwell B, Wong KP. Action of Diclofenac on kidney mitochondria and cells. *Biochem Biophys Res Commun* 2006; 348(2):494-500.
14. Dixit MP, Nguyen C, Carson T, Guedes B, Naznin MD, Bell MJ, Wang Y. non-steroidal anti-inflammatory drugs-associated acute interstitial nephritis with granular tubular basement membrane deposits. *Paed Nephrol* 2008; (23):145-148.
15. Meteyer CU, Rideout BA, Gilbert M, Shivaprasad H, Land Oaks JL. pathology and proposed pathophysiology of diclofenac poisoning in free-living and experimentally exposed oriental white-backed vultures (*Gyps bengalensis*). *J Wild Life Disease* 2005;41(4):705-716.
16. Gómez-Lechón MJ, Ponsoda X, O'Connor E, Donato T, Castell JV, Jover R. Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS. *Biochem Pharmacol* 2003;66(11):2155-2167.
17. Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeability transition in Diclofenac-induced hepatocyte injury in rats. *Hepatology* 2002;35:544-551.
18. Kretz-Rommel A, Boelsterli UA. Diclofenac covalent protein binding is dependent on acyl

- glucuronide formation and is inversely related to acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol 1993;120:155-161.
19. Hickey EJ, Raje RR, Reid VE, Gross SM, Ray SD. Diclofenac induced in vivo nephrotoxicity may involve oxidative stress-mediated massive genomic DNA fragmentation and apoptotic cell death. Free Radic Biol Med 2001;31(2):139-152.
20. Uyemura SA, Santos AC, Mingatto FE, Jordani MC, Curti C. Diclofenac sodium and mefenamic acid: Potent inducers of the membrane permeability transition in renal cortex mitochondria. Arch Biochem Biophys 1997; 342(2):231-235.

Address for Corresponding Author:**Prof. Dr. Talat Mirza**

Professor of Pathology

Dow International Medical College (DUHS),

Karachi.

E-Mail: talat.mirza@duhs.edu.pk

Electronic Copy

Efficacy of Platelet Rich Plasma Application in Comparison to Conventional Dressing Therapy in Partial Thickness Burn Wound

1. Ehmer-Al-Ibran 2. Masood Hussain Rao 3. Maria Khan 4. Farrukh Hasan
5. Raaziyah Abdul Khaliq 6. Syeda Zehra

1. Asstt. Prof. of Burns, DUHS, Karachi 2. Principal Research Officer, PMRC Research Centre, DMC, Karachi
3. PG Student, DUHS, Karachi 4. Medical Director, Vice President of South Asian Association of Transfusion
Medicine 5,6. PG Students, DUHS, Karachi

ABSTRACT

Objective: To determine the efficacy of Platelet Rich Plasma application in comparison to conventional dressing therapy in partial thickness burn wound

Study Design: Comparative analytical study

Place and Duration of Study: This study was carried out at Department of Burns, Civil Hospital Karachi from March 2011 to January 2013.

Materials and Methods: A comparative analytical study was conducted to determine the efficacy of Platelet Rich Plasma application in comparison to conventional dressing therapy in partial thickness burn wound at Department of Burns, Civil Hospital Karachi. All the admitted patients of either sex having age between 20-40 years, victims of fire and scald burn, having partial thickness burn with 10-30% of TBSA involved. Patients were divided into two groups on random basis. In group "A", Platelet Rich Plasma (PRP) application was given with three day gap between two applications until full recovery of the wound. While in group "B" conventional dressing therapy was adopted till full recovery of wound.

Results: All 30 patients of group A, selected for PRP application, were recovered maximally within 18 days (6 therapies with a gap of 3 days). Whereas in other 30 cases, of group B selected for conventional dressing therapy, it took minimum 21 days or more for complete recovery. Hence recovery was found slow in conventional dressing therapy as compared to PRP and it is statistically significant at P,0.05.

Conclusion: Platelet-rich plasma application in non-healing deep partial and full thickness burn wound accelerate the wound healing as compared to conventional dressing therapy and is very effective in preparing healthy beds for grafting and provides 100% graft take. Now it is up to the Burns surgeon to select it for rapid results to save time and cost with availability of more beds in Burn Centre.

Key Words: Platelet Rich plasma, Burns, Conventional dressing, wound healing.

INTRODUCTION

Burn injuries occur as a result of fire and hot water or liquid (scald burn). It may lead to extensive damage to skin surface and also its depth, depending on the intensity of heat delivered to the skin and time of contact. As a result of damage to the skin surface, the protective function gets compromised and results in the exposure of the sub-epithelial skin layers. It depends upon the depth of injury which immediately comes in contact with the external environment specially the micro-organisms like bacteria, fungi, yeast, virus etc. that cause infection on the burnt surface, initially confined to the wound surface but as pathological events progress deeper down they may invade the circulation (bacteremia). If not stopped, further progress leads to septicemia, septic shock and finally death of the patient. In order to avoid these complications, early healing of wound and coverage of damaged skin surface in deeper injuries is necessary to decrease the

chances of above mentioned life threatening consequences.

Platelet Rich Plasma has attained a significant importance in facilitating wound healing in many fields of surgery. According to many health workers platelets^{1,2} and natural sources of growth factors^{3,4,5} play a fundamental role in homeostasis and healing as well⁶. They also release chemotactic factors^{7,8} and induce proliferation of fibroblasts and endothelial cells for neo-angiogenesis hence they have a significant effect on minimizing wound infection which is very effective in wound healing⁹ in superficial burn wounds and also equally important in providing early well vascularized healthy granulation tissue for resurfacing deep wounds by grafting.

We have all the studies from abroad and no work has been done in Pakistan so far. After studying the results obtained from work done by Marquez-de-Aracena¹⁰, Kazakook¹¹ and Knighton,¹² etc, we want to apply PRP on burn wounds to get a comparative analysis in partial thickness burn wound.

MATERIALS AND METHODS

This comparative analytical study was carried out from March 2011 to January 2013 at Burns Centre, Civil Hospital, Karachi. We have selected 60 patients suffering from fire and scald burn resulting in partial thickness burn. We excluded electrical, chemical and fire burn of superficial and deep thickness. We have also excluded smokers, diabetics, hypertensive and patients with other cardiac problems and also pregnant women.

We have divided these patients into two groups. Group A was treated by PRP while Group B was treated by conventional dressing therapy.

Platelet concentrate was achieved by extracting platelets from one pint of whole blood. Donor should be healthy, free of communicable blood-borne disease, ABO compatible and should have normal values of complete blood picture on lab test evaluation. Platelet is extracted by CRYOFUGE (centrifuge machine) made by JOVAN (France). The extracted platelets are suspended in 50-100ml plasma in transfusion bag having 3-5 times the concentration as compared to whole blood.

Before each application of PRP in Group A, the patient was shifted to Operation Theater. The wound was carefully examined and if any slough or dead tissue was found that was removed by desloughing or debridement. All procedures are done under strict aseptic conditions. If slough or dead tissue is not found then the wound is washed with NaCl. Before application, the platelet extract received from the blood bank in the transfusion bag is mixed with CaCl₂ which is present in a separate syringe provided by the blood bank. As a result of this mixing, the platelets degranulate and start releasing growth factors. The activated PRP is then applied over the wound surface and within 10 minutes the wound is covered with sterile dressing. It is left for 3 days because the activity of the platelet borne factors is supposed to be maximum during this period. So we plan next application after 3 days.

In Group B, thirty patients were selected for giving treatment with conventional dressing therapy. Dressing is done in Operation Theater under sterile conditions. The wound was examined, and washed with normal saline. The dead and devitalized tissues are removed and non-adhesive dressing is done by 1% silver sulphadiazine and then dressing is done. Initially the dressing change depends upon the soakage, the condition wound and the half life of the topical anti bacterial cream.

These procedures were adopted till the completion of wound healing. During this period, the wound was observed for the presence of infection, time of infection eradication from wound, changes in pain perception,

total time of wound healing and time of hospital stay during treatment.

RESULTS

According to the analysis of the data, we have selected 60 patients suffering from fire and scald burn resulting in partial thickness burn. These patients were divided into two groups through systematic random sampling. Out of these, 29 (48.3%) patients who were suffering with 10-19%, only 5 (17.0%) required debridement, where as in 31 patients with 20-30 % of burn, 22(71.0%) required debridement which was done. Over all 27 (45.0%) patients requiring debridement (Table 1) All 60 patients selected for this study were divided in two equal groups. Group A was selected for PRP application and its effects on wound healing were observed and Group B was treated by conventional dressing therapy. All selected patients had partial thickness burn wounds of fire and scald burns, categorized on the basis of history and clinical examination before application of PRP (Group A) and dressing (Group B).

Table No.1: Patients with % of burn requiring debridement

S. No.	No. of Patients	% of Burn	Debride-ment not done	Debride-ment done	Total
1.	29	10-19	24	5	29
2.	31	20-30	9	22	31
Total:	60		33	27	60

Table No.2: Epithelization time of burn wound and no of PRP applications

No of patients	PRP applications with a 3 day gap	Total no of days of therapy
16	Three (3)	9
9	Four (4)	12
5	Six (6)	18
Total : 30	Maximum 6 therapy	Maximum 18 days for full recovery.

Table No.3: Epithelization of burn wound with conventional dressing method

No. of patients	Duration of dressing
16	21-30 days
11	31-40 days
3	>40 days
Total : 30	

PRP application was given in Group A (30 patients) at a gap of three days between two consecutive applications to achieve maximum effect of PRP which lasts for three days. 16 out of 30 (53.4%) showed epithelization after 3 applications with a 3 day gap in between every application i.e. 9-day therapy. 9 out of 30 (30%)

showed epithelization after 4 applications, 3 days apart i.e. 12 days therapy and 5 out of 30 (16.7%) showed proper epithelization after 6 applications i.e. maximum 18 days required for complete healing. (Table 2).

In conventional dressing method Group II dressing was done by 1% silver sulphadiazine and wound was covered by Gamgee dressing, 16 out of 30 (53.3%) patients took 21-30 days, 11 out of 30 (36.7%) took 31-40 days, 3 out of 30 (10.0%) patients took more than 40 days to show proper epithelization (Table 3)

The results of these two groups were compared to get an idea regarding the efficacy of PRP in rapid wound healing and it was found that Platelet Rich Plasma application in comparison to conventional dressing therapy in partial thickness burn wound which is statistically significant at $P < 0.05$ (Table 4)

Table No.4: Comparison of epithelization of burn wound treated with PRP and with conventional dressing method

No. of days	No. of patients fully recovered with PRP	No. of patients recovered with conventional dressing method
<10	16 (53.3%)	0
11-20	14 (46.7%)	0
21-30	—	16 (53.3%)
31-40	—	11 (36.7%)
>40	—	3 (10.0%)

DISCUSSION

Fire and scald burn are common in burn cases and rapid recovery is the main issue in partial thickness burn wounds. We have designed a study to compare the efficacy of PRP with conventional dressing methods in partial thickness burn wound. Partial thickness burn wound specially in fire and scald burn have an advantage of healing spontaneously nearly within 3 weeks, provided all protocols of sterilization are followed, otherwise if partial thickness burn wound gets infected, the depth of the wound may extend deep down and the partial thickness burn may turn into deep partial thickness wound where the healing takes a longer time and most of the healing occurs by formation of fibrous tissue which ends up in hypertrophic scar, keloid or contracture formation. As far as effect of PRP on burn wound is concerned, few studies are present so far, Marquez-de-Aracena et al (2007)¹⁰ applied PRP on ten Ocular burn patients and got very good results regarding fast and excellent healing. According to him, he got very good corneal healing after application in eye suffering from chemical burn involving the cornea. He also observed minimal post burn scarring after sub-conjunctival injection of PRP.

According to Kazakos K et al (2008)¹¹ it is very effective in partial thickness burn wounds. No study was found on PRP application in Burn patients of higher % of body surface area involvement.

Many workers used it in deep wounds as Ganco et al³ showed faster epithelization of chronic lower extremity ulcers where he found appropriate results. Knighton DR et al¹² also showed successful treatment of non-healing wounds after application of PRP.

In our study, the comparison clearly showed that the conventional dressing method takes twice longer time as in Group B the average healing time was 21 days to >40 days as compared to Group A where the average healing time was 9 days to maximum 18 days which definitely affects the duration of hospital stay.

The other advantage of PRP application in Group A as opposed to Group B is the decrease in pain, rapid control of infection and hence faster epithelization.

A broad majority of workers used PRP on small area of burn wounds so mostly they used autogenous PRP in their studies like Martinez Zapata¹³ was in favor of autogenous PRP, but in our study we had to apply PRP on a larger % of body surface area so it was not possible to use autogenous PRP. Other factors also contributed to make it impossible such as the patients admitted in our hospital belong to very low socio-economic class and their health status is also very low at the time of admission and after admission, G.I. upset due to exposure to micro-organisms, heavy antibiotic therapy, systemic infection, intolerance to food intake, non-availability to food supplements leading to low caloric intake lead to a decreased hemoglobin making it impossible to use autogenous PRP.

The quantity of PRP required for single application for burn wound between 10-30% of body surface area needs 2 pints of blood for extraction of platelets. We have to consult blood bank and use donated blood therefore we cannot avoid chances of allergic reactions so this is a drawback of not using autogenous PRP. But its advantages over conventional dressing such as decrease in duration of healing time, decrease in pain, infection and hospital stay are more convincing for its use in partial thickness burn wounds.

CONCLUSION

According to our study results, Platelet-rich plasma application in non-healing deep partial and full thickness burn wound accelerate the wound healing as compared to conventional dressing therapy and is very effective in preparing healthy beds for grafting and provides 100% graft take. Now it is up to the Burns surgeon to select it for rapid results to save time and cost with availability of more beds in Burn Centre or to use the conventional dressing therapy according to the condition of the patient.

REFERENCES

1. Everts PA, Brown C, Hoffman JJ, Schonberger JP, Box HA, Van Zundert A, et al. Platelet-rich plasma and platelet gel: a review. *J Extra Corpor Technol* 2006;38(2):174-87.

2. Henderson JL, Cupp-CL-Ross EV, Shick PC, Keefe MA, Wester DC, et al. The effects of autologous platelet gel on wound healing. *Ear Nose Throat J* 2003; 82(8): 598-602.
3. Ganio C, Tenewitz FE, Wilson RC, Moyles BG. The treatment of chronic non healing wounds using autologous platelet-derived growth factors. *J Foot Ankle Surg* 1993; 32(3):263-8.
4. Sammartino G, Tia M, Marenzi G, Di Lauro AE, D'Agostino E, Claudio PP. Use of autologous Platelet Rich Plasma (PRP) in periodontal defect treatment after extraction of impacted mandibular third molars. *J Oral Maxillofac Surg* 2005; 63: 766-70.
5. Cervelli V, Gentile P, Grimaldi M. Regenerative surgery: use of fat grafting combined with platelet-rich plasma for chronic lower-extremity ulcers. *Aesthetic Plast Surg* 2009; ISBN/ISSN 1432-5241(Electronic): doi:10.1007/s00266-008-9302-z.
6. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: implications for wound healing. *Plast Reconstr Surg* 2004;114(6): 147e-59e.
7. Pierce G, Mustoe TA, Altrock BW, Deuel TF, Thomason A. Role of platelet-derived growth factor in wound healing. *J Cell Biochem* 1991;45: 319-26.
8. Eppley BL, Pietrzak WS, Blanton M. Platelet-rich plasma: a review of biology and applications in plastic surgery. *Plast Reconstr Surg* 2006; 118(6):147e-59e.
9. Pietrzak WS, Eppley BL. Platelet rich plasma: biology and new technology. *J Craniofac Surg* 2005; 16(6):1043-54.
10. Marquez-de-Aracena R, Montero-de-espinosa I, Munoz M, Pereira G. Subconjunctival application of plasma platelet concentrate in the treatment of ocularburns. Preliminary results. *Arch Soc Esp Oftalmol* 2007; 82(8):475-81
11. Kazakos K, Lyras DN, Verettas D, Tilkeridis K, Tryfonidis M. the use of autologous PRP gel as an aid in the management of acute trauma wounds. *Injury* 2008; ISBN/ISSN 1879-0267 (Electronic); doi:10.1016/j.injury.2008.05.002.
12. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler ET. Classification and treatment with autologous platelet derived wound healing factors (PDWHF). *Ann Surg* 1986; 204(3):322-30
13. Martinez-Zapata MJ, Marti-Carvajal A, Sola I, Bolibar I, Angelo Exposito J, Rodriguez L, et al. Efficacy and safety of the use of autologous plasma rich in platelets for tissue regeneration: a systematic review. *Transfusion* 2009; 49(1):44-56.

Address for Corresponding Author:**Dr. Ehmer-Al-Ibran,**Assistant Professor, Dept. of Burns,
Dow University of Health Sciences,

Civil Hospital, Karachi,

Mobile: 0333-2262820

Email: dr.ehmer@yahoo.com

Electronic Copy

Prediction of Large Esophageal Varices in Patients with Decompensated Cirrhosis by Child-Pugh Score, in Medical Unit-II, Chandka Medical College Hospital, Larkana

1. Muhammad Aslam Soomro 2. Imdad Ali Ansari 3. Ghulam Yasin Abro
4. Sayed Aftab Ahmed Shah 5. Sayed Shafiq Rahman Shah

1. Senior Registrar of Medicine 2. Asstt. Prof. of Medicine 3. Senior Registrar of Medicine 4. Prof. of Medicine
5. Senior Registrar of Medicine, Chandka Medical College & Hospital Larkana.

ABSTRACT

Objective: To assess prediction of large esophageal varices in patients with decompensated cirrhosis by Child-Pugh score, in Medical Unit-II, Chandka Medical College Hospital Larkana.

Study Design: Cross sectional study

Setting and Duration of Study: This study was carried out at Medical Unit II, Chandka Medical College & Hospital, Larkana from November 2011 to November 2012.

Materials and Methods: In this study 88 consecutive cirrhotic patients with ascites (those Patients who fulfilled the inclusion criteria) were included; blood samples for Serum bilirubin, serum albumin, and INR ratio were sent to single laboratory. Then, child Pugh score were assigned to each patient on the basis of clinical and to laboratory parameter. The ultrasound of abdomen was carried out for size of liver and spleen, portal vein diameter, and quantification of ascites. Eligible patients were subjected for upper gastrointestinal endoscopy for the presence of esophageal varices and their grading. The data was analyzed using SPSS version 19.

Results: The mean age of enrolled patients was 43.19 ± 7.1 years. Of 88 patients, 69 (78.4%) were male and 19 (21.6%) were female. Child Pugh class relation to number of patients were; 52, 20, and 16 in class A, B, and C respectively. While Child Pugh class relation to frequency of esophageal varices were; 6, 11 and 14 in class A, B, and C respectively. Frequency of grading of esophageal varices was; 4, 13, and 14 in grade one, two, and three respectively. Distribution of large esophageal varices (LEVX) in relation to child Pugh class is one in class A, two in class B and 11 in class C.

Conclusions: It is concluded from this study that as the child pugh score advances, the number and size of esophageal varices increases, and chance of absence of varices decreases.

Key Words: Esophageal varices, Child Pugh score, Grades of varices

INTRODUCTION

Cirrhosis is an end result of various hepatic diseases resulting to fibrosis with replacement of normal hepatic architecture in to nodular form leading to opening of Porto-systemic shunts. Some patients with cirrhosis are completely asymptomatic and have a reasonably normal life expectancy. Others have symptoms of end-stage liver disease and have a limited chance for survival. Chronic liver disease and cirrhosis result in about 35,000 deaths each year in the United States. Cirrhosis is the ninth leading cause of death in the United States and is responsible for 1.2% of all US deaths. Many patients die from the disease in their fifth or sixth decade of life. Cirrhosis was the 10th leading cause of death for men and the 12th for women in the United States in 2001, killing about 27,000 people each year.¹ 26% of hepatitis B and 15% of hepatitis C leads to liver cirrhosis worldwide.² Many patients of liver cirrhosis ultimately develop complications; amongst them portal hypertension is one of the major complication manifested as esophageal varices.²

The portal vein carries approximately 1500 ml/min of blood from the small and large bowel, spleen, and the stomach to the liver. Obstruction of portal venous flow, whatever the etiology, results in a rise in portal venous pressure. The response to increased venous pressure is the development of a collateral circulation diverting the obstructed blood flow to the systemic veins. These Porto - systemic collaterals form by the opening and dilatation of preexisting vascular channels connecting the portal venous system and the superior and inferior vena cava.

In Western countries, alcoholic and viral cirrhosis are the leading causes of portal hypertension and esophageal varices. Thirty percent of patients with compensated cirrhosis and 60-70% of patients with decompensate cirrhosis have gastro esophageal varices at presentation. The de novo rate of development of esophageal varices in patients with chronic liver diseases is approximately 8% per year for the first 2 years and 30% by the sixth year. The risk of bleeding from esophageal varices is 30% in the first year after identification. Bleeding from esophageal varices

accounts for approximately 10% of episodes of upper GI bleeding.

At least two thirds of cirrhotic patients develop esophageal varices during their lifetime. Severe upper gastrointestinal (UGI) bleeding as a complication of portal hypertension develops in about 30%-40% of cirrhotic,³ the reported mortality from first episode of variceal bleeding in western studies ranges from 17% to 57% as compared to 5-10% mortality reported in our population.⁴

Upper GI endoscopy is gold standard investigation for diagnosis of esophageal varices⁵. But because of various limitations (not available commonly at primary and secondary care centers, lack of experts and cost of procedure), and not all patients of cirrhosis are developing esophageal varices, so it cannot be performed in every patients. Therefore an alternate, easy, less costly, non invasive way to identify the high risk patients for large esophageal varices has to be sorted out. So this study may help us to detect those high risk patients of liver cirrhosis.

MATERIALS AND METHODS

This Cross-sectional study was conducted in medial unit II, Chandka Medical College & Hospital Larkana, over a period of one year, from November 2011 to October 2012.

After the approval from Ethical Review Committee of Chandka medical college hospital Larkana, Patients were selected from medical unit II indoor department those Patients who fulfilled the inclusion criteria (Cirrhotic patients with ascites, aged >12 years, of either sex, without past history of upper and lower GI bleeding) were enrolled in this study. A verbal and written consent was obtained from all the patients after having fully explained the purpose and protocol of the study by researcher.

After taking history and clinical examination, blood samples for Serum bilirubin, serum albumin, and INR ratio were sent to laboratory. Then, on the basis of clinical and lab parameter child Pugh scoring were assigned. The ultrasound of abdomen was carried out for size of liver and spleen, portal vein diameter, and quantification of ascits, by an expert having at least 5 years experience.

Upper gastrointestinal endoscopy of eligible patients was performed after explaining the procedure and getting written consent from patient. After premedication with intravenous injection of 2 mg Midazolam and Xylocaine 1% spray as a topical anesthetic, procedure was done with Fiberoptic Endoscope by expert endoscopist and esophageal varices were graded on the basis of de-Franchis classification, i.e. Grade1 (small size); small straight varices, not occupying the lumen. Grade 2 (medium size); enlarged tortuous varices occupying less than one third of the lumen. Grade 3 (large size) ; large coil-

shaped varices occupying more than one third of the lumen.

Following patients were excluded from our study. Patients who were taking medications for prophylaxis of variceal bleed. Patients who had previously underwent sclerotherapy or band ligation. Patients with hepatocellular carcinoma, previous portosystemic anastomosis or portal vein thrombosis. Patients with medical contraindications to upper gastrointestinal endoscopy like shock, atlanto-axial subluxation, any coagulation disorder or not willing for endoscopy. Patients of age less than 12 years.

Data Analysis: All the data were entered and analyzed using SPSS version 19.0. Frequency and percentages was computed for categorical variables like gender, child Pugh classification and classification of esophageal varices. Mean \pm S.D. was computed for quantitative variables age. Child Pugh scoring was correlated with grading of esophageal varices and their signification was assessed by chi-square test.

RESULTS

In this study 88 patients were enrolled, male were 69 (78.4%) and female were 19 (21.6%), with male to female ratio were 3.6:1. Mean age of enrolled participants was 49 + 15.538.

Out of 88 study population 52 (29.1%) patients were found in Child Pugh class A, 20 (22.7%) in class B, and 16 (18.2%) in class C. Table: 1

Table No.1: Salient Features of Study Population

Gender	Male. 69 (74.41%)	Female. 19 (21.59%)	Male to Female Ratio (3.6:1)
Child Pugh Class (Frequency & Percentage)			
Class A	52 (29.1%)		
Class B	20 (22.7%)		
Class C	16 (18.2%)		
Esophageal Varices (Frequency & Percentage)			
Present	31 (35.2%)		
Absent	57 (64.8%)		
Grading Of Esophageal Varices (Frequency & Percentage)			
Grade 1 (small)	4 (4.5%)		
Grade 2 (medium)	13 (14.8%)		
Grade 3 (large)	14 (15.9%)		

Esophageal varices were present in 31(35.2%) out of 88 study population, Grade one (GI) esophageal varices were found in 4 (12.90%), Grade two (GII) in 13(41.94%) and Grade three (GIII) in 14 (45.16%) patients.

Correlation of Child Pugh class with esophageal varices and their grade shows that, in Child Pugh class

A out of 52 patients; oesophageal varices were present in 6 (11.5%) patients, and out of 6 patients 3(50%) were in grade one, 2 (33.3%) were in grade two, and 1(16.7%) was in grade three. Table: 2

In Child Pugh class B out of 20 patients; 11(55%) had esophageal varices, and out of 11 patients 1(9.1%) had grade one, 8 (72.7%) had grade two, and 2 (18.1%) had grade three esophageal varices. Table: 2

Table No. 2: Child Pugh * Grades of esophageal varices (EV) Cross tabulation

			Grades of Esophageal Varices				Total
			No Varices	Grade 1	Grade 2	Grade 3	
Child Pugh	Class A	Count	46	3	2	1	52
		% within Child Pugh	88.5%	5.8%	3.8%	1.9%	100.0%
		% within Grades	80.7%	75.0%	15.4%	7.1%	59.1%
		% of Total	52.3%	3.4%	2.3%	1.1%	59.1%
	Class B	Count	9	1	8	2	20
		% within Child Pugh	45.0%	5.0%	40.0%	10.0%	100.0%
		% within Grades	15.8%	25.0%	61.5%	14.3%	22.7%
		% of Total	10.2%	1.1%	9.1%	2.3%	22.7%
	Class C	Count	2	0	3	11	16
		% within Child Pugh	12.5%	.0%	18.8%	68.8%	100.0%
		% within Grades	3.5%	.0%	23.1%	78.6%	18.2%
		% of Total	2.3%	.0%	3.4%	12.5%	18.2%
Total		Count	57	4	13	14	88
		% within Child Pugh	64.8%	4.5%	14.8%	15.9%	100.0%
		% within Grades	100.0%	100.0%	100.0%	100.0%	100.0%
		% of Total	64.8%	4.5%	14.8%	15.9%	100.0%

Chi-square = 61.273, df=6, p= < 0.05

While in Child Pugh class C out of 16; esophageal varices were found in 14 patients, among them grade one was not found in any patient, grade two in 3 (21.4%) patients, while grade three in 11(78.6%) patients. Table: 2

It means that; as the child pugh class advances (A to C) the number and size of esophageal varices increases (in Child Pugh class A 50% in grade one, in class B 72% in grade two and in class C 78% in grade three) it was statistically significant (p= < 0.05). Table: 2

DISCUSSION

Cirrhosis is the most advanced form of liver disease and variceal hemorrhage is one of its lethal complications. Over half of the patients with cirrhosis develop varices. The risk of bleeding once varices formed is 20% to 35% within 2 years,⁵ and the reported mortality rate from first episode of variceal bleeding is 17% to 57%, and of those who survive the initial episode of bleeding and who do not receive active treatment, the risk of recurrent bleeding is approximately 66% and usually occurs within 6 months of the initial bleeding episode.^{6,7}

Because cirrhotic patients with large esophageal varices are at a high risk for bleeding, an overt hemorrhage from the gastric mucosa occurred in 60% of patients with severe PHG. It has been documented that empiric beta-blocker therapy for the primary prophylaxis of variceal hemorrhage is a cost-effective measure, and it decreases the incidence of bleeding and an effect on bleeding related mortality. The use of screening

endoscopy to guide therapy adds significant cost with only marginal increase in effectiveness. This added cost to screening endoscopy is presumably due only to the large number of unplanned endoscopies; where the endoscopic findings do not significantly alter the treatment plan, hence identification of non invasive parameters that can accurately predict esophageal varices and help to identifying patients at greatest risk is important to improve the yield and cost- effectiveness of endoscopic screening.⁸

In this study esophageal varices has been related to child-pugh categories, to identify the large esophageal varices, in order to do endoscopy in selective patients and or to start the oral beta blockers in those who are not willing or fit for endoscopy.

In this study esophageal varices observed in 31 (35.2%) patients. Of 31 cases of varices, 12.90% were of Grade I, 41.94% in Grade II and 45.16% in Grade III. While some of local and European studies suggest higher frequencies of esophageal varices observed in cirrhotic patients, like 91.7% by Said HEE et al,⁹ 70% by Gill ML et al,¹⁰ 70.6% by Prihartini J et al,¹¹ 70.7% by Hong WD et al,¹² 76.9% by Stojanov DB et al,¹³ and 80 % by Kaji BC et al.¹⁴

On other hand few studies suggest little bit lower frequencies, 29% by Almani SH et al,¹⁵ 50% by thompoulos KC et al,¹⁶ and two studies show 51% by Carles P et al¹⁷ and Madhotra et al,¹⁸ 55% by schwarzenberger E et al,¹⁹ 58.4% by Sethar GH et al,²⁰ and 61% by Giannini E et al.²¹ In all above studies other non invasive parameters were used for the

detection of esophageal varices. In our study large esophageal varices were present in 45.16 % of cases. In comparison to other studies large oesophageal varices were observed were, 30%¹⁰, 33%,¹⁶ 34%¹⁴ and 46% by Sharma SK et al,²² 50% Barrera F et al,²³ and 65%.¹³ Study by Madhotra,¹⁸ shows distribution of esophageal varices to child pugh category A, 35%; B, 60%; C, 69% and large varices were 29% in category A, 24 % in category B and C, while in our study frequency of large esophageal varices were, 16.66% in class A, 18.18% in class B, and 92.85% in class C, which correlates with study by Said HEE,⁹ they also observed increasing frequency of esophageal varices with advancement of child-pugh class (50% in A, 93.5% in B and 100% in C). In our study frequency and size of esophageal varices is correlated rather than frequency alone.

CONCLUSION

In this study we conclude that as the Child Pugh score advances the frequency of esophageal varices increases especially the large varices. So we recommend that those patients in which upper gastrointestinal endoscopy is not feasible of any reason, and having history of upper gastrointestinal bleeding, with Child Pugh class "C" then beta blocker drugs should be given for prophylaxis if there are no contraindications.

REFERENCES

- Anderson RN, Smith BL. Deaths: leading causes for 2001. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2003;52(9):56-8.
- Groszmann RJ. Hyperdynamic circulation of liver disease 40 years later: pathophysiology and clinical consequences. *Hepatology* 1994;20(5):1559-63.
- Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. *Gastroenterol* 2002;122:1620-30.
- Farooqi RJ, Farooqi JI, Rehman M, Ahmad H, Ahmad F, Gul S. Outcome after injection sclerotherapy for esophageal variceal bleeding in patients with liver cirrhosis and COPD.
- Garcia-Tsao G. Spontaneous bacterial peritonitis. *Gastroenterol Clin North Am* 1992; 21(1):257-75.
- Gines P, Arroyo V, Quintero E. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. *Gastroenterol* 1987;93(2): 234-41.
- Ochs A, Rossle M, Haag K. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. *N Engl J Med* 1995; 332(18):1192-7.
- Garrison RN, Cryer HM, Howard DA. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. *Ann Surg* 1984;199(6):648-55.
- Said HEE, Elsayed EY, Ameen A, Elal HA. Cytopenia as predictor of oesophageal varices in patients with liver cirrhosis. [http://www.sciencepub.net/report/7/7/2010:2\(7\)17-23](http://www.sciencepub.net/report/7/7/2010:2(7)17-23).
- Gill ML, Atiq M, Sattar S, Khokhar N. Non-endoscopic parameters for the identification of esophageal varices in patients with chronic hepatitis. *JPMA* 54:575;2004.
- Prihartini J, Lesmana LA, Manan C, Gani RA. Detection of esophageal varices in liver cirrhosis using non invasive parameters. *Acta Med Indones J Intern Med* 2005; 37;(3):126-131.
- Hong WD, Zhu QH, Huang ZM, Chen XR, Jiang ZC, Xu SH, Jin K. Predictor of esophageal varices in patients with HBV- related cirrhosis: a retrospective study. *BMC Gastroenterol* 2009; 9(11):1-7.
- Stojanov DB, Nagorni A, Bjelakovic G, Milanovic J, Stojanov D. Predictive factors of bleeding from esophageal varices in patients with liver cirrhosis and portal hypertension. *Med and Biol* 2006;13(3): 164-167.
- Kaj BC, Bhavsar YR, Patel N, Garg A, Kevadiya H, Mansuris Z. A Study of Clinical Profile of 50 Patients with Portal Hypertension and to Evaluate Role of Noninvasive Predictor of Esophageal Varices. *Ind J Clin Prac* 2012;22(9):454-457.
- Almani SA, Memon AS, Memon AI, Shah MI, Rahpoto MQ, Solangi R. Cirrhosis of liver: etiological factors, complications and prognosis. *JLUMHS* 2008;61-66.
- Thomopoulos KC, Karatza L, Mimidis KP, Iconomou G, Nikolopoulou VN. Non invasive predictors of the presence of large esophageal varices in patients with cirrhosis. *Digestive Liver Dis* 2003;35(7): 473-8.
- Carles P, Desmorat H, Vinel JP, Caucanas JP, Ravaud A, Gerin P, et al. Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. *Gut* 1990;31:1298-1302.
- Madhotra, Ravi, Mulchy, Hugh E, Wilner I, Ira, Reubn, Adrian. Prediction of esophageal varices in patients of cirrhosis. *J Clin Gastroenterol* 2002; 34(1): 81-85.
- Schwarzenberger E, Meyer T, Golla V, Sadala NP, Min AD. Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. *J Clin Gastroenterol* 2010;44 (2):146- 50.
- Sethar GH, Ahmed R, Rathi SK, Shaikh NA. Platelet count/splenic size ratio: a parameter to predict the presence of esophageal varices in

- cirrhotics. J Coll Physicians Surg Pak 2006;16(3): 183-6.
21. Giannini E, Botta F, Borro P, Malfatti F, Fumagalli A, Testa F, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003;98 (11):2516-20.
22. Sharma SK, Aggarwal R. Prediction of large esophageal varices in patients with cirrhosis of the liver using clinical, laboratory and imaging parameters. J Gastroenterol Hepatol 2007;22 (11): 1909-15.
23. Barrera F, Riguelme A, Soza A, Contreras A, Barrios O, Viviani P, et al. Platelet count/spleen diameter ratio for non-invasive prediction of high risk esophageal varices in cirrhotic patients. Ann Hepatol 2009;8(4):325-30.

Address for Corresponding Author:**Dr. Muhammad Aslam Soomro**Senior Registrar Department of Medicine
Chandka Medical College & Hospital Larkana

E-mail: dr_soomro_aslam@outlook.com

Cell #: 0333-7543724

Electronic Copy

Cognition-Enhancing Effect of Oral Therapeutic Doses of Methylphenidate in Rats

1. Nausheen Alam 2. Rahila Najam

1. Asstt. Prof. of Pharmacology, Faculty of Pharmacy, Federal Urdu University, Karachi
2. Prof. of Pharmacology, Faculty of Pharmacy, University of Karachi.

ABSTRACT

Objective: To determine the effects of oral therapeutic doses of methylphenidate, on memory. It was thought that long term use of methylphenidate possibly may lead to tolerance in the ability of the drug elicit enhancement of learning and memory. A dose-dependent effect may therefore help to extend the therapeutic use of the drug for better clinical response.

Study Design: Experimental / Analytic study

Place and Duration of Study: This study was conducted in the Department of Pharmacology, Faculty of pharmacy, University of Karachi, Karachi for a period of period of 4 weeks.

Materials and Methods: Twenty-four male Albino Wister rats (weighing 180-220g) were randomly assigned to four groups, one control and 3 test groups. The experimental protocol was designed to administer methylphenidate orally two times daily for 4 weeks. Four groups were: (i) Saline (1.0 ml/kg/ day), (ii) Methylphenidate (2mg/kg/day) (iii) Methylphenidate (5mg/kg/day) (iv) Methylphenidate (8mg/kg/day) treated groups. Behavioral activity of rats i.e. performance of rats in passive avoidance test was monitored weekly. The experiment was performed in a balanced design to avoid the order effect.

Results: In the present study methylphenidate treated rats exhibited an increased in Passive Avoidance learning as there was increased in the latency time to reach the punished compartment as compared to control rats. This memory improvement effect of methylphenidate on PA was dose dependent in 1st week as the rats treated with 8 mg/kg/day took greater time to reach the dark box than 5mg/kg/day and 2mg/kg/day, but in 2nd, 3rd and 4th week it was seen that rats treated with fore mention doses took same time but greater than 1st week to enter the punishable compartment

Conclusion: It can be concluded that high dose produce greater cognitive effect in short term treatment than low and moderate doses, however in long-term treatment all the doses produce similar improvement in memory without tolerance in cognition

Key Words: methylphenidate, oral dose, cognition, passive avoidance test.

INTRODUCTION

Cognition enhancement has received much attention in recent scientific literatures due to our aging society and the increasing prevalence of Alzheimer's disease. However, the healthy young population also engages in drug use to enhance memory. Methylphenidate a medication effective to enhance attention^{1,2,3}, and cognition⁴ in ADHD patients, as well as in healthy subjects^{5,6,7,8}. This has raised concern regarding the ethical and safety aspects of potential cognition-enhancing drugs^{9,10,11}. These issues aside, it is important to know if the drug does actually have cognition-enhancing effect after long-term administration.

Methylphenidate blocks the dopamine transporter and the noradrenaline transporter^{12,13,14,15}, thus increasing the extracellular concentrations of these catecholamines. The attention-improving characteristic of methylphenidate has been attributed to the amplification of dopamine release in the central nervous system¹⁶. Dopamine (DA) modulates cognitive performance in part via its regulation of the prefrontal cortex through dopamine D1 and D2 receptors¹⁷. Methylphenidate (MPH) increase DA signaling in the brain and are used in the treatment of attention deficit

hyperactivity disorder (ADHD) and other neuropsychiatric disorders to enhance attention and cognition^{18,19,20,21}.

Purpose of our study was to monitor the effects of oral therapeutic doses of methylphenidate, on memory function in rats. It was thought that long term use of methylphenidate possibly may lead to tolerance in the ability of the drug elicit enhancement of learning and memory. A dose-dependent effect may therefore help to extend the therapeutic use of the drug for better clinical response.

MATERIALS AND METHODS

2.1 Test systems used (Animals):

Locally bred Albino Wister rats (weighing 180-200g) were housed individually under 12 h light and dark cycles (light on at 06:00h) and controlled room temperature (24±2°C) with free access to tap water and cubes of standard rodent diet at least 7 days before the start of experiment so that they could become familiar to the environment. They were accustomed to various handling procedures to nullify stress effects. All experiments were performed according to the protocols approved by the local animal care committee.

2.2 Behavioral assessment

Passive Avoidance Test: Passive avoidance paradigm consists of two compartments as an illuminated 'safe' and a dark 'punishable' one. Both compartments were connected with a door that enable free crossing from one compartment to another. Both compartments had a grid floor. The diameter of rods was 5 mm with 0.5 cm distance between the rods.

In the training session, rat was placed in an illuminated box. Once the rats prompted by their instinct stepped its four paws into the dark compartment, rats received 1.5 mA foot shock through the grid floor to its paws for 5 seconds. After receiving the foot shock, it immediately came back to illuminated safe compartment. During the test period (24 hour later), rats were placed in the bright compartment again for a maximum of 5 minutes. The step-through latency that indicates the time elapsed before the rat entered the dark compartment was recorded in the test session as described earlier [22]. Passive avoidance test of all drug treated and control animals were performed weekly in a balance design to avoid order effect.

2.3. Drugs: Methylphenidate HCl was obtained from local medical store and prepared in 0.9% NaCl (saline). Drug was administered in a volume of 1 ml/kg of body weight by per oral route twice a day to the treated animals and control animals were treated with saline (0.9%) at the dose of 1 ml/kg per oral twice a day.

2.4. Experimental protocol: Twenty-four male Albino Wister rats (weighing 180-220g) were randomly assigned to four groups, one control and 3 test groups each containing six animals. The experimental protocol was designed to administer methylphenidate orally two times daily for 4 weeks.

Four groups were: (i) Saline (1.0 ml/kg/day), (ii) Methylphenidate (2mg/kg/day) (iii) Methylphenidate (5mg/kg/day) (iv) Methylphenidate (8mg/kg/day) treated groups.

Behavioral activity of rats i.e. performance of rats in passive avoidance test was monitored weekly. The experiment was performed in a balanced design to avoid the order effect.

2.5. Statistical analysis: Results are represented as mean \pm S.D. Statistical analysis of passive avoidance test was performed by two-way analysis of variance (ANOVA) repeated measure design. Post hoc comparison of groups was performed by Newman-Keul test. Values of $p < 0.05$ and $p < 0.01$ were considered as significant.

RESULTS

Dose related effect of methylphenidate on performance of rats in passive avoidance test.

Fig. shows the effects of methylphenidate doses on the performance of rats in PA test. Two-way ANOVA repeated measure revealed a significant dose ($F=200.4$, $df=3,20$, $P < 0.01$), week ($F=32.9$, $df=3,20$, $P < 0.01$)

effect and also a significant interaction between the two factors ($F=10.97$, $df=9,60$, $P < 0.01$).

Post hoc comparison by Newman-keuls test showed that retention of Passive Avoidance was improved in test rats than in controls as low dose (2 mg/kg/day), moderate dose (5 mg/kg/day) and high dose (8mg/kg/day) of methylphenidate significantly ($P < 0.01$) increased latency time in all 4 weeks compared to similar week saline treated rats and in 2nd, 3rd and 4th week from 1st week values.




Figure No. 1: Passive Avoidance

DISCUSSION

Methylphenidate has been shown to potentiate the cognitive effect and is the main medication prescribed for attention deficit hyperactivity disorder²³ to improve memory²⁴ attention and concentration^{25,26,27}, yet there is increasing evidence that they do not promote learning²⁷, which can be due to tolerance to the cognitive effect of the drug.

In the current study we chose passive avoidance test to measure effects in memory function following methylphenidate administration at three different doses. Study showed methylphenidate treated rats exhibited an increased in Passive Avoidance learning as there was increased in the latency time to reach the punished compartment as compared to control rats. This memory improvement effect of methylphenidate on PA was dose dependent in 1st week as the rats treated with 8 mg/kg/day took greater time to reach the dark box than 5mg/kg/day dose and the rats treated with 5mg/kg/day day took greater time to reach the dark box than 2mg/kg/day dose, but in 2nd, 3rd and 4th week it was seen that rats treated with fore mention doses took same time to enter the dark punishable compartment which showed that high dose produce greater cognitive effect in short term treatment however in long-term treatment all the doses produce similar cognitive effect.

Central dopaminergic systems play a critical role in the regulation cognitive behavior. Memory improvement effect of methylphenidate in the present study is due to increased DA levels as there is an overwhelming evidence for a critical role of dopamine in

cognition^{28,29}. Cognitive symptoms have been associated with dopamine dysregulation in numerous diseases including schizophrenia³⁰, depression³¹, drug addiction³² and Parkinson disease³³. Support for a role of dopamine in cognition also comes from studies of dopaminergic drug in normal subject³⁴

Methylphenidate blocks the dopamine transporter^{12,13,14,15} thus increasing the extracellular concentrations of these dopamine. The memory improvement effect of methylphenidate has been attributed to the amplification of dopamine release in the central nervous system¹⁶. Dopamine (DA) modulates cognitive performance in part via its regulation of the prefrontal cortex through dopamine D1 and D2 receptors¹⁷. Methylphenidate (MPH) increases DA signaling in the brain and is used in the treatment of attention deficit hyperactivity disorder (ADHD) and other neuropsychiatric disorders to enhance attention and cognition^{18,19,20,21}

CONCLUSION

In summary this study provides the documentation of significant relationship between oral therapeutic doses of methylphenidate and cognition. Our results suggest that initially cognitive enhancing effect is dose dependent, but later on cognitive improvement response in low, moderate and high doses of methylphenidate became similar after long term use.

REFERENCES

1. Solanto MV, Wender EH, Bartell SS. Effects of methylphenidate and behavioral contingencies on sustained attention in attention-deficit hyperactivity disorder: a test of the reward dysfunction hypothesis. *J Child Adolesc Psychopharmacol* 1997;7:123–136.
2. Hawk LW, Jr, Yartz AR, Pelham WE, Lock TM. The effects of methylphenidate on prepulse inhibition during attended and ignored prestimuli among boys with attention-deficit hyperactivity disorder. *Psychopharmacol* 2003;165:118–127.
3. Overtom CCE, Verbaten MN, Kemner C, Kenemans JL, Van Engeland H, Buitelaar JK, et al. Effects of methylphenidate, desipramine, and l-dopa on attention and inhibition in children with attention deficit hyperactivity disorder. *Behav Brain Res* 2003;145:7–15.
4. Mehta MA, Goodyer IM, Sahakian BJ. Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity. *J Child Psychol Psychiatr* 2004;45:293–305.
5. Elliott R, Sahakian BJ, Matthews K, Bannerjea A, Rimmer J, Robbins TW. Effects of methylphenidate on spatial working memory and planning in healthy young adults. *Psychopharmacol* 1997;131:196–206.
6. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. *J Neurosci* 2000;20:RC65.
7. Pietras CJ, Cherek DR, Lane SD, Tcheremissine OV, Steinberg JL. Effects of methylphenidate on impulsive choice in adult humans. *Psychopharmacol* 2003;170:390–398.
8. Volkow ND, Wang G-J, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. *Am J Psychiatr* 2004;161:1173–1180.
9. Greely H, Sahakian B, Harris J. Towards responsible use of cognitive-enhancing drugs by the healthy. *Nature* 2008;11:702–705.
10. Larriviere D, Williams MA, Rizzo M, et al. Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee. *Neurol* 2009;73(17):1406–1412.
11. Sahakian B, Morein-Zamir S. Professor's little helper. *Nature* 2007;450(7173):1157–1159.
12. Ferris RM, Tang FLM. Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypradol on the uptake of *l*-[³H]norepinephrine and [³H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. *J Pharmacol Exp Ther* 1979;210:422–428.
13. Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. *Science* 1987;237:1219–1223.
14. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. *Pharmacol Biochem Behav* 2001;68:611–627.
15. Barrett SP, Darredeau C, Bordy LE, Pihl RO. Characteristics of methylphenidate misuse in a university student sample. *Can J Psychiatr* 2005;50:457–461.
16. Volkow ND, Wang G-J, Fowler JS, Logan J, Jayne M, Franceschi D, et al. Nonhedonic food motivation in humans involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. *Synapse* 2002;44:175–180.
17. Goldman-Rakic P. The cortical dopamine system: role in memory and cognition. *Adv Pharmacol* 1998;42:707–711.
18. Ackerman P, Dykman R, Holcomb P, McCray D. Methylphenidate effects on cognitive style and reaction time in four groups of children. *Psychiat Res* 1982;7:199–213.

19. Camp-Bruno J, Herting R. Cognitive effects of milacemide and methylphenidate in healthy young adults. *Psychopharmacol (Berl)* 1994;115:46–52.
20. Clatworthy P, Lewis S, Brichard L, Hong Y, Izquierdo D, Clark L, et al. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. *J Neurosci* 2009; 29:4690–4696.
21. Izquierdo I, Bevilaqua L, Rossato J, Lima R, Medina J, Cammarota M. Age-dependent and age-independent human memory persistence is enhanced by delayed posttraining methylphenidate administration. *Proc Natl Acad Sci USA* 2008; 105:19504–19507.
22. Khaliq S, Haider S, Ahmed SP, Perveen T, Haleem DJ. Relationship of brain tryptophan and serotonin in improving cognitive performance in rats. *Pak J Pharm Sci* 2006;19(1):11-5.
23. Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. *Biological Psychiatry* 2005; 57(5):456-463.
24. Gonzalez-Garrido AA, Barrios FA, de la Serna-Tuya JM, Cocula-León H, Gómez-Velázquez FR: (Methylphenidate and short-term memory in young females with attention deficit hyperactivity disorder. A study using functional magnetic resonance imaging). *Rev Neurol* 2009;48(10): 509-14.
25. Pietrzak RH, Mollica CM, Maruff P and Snyder PJ. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. *Neuroscience & Biobehavioral Reviews* 2006;30(8):1225-1245.
26. Bedard AC, Jain U, Hogg-Johnson S and Tannock R. Effects of methylphenidate on working memory components: influence of measurement. *J Child Psychol and Psychiatr* 2007;48:872–880.
27. Advokat CD, Guidry D, Martino L. Licit and Illicit Use of Medications for Attention-Deficit Hyperactivity Disorder in Undergraduate College Students. *J Am Coll Health* 2008;56(6):601-606.
28. Wilkerson A, Levin ED. Ventral hippocampal dopamine D1 and D2 systems and spatial working memory in rats. *Neuroscience* 1999;89(3):743-9.
29. Liao RM, Lai WS, Lin JY. The role of catecholamines in retention performance of a partially baited radial eight arm maze for rats. *Chin J Physiol* 2002;45(4): 177-85.
30. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. *J Psychopharmacol* 1997;11:123-131.
31. Jimerson DC. Role of dopamine mechanisms in affective disorders. *Psychopharmacol* 1987; 505-511.
32. Wise RA. Neurobiology of addiction. *Curr Opin Neurobiol* 1996;6:243-251.
33. Gotham AM, Brown RG, Marsden CP. Frontal cognitive function in patients with Parkinsons disease on and off levodopa. *Brain* 1988;111: 299-321.
34. Luciana M, Collins PF, Depue RA. Opposing role of dopamine and serotonin in the modulation of human spatial working memory functions. *Cereb Cortex* 1998;8:218-226.

Address for Corresponding Author:

Dr. Nausheen Alam,
Asstt. Prof. of Pharmacology,
Faculty of Pharmacy,
Federal Urdu University, Karachi

EPI Status under One Year

Children and their Mothers attending Paediatric Department Sheikh Zayed Medical College & Hospital, Rahim Yar Khan

1. Jamal Anwer 2. M.I.Babar 3. Kifayat Niazi 4. Zahid Mahmood

1. Asstt. Prof. of Paediatrics 2. Asstt. Prof. of Paediatrics 3 & 4. PG Students of Paediatrics, Sheikh Zayed Medical College & Hospital, Rahim Yar Khan

ABSTRACT

Objective: To determine the EPI status in children <1 year of age and the status of Tetanus immunization in their mothers attending paediatric department. This will help us to determine the facts and figures in our population and to construct a plan to improve the vaccination status.

Study Design: Cross-sectional analytical study

Place and Duration of Study: This study was conducted at the Department of Paediatrics, Sheikh Zayed Medical College & Hospital, Rahim Yar Khan from April 2011 to July 2011.

Materials and Methods: In the study 492 consecutive children whether admitted in the ward or visited in Paediatric OPD and their mothers were inquired about EPI status in the child and the status of Tetanus immunization in their mothers, strictly following the inclusion and exclusion criteria.

Results: Out of 492 patients, we have found three groups. Group 1 includes those children who were unvaccinated. Group 2 includes those children who were incompletely vaccinated. Group 3 include those who were completely vaccinated according to EPI schedule. Similarly three groups were found in mothers. Group 1 includes those who were unvaccinated. Group 2 includes incompletely vaccinated ladies. Group 3 include those who were completely vaccinated according to EPI schedule.

Conclusion: In our study, we found that EPI status is very poor in our low socioeconomic and illiterate population. Those people living in peripheries and remote areas are particularly not properly following the EPI programme.

Key Words: EPI (Expanded Program on Immunization), Immunization, Vaccines, Tetanus, Tetanus Toxoid(TT)

INTRODUCTION

The Expanded Program on Immunization is a World Health Organization program with the goal to make vaccines available to all children throughout the world.

For evaluation community-based surveys are applied using a modified cluster sampling survey method developed by the World Health Organization. Vaccine coverage is evaluated using a two-stage sampling approach in which 30 clusters and seven children within each cluster are selected. Health care workers with no or limited background in statistics and sampling are able to carry out data collection with minimal training¹. Such a survey implementation provides a way to get information from areas where there is no reliable data source. It is also used to validate reported vaccine coverage (for example, from administrative reports) and is expected to estimate vaccine coverage within 10 percent. Surveys or questionnaires, though frequently considered inaccurate due to self-reporting, can provide more detailed information than administrative reports alone². A survey in Thailand has found effective expanded programme of immunization³.

Expanded Programme on Immunization (EPI) in Pakistan: The Expanded Programme on Immunization

(EPI) was launched in Pakistan in 1976 by WHO and UNICEF to protect children by immunizing them against childhood tuberculosis, poliomyelitis, diphtheria, pertussis, tetanus and measles.

The programme also vaccinates pregnant women with tetanus toxoid vaccine to protect the new born from neonatal tetanus. With support from the Government of Pakistan and development partners, the programme has added hepatitis B (Hep B) and Hemophiles influenza type B (Hib) vaccinations to its childhood immunization schedule. In 2002, the programme introduced hepatitis B vaccine with support from the Global Alliance for Vaccine and Immunization (now called GAVI). In 2006, a tetravalent combination vaccine was introduced replacing separate diphtheria, tetanus and pertussis and hepatitis B vaccines. This was later switched in 2008 to the pentavalent (DPT, Hep B, Hib) vaccine with the addition of the new Hib vaccine. Now a child needs only five visits during the first year and one visit during the second year of his/her life to complete the vaccination with four antigens against eight dreadful diseases.

Programme Development: From mid 2012 pneumococcal conjugate vaccine was added in immunization programme. This new vaccine will protect children from pneumonia and meningitis due to

pneumococcal infection. The programme also plans to introduce Rota virus vaccine, which will prevent diarrhea due to rotavirus. The new vaccines may together avert 17% of childhood mortality in Pakistan and thus help in achieving Millennium Development Goal 4 on reducing child mortality.

Safer Demmunization: The programme has adopted new technology to make immunization safer and more clients compliant. Since 2002, to prevent the risk of blood borne diseases, the programme has been using auto-disable syringes for all immunization injections and safety boxes for proper disposal of sharps waste⁴.

Programme objectives: The aim is to reduce mortality and morbidity resulting from the eight EPI target diseases by immunizing children aged from 0 to 11 months and pregnant women.

The specific objectives of the programme are interruption of polio virus by 2012, elimination of neonatal tetanus by 2015, elimination of measles by 2015, reduction of diphtheria, pertussis and childhood tuberculosis to a minimum level so that they do become a public health problem, control of other diseases by introducing new vaccines in EPI as and when they become available, using EPI as a spearhead for promoting other primary health care activities, integrating EPI into primary health care.

Current situation: Despite significant efforts by the government and its partners, Pakistan's immunization indicators have yet to reach the expected benchmarks. The key goals of polio eradication, and measles and neo-natal tetanus elimination, have not been achieved. People coming from remote areas have poor knowledge and facilities of vaccination^{5,6}. A study published by Furqan Kurshid found poor vaccination coverage of mothers during pregnancy with tetanus toxoid and infant after birth⁷.

Routine vaccination coverage is still suboptimal for achieving the desired goals. Poor routine coverage is also evidenced by the occurrence of numerous outbreaks of measles, pertussis and diphtheria in different parts of the country. A study conducted by Shaikh S. "Immunization status and reasons for low vaccination in children, attending O.P.D. at Liaquat University Hospital" found poor knowledge of vaccination in community⁸.

MATERIALS AND METHODS

We have included the children who were below one year age. Data collected by taking interview from mothers, whether the child was admitted in Pediatric unit due to some illness or visited paediatric OPD. The Performa was filled strictly following the rules. Their mothers were asked about the EPI status of the child i.e.; BCG, polio, pentavalent (DPT, HiB, Hep B) and measles 1. Child's mother was interviewed by using a structured pre-tested questionnaire, regarding the EPI coverage of her child, her own T.T. coverage and other

demographic and potential risk factors for low vaccination coverage. EPI cards were checked where ever available and if not, the subjects were inquired verbally and BCG scars were checked. We gathered information on characteristics such as basic demographics, socio-economic status, reproductive history, health services utilization, immunization coverage of mother and child and reasons for non-compliance with the EPI schedule.

The children who were below one year of age admitted in Pediatric unit due to some illness or visited paediatric OPD and their mothers were included in the study.

The children above one year of age were excluded from the study.

EPI Schedule For Children

Age	Injection or Drops
Immediate after birth	BCG , Polio (birth)
6 weeks	OPV-1, Pentavalent – Pneumococcal – 1
10 weeks	OPV-2, Pentavalent – Pneumococcal – 2
14 weeks	OPV-3, Pentavalent – Pneumococcal – 3
9 months	Measles – 1
15 months	Measles – 2

Tetanus Vaccination Schedule for Pregnant Women

Sr. No.	Schedule	Vaccination
1	During Pregnancy	TT-1
2	After one month of 1 st dose of vaccination	TT-2
3	After six month of 2 nd dose of vaccination	TT-3
4	After one year of 3 rd dose of vaccination	TT-4
5	After one year of 4 th dose of vaccination	TT-5

RESULTS

492 children of age less than one year, who were admitted in pediatric unit due to some ailment or visited Paediatric OPD and their mothers, were interviewed. The mean age of the infants was 5.4 +_3.5 months. We have found three groups. Group 1 includes those children who were unvaccinated. Group 2 includes those children who were incompletely vaccinated. Group 3 include those who were completely vaccinated according to EPI schedule.

Group 1 Unvaccinated : 92(18.69%)
 Group 2 Incompletely vaccinated : 177(35.97%)
 Group 3 Completely vaccinated : 223(45.32%)

Out of 492, twenty one percent had received no vaccination. Sixty two percent of mothers had received one to four doses of T.T. Seventeen percent had

received full vaccination coverage. When inquired about the total number of T.T doses received in lifetime by the mothers, we learnt that there were 102 women who had received just one dose. The rest of the women 203 had received 2-4 doses of TT.

- Group 1 Unvaccinated : 103(21%)
- Group 2 One to four doses of T.T : 305(62%)
- Group 3 Completely vaccinated : 84(17%)

Table No.1: Demographic information of the families surveyed to determine EPI coverage

Sr. No.	Characteristic	Number of subjects (%)
1.	Fathers education	
i.	Primary	226 (46%)
ii.	Matric	147 (30%)
iii.	Inter and above	119 (24%)
2.	Mother education	
i.	Primary	290 (59%)
ii.	Matric	118 (24%)
iii.	Inter and above	84 (17%)
3.	Knowledge about vaccination	
i.	Poor	259 (53%)
ii.	Good	233 (47%)
4.	Fathers' occupation	
i.	Unskilled labor	93 (19%)
ii.	Government service	9 (1.82%)
iii.	Private service	206 (42%)
iv.	Business	73 (15%)
v.	Skilled labor	14 (3%)
vi.	Unemployed	0
vii.	Farming	44 (9%)
viii.	Landlord	19 (4%)
5.	Fathers' ethnicity	
i.	Punjabi	139(28%)
ii.	Saraiki	202(41%)
iii.	Urdu speakers	71(14%)
iv.	Balochi	32(7%)
v.	Sindhi	29(6%)
vi.	Pathan	10(2%)
vii.	Others	10(2%)
6.	Mothers' occupation	
i.	Housewives	330(67%)
ii.	Skilled labor	133(27%)
iii.	Government service	29(6%)




Figure No.1: Vaccination of children below one year




Figure No.2: Vaccination of mothers

DISCUSSION

The age-appropriate vaccination coverage for infants in our study was 54.6%. A study conducted in peri-urban Karachi To determine the age-appropriate EPI coverage of under one year old children and Tetanus Toxoid (TT) coverage of their mothers determined that 44.8% coverage⁹. In another study in Chicago, USA, among inner city pre-school children reported coverage of 47% but in this study, the age of the children was between 19 to 35 months. Another study conducted in Gondar, Ethiopia among 12-24 months old children reported 47.4% as fully immunized¹⁰. A baseline study done in four regions of Pakistan showed EPI coverage of 48%. In another study in the North West Frontier Province (NWFP) of Pakistan, 65% of children were fully immunized by three years of age¹¹. However a cross-sectional study conducted in Peshawar/Abottabad found poor vaccination coverage in women in reproductive age^{12,13}. Fasih et al reported EPI coverage of 26.5% by age 2 years in Karachi, Pakistan¹⁴. Enhancing the vaccination provision may increase the coverage¹⁵ Nisar N and colleges found poor knowledge and attitude of women regarding vaccination¹⁶. In our study, despite using relatively strict criteria by enrolling less than one year old children comparable or better coverage has been found

CONCLUSION

We concluded that proper knowledge of vaccination is very important. For this education of both parents plays a significant role in child's immunization coverage. Mothers' TT coverage status was significantly related with child's EPI coverage status, which reflects the health seeking behavior of a more conscious mother making good health choices for herself as well as for her child.

REFERENCES

- Henderson RH, Keja J. Global control of vaccine-preventable diseases: How progress can be evaluated. Rev Infect Dis 1989; 11: 649-54
- Vellinga A, Depoorter A, Van Damme P. Vaccination coverage estimates by EPI cluster

- sampling survey of children (18-24months) in Flanders, Belgium. *Acta Paediatr* 2002;91: 599-603.
3. Bhunbhu T. Expanded Programme on Immunization in Thailand. *Rev Infect Dis* 1989; 11:514-7.
 4. Tarin E, Khalil M, Mustafa T, Alvi ZM, Sy ITS, Thomson SJ, et al. Impact of community based intervention on immunization coverage against vaccine preventable diseases in Pakistan. *Pakistan J Health* 1999;36:53-6.
 5. Anjum Q, Omair A, Inam SNB, Ahmad Y, Usman Y, Shaikh S. Improving Vaccination Status of children under five through Health Education. *J Pak Mod Assoc* 2004;54:610-13.
 6. Rahman M, Islam MA, Mahalanabis D. Mothers' knowledge about vaccine preventable diseases and immunization coverage in a population with a high rate of illiteracy. *J Trop Pediatr* 1995; 41: 376-8.
 7. Hashmi FK, Islam M, et al. Vaccination coverage of mothers during pregnancy with tetanus toxoid and infant after birth. *Pak J Pharm* 2011;24(2): 35-39.
 8. Shaikh S. Immunization status and reasons for low vaccination in children, attending O.P.D. at Liaquat University Hospital. *Pak Ped J* 2003; 27: 81-6.
 9. Siddiqi N, Khan A, Nisar N. Assessment of EPI (Expanded program of immunization) vaccine coverage in a peri-urban area. *JPMA* 2007; 57: 391.
 10. Gedlu E, Tesemma T. Immunization coverage and identification of problems associated with vaccination delivery in Gondar, northwest Ethiopia. *East Afr Mod J* 1997; 74:239-41.
 11. Ahmad N, Akhtar T, Roghani MT, Byas HM, Abroad M. Immunization coverage in three districts of North West Frontier Province (NWFP). *J Pak Mod Assoc* 1999;49: 301-5.
 12. Afridi NY, Hatcher J, Mahmud S, Nanan D. Coverage and factors associated with tetanus toxoid vaccination status among females of reproductive age in Peshawar. *J Coll Physicians Surg Pak* 2005;15: 391-5.
 13. Naeem, Khan ZI, et al. Coverage and factors associated with Tetanus toxoid Vaccination among married women of reproductive age. A cross sectional study in Peshawar *J Ayub Med Coll Abbotabad* 2010;22(3).
 14. Fasih Z, Hussain E, Ali Z. Risk Factors for complete un-immunization & under immunization of children under 2 years of age in third world countries. *J Pak Pediatr Assoc* 2000; 24:145-52.
 15. Mansuri FA, Baig LA. Assessment of immunization services in perspective of both the recipients and the providers: A reflection from focus group discussions. *J Ayub Med Coll Abbotabad* 2003; 15:14-8.
 16. Nisar N, Mirza M, Qadri MH. Knowledge, Attitude, and practices of mothers regarding immunization of one year old child at Mawatch Goth, Kemari Town Karachi *Pak J Med Sci* 2010;26(1):103-6.

Address for Corresponding Author:**Dr. Jamal Anwer,**

Asstt. Prof. of Paediatrics,

Sheikh Zayed Medical College & Hospital,

Rahim Yar khan

Functional Outcome of Cemented Versus Uncemented Hemiarthroplasty for Intracapsular Hip Fractures

1. Manqoosh ur Rehman 2. Muhammad Imran 3. Tanveer Ahmad Kang

1, 2 & 3. Asst. Profs. of Orthopaedics, Multan Medical & Dental College,
Ibn e Siena Hospital & Research Institute Multan

ABSTRACT

Objectives: To determine the functional outcome of cemented versus uncemented hemiarthroplasty in displaced intracapsular fractures of the hip.

Study Design: Randomized control trial.

Place and Duration of Study: This study was carried out at the Orthopaedics Department, Shaikh Zayed Hospital Lahore and Ibn e Siena Hospital & Research Institute Multan from August 2010 to August 2013.

Materials and Methods: 110 patients with hip fractures fulfilling the criteria were included, 55 patients in each group were randomized. Patients in group A were having cemented hemiarthroplasty and in group B were having uncemented hemiarthroplasty respectively. After surgery all patients were mobilized as soon as they were able. All patients were reviewed at 12 weeks follow up using a pain scale of one to six and a mobility scale of zero to nine.

Results: In group A, the preoperative mean pain score was 5.91 ± 0.29 and postoperative mean residual pain score at 12 weeks was 2.73 ± 0.45 . In group B, the preoperative mean pain score was 5.91 ± 0.29 and postoperative mean residual pain score at 12 weeks was 3.00 ± 0.64 . P value of 0.000 was significant in the favor of cemented hemiarthroplasty.

In group A, the preoperative (before fracture) mean mobility score was 7.20 ± 0.75 and postoperative mean reduction in mobility score at 12 weeks was 2.80 ± 0.76 . In group B, the preoperative (before fracture) mean mobility score was 7.20 ± 0.75 and postoperative mean reduction in mobility score at 12 weeks was 3.20 ± 0.76 . P value of 0.000 was significant in the favor of cemented hemiarthroplasty.

Conclusion: The use of cemented hemiarthroplasty lead to less pain in the hip and improved return of mobility as compared to an uncemented prosthesis.

Key Words: Hip Fractures, Hip Prosthesis, Femoral Neck Fractures

INTRODUCTION

Hip fractures are relatively common injuries in elderly people. The incidence of hip fractures is increasing as the general life expectancy of the population has increased significantly during the past few decades. More than 280,000 hip fractures occur in the United States every year and this incidence is expected to double by 2050.¹ These fractures are associated with substantial morbidity and mortality.²

These fractures in elderly individuals occur mostly due to moderate or minimal trauma.^{3,4} The goal of treating hip fractures is to return patients to their pre-fracture levels of function without long-term disability. The advantages of prosthetic replacement allow immediate weight bearing to return elderly patients to the activity and help avoid complications of recumbency and inactivity.^{5,6}

Displaced intracapsular hip fractures in elderly individuals are commonly treated by hemiarthroplasty. The two most common types of hemiarthroplasty used for treatment of a displaced intracapsular hip fracture are the uncemented Austin-Moore hemiarthroplasty and the cemented Thompson hemiarthroplasty. It is thought that cementing the prosthesis provide more secure

fixation and may result in less residual pain and better functions.⁷

Most of the time uncemented hemiarthroplasty is preferred in our setup but it has been found in limited international literature that cemented hemiarthroplasty with Thompson prosthesis led to less pain, improved mobility and reduced hospital stay compared to an uncemented hemiarthroplasty with Austin-Moore prosthesis with no increase in mortality related to use of cement.^{8,9,10,11,12}



Austin Moore and Thompson Prosthesis

The continued use of a mixture of uncemented and cemented prosthesis reflects uncertainty as to the relative advantages and disadvantages of using bone cement.^{13,14} Keeping in view the limited evidence of improved functional outcome with cemented over uncemented prosthesis in worldwide literature, and limited or perhaps no study regarding this have been found in our setup, we have decided to conduct study on functional outcome of cemented versus uncemented hemiarthroplasty for intracapsular hip fractures.

MATERIALS AND METHODS

We undertook a randomized controlled trial of 110 patients with a displaced intracapsular fracture of the hip to determine the functional outcome of cemented versus uncemented hemiarthroplasty. The study was carried out at the Orthopaedics Department, Shaikh Zayed Hospital Lahore and Ibn e Siena Hospital & Research Institute Multan. The duration of study was 3 year from August 2010 to August 2013.

After approval from the hospital ethical committee, 110 patients with hip fractures fulfilling the criteria admitting through outpatient and emergency department were included. Written informed consent, demographic information, history and examination were taken. 55 patients in each group were randomized by the opening of a sealed opaque numbered envelope, prepared by a person independent of the study, containing detail of the procedure to be undertaken. Patients in group A were having cemented hemiarthroplasty and in group B will be having uncemented hemiarthroplasty respectively. All operations were performed or supervised by the same orthopaedic surgeon and by a standard lateral approach. Same Brand of Austin Moore and Thompson prosthesis with cement was used in all patients. Standard techniques were used for cement when femur has been prepared by reaming and saline irrigation. All patients received perioperative antibiotic prophylaxis and 14 days of low molecular weight heparin as thrombo-embolic prophylaxis. After surgery all patients were mobilized as soon as they were able, with no restriction on hip movements or weight bearing.

All patients were reviewed at four, eight and twelve weeks in outpatient department after the surgery. For the follow up assessment, pain was assessed using a pain scale of one to six. All patients' pre and postoperative mobility was assessed using a mobility scale of zero to nine. All assessments were recorded on especially designed proforma.

Inclusion Criteria:

1. Displaced intracapsular hip fracture (Garden type III and IV)
2. Patient age > 60
3. Both genders

Exclusion Criteria:

1. Patients with pathological hip fractures

2. Previous treatment to same hip for a fracture
3. Patient with significant arthritis of the hip assessed radiologically

All the collected information were entered into SPSS version 17 for the analysis of data. The quantitative variables like age, residual pain score and mobility score were presented as mean and standard deviation. The qualitative variables like gender were presented as frequency and percentage. Mobility score was calculated preoperatively (i-e before fracture) and at 12 weeks post-operatively to calculate mean reduction in mobility score.

Pain Scale (1 – 6)

No pain	1
Occasional and slight pain	2
Pain when starting walking but getting better with occasional analgesia	3
No pain at rest, pain with activities, frequent mild analgesia	4
Constant but bearable pain, stronger analgesia used occasionally	5
Constant pain with frequent strong analgesia	6

Mobility Scale (0 – 9)

Could they get about the house? Was the patient able to get out of the house? Could they do their shopping?	
Without any difficulty	3
On their own with an aid	2
Only with someone else help	1
Not at all, bed or chair bound	0

Variables of interest such as residual pain and reduction in mobility score in the two groups were compared using t-test taking p value ≤ 0.05 as significant.

RESULTS

110 patients were divided into two groups i.e. A and B. In group A cemented hemiarthroplasty and in group B uncemented hemiarthroplasty was done. The mean age of the patients in group A was 68.44±6.73 year and in group B was 71.24±8.73 year. (Table 1)

In group A, 35 (63.6%) patients were male and 20 (36.4%) patients were female. In group B, 29 (52.7%) patients were male and 26 (47.3%) patients were female. (Table 1)

In group A, the preoperative mean pain score was 5.91±0.29 and postoperative mean residual pain score at 12 weeks of follow up was 2.73±0.45. In group B, the preoperative mean pain score was 5.91±0.29 and postoperative mean residual pain score at 12 weeks of follow up was 3.00±0.64. P value of 0.000 was

significant in the favor of cemented hemiarthroplasty. (Table 2 & 3)

In group A, the preoperative (before fracture) mean mobility score was 7.20 ± 0.75 and postoperative mean reduction in mobility score at 12 weeks of follow up was 2.80 ± 0.76 . In group B, the preoperative (before fracture) mean mobility score was 7.20 ± 0.75 and postoperative mean reduction in mobility score at 12 weeks of follow up was 3.20 ± 0.76 . P value of 0.000 was significant in the favor of cemented hemiarthroplasty. (Table 2 & 3).

Table No 1: Mean Age and Gender Distribution in Group A (Cemented) and Group B (Uncemented)

	Group A (Cemented)	Group B (Uncemented)
Number of Patients	55	55
Mean Age (Std. Deviation)	68.44 (6.738)	71.24 (8.737)
Male (%)	35 (63.6%)	29 (52.7%)
Female (%)	20 (36.4%)	26 (47.3%)

Table No 2. Preoperative Mean Pain Score and Mean Mobility Score in Group A (cemented) and Group B (uncemented)

Preoperative	Group A (Cemented)	Group B (Uncemented)
Mean Pain Score	5.91 ± 0.29	5.91 ± 0.29
Mean Mobility Score (before fracture)	7.20 ± 0.75	7.20 ± 0.75

Table No 3: Postoperative Mean Residual Pain Score and Mean Reduction in Mobility Score in Group A (Cemented) and Group B (Uncemented)

Postoperative Outcome (12 weeks follow up)	Group A	Group B	P-value
Mean Residual Pain Score	2.73 ± 0.449	3.00 ± 0.638	0.00
Mean Reduction in Mobility Score	2.80 ± 0.755	3.20 ± 0.755	0.00

Table No 4: Paired Samples Correlations after t-test

	N	Correlation	Sig. value after T test
Pair 1 Residual Pain Score Group A & Residual Pain Score Group B	55	0.258	0.004
Pair 2 Mobility Score Group A & Mobility Score Group B	55	-0.156	0.013

DISCUSSION

This study is the first randomised trial to date on this topic in Pakistan and confirms the results of the previous international studies of patients with an intracapsular hip fracture which found that a cemented hemiarthroplasty leads to less residual pain and a better return of mobility than an uncemented prosthesis.¹⁵ We were able to demonstrate that the marginally increased operation time and the potential operative complications associated with cement were not detrimental. Indeed, the reverse was true, with a clear trend to fewer general medical complications, fewer re-operations and a shorter hospital stay with the cemented prosthesis. The most important outcomes measured were pain and return of function.

The first hip fracture endoprostheses were designed for cementless use, but cemented fixation has become the preferred technique with current femoral components. Numerous reports have documented improved outcomes with cemented implants. The outcome of secondary surgery, particularly revision of the implant, was not significantly different between the two groups, although there was a tendency to more revision arthroplasties in the uncemented group.

Previously published randomised trials comparing cemented and uncemented hemiarthroplasties for patients with a fracture of the hip have been identified and summarized in the Cochrane Review on this subject. Sonne-Holm, Walter and Jensen, in 1982, compared the results of a cemented and an uncemented Austin-Moore hemiarthroplasty in 112 patients.¹⁶ There was no difference in mortality between the two groups. Better walking ability and less pain was observed in those treated with the cemented prosthesis. Similar findings were recorded in a later study of 50 patients which compared a cemented and an uncemented bipolar hemiarthroplasty.¹⁷ There was no difference in mortality between the groups, but significantly less pain in those treated with the cemented prosthesis. Walking ability was also superior with the cemented prosthesis.

Santini et al also compared a cemented and an uncemented bipolar hemiarthroplasty in 106 patients.¹⁸ Again, there was no difference in mortality or functional activity between the two groups. Two studies involving a total of 190 patients compared a cemented with an uncemented Thompson prosthesis. Both reported no statistically significant difference between the groups for mortality, and significantly more residual pain in those treated with an uncemented prosthesis.^{19,20}

Branfoot, Faraj and Porter also compared a cemented with an uncemented Thompson prosthesis in 91 patients and reported no significant difference in mortality.²¹ The mean pain scores in the 70 surviving patients tended to be higher, indicating more pain, for the uncemented

prosthesis, although the results were not statistically significant.

We chose the two prostheses used in this study as they are currently the most commonly used in the practice. It is possible that a modern uncemented prosthesis, perhaps with hydroxyapatite coating may produce superior outcomes to the uncemented Austin-Moore prosthesis which we used, but this remains to be proved in a randomized controlled trial. The only study that has compared an uncemented Austin-Moore with a hydroxyapatite-coated Furlong prosthesis in 84 patients was too small to make any definite conclusions on any difference between the two implants.²²

In summary, this study found that a cemented Thompson hemiarthroplasty led to less pain in the hip, improved return of mobility and a reduced hospital stay compared to an uncemented Austin-Moore prosthesis. There was no increase in complications or mortality related to the use of cement.

CONCLUSION

Our study found that a cemented Thompson hemiarthroplasty led to less pain in the hip and improved return of mobility compared to an uncemented Austin-Moore prosthesis. There was no increase in complications or mortality related to the use of cement. In conjunction with previous studies which have also reported improved outcomes for a cemented rather than an uncemented hemiarthroplasty, we suggest that when a hemiarthroplasty is used for a fracture of the hip it should be cemented in place.

REFERENCES

1. Leighton RK. Fractures of the neck of femur. In: Bucholz RW, Heckman JD, Court-Brown CM, editors. Rockwood and green's fractures in adults. Philadelphia: Lippincott;2006.p.1753.
2. Lavelle DG. Fractures and dislocations of the hip. In: Canale ST, Beaty JH, editors. Campbell's operative orthopaedics. Philadelphia: Mosby; 2008. p. 3237.
3. Stevens JA, Olson S. Reducing falls and resulting hip fractures among older women. *MMWR Recomm Rep* 2000;49:3-12.
4. Mamji F, Hasan JA, Sabri S. Risk factors for osteoporosis in post-menopausal women with hip fractures. *J Surg Pak* 2010;15:82-6.
5. Hayat K, Ashfaq K, Tago IA, Bhatti A, Minhas S, Mehboob G. Factors related to development of traumatic osteonecrosis of femoral head. *J Pak Orthop Assoc* 2008;20:108-13.
6. Shafee M, Asghar M, Tariq MA. Pauwel's osteotomy and oseosynthesis; Its use in patients with nonunion of femoral neck fractures. *Prof Med J* 2007;14:89-97.
7. Parker MI, Pryor G, Gurusamy K. Cemented versus uncemented hemiarthroplasty for intracapsular hip fractures: A randomised controlled trial in 400 patients. *J Bone Joint Surg Br* 2010;92:116-22.
8. Figved W, Opland V, Frihagen F, Jervidal T, Madsen JE, Nordsletten L. Cemented versus uncemented hemiarthroplasty for displaced femoral neck fractures. *Clin Orthop Relat Res* 2009;467: 2426-35.
9. Vohteloo AJ, Niesten D, Riedijk R, Rijnberg WJ, Bolder SB, Koëter S, et al. Cemented versus non-cemented hemiarthroplasty of the hip as a treatment for a displaced femoral neck fracture: Design of a randomised controlled trial. *BMC Musculoskeletal Disorders* 2009;10:56.
10. Khan RJ, MacDowell A, Crossman P, Datta A, Jallali N, Arch BN, Keene GS. Cemented or uncemented hemiarthroplasty for displaced intracapsular femoral neck fractures. *Int Orthop* 2002;26:229-32.
11. Khan RJ, MacDowell A, Crossman P, Keene GS. Cemented or uncemented hemiarthroplasty for displaced intracapsular fractures of the hip: A systematic review. *Injury* 2002;33:13-7.
12. Foster AR, Thompson NW, Wong J, Charlwood AP. Periprosthetic femoral fractures--a comparison between cemented and uncemented hemiarthroplasties. *Injury* 2005;36:424-9.
13. Lennox IA, McLauchlan J. Comparing the mortality and morbidity of cemented and uncemented hemiarthroplasties. *Injury* 1993;24: 185-6.
14. Singh GK, Deshmukh RG. Uncemented austin-moore and cemented thompson unipolar hemiarthroplasty for displaced fracture neck of femur--comparison of complications and patient satisfaction. *Injury* 2006;37:169-74.
15. Parker MJ, Gurusamy K. Arthroplasties (with and without bone cement) for proximal femoral fractures in adults. (Cochrane Review). The Cochrane Library, Chichester: Wiley; 2006.
16. Sonne-Holm S, Walter S, Jensen JS. Moore hemiarthroplasty with and without bone cement in femoral neck fractures: a clinical controlled trial. *Acta Orthop Scand* 1982;53:953-6.
17. Dorr LD, Glousman R, Sew Hoy AL, Vanis R, Chandler R. Treatment of femoral neck fractures with total hip replacement versus cemented and noncemented hemiarthroplasty. *J Arthroplasty* 1986;1:210-18.
18. Santini S, Rebeccato A, Bolgan I, Turi G. Hip fractures in elderly patients treated with bipolar hemiarthroplasty: comparison between cemented and cementless implants. *J Orthop Traumatol* 2005;6:80-7.

19. Anderson GH, Dias JJ, Hoskinson J, Harper WM. A randomized study of the use of bone cement with thompson's prosthesis in the treatment of intracapsular fractures of the femoral neck. J Bone Joint Surg 1992;74:132-3.
20. Emery RJH, Broughton NS, Desal K, Bulstrode CJK, Thomas TL. Bipolar hemiarthroplasty for subcapital fracture of the femoral neck: a prospective randomized trial of cemented Thompson and uncemented Moore stems. J Bone Joint Surg 1991;73:322-4.
21. Branfoot T, Faraj AA, Porter P. Cemented versus uncementedthompson's prosthesis: A randomised prospective functional outcome study. Injury 2000;31:280-1.
22. Livesley PJ, Srivastava VM, Needoff M, Prince HG, Moulton AM. Use of a hydroxyapatite-coated hemiarthroplasty in the management of subcapital fracture of the femur. Injury 1993;24:236-40.

Address for Corresponding Author:**Dr. Manqoosh ur Rehman**

Assistant Professor of Orthopaedics

Multan Medical & Dental College

Ibn e Siena Hospital & Research Institute Multan

Electronic Copy

Efficacy of Intra Articular Injections in Different Grades of Osteoarthritis of Knee

1. Muhammad Imran 2. Manqoosh ur Rehman 3. Tanveer Ahmad Kang

1, 2 & 3. Asstt. Profs. of Orthopaedics, Multan Medical & Dental College, Ibn e Siena Hospital & Research Institute Multan

ABSTRACT

Objectives: To assess the efficacy of intra articular injections in different grades of osteoarthritis of knee.

Study Design: Descriptive study

Place and Duration of Study: This study was conducted at the Department of Orthopedics Railway Hospital Rawalpindi and Ibn-e-Seina Hospital & Research Institute Multan started from June 2008 to June 2012.

Materials and Methods: This study included 90 patients of either sex having mild, moderate and severe grades of osteoarthritis of knee based on radiographic findings. A study proforma was designed in which bio-statics and results of the study were recorded. Five intra-articular injections of hyaluronic acid were given on weekly basis and patients were assessed for pain and functional activity at intervals of 0, 6 and 12 weeks by KSKS, WOMAC and VAS scoring system. These patients were selected consecutively.

Results: In this study patients with mild and moderate grades of osteoarthritis of knee showed improvement but patients with severe grades of osteoarthritis either showed no response or less improvement.

Conclusion: Intra-articular injection of hyaluronic acid is an effective modality in early stages of osteoarthritis of knee.

Key Words: Osteoarthritis, Hyaluronic acid, Knee

INTRODUCTION

Osteoarthritis is the most common joint disorder in the elderly.¹ The prevalence of osteoarthritis ranges from 1% below the age of 30 years to over 50% in people above the age of 60.² In osteoarthritis of knee there is progressive cartilage destruction which results in sub-articular cysts and osteophyte formation. There is also sclerosis of the surrounding bone and capsular fibrosis. Patient with osteoarthritis of knee usually presents with pain in one or both joints, stiffness, intermittent swelling and loss of function.

Although knee arthroplasties are performed in sufficient number in Pakistan but still this group represents only a small number of patients with knee osteoarthritis. Most patients avoid surgeries due to their high cost by using a variety of non-operative treatments like oral analgesics, nonsteroidal anti-inflammatory drugs, exercise and physiotherapy, weight relieving braces or different types of intra articular injections.³

Hyaluronic acid is a critical component of normal synovial fluid and an important contributor to joint homeostasis.⁴ In osteoarthritis, both the concentration and the molecular weight of intra-articular endogenous hyaluronic acid is decreased, which reduces the viscoelasticity of the synovial fluid.^{5,6} Therefore, the original rationale for intra articular injection of hyaluronic acid was to restore the viscoelasticity of synovial fluid.^{7,8} In addition, it has been found that injected hyaluronic acid augments the flow of synovial fluid, normalize the synthesis and inhibit the

degradation of endogenous hyaluronic acid, and relieve joint pain.^{9,10}

Clinical trials have demonstrated the safety and efficacy of hyaluronic acid injections for the treatment of knee osteoarthritis.¹¹ But studies in our setup are inconclusive regarding the best responders with respect to age, grade of osteoarthritis, level of symptoms and level of physical activity. This study was undertaken to access the efficacy of intra articular hyaluronic acid in different grades of osteoarthritis of knee defined radiologically.

MATERIALS AND METHODS

This multicentered, prospective and observational study included those patients who satisfied the inclusion criteria. Patients were offered enrolment until planned number of patients were reached. Patients were enrolled between June 2008 to June 2012.

Inclusion criteria was age above 30 years, radiological evidence of symptomatic osteoarthritis of knee and failure of other non operative modalities like NSAIDS, physical therapy and knee braces.

Exclusion criteria was pregnant and lactating mothers, radiographic evidence of chondrocalcinosis or if physical examination demonstrated insufficiency of ligaments of the knee and neuropathic joints. The study was approved by the ethical committee and patients were explained about the study. Follow up of the patients was ensured.

Data including sex, age, height, weight and site of involvement was recorded. Weight bearing

anteroposterior and lateral radiographs of the involved knee were obtained. Findings on the initial radiographs were graded by the radiologist as mild, moderate and severe arthritis. Mild arthritis was defined as minimal loss of joint space and osteophyte formation. Moderate arthritis was defined as up to 75% loss of joint space, subchondral changes and more noticeable osteophyte formation. Severe arthritis was defined as total loss of joint space and more severe changes. During grading all the three compartments including medial and lateral tibiofemoral and patellofemoral were graded and worse grade was recorded.

The efficacy assessment included Knee Society Knee Score (KSKS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score and Visual Analogue Scale (VAS) score for pain at rest and following walking and stepping activities.^{12,13}

With KSKS clinical rating scale a score of < 55 point indicate a poor result, 55-64 fair result, 65-79 good result and 80-100 excellent result. WOMAC was used as self-administered questionnaire. With WOMAC a lower number represent a better result ranging from zero (Best) to 96 (Poor). Visual Analogue Scale was also administered to the patient ranging from 0-100mm with lower number representing less pain and higher number representing more pain.

All the three instruments were used to assess the patients during the time of enrollment, at 6 weeks and then at 12 weeks. One of the medical officer who was skilled to use the study instruments was appointed to assess the patients.

Hyaluronic acid injections (Hyalgan) were administered as a course of five weekly injections. All injections were given in the similar manner with the patient lying supine and the knee joint approached through superolateral pouch under the superolateral edge of patella. Ethylchloride spray was used immediately prior to the injection for the patient comfort. A 22 gauge needle was used to inject the prefilled 2ml syringe. In case of the knee effusion 18 gauge needle was used for the aspiration and then the needle was left in place for the injection. Patients was encouraged to avoid strenuous activity for a day following the intra articular injection.

The results obtained from KSKS, WOMAC, VAS were tested separately. Two-way Anova (Analysis of Variance) technique and F-Test were used.

RESULTS

This study included 100 patients having symptomatic osteoarthritis of the knee. 10 patients left the follow up. Mean age of the patients was 50.45±0.90 years with range of 35-75 years. Majority of the patients were above 40 years of age. There were 68 (75.5%) patients who were 41-60 years of age. There were 16 (17.7%) patients who were less than or equal to 40 years of age

and 6 (6.6%) patients were above 60 years of age. Mean weight of the patients was 80.30±0.75 kg. (Table No.1) There were 52 (57.8%) male and 38 (42.2%) female patients. 20 (22.2%) patients had low socioeconomic status, 55 (61.1%) had middle and 15 (16.6%) had high socioeconomic status. In 38 (42.2%) patients left side was involved while in 44 (48.9%) patients right side was involved and in 8 (8.9%) patients both sides were involved. 30 (33.3%) patients had mild, 30 (33.3%) patients had moderate and 30 (33.3%) patients had severe grade of osteoarthritis.

Table No.1: Characteristics of patients with OA Knee (n=90)

	No. of Patients (%)	No. of Patients (%)	No. of Patients (%)
Age (yrs)	≤ 40 = 16 (17.7%)	41-60 = 68 (75.5%)	≥ 60 = 6 (6.6%)
Socioeconomic Status	Low = 20 (22.2%)	Middle = 55 (61.1%)	High = 15 (16.6%)
Side Involvement	Left = 38 (42.2%)	Right = 44 (48.9%)	Both = 8 (8.9%)
Arthritis Grade	Mild = 30 (33.3%)	Moderate = 30 (33.3%)	Severe = 30 (33.3%)

Table No.2: Knee Society Knee Score (KSKS) in Patients with OA Knee (n=90)

	Mild	Moderate	Severe	All
KSKS	N=30 Mean=62.400 S.D=4.739	N=30 Mean=54.933 S.D=2.434	N=30 Mean=37.600 S.D=4.280	N=90 Mean=51.644 S.D=11.151
KSKS-b	N=30 Mean=87.900 S.D=4.831	N=30 Mean=70.600 S.D=6.806	N=30 Mean=42.500 S.D=3.655	N=90 Mean=67.000 S.D=19.519
KSKS-c	N=30 Mean=90.900 S.D=3.872	N=30 Mean=65.567 S.D=10.516	N=30 Mean=40.267 S.D=3.483	N=90 Mean=67.444 S.D=22.006
All	N=90 Mean=80.400 S.D=13.607	N=90 Mean=65.567 S.D=10.516	N=90 Mean=40.122 S.D=4.282	N=270 Mean=62.030 S.D=19.534

Table No.3: WOMAC in Patients with OA Knee (n=90)

	Mild	Moderate	Severe	All
WAM AC-a	N=30 Mean=45.467 S.D=2.825	N=30 Mean=51.967 S.D=2.173	N=30 Mean=61.000 S.D=3.806	N=90 Mean=52.811 S.D=7.063
WAM AC-b	N=30 Mean=22.167 S.D=5.032	N=30 Mean=37.033 S.D=6.636	N=30 Mean=55.067 S.D=3.868	N=90 Mean=38.089 S.D=14.507
WAM AC-c	N=30 Mean=17.133 S.D=6.213	N=30 Mean=36.467 S.D=10.095	N=30 Mean=58.167 S.D=5.167	N=90 Mean=37.256 S.D=18.400
All	N=90 Mean=28.256 S.D=13.322	N=90 Mean=41.822 S.D=10.059	N=90 Mean=58.078 S.D=4.922	N=270 Mean=42.719 S.D=15.792

Using KSKS, mild grades showed mean score of 62.40 at the start and after 12 weeks mean score was 90.90. Moderate grades showed mean score of 54.93 at the start and after 12 week mean score was 65.56. Severe grades showed mean score of 37.60 at the start and after 12 week mean score was 40.26.

Using WOMAC, mild grades showed mean score of 45.46 at the start and after 12 weeks mean score was

17.13. Moderate grades showed mean score of 51.96 at the start and after 12 weeks mean score was 36.46. Sever grades showed mean score of 61.00 at the start and after 12 week mean score was 58.16.

Table No.4: Visual Analogue Scale (VAS) in Patients with OA Knee (n=90)

	Mild	Moderate	Severe	All
VAS-a	N=30 Mean=56.000 S.D=4.433	N=30 Mean=68.167 S.D=2.780	N=30 Mean=78.333 S.D=3.304	N=90, Mean=67.500 0 S.D=9.837
VAS-b	N=30 Mean=26.500 S.D=8.610	N=30 Mean=48.000 S.D=8.367	N=30 Mean=70.687 S.D=5.231	N=90 Mean=48.456 S.D=19.493
VAS-c	N=30 Mean=20.000 S.D=8.610	N=30 Mean=45.467 S.D=15.204	N=30 Mean=74.500 S.D=6.867	N=90 Mean=46.656 S.D=24.823
All	N=30 Mean=34.167 S.D=17.178	N=90 Mean=53.878 S.D=14.317	N=90 Mean=74.567 S.D=6.102	N=270 Mean=54.204 S.D=21.233

Similarly using Visual Analogue Scale, mild grades showed mean score of 56.00 at the start and after 12 weeks mean score was 20.00. Moderate grades showed mean score of 68.16 at the start and after 12 weeks mean score was 45.46. Severe grades showed mean score of 78.33 at the start and after 12 weeks mean score was 74.50.

These results showed the improvement more in mild and moderate grades of osteoarthritis of knee than in severe grades of osteoarthritis of knee.

DISCUSSION

The present study showed the treatment effect of hyaluronic acid injection in different grades of osteoarthritis of knee. Although intra-articular injections have shown improvement in all grades but effects are more in mild and moderate grades as compared to severe grades in our population as well. No radiological grading system has undergone interobserver and intraobserver reliability testing, this should be considered a limitation for any study that draws interference between radiological grades and outcome.

The meta-analysis by Wang CT, et al showed significant improvement in pain and functional outcome except those who had severe osteoarthritis.¹⁴ Similarly a prospective randomized study by Petrela RJ and Petrela M showed patient satisfaction in terms of pain relief and functional improvement by hyaluronic acid.¹⁵

In this study 10 patients were slipped during the course of treatment as it require five weeks to complete so it is concluded that the course should be of shorter duration. As new variants of hyaluronic acid are discovered, single intra-articular injection with 6ml Hylan G-F 20 can replace routine method of once a week for five weeks.¹⁶ The effect of hyaluronic acid at molecular level has also been established.^{17,18}

CONCLUSION

Intra-articular injection of hyaluronic acid is an effective modality in early stages of osteoarthritis of knee.

REFERENCES

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. *Arthritis Rheum* 1998;41: 1343-55.
2. Felson DT, Naimark A, Anderson J, Kazis L, Castelli W, Meenan RF. The prevalence of knee osteoarthritis in the elderly. *Arthritis & Rheumatism* 1987;80:914-8.
3. Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. *J Am Acad Orthop Surg* 2000;8:277-84.
4. Pendleton A, Arden N, Dougados M, Doherty M, Bannwarth B, Bijlsma JW, et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCIIT). *Ann Rheum Dis* 2000;59:936-44.
5. Laurent TC, Fraser JR. Hyaluronan. *FASEB J* 1992;6:2397-404.
6. Lee YT, Shao HJ, Wang JH, Liu HC, Hou SM, Young TH. Hyaluronic acid modulates gene expression of connective tissue growth factor (CTGF), transforming growth factor -beta1 (TGF beta1), and vascular endothelial growth factor (VEGF) in human fibroblast-like synovial cells from advanced stage osteoarthritis in vitro. *J Orthop Res* 2010;28:492-6.
7. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid. I. Molecular parameters of hyaluronic acid in normal and arthritis human fluids. *Arthritis Rheum* 1967;10:357-76.
8. Evanich JD, Evanich CJ, Wright MB, Rydlewicz JA. Efficacy of intraarticular hyaluronic acid injections in knee osteoarthritis. *Clin Orthop Relat Res* 2001;390:173-81.
9. Peyron JG. A new approach to the treatment of osteoarthritis: viscosupplementation. *Osteoarthritis Cartilage* 1993;1:85-7.
10. Rydell N, Balazs EA. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granulation tissue formation. *Clin Orthop* 1971;80:25-32.
11. Foti C, Cisari C, Carda S, Giordan N, Rocco A, Frizziero A, et al. A prospective observational study of the clinical efficacy and safety of intra-articular sodium hyaluronate in synovial joints with

- osteoarthritis. Eur J Phys Rehabil Med 2011; 47:407-15.
12. Turajane T, Tanavaree A, Labpiboonpong V, Maungsiri S. Outcomes of intra-articular injection of sodium hyaluronate for the treatment of osteoarthritis of the knee. J Med Assoc Thai 2007;90:1845-52.
 13. Bellamy N. Pain assessment in osteoarthritis experience with the WOMAC osteoarthritis index. Semin Arthritis Rheumatol 1988;15:1833-40.
 14. Wang CT, Lin J, Chang CJ, Lin YT, Hou SM. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized control trials. JBJS 2004;86:538-45.
 15. Petrella RJ, Petrella M. A prospective, randomized, double blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee. J Rheumatol 2006; 33:951-6.
 16. Abate M, Pulci D, Di Lorio A, Schiavone C. Viscosupplementation with intra articular hyaluronic acid for treatment of osteoarthritis in the elderly. Curr Pharm 2010;16:631-40.
 17. Phiphobmongkol V, Sudhasaneya V. The effectiveness and safety of intra-articular injection of sodium hyaluronate (500-730 kDa) in the treatment of patients with painful knee osteoarthritis. J Med Assoc Thai 2009;92:1287-94.
 18. Kolarz G, Kotz R, Hochmayer I. Long-term benefits and repeated treatment cycles of intra-articular sodium hyaluronate (Hyalgan) in patients with osteoarthritis of the knee. Semin Arthritis Rheum 2003;32:310-9.

Address for Corresponding Author:

Dr. Muhammad Imran

Assistant Professor of Orthopaedics

Multan Medical & Dental College

Ibn e Siena Hospital & Research Institute Multan

Electronic Copy

Effect of Thiamine on Glycemic Control in Induced Diabetic Rat Model

1. Muhammad Bachal Pandhiani 2. Maria Kazi 3. Saif-ur-Rehman 4. Navaid Kazmi
5. Salman Ahmad Farsi Kazi 6. Haji Khan Khoharo

1. Asstt. Prof. of Anatomy, Al-Tibri Medical College, Karachi 2. Asstt. Prof. of Biochemistry, Al-Tibri Medical College, Karachi 3, 4. Asstt. Profs. of Physiology, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad 5. Asstt. Prof. of Forensic Medicine, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad 6. Asstt. Prof./Consultant Physician, Dept. of Physiology/Medicine, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad

ABSTRACT

Objective: To evaluate the effect of high dose thiamine on postprandial blood glucose (PPBG) and hemoglobin A1C levels in induced diabetic albino rat model.

Study Design: Experimental/Analytical study

Place and Duration of Study: Animal House, Isra University Hyderabad from March to October 2013.

Materials and Methods: Forty adult albino rats were divided into four groups; Group I. Controls receiving normal diet, Group II. Controls receiving thiamine fortified diet, Group III. Diabetics receiving normal diet and Group IV. Diabetics receiving thiamine fortified diet. Diabetes mellitus was induced using Streptozocin. Thiamine was given at a dose of 1.6 g/kg body weight. Venous blood samples were drawn from animal's tail with a small bore cannula before and after 12 weeks of experimentation. The PPBG levels and Glycosylated HbA (HbA1c) were measured. The data was converted into database and analyzed on SPSS version 21.0 by ANOVA and Tukey-Kramer's test. A p-value of ≤ 0.05 was taken statistically significant.

Results: The PPBG and HbA1c levels were found statistically significant in groups I vs. III ($p=0.0001$), I vs. IV ($p=0.0001$), II vs. III ($p=0.0001$), II vs. IV, ($p=0.001$) and III vs. IV ($p=0.024$) at 12th week of experimentation. The study shows significant reduction in the PPBG and HbA1c levels of rats taking thiamine compared to controls ($p=0.001$). Significant differences in HbA1c levels were observed between control groups I and II vs. experimental groups III and IV ($p=0.024$) ($p=0.0001$) respectively. A highly significant difference in HbA1c was observed in rats given thiamine fortified diet compared to those not given ($p=0.001$).

Conclusion: The thiamine improves glucose metabolism in induced diabetic rat models, hence it is concluded that the thiamine may be given along with anti-diabetic drugs to overcome defects of glucose metabolism.

Key words: Thiamine, Glycemic control, HbA1c, Diabetic rats

INTRODUCTION

The number of diabetic population older than twenty is estimated to rise from 285 million in 2010 to 439 million in 2030 as reported by International Diabetes Federation (IDF).¹ The current rise in diabetic population has put Pakistan at sixth position in the world.² According to an estimate, 15% of Pakistani population is diagnosed of having diabetes mellitus (DM) and millions more are unaware and undiagnosed of having DM.^{3,4} According to the estimates of Pakistan National Diabetes Survey (PNDS), for each diagnosed case of DM, there are approximately two cases of undiagnosed DM and three cases of impaired glucose tolerance who remain unaware of it.^{5,6} The DM is characterized by chronic hyperglycemia which in long term causes damage in the target organs like kidney, nerves, eyes, heart and blood vessels.^{7,8} The DM is a multifactorial metabolic disorder, mainly characterized by abnormal glucose metabolism which is responsible for most of its symptoms and complications. But the thiamine deficiency is also linked with the pathogenesis and complications of DM

as has been reported in many studies.^{9, 10, 11} The thiamine is known as vitamin B₁. Thiamine forms an indispensable co-enzyme and participates in several steps of glucose and intermediary metabolisms. In human body it plays role in glucose metabolism by forming co-enzymes essential for functioning of enzymes of glycolysis and citric acid cycle. The DM has been characterized by thiamine deficiency due to amplified glucose metabolism.¹¹ Thiamine deficiency causes disturbed glucose metabolism, and accelerates DM complications through various mechanisms.¹¹ The various mechanisms which have been postulated causing diabetic complications include the activation of polyol pathway, formation of advanced glycation end products (AGES), activation of protein kinase C (PKC) and increased flux through the hexosamine biosynthetic pathway (HBP).¹¹ These metabolic abnormalities are triggered through increased formation and elevated concentration of triose-phosphate intermediates of glycolysis.^{12, 13} Triose-phosphate can be suppressed by the activation of reductive pentose phosphate pathway (PPP) by high-dose thiamine therapy that would increase transketolase (TK) activity and stimulate the

conversion of glyceraldehyde-3-phosphate (GA3P) and fructose-6-phosphate (F6P) to ribose-5-phosphate (R5P), thus reducing the risk of the development of diabetic complications.⁹ The present study hypothesizes that high doses of thiamine administration would be independently associated with glucose metabolism and that this association is modified by blood glucose level. The present experimental study aims to evaluate the metabolic effects of high dose thiamine on blood glucose and HbA1c in induced diabetic rat model.

MATERIALS AND METHODS

This experimental study was conducted at Animal House of Isra University Hyderabad from June 2012 to December 2013. Forty 12-week old male albino rats were selected through non-probability purposive sampling. The normal healthy rats of 150-250g body weight were included while sick rats and rats not feeding properly were excluded from study. Rats were habitated in stainless steel cages, at room temperature with 55-60% humidity. The rats were kept under standard conditions. Pelleted form of diet was given to animals throughout study period. The diet was made available freely to feed *ad-libitum*. Water was made available in separate containers. Pelleted diet was fortified with thiamine at a dose of 1.6 gms/ kg for the specified groups *as referenced*.¹⁴ Twenty rats were separated as controls, while another twenty rats were injected streptozocin to damage β -cells to induce DM at a dose of 60mg intraperitoneally.^{15,16} The rats (N=40) were divided into four groups by random selection, containing ten rats in each group. Group I (n=10) included normal healthy rats as controls receiving normal pelleted diet, Group II (n=10) included normal healthy rats as controls receiving normal diet, fortified with thiamine, Group III (n=10) diabetic rats given normal diet and Group IV (n=10) included diabetic rats given thiamine fortified diet. The study duration was twelve weeks. Venous blood samples were drawn from animal's tail with a small bore cannula, to measure random blood glucose and glycosylated HbA (HbA1c).

Random blood glucose was measured by glucose oxidase method and HbA1c by enzyme calorimetric method on spectrophotometer (Hitachi, USA). Normal blood glucose level was taken as 52-105mg/dl. HbA1c range for rats was taken normal as 3-8.8%.¹⁵ The data was converted into database onto SPSS version 21.0. The continuous variables were analysed by ANOVA and Tukey-Kramer's test. The data was presented as mean \pm SD. A p-value of ≤ 0.05 was taken statistically significant.

RESULTS

The blood glucose level and HbA1c were measured before and after intervention in all groups of rats. The continuous variables are presented as mean \pm SD in Table I for groups. The difference in blood glucose level and HbA1c in control groups I and II and experimental groups III and IV were found statistically non-significant before intervention ($p > 0.05$). However, the blood glucose level and HbA1c were found statistically significant in groups I vs. III ($p=0.0001$), I vs. IV ($p=0.0001$), II vs. III ($p=0.0001$), II vs. IV, ($p=0.001$) and III vs. IV ($p=0.024$) after intervention at twelve weeks of experimentation. The study shows significant reduction in the blood glucose level and HbA1c of rats taking thiamine compared to controls ($p=0.001$). Although the study duration was twelve weeks, still significant differences in HbA1c levels were observed between control groups I and II vs. III and IV ($p=0.024$) ($p=0.0001$) respectively. A highly significant difference in HbA1c was observed in rats taking thiamine fortified diet compared to those not taking thiamine ($p=0.001$). From the observations of present study, it is concluded that thiamine has a definitive role in regulating glucose metabolism. The thiamine shows positive effect in reducing blood glucose level through enhanced metabolism and reduces formation of HbA1c. The observations of thiamine effect on blood glucose level are of practical importance while treating diabetic subjects by clinicians.

Table No.I. Postprandial blood glucose (PPBG) level and Hemoglobin A1c in study animals (n=40)

Variable	Group I		Group II		Group III		Group IV	
	Control group (Thiamine ^{-ve} diet)		Control group (Thiamine ^{+ve} diet)		Diabetic group (Thiamine ^{-ve} diet)		Diabetic group (Thiamine ^{+ve} diet)	
	Before	After	Before	After	Before	After	Before	After
PPBG level (mg/dl)	79 \pm 4.7	80 \pm 3.9	80 \pm 1.5	80 \pm 3.5	78 \pm 2.5	153 \pm 15.6	80 \pm 2.7	145 \pm 13.5
HbA1c (%)	3.48 \pm 0.23	3.49 \pm 0.22	3.49 \pm 0.24	3.51 \pm 0.21	3.47 \pm 0.24	5.98 \pm 0.89	3.49 \pm 0.21	5.13 \pm 0.79

DISCUSSION

The studies regarding the effect of high dose thiamine therapy on blood glucose and HbA1c are lacking in medical literature of Pakistan. A few studies are reported on role of thiamine in diabetics.^{9,15} It is

reported by various studies that diabetics are thiamine deficient.^{9,10,15-17} The present study shows that high doses of thiamine improves blood glucose level and results are comparable to previous studies.^{9,10,15} In present study we found statistically significant

differences in blood glucose levels among in all four groups after intervention. The blood glucose levels are significantly elevated in group IV diabetics compared with group I controls and group II controls taking thiamine ($p=0.0001$) (Table I). Statistically significant differences in blood glucose levels are observed between group III diabetics and groups IV diabetics taking thiamine in diet. ($p=0.001$). The present study also observes statistically significant differences in HbA1c levels among controls, diabetics and diabetics with thiamine intake. ($p=0.001$). The statistically significant differences in HbA1c observed in present study are contrary to previous studies.^{9,15} The differences are observed because of long duration of present study compared to previous study¹⁵ i.e; 4 vs. 12 weeks. A previous study reported that the thiamine intake was inversely associated with blood glucose levels and this shows improved glucose metabolism.¹⁷ The findings support our present study. Babaei-Jadidi et al.¹⁸ conducted experimental study on diabetic rats and reported positive effects of thiamine intake on blood glucose and lipid levels. Our findings support this previous study regarding improved blood glucose levels. In that previous study, it was concluded that the hepatic expression of thiamine dependent enzymes is sensitive to decrease transketolase (TK) and pyruvate dehydrogenase (PDH) activities,¹⁸ both of which are important in regulating intracellular glucose metabolism. The Berrone E et al.¹⁹ conducted study on role of thiamine and benfotiamine on intracellular glucose and polyol pathway in cultured vascular cells and reported improved glucose uptake and metabolism by vascular cell cultures. The previous study concluded that high doses of thiamine and benfotiamine may prevent development of microvascular complications of diabetics.¹⁹

The findings are in keeping with the present study as we observed better glucose metabolism in *thiamine-fed* rats. The present study shows that the thiamine improves blood glucose levels and HbA1c in induced diabetic rat models.

CONCLUSION

The thiamine improves glucose metabolism in induced diabetic rat models as observed in present study. The present study concludes that the thiamine may be given along with antidiabetic drugs to overcome defects of glucose metabolism as it improves glycemic control.

REFERENCES

1. Rodriguez DL, Castela AM, Gorriz JL, de-Alvaro F, Gonzalez JFN. Pathophysiological role and therapeutic implications of inflammation in

- diabetic nephropathy. *World J Diabet* 2012;3 (1): 7-18.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabet care* 2004; 27 (5):1047-53.
3. Shera ASA, Jawad FA, Maqsood AA. Prevalence of diabetes in Pakistan. *Diabet Res Clin Pract* 2007;76: 219-22.
4. Shahid SM, Nawab SZ, Shaikh R, Mahboob T. Glycemic control, dyslipidemias and endothelial dysfunction in co-existed diabetes, hypertension and nephropathy. *Pak J Phrama Soci* 2012;1: 123-29.
5. Afghani T, Qureshi N, Chaudhry KSA. Screening for diabetic retinopathy: A comparative study between hospital and community based screening and between paying and non-paying patients. *J Ayub Med Coll* 2007; 19 (1):16-22.
6. Harris MI. Undiagnosed NIDDM: clinical and public health issues. *Diabet care* 1993; 16: 642-52.
7. American Diabetes Association. Standards of medical care in diabetes. *Diabet Care* 2012;35 (Suppl 1):S11-S63.
8. Masharraf U. Diabetes mellitus and hypoglycemia. In: Mc Phee SJ, Papadakis MA, Rabow MW, editors. *Current medical diagnosis and treatment*. 51st ed. Mc-Graw Hill companies: Inc New York; 2012.p.1161-1211.
9. Waheed P, Naveed AK, Ahmed T. Thiamine deficiency and its correlation with dyslipidaemia in diabetics with microalbuminuria. *J Pak Med Assoc* 2013; 63(3): 340-5.
10. Michael M, Kulkarni R, Postic C, Previs S, Shulman G, Magnuson M, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. *Mol Cell* 2000;6:87-97.
11. Beltramo E, Berrone E, Tarallo S, Porta M. Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications. *Acta Diabetol* 2008; 45: 131-41.
12. Tilton R, Baier L, Harlow J, Smith S, Ostrow E, Williamson J. Diabetes-induced glomerular dysfunction: links to a more reduced cytosolic ratio of NADH/NAD. *Kidney Int* 1992; 41: 778-88.
13. Nishikawa T, Edelstein D, Du X, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature* 2000; 404: 787-90.
14. Babaei-Jadidi R, Karachalias N, Battah S, Ahmed N, Thornalley PJ. Prevention of incipient diabetic

- nephropathy by high dose thiamine and Benfotiamine. *Diabetes* 2003; 52:2110-20.
- Qamar T, Fatima K, Saleem S. Effect of Thiamine on Glycemic Control in Diabetic Rats. *Ann Pak Inst Med Sci* 2011; 7(4): 213-6.
16. Page GLJ, Laight D, Cummings MH. Thiamine deficiency in diabetes mellitus and the impact of thiamine replacement on glucose metabolism and vascular disease. *Int J Clin Prac* 2011;65:684-90.
17. Rabbani N, Thornalley P. Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy. *Diabet Obes Metab* 2011; 13(7): 577-83.
18. Babaei-Jadidi R, Karachalias N, Kupich C, Ahmed N, Thornalley PJ. High dose thiamine therapy counters dyslipidemias in streptozotocin-induced diabetic rats. *Diabetol* 2004; 47: 2235-46.
19. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of Intracellular Glucose and Polyol Pathway by Thiamine and Benfotiamine in Vascular Cells Cultured in High Glucose. *J Biol Chem* 2006; 281: 9307-13.

Address for Corresponding Author:**Dr. Haji Khan Khoharo,**

Assistant Professor/Consultant Physician,

Department of Physiology/Medicine

Faculty of Medicine and Allied Medical Sciences, Isra

University, Hyderabad.

Tel: 0331-2662500

Electronic Copy

Pentoxifylline Protects against Carbon Tetrachloride Induced Liver Injury in Adult Male Wistar Rat Model

1. Maria Kazi 2. Muhammad Bachal Pandhiani 3. Salman Ahmad Farsi Kazi
4. Saif-ur-Rehman 5. Haji Kjan Koharo

1. Asstt. Prof. of Biochemistry, Al-Tibri Medical College, Karachi 2. Asstt. Prof. of Anatomy, Al-Tibri Medical College, Karachi 3. Asstt. Prof. of Forensic Medicine, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad 4. Asstt. Prof. of Physiology, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad 5. Asstt. Prof./Consultant Physician, Dept. of Physiology/Medicine, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad

ABSTRACT

Objective: To investigate the protective effect of Pentoxifylline (PTX) in carbon tetrachloride (CCl₄) induced liver injury in adult male Wistar rat model.

Study design: Experimental/Analytical study

Place and Duration: Animal House, Isra University Hyderabad from May to December 2012.

Subjects and Methods: Forty five adult male Wistar rats were divided into three groups; Group A. controls received 0.9% isotonic saline, Group B. received CCl₄ orally (1.9mg/kg) mixed in olive oil, and Group C. received the PTX+ CCl₄. Blood samples were collected for liver biochemical assays. The animals were sacrificed, liver tissue, after fixation in 4% formaldehyde, was embedded in paraffin. Tissue sections of 5μ thickness were subjected to haematoxylin and eosin staining and were assessed by light microscopy. The data was analyzed on SPSS 21.0 using one-way ANOVA, Tukey-Cramer and Chi-square tests. A p value of ≤ 0.05 was taken statistically significant.

Results: The liver biochemical and histological findings reveal statistically significant differences among the controls, CCl₄ and PTX+ CCl₄ groups (p=0.0001). Liver enzymes and histology was deranged significantly in CCl₄ group compared to controls and PTX+ CCl₄ group (p=0.0001). The CCl₄+PTX group shows less elevation of liver enzymes and derangement in liver histology when compared to CCl₄ group (p=0.001). The histological findings of congestion, inflammatory cell infiltrate, vacuolar degeneration and necrosis are found prominent in CCl₄ group.

Conclusion: The Pentoxifylline protects against oxidative damages caused by carbon tetrachloride induced liver injury in rat model.

Key words: Carbon tetrachloride, Liver injury, Pentoxifylline

INTRODUCTION

Liver is the largest gland of human body. The parenchyma cells of liver are known as the hepatocyte, which performs biochemical and metabolic functions.¹

The oxygen is a precursor of a number of free radicals which are collectively known as the reactive oxygen species (ROS). The ROS are implicated in the pathogenesis of most liver diseases both inflammatory and non-inflammatory like ischemia/reperfusion injury, chronic viral hepatitis, alcoholic hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and cholestasis.² The liver is a metabolically active organ, and protects against drug toxicity for two reasons 1). As it is interposed between porto-systemic circulation i.e. between absorption of intestinal contents containing toxins. 2). Hence preferred site of toxin metabolism and elimination through intestine. Drug induced liver injury poses body systems to possible injury if toxins access to systemic circulation.^{3,4}

Carbon tetrachloride (CCl₄) is a hepatotoxic compound. The CCl₄ has been has been used extensively in

laboratory animals for induction of liver injury, elucidate the underlying mechanism of liver injury and hepatoprotective effects of various therapeutic agents.⁵ One of the postulated mechanism of CCl₄ induced liver injury is the formation of ROS. The ROS disrupts the hepatocyte at cell membrane level through the lipid peroxidation^{5,6} causing anatomical disruption of liver architecture and physiological disturbances.⁷ The hepatocyte injury causes leakage of cytoplasmic and mitochondrial enzymes in the blood streams.⁸

The cytoplasmic and mitochondrial enzymes are clinically used as markers of liver injury, and for monitoring and treating the liver diseases also. The liver enzymes which appear in the blood as a result of liver injury include; alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) are important enzymes that are often employed in assessing liver injury.^{1,5}

The Pentoxifylline (PTX) is a well known methyl xanthine. The PTX is a non-specific inhibitor of phosphodiesterase-4 type. The PTX is used clinically in peripheral arterial disease with intermittent

claudication. The mechanism underlying its therapeutic effects seems to be related to improvement of microcirculation, tissue perfusion and cell functions. The PTX is reported to possess anti-inflammatory and hepatoprotective effects against chemical-induced liver injury like alcohol.^{4,9,10}

The present study aims to investigate the possible protective effects of Pentoxifylline (PTX) against Carbon tetrachloride (CCl₄)-induced hepatotoxicity in experimental animals.

MATERIALS AND METHODS

An experimental study was conducted at the animal house of Isra University on rabbit model over a period of one year, from January to December 2012. Adult male Wistar rats of 250-300 grams were included in the study. Female rats, weight <250 grams or >300 grams were excluded from the study. Animals were housed in animal house at an optimal room temperature with 55-60% humidity and exposed to 12 hour light-dark cycles. The chaw like fresh alfalfa and clean water are provided freely. The rats were divided into three groups;

Group A. Control Group (n=15) Rats received 0.9% isotonic saline orally on alternate day for three successive weeks and served as control group,

Group B. Carbon tetrachloride Group (n=15) Rats were given CCl₄ orally mixed in olive oil on alternate day for three successive weeks and

Group C. Experimental Group (n=15) Rats received PTX (200 mg/kg intraperitoneally) and CCl₄ on alternate days for three successive weeks

Experimental Details: The PTX was purchased from Medical store of Isra University Hospital. The PTX was administered in a dose of 200 mg/kg intraperitoneally.⁴ Carbon tetrachloride was purchased from scientific drug store at Hyderabad City. The CCl₄ dissolved in olive oil as vehicle (1:1 Ratio) at a dose level of 1.9 ml/kg orally on alternate day for three successive weeks and sacrificed at the end of their respective period of time.¹

Sacrifice of animals: The animals were sacrificed using standard method as described by Nayak et al. (2006)¹¹ In order to examine the liver tissue, the liver of the sacrificed animals was removed promptly and preserved in formaldehyde.

Blood sample Processing: The blood samples were collected from peripheral veins at twenty four hours of experimental period. Sera were separated by centrifugation at 300xs for ten minutes. Serum samples were used to determine liver enzymes.

Liver enzyme assay: Liver enzyme assays were determined for alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) using commercially available diagnostic kits.

Histological studies: After fixation in 4% formaldehyde, samples were embedded in paraffin. Sections of 5 μ thickness were subjected to haematoxylin and eosin Hepatic morphology was assessed by light microscopy. A total of five sections for each liver tissue sample were observed under light microscope.

In H & E staining, damaged hepatocytes graded as 0= normal, += mild damage (swollen and pale cytoplasm), ++= moderate damage (vacuolated cytoplasm), +++= severe damage and ++++= very severe damage (pyknotic nucleus and eosinophil cytoplasm).¹²

The data was analyzed on SPSS version 21.0 (IBM corporation). The continuous variables were presented as mean \pm SD using one-way ANOVA and Tukey-Cramer test for multiple comparisons. Chi-square test was used for categorical variables. A p-value of ≤ 0.5 was taken statistically significant.

RESULTS

The present study observes major differences in liver injury between and among groups as indicated by blood enzyme levels in different animal groups. The LDH, ALP, and ALT, AST in serum of Rats treated with carbon tetrachloride were found elevated compared with control group after three weeks, with a highly significant p-value for multiple comparisons (p=0.001). The CCl₄+PTX group shows a significant reduction in the liver enzymes compared with the CCl₄ group (p=0.001) and control group (p=0.001). The animals CCl₄+PTX group shows significant reduction in the liver enzyme elevation compared to CCl₄ group alone (p=0.001). The finding shows significant hepato protection by the PTX in CCl₄ induced injury. The liver enzyme assays among different groups are shown in table.1.

Table No. 1: Liver enzyme levels in controls, *CCl₄ and CCl₄+ Pentoxifylline groups

Groups	LDH (IU/L)	ALP (IU/L)	ALT (IU/L)	AST (IU/L)
Group. A (Controls)	711.5 \pm 51.7	93.6 \pm 8.91	48.9 \pm 3.19	91.2 \pm 16.81
Group. B (CCl ₄)	2778.8 \pm 139.6	167.1 \pm 8.02	189.6 \pm 11.91	499.7 \pm 21.9
Group. C (CCl ₄ + PTX)	2138.6 \pm 153.3	136.7 \pm 18.14	87.7 \pm 17.92	171.3 \pm 19.3

*Carbon tetrachloride

Different parameters of histological score of liver injury are shown in Table. 2. The Liver sections of the control group animals show intact central venules and hepatocytes arranged in compact cords. Normal looking hepatocytes with prominent nucleus, nucleolus and well preserved cytoplasm are seen in control group (Figure.1). On the contrary, the CCl₄ group shows derangement of hepatocytes cords, hydropic changes

with congestion of central venules and sinusoids, and abundant inflammatory cell infiltration (Figure.2).




Figure No.1: Liver slide of control group shows normal looking hepatocytes arranged in cords. Central vein (CV) is shown (A) separated by sinusoids




Figure No.2: CCl₄ group showing hydropic degeneration (arrow), inflammatory cell infiltrate and necrosis




Figure No.3: CCl₄ + Pentoxifylline group showing normal hepatocyte arranged in cords with congested sinusoids, and few lymphocytic infiltrations.

The centrilobular hepatocytes show hydropic changes and necrosis, while midzonal and peripheral hepatocytes show vacuolar degeneration and fatty changes in CCl₄ group (Figure 2). In CCl₄+PTX

animals, liver tissue sections reveal less significant derangement of hepatocytes cords, hepatocytes damage and necrosis was limited compared with CCl₄ group (Figure.3).

Table No. 2: Histology of liver injury of controls, *CCl₄ and CCl₄+ Pentoxifylline groups

Groups	Inflamm-atory cell infiltrate	Conges-tion	Vacuolar degenera-tion	Necrosis
Group. A (Controls)	0	0	0	0
Group. B (CCl ₄)	++++	++++	+++	++++
Group. C (CCl ₄ + PTX)	+++	++	++	++

*Carbon tetrachloride

DISCUSSION

The present study is an original research work, which investigates the effect of Pentoxifylline (PTX) on carbon tetrachloride (CCl₄) induced liver injury in adult male Wistar rats. The Null hypothesis is rejected because the study observes hepatoprotective effects of PTX as evidenced by biochemical and histological marker of liver injury. The present study shows liver damage caused by the carbon tetrachloride as indicated by serum levels of liver enzymes compared to control group in rat model. The carbon tetrachloride induced liver injury with release of liver enzymes is comparable finding to reported previously by Hurkkeri et al.¹³ The Hurkkeri¹³ reported elevated hepatocyte enzyme of liver as a consequence of CCl₄ induced liver injury in animal model. The release of large quantities of cytoplasmic and mitochondrial enzymes of liver is a clinical indicator of hepatocyte cell membrane damage and rupture sufficient to produces change in enzyme levels in blood.¹⁴ The effect of PTX has been studied on the hepatic encephalopathy,^{15,16} hepatorenal syndrome,¹⁷ and alcoholic hepatitis by some researchers.¹⁸ PTX inhibits profibrogenic cytokine and procollagen I expression,¹⁹ decreases the AST and ALT and its anti-TNF- α improves symptoms of liver tissue in patients with Non-alcoholic steatohepatitis (NASH) Non-alcoholic fatty liver disease (NALFD).²⁰

The present study shows that the damage of liver caused by CCl₄ is evident by the rise in serum enzymes levels beside the histological changes in liver tissue. Administration of CCl₄ significantly increases the serum levels of liver enzymes; LDH, ALP, ALT and AST, which are indices of hepatocyte damage and leakage of enzymes from cells.^{21,22}

The histological examination of present research study correlates in parallel to disturbance in biochemical markers of liver injury. The histology of liver tissue shows disruption of liver architecture, hepatocytes, hepatic lobules and arrangement of hepatocytes in

cords. The hepatocytes show findings of cellular injury with marked cytoplasmic vacuolization. The injured hepatocytes show pyknotic nuclei with lymphocyte infiltrations. The pyknotic nuclei are a sign of severe cellular injury caused by a toxin like carbon tetrachloride. The histological and biochemical findings of present study are comparable to those mentioned previously.²³⁻²⁵ The carbon tetrachloride is metabolized to free radical during its metabolism and detoxification in smooth endoplasmic reticulum by the cytochrome P450.²⁶ The Movassaghi, et al⁴ (2013) studied hepatoprotective effects of PTX on ecstasy induced liver damage and reported effects of PTX. The PTX reduced liver injury in this previous study by reducing apoptosis and fibrosis caused by ecstasy in rat liver model. The present study concludes that the PTX decreases the carbon tetrachloride induced liver damage.

CONCLUSION

The Pentoxifylline protects against oxidative damages caused by carbon tetrachloride induced liver injury in rat model. The Pentoxifylline may be used as an effective protector against chemical induced liver damages; however, further studies are warranted.

REFERENCES

1. Essawy AE, Abdel-Moneim AM, Khayyat LI, Elzergy AA. Nigella sativa seeds protect against hepatotoxicity and dyslipidemia induced by carbon tetrachloride in mice. *J Appl Pharm Sci* 2012;2 (10):021-5.
2. Wafay H, El-Saeed G, El-Toukhy S, Youness E, Ellaithy N, Agaibi M, Eldaly S. Potential effect of garlic oil and silymarin on carbon tetrachloride induced liver injury. *Austr J Basic Appl Sci* 2012; 6 (3):409-14.
3. Russmann S, Kullak-Ublick GA, Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. *Curr Med Chem* 2009; 16:3041-53.
4. Movssaghi S, Sharifi ZN, Mohammadzadeh F, Soleimani M. Pentoxifylline protects the rat liver against fibrosis and apoptosis induced by acute administration of 3,4-Methyleneoxy methamphetamine (MDMA or Ecstasy). *Ir J Basic Med Sci* 2013; 16: 922-27.
5. Obi FO, Omogbal LA, Orlafo OS, Ovat OD. Effect of a Short Time Post Carbon Tetrachloride Treatment Interval on Rat Plasma Enzyme Levels and Percentage Mortality. *J Applied Sci Environ Mgt* 2001; 5: 5-8.
6. Muriel P, Albo N, Perez-Alvarez VM. Kupffer cells inhibition prevents hepatic lipid peroxidation and damage induced by carbon tetrachloride. *Comp Biochem Physiol C Toxicol Pharmacol* 2001;130: 219-26.
7. Rasha SA, Ashraf AA, Aly R. Carbon tetrachloride-induced liver disease in rats: the potential effect of supplement oils with vitamins E and C on the nutritional status. *German Med Sci* 2009; 7: 1612-3174.
8. Rost DA, Welker DA, Welker J, Millionig G, Berger I, Autschbach F, et al. Liver-homing of purified glucose oxidase: A novel in vivo model of physiological hepatic oxidative stress (H₂O₂). *J Hepatol* 2007; 46: 482-91.
9. Seiffge D. Pentoxifylline: its influence on interaction of blood cells with the vessel wall. *Atherosclerosis* 1997;131:27-28.
10. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. *Gen Pharmacol* 1997; 29:181-196.
11. Nayak S, Nalabothu P, Sandiford S, Bhogadi V, Adogwa A. Evaluation of wound healing activity of *Allamanda cathartica* L. and *Laurus nobilis* L. Extracts on rats. *BMC Compl Alt Med* 2006; 6: 12.
12. Murat-Bilgin H, Atmaca M, Deniz-Obay B, Ozekinci S, Taşdemir E, Ketani A. Protective effects of coumarin and coumarin derivatives against carbon tetrachloride-induced acute hepatotoxicity in rats. *Exp Toxicol Pathol* 2011; 63(4): 325-30.
13. Harkkeri VI, Jaiparkash B, Lavhale RV, Karadi RV, Kuppast IJ. Hepatoprotective activity of *Anthus Excelsa* Roxb leaf extract on experimental liver damage in rats. *J Pharmacogn* 2002;11: 120-28.
14. Shaarawy SM, Tohamy AA, Elgendy SM, Elmageed ZY, Bahnasy A, Mohamed MS, et al. Protective effects of garlic and silymarin on NDEA-induced rats hepatotoxicity. *Int J Biol Sci* 2009; 5(6): 549-57.
15. Assimakopoulos SF, Thomopoulos KC, Labropoulou-Karatza C. Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? *World J Gastroenterol* 2009;15: 3194-3195.
16. Amini M, Runyon BA. Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy. *World J Gastroenterol* 2010 21; 16:4905-4912.
17. McHutchison JG, Runyon BA, Draguesku JO, Cominelli F, Person JL, Castracane J. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. *Hepatol* 1991; 14:96.
18. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. *Gastroenterol* 2000; 119:1637-48
19. Raetsch C, Jia JD, Boigk G, Bauer M, Hahn EG, Riecken EO, et al. Pentoxifylline downregulates

- profibrogenic cytokines and procollagen I expression in rat secondary biliary fibrosis. Gut 2002; 50:241-7.
20. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis 2011; 10:49.
 21. Rajesh M and Latha M. Preliminary evaluation of anti-hepatotoxic activity of Kamilari, a polyherbal formulation. J Ethnopharmacol 2004; 91: 99-104.
 22. Bashandy S, and Al-Wasel S. Carbon tetrachloride-induced hepatotoxicity and nephrotoxicity in rats: Protective role of vitamin C. J Pharm Toxicol 2001; 16(30): 283-92.
 23. Trivedi P, Mowat A. Carbon tetrachloride-induced hepatic fibrosis and cirrhosis in the developing rat: an experimental model of cirrhosis in childhood. Br J Exp Pathol 1983; 64(1): 25-33.
 24. Berman E, House D, Allis J, Simmons J. Hepatotoxic interactions of ethanol with allyl alcohol or carbon tetrachloride in rats. J Toxicol Environ Health 1992;37(1): 161-76.
 25. Brandao C, Ferreira H, Piovesana H, Polimeno N, Ferraz J, de-Nucci G. Developmental model of liver cirrhosis in rabbits. Clin Exp Pharma Physiol 2000;27:(12): 987-90.
 26. Wang P, Kaneko T, Tsukada H, Nakano M, Nakajima T, Sato A. Time courses of hepatic injuries by chloroform and by carbon tetrachloride comparison of biochemical and histopathological changes. Arch Toxicol 1997; 71: 638-45.

Address for Corresponding Author:**Dr. Haji Khan Khoharo,**

Assistant Professor/Consultant Physician,

Department of Physiology/Medicine

Faculty of Medicine and Allied Medical Sciences, Isra

University, Hyderabad.

Tel: 0331-2662500

Electronic Copy

Validity of Pleural Fluid Protein in Differentiating Tuberculous from Malignant Pleural Effusion

1. Ghulam Nabi Khokhar 2. Muhammad Ashfaq 3. Ikram Ullah Khan
4. Muhammad Ishaq 5. Israr Ahmed

1. Prof. of Pharmacology 2. Assoc. Prof. of ENT 3. Asstt. Prof. of Pharmacology 4. Prof. of Surgery
5. Prof. of Physiology, Jinnah Medical College, Peshawar

ABSTRACT

Objective: Validity of pleural fluid protein in differentiating tuberculous from malignant pleural effusion keeping histopathology as gold standard.

Study Design: Cross sectional study.

Place and Duration: This study was conducted in the Pulmonology department post graduate medical institute, Lady Reading Hospital Peshawar, Khyber Pakhtunkhwa (KPK) Pakistan from March 2009 to March 2010.

Materials and Methods: One hundred and seventy nine patients having clinical suspicion of pulmonary tuberculous and malignancy and fulfilling the inclusion criteria were subjected to Abrams needle biopsy, plural tissue was examined by histopathology. Biopsy in order to know the significant difference of pleural fluid protein level between tuberculous and malignant pleural effusion, histopathology finding and protein concentration were determined their frequency and percentage.

Results: Among total number of 179 patients one hundred and fourteen (62.69%) were male and sixty five (36.32%) were female. The age limit from 15-80 years, the result shows that 60.9% were tuberculous and 39.9% were malignant pleural effusion, among these malignant 20 (11.2%) showed primary and 50 (27.9%) secondary malignancy. Tuberculous PE was more common in younger age group while malignant PE in older age group, 32 number of patients falling in category A, 59 in category B, and 88 in category C. A protein level in belonging to category C, there was statistically significant difference between tuberculous and malignant PE, tuberculous PE have high concentration of protein than malignant PE. The category "A" have malignant PE.

Conclusion: Plural fluid total protein level determination and differentiating is a valuable tool in reaching to the diagnosis of suspected tuberculous from malignant pleural effusion provided it is used in addition to the adequate clinical scenario.

Key Words: Tuberculous pleural effusion, malignant pleural effusion, Exudates, pleural fluid protein.

INTRODUCTION

Pleural effusion (PE) is a common clinical problem both in developed and developing countries.⁽¹⁾ The etiological investigation of a pleural effusion is to determine whether the effusion is a transudate or exudates. Transudates reflect the presence of systemic disease with repercussion. On the mechanism of pleural fluid production and production and reabsorption.⁽²⁾ In contrast, exudates reflect, the presence of primary pleural disease and require etiological investigation.⁽³⁾ So in case with transudate PE, the diagnosis is usually made without any difficulty but exudative PE, require careful differential diagnosis that include tuberculous (TB) and metastatic cancers, which are often found to be the cause in a large number of patients.⁽⁴⁾⁽⁵⁾ Disease in any organ can cause exudative PE through a variety of mechanisms including, malignancy, immunologic response, lymphatic abnormality and non-infections inflammation.⁽⁶⁾ Tuberculous and malignancy are the most common causes of exudative PE in our country.⁽⁷⁾ The gold standard for diagnosis of pleural tuberculous is the identification of mycobacterium tuberculous in

pleural fluid or tissue⁽⁸⁾ however in clinical practice this identification is problematic of the low identification rate of the bacillus (less than 30% in pleural fluid and approximately 50% in the pleura) and the slow growth of mycobacterium in culture (about 60 days).⁽⁹⁾ The diagnosis of neoplastic pleural effusion is made based on the presence of malignant cells in the pleural fluid or tissue. The positivity rate of the cytological examination ranges from 40 to 87% higher than that obtained with a needle biopsy which ranges from 35 - 65%.⁽¹³⁾ Several tests for the diagnosis of tuberculous in pleural effusion have been used as tuberculous identification such as Adenosine deaminase, interferon, Lysozyme, the polymerase chain reaction.⁽¹¹⁾ and specific C antibodies.⁽¹²⁾ However these test need specific measure and expensive equipment that are not available in most laboratories particularly in developing countries, similarly in developed countries various new parameters like pleural viscosity, C- reactive protein, carcinoembryonic antigen, interleukin, interferon, vascular endothelial growth factor, tumor necrosis factor and pleural fluid T-cells are used for the determination of tuberculous and malignancy.⁽¹³⁾ In our

country only closed pleural biopsy and pleural fluid analysis are carried out for the diagnosis of tuberculose and malignancy. Yetkin et al. (2007)⁽¹⁴⁾ have discuss the role of viscosity in the differential diagnosis of excaudate pleural effusion. The pleural fluid protein level was > 30 g/l in excaudate in the contrast of a normal serum protein level. The Lights criteria⁽¹⁵⁾ indicate the concentration of protein in exudates is ratio of pleural fluid protein/serum protein >0.5. This study was aimed to explore the role of pleural fluid protein in differentiating tuberculose from malignant pleural effusion.

MATERIALS AND METHODS

The study was conducted at pulmonary department Post Graduate Medical Institute Lady Reading Hospital Peshawar, KPK, from March 2009 to March 2010. 179 patients were selected in this study, attending to pulmonology unit OPD, Emergency department and private clinics were evaluated. Patient's unit exudate pleural effusion was subjected to Abrams needle biopsy after taken informed written consent. The specimen was sent from Histopathological examination and pleural fluid for biochemical examination. The biopsy and laboratory analysis reports were collected and recorded in Proforma designed for this study, one standard laboratory was used for plural fluid analysis and pleural tissue was examined by well experience histopathologist to the diagnosis of malignant pleural effusion is based on the finding of neoplastic cells in pleural fluid or pleural tissue obtained by Abrams needle biopsy. Lymphocytic exudative pleural effusion, sign and symptoms consistent with Tuberculous Pleural Effusion, sign and symptom consistent with malignant pleural effusion all the patients male and female from 15-80 years of age. Transudative pleural effusion, cases of in conclusion pleural biopsy, polymorphic exudative pleural effusion/ emphyema, those patients who were uncooperative or not willing for pleural biopsy. Sample size was 179, using 9% prevalence, 95% confidence level and 4.2% margin of error, under W.H.O formula of sample size determination. In order to know the significant difference of pleural fluid level between tuberculose and malignant pleural effusion three categories were made is category "A" having from 4-5 g/dl and category C, having protein concentration higher than 5 g/dl. Data was analyzed using statistical package for social sciences (SPSS) version 10.0. Mean \pm standard deviation was calculated for age and pleural fluid protein level. Qualitative variables such as gender, pleural biopsy histopathology result were calculated in frequencies and percentages. Chi-square test was calculated for total pleural fluid protein level for tuberculose and malignant pleural effusion and P valve was significant it found < 0.05.

RESULTS

Total no of patients were 179. There were 114 (63.69%) male and 65(36.32%) were female. Age limit

was from 15-80 years, age wise distribution and result of TPE & MPE are given. Table (1). Age range was as follows the no of patients with age range 15-20 years was 12 (6.7%), 20 to 40 years 72 (40.2%), 41-60 years 67 (37.4%) and the patients age range of 61-80 years old were 28 (15.6%). TPE and MPE in various age groups was analyzed as that TPE was more common in age groups of < 20 years and 20-40 years, while in age groups of 41-60 years the tuberculous pleural effusion (TPE) cases were 22(20.9%) the mean age in tuberculose pleural effusion was 35.8+15.435D similarly in age groups of 61-80 years, the MPE was common than TPE. The mean age for malignant pleural effusion groups was 57+ 13.13 SD. TPE was common in younger age groups whole malignant, in older age group. Table (2). The pleural fluid protein were analyzed as n=32(17.9%) of patients were having PFP level of category A, n=59(33%) were in the category B, and n=88 (49.2%) of the patients were having protein level in category C, Table⁽³⁾.

Table No 1: Age – wise distribution of Tuberculous and malignant pleural effusion

Age Groups in Years	Diagnosis		Total
	TPE	MPE	
< 20 Year	11 10.1%	1 1.4%	12 6.7%
20-40 Years	67 61.5%	5 7.1%	72 40.2%
41-60 Years	22 20.2%	45 64.37%	67 37.4%
61-80 Years	9 8.3%	19 27.1%	28 15.6%
Total	109 100%	70 100%	179 100%

Table No. 2: Sex-wise distribution of Tuberculous and Malignant Pleural Effusion

Sex	Biopsy Result		Total
	TPE	MPE	
Male	76 69.7%	38 56.3%	114 63.7
Female	33 30.3%	32 45.7%	65 36.3
Total	109 100%	70 100%	179 100%

Table No. 3: The Categories of Pleural Fluid Protein Sensitivity and Specificity

Category	Frequency	%age	Sensitivity	Specificity
A	32	17.9	100.00	0
B	59	33.0	97.20	41.43
C	88	49.2	73.30	90.60

The sensitivity and specificity of pleural fluid protein of various categories was analyzed that at category A, the sensitivity was reaching to 100% but the specific was having the lowest value. At category "B" the sensitivity was 97.2% and specificity was 41.43% in category "C"

the sensitivity was the lowest of three having value 73.39% while the specificity was highest reaching to 90.6%. The positive (PPV) and negative predictive (NPV) values were analyzed for the three categories of plural fluid protein as that PPV was lowest for category C having value of 2.7 while NPV was 58.57 for category B, the PPV was 26.6 while the NPV was having value of 52.87. The PPV was highest for category "A" reading to the value 73.4 similarly the PPV was also highest in this category reading to the value of 88.57.

DISCUSSION

The distinction between tuberculous and malignant pleural effusion poses a diagnostic challenge to the physician. This is mainly due to the large proportion of cases in which no confirmatory diagnosis of pleural tuberculose is achieved by microbiological methods, and the sensitivity of cytological studies for malignancy is inadequate⁽¹⁶⁾. Tuberculose and malignancy are the most important and commonest causes of lymphocytic exudative pleural effusion. But the ratio is different in developed and developing countries. In areas where the tuberculose is not prevent MPE is more common than TPE. In a study, conducted in Spain (2003) on 392 patients 73% cases were MPE and 27% were TPE.⁽¹⁷⁾ Our study also showed that fact that TPE was commoner than MPE, accounting for 60.9% of total classes. Rest of cases (39.1 %) was malignant PE. Age has also been an important complementary variable while deciding about tuberculous or malignant PE. In our study the TPE was commoner in younger age group than MPE, Which was more in older age group. The mean age for TPE was 35.8 + 15.43 SD while 57 + 13.13 SF was the mean age for MPE. Our findings were comparable with the international studies Porcel JM et al (2003) reported in their study, the mean age of 30 years (range 22-40) in TPE while the mean age was 68(58-76) years in MPE cases.⁽¹⁸⁾ In our study we showed that pleural fluid protein level was higher in TPE than MPE and the difference was statistically significant at > 5g/dl (category "C") at < 4g/dl(category "A"). The MPE was commoner than TPE and the difference was significant. These finding were consistent with international data. Porcel- Perez JM et al (2004) reported that 73% of TPE were having pleural fluid protein level > 5g/dl. This value was the cutoff point for considering tuberculous etiology of the lymphocytic educative PE⁽¹⁴⁾. In another Spanish study conducted on 105 patients of TPE, 57% of patients showed pleural fluid protein level above 5g/dl.⁽¹⁹⁾ Antonangelo et al (2007) reported higher protein level in TPE than MPE. The protein level was 5.3+0.8g/dl in tuberculous PE while 4.2+1 was the level in MPE. The difference was statically significant.⁽²³⁾ Along with other laboratory parameters, protein level was utilized for discrimination

between tuberculous and malignant PE. The same findings were found in the study conducted by Liam et al (2000) on patients having tuberculous or malignant PE⁽²⁰⁾. Melo et al proposed 4.5g/dl as cutoff value for diagnostic presumption of TPE⁽²¹⁾. Porcel JM et al (2003) reported protein level of 5.4g/dl in tuberculous while the level was 4.2g/dl in malignant pleural effusion. The difference was statistically significant.⁽¹⁸⁾ The study recommended two scoring models for differentiation between tuberculous and malignant PE. It also revealed that in areas where ADA facility is unavailable, plural fluid total protein level can be used for differentiation between tuberculous and malignant PE as used in one of the scoring model lacking ADA. The pleural fluid protein showed sensitivity of 77% and specificity of 80%. These results are comparable with those of our study which showed 73.30% sensitivity and 90.60% specificity at pleural fluid protein level of > 5g/dl.

CONCLUSION

Plural fluid total protein level determination and differentiating it is a valuable tool in reaching to the diagnosis of suspected tuberculose from malignant pleural effusion provided it is used in addition to the adequate clinical scenario.

REFERENCES

- Magsi JA khan SU, Awan SR. Pleural biopsy in the diagnosis of lymphatic educative pleural effusion. Ann king Edward Med Coll 2005;11:572-4.
- Maskell NA, Butland JA. BTS Guidelines for the investigation of unilateral pleural effusion in adults. Thorax 2003;58:8-17.
- Story DD, Dines DE, Coles DT. Pleural effusion: a diagnosis dilemma. Am J med Assoc 1976; 236: 2183-6.
- Gannels JJ, Perplexing plural effusion. Chest 1978; 47:390-3.
- Kesmiri M, Hashemzadeh M. use of cholesterol in differentiating of educative and trasudative pleural effusion. Med Iran 1997;2:187-9.
- Sahn SA. Plural anatomy, physiology and diagnostic producers. In: Baum GL, editors, Textbook of pulmonary diseases. 6th ed. Philadelphia: Lippincott Raven;1998.p.255-65.
- Anwar R, Farooqi Ji causes of lymphocytic exudative pleural effusion as revealed by percutaneous pleural biopsy: experience from Peshawar. Pak J Med Sci 2005;21:39-43.
- Gopi A, Madahavan SM, Sharma SK, Diagnosis and treatment of tuberculous pleural effusion in 2006. Chest 2007;131:880-9.
- Valdes L, Pose A, San-jose E, Martinez – Vazquez JM. The positive pleural effusion. A retrospective study of cytopathologic diagnosis with autopsy confirmation. Actacytol 1992;36:329-32.

10. Villena V, Rebollo MJ, Aguado JM, Galan A, Encuentra AL, palenque E. polymerase chain reaction for the diagnosis of plural tuberculose in immunocompromised and immunocompetent patients. Clin infect Dis 1998;26:212-4.
11. Caminero JA, de-Castro T, Lafarga B, Daiz F, Cabrera P. Diagnosis of plural tuberculose by detection of specific IgG anti-antigen 60 in serum and plural fluid. Respiration 1993;60:58-62.
12. Hashimoto K. T-Helper type 1/T-Helper type 2 balance in malignant pleural effusions compared to tuberculose effusion. Chest 2005;128:4030-5.
13. Chakrabarti B, Ryland I, sheard J, Christopher J, Earis EJ. The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusion. Chest 2006;129:1549-55.
14. Antonangelo L, varges FS, Seisceno M, Bomboarda S, Teixeira L, Sales RK. Clinical and laboratory parameters in the differential diagnosis of plural effusion secondary to tuberculose or cancer. Clinics 2007;62:585-90.
15. Yetkin O, Tek I, Yethkin F, Numanoglu N. Role of plural viscosity in the differential diagnosis of exudative pleural effusion. Respirol 2007;12: 267-71.
16. Light RW, MacGreg MI, Luchsinger PC, Ball WC. Pleural effusion: the diagnostic separation of transudates pleural effusions. Chest 1997;111: 970-80.
17. Porcel JM, Vives M. Differentiating tuberculose from malignant pleural effusion: A scoring model. Med Scimonit 2003;9:175-80.
18. Chierakul N, Kanitsap A, Chaiprasert A, Virivataveekul R. A simple Reactive protein measurement for the differentiation between tuberculose and malignant pleural effusion. Respirol 2004;9:66-9.
19. Haro M, Ruiz -Manzano J, Gallego M, Abad J, Manterola JM, Morera J. Pleural tuberculose: analysis of 105 cases. Enferm Infect Microbiol Clin 1996;14:285-9.
20. Liam CK, Lim Wong CM. Differences in plural fluid characteristic, white cell count, biochemistry of tuberculose and malignant plural effusions. Med Malaysia 2000;55:21-8.
21. Melo AF, Santos ML. Diagnostico Da tuberculose pleural pelaada, Isolada ou combinadaaoutras variaveis inclusive em hiv positivos. Folha Med

Address for Corresponding Author:**Prof. Dr. Muhammad Ishaq**

Chairman & Founder

Jinnah Medical College

Wazirabad Road Peshawar

Cell: +92-333-9152060

Email: Ishaq@Jmcp.Edu.Pk : Faizimrd@Gmail.Com

Electronic Copy

To Assess the In vitro Genotoxicity of Metformin and Aspartame alone & In Combination

1. Amna Nazar 2. Rafique Ahmed 3. Sajida Bano 4. Muhammad Ashraf 5. Imran Altaf
6. Aqeel Javeed

1. Senior Lecturer of Pharmacology, HM&DC, Gujrat 2. Prof. of Anatomy, HM&DC, Gujrat 3. Prof. of Biochemistry, HM&DC, Gujrat 4. Prof. & Chairman of Pharmacology, UVAS, Lahore 5. Asstt. Prof. of Microbiology, UVAS, Lahore 6. Asstt. Prof. of Pharmacology, UVAS, Lahore

ABSTRACT

Objective: Metformin is a known oral antidiabetic agent belonging to the class of biguanides, widely prescribed for the treatment of type 2 Diabetes Mellitus (DM). In this study the genotoxic potential of metformin was studied alone and in combination with an artificial sweetener aspartame as most of the diabetic patients utilized this low calorie sweetener to reduce their sugar consumption per day. Many complaints regarding its potential to cause DNA damage have been submitted to FDA

Study Design: Experimental study

Place and Duration of Study: This study was carried out at the Department of Pharmacology and Toxicology, University of Veterinary and Animal Sciences Lahore from 1st Jan 2011 to Dec 2011.

Materials and Methods: Peripheral Blood Lymphocytes were exposed to various concentrations of metformin, aspartame and their combination. DNA damage was checked by comet assay. The data was analyzed by using Analysis of Variance (ANOVA) by Statistical Package of Social Sciences SPSS

Results: Exhibited dose dependant rise in comet tail lengths. Moreover the data advocates that tail lengths of lymphocytes after exposure to aspartame were high as compared to metformin. When lymphocytes were exposed to combination of aspartame and metformin and DNA damage was checked by comet assay, the results were significantly different ($p < 0.05$) as compared to metformin and aspartame alone.

Conclusion: It can be concluded from the present study that aspartame is posing great genotoxic threat to the cells as compared to metformin and the combination is even more toxic to DNA, so the drug regime of diabetic patient must be closely monitored. There is further need of more studies in this regard.

Key Words: Metformin, Aspartame, Diabetes Mellitus, Comet Assay, DNA damage.

INTRODUCTION

Among the antidiabetic agents, metformin (1-(diaminomethylidene)-3,3-dimethyl-guanidine) is reported to have several properties, such as it reduces formation of Advance glycation end products (AGE), helps to regain the reduced levels of glutathione in DM and increases the antioxidant defense¹. A recent study demonstrates that metformin increases AMPK activation in MIN6 cells responsible for insulin production and primary rat beta cells in dose dependant manner. Prolonged exposure of metformin (>24h) resulted in a gradual rise in apoptotic beta-cells similar to the effect which was documented for AMPK-activator AICAR².

AMPK is an enzyme that plays a role in cellular energy homeostasis and its persistent activation has recently been concerned with apoptosis of beta cells of pancreas and in cell death of islets of langerhans³.

Activation of AMPK by metformin might be mediated by the mitochondria-derived RNS in vivo in C57BL6 mice⁴. There are certain studies supporting that metformin stimulate cell death in p53-deficient HCT116 cells in condition of limited glucose availability. So metformin can be beneficial to be used

in patients with p53 deficient tumors which have become resistant to chemotherapy⁵.

The antidiabetic drug has also been reported to cause a decline in the occurrence of mammary carcinomas in hamsters when administered in therapeutic doses. Most probably it would have damaged the genetic material of the carcinoma cells to reduce chances of cancer prevalence in mammary cells of hamster⁶. Certain reports support combination therapy of metformin and doxorubicin which kills both cancer stem cells and non-stem cancer cells in culture, and cause reduction in tumor mass and delays relapse more efficiently than metformin of doxorubicin can do alone⁷.

Onaran et al. (2006) suggested that therapeutic concentrations of metformin could not check DNA damage caused by oxidative stimulus in cultured human lymphocytes regardless of its anti oxidant characteristic⁸.

The use of artificial sweetener aspartame is increasing day by day by both diabetic as well as non diabetic population as a sugar substitute. Aspartame is mainly composed of phenylalanine (50%), aspartic acid (40%) and methanol (10%). In this study different doses of aspartame was administered to check the cellular effects of aspartame on brain and it was revealed that

consistent use of aspartame might cause various mental disorders due to damage to the brain cells⁹.

The effect of an artificial sweetener Aspartame was studied to investigate oxidative stress and brain monoamines in normal conditions and also after administration of lipopolysaccharides intraperitoneally in mice. The results revealed that aspartame alone and in combination with any mild systemic inflammatory response enhance inflammation and oxidative stress in brain cells¹⁰.

MATERIALS AND METHODS

Chemicals: Tested chemicals i.e., Aspartame and Metformin were provided by Popular Laboratories, Lahore Pakistan. Dimethyl Sulfoxide (DMSO) was purchased from Merck Pakistan. All other chemicals and media used were of analytical grade.

Comet Assay: Cavity slides were layered with 1% Normal melting Agarose and placed in refrigerator for 2-12 hours. Peripheral blood lymphocytes were separated by using Lymphocyte separating medium. 3ml of 1:1 ratio of peripheral blood with PBS was layered onto 4ml of Lymphocyte separating medium and after centrifuging lymphocyte suspension was made in RPMI-1640¹¹. Now the lymphocytes were exposed to various concentrations of test chemicals i.e. metformin, aspartame and combination doses of aspartame and metformin. The exposed cells were mixed 1% low melting point agarose and layered onto the precoated slides. After solidification 3rd layer of Agarose 1% was layered onto the same slide and allowed to solidify. Subsequently the slides were dipped in the lysing solution (pH 10) consisting of high salt concentration and detergent for 2 hours. After that slides were exposed to alkaline buffer (pH > 13) consisting of 1mM EDTA and 300mM NAOH for DNA unwinding for 20 minutes. The cells were subjected to electrophoresis for 20 minutes at 25 volts and 300mA. Slides were washed with 0.4M TRIS buffer/ Neutralizing buffer (pH 7.5) 3 times and then stained with Ethidium bromide¹². PBS was used as negative control and DMSO 20% was used as positive control¹³.

Microscopic Analysis: The slides were visualized by using Fluorescent Microscope at 40X objective. The DNA damage was quantified by measuring tail lengths of 25 consecutive cells and quantification was done in triplicate manner. Four damage categories were established according to the method described by Valencia-Quintana and coworkers (Valencia-Quintana et al. 2012).

Class 0= Undamaged cells

Class 1= Tail length \leq Head Diameter

Class 2= Tail Length > Head Diameter BUT Tail Length \leq Double of Head Diameter

Class 3= Tail Length > Double of Head Diameter

The damage to the DNA was expressed as %age fragmentation and ultimately finding the DNA damage

index of each concentration according to the following formula.

Damage Index= No. of cells in Class.1+ (2×No. of cells in Class.2) + (3×No. of cells in Class.3)

Fragmentation %= $\frac{\text{No. of cells in Class.1} + \text{No. of cells in Class.2} + \text{No. of cells in Class.3}}{\text{Total Number of cells under observation}} \times 100$

Total Number of cells under observation

Statistical Analysis: The data was analyzed by using Analysis of Variance (ANOVA) by Statistical Package of Social Sciences SPSS for windows (version 16; SPSS Inc; Chicago IL; USA) and Tukey's test was applied. The value of $p < 0.05$ was considered significant.

RESULTS

The results of comet assay on lymphocyte sampled from peripheral blood treated with different concentrations of metformin are presented in Table 1. Treatment with different doses of metformin induced a significant increase in DNA damage at 200, 250, 300, 350 and 400 $\mu\text{g/ml}$ as these values were significantly higher ($p < 0.01$) than that found in the negative control. It is noted that percentage of fragmentation of DNA and damage index increases as the concentration of metformin increases reaching a maximum value at 400 $\mu\text{g/ml}$. The effect observed with 10, 20, 80, 100 and 150 $\mu\text{g/ml}$ do not show significant differences ($p < 0.05$) when compared with the negative control.

Lymphocytes were exposed to 10 different concentrations of aspartame presented in the Table 2. The treatment with various doses of aspartame showed same order of genotoxicity as that of metformin. Aspartame caused significant rise ($p < 0.01$) in DNA damage at 500, 1000, 2000, 4000, 8000 $\mu\text{g/ml}$ as compared to the DNA damage caused by negative control. The percentage fragmentation of DNA and Damage Index becomes high when the exposed concentration of aspartame increases and the maximum DNA damage index is found at 8000 $\mu\text{g/ml}$. However the results with lower doses i.e. 12.5, 25, 50, 100 and 250 $\mu\text{g/ml}$ did not show any significant rise ($p < 0.05$) in the DNA damaging potential as compared to negative control.

When the cells were exposed to the combination of aspartame and metformin, the results were significantly high ($p < 0.05$) as compared to metformin and aspartame individually. Here again dose dependant rise in genotoxicity is observed in manner similar to the individual drugs. We can see a significant rise ($p < 0.01$) in DNA damage index at 500:200, 1000:250, 2000:300, 4000:350, 8000:400 $\mu\text{g/ml}$ as compared to the negative control (Table 3). Percentage fragmentation and DNA damage index increases as the concentration of aspartame and metformin increases with maximum DNA damage index obtained at 8000:400 $\mu\text{g/ml}$ which has highly significant difference ($p < 0.001$) with negative control.

Table No.1: DNA Damage induced by different concentration of Metformin in lymphocytes evidenced from Comet assay.

Sr. No.	Conc.	Class 0	Class 1	Class 2	Class 3	Fragmentation %	Damage Index
A	DMSO 20%	2	2	6	15	92	59
B	-ve Control	24	1	0	0	4	1
1	10µg/ml	24	1	0	0	4	1
2	20 µg/ml	23	2	0	0	8	2
3	80 µg/ml	22	3	0	0	12	3
4	100 µg/ml	22	3	0	0	12	3
5	150 µg/ml	22	2	1	0	12	4
6	200 µg/ml	20	2	3	0	28	8*
7	250 µg/ml	16	5	4	0	36	13*
8	300µg/ml	14	4	6	1	44	19*
9	350 µg/ml	13	3	7	2	48	23*
10	400 µg/ml	12	3	8	2	52	25*

*=significant difference (p<0.01) as compared to negative control analyzed by SPSS Windows Version 16 Tukey's Test.

Table No.2: DNA Damage induced by different concentration of Aspartame in lymphocytes evidenced from Comet assay.

Sr. No.	Conc.	Class 0	Class 1	Class 2	Class 3	Fragmentation %	Damage Index
A	DMSO 20%	2	2	6	15	92	59
B	-ve Control	24	1	0	0	4	1
1	12.5 µg/ml	24	1	0	0	4	1
2	25 µg/ml	23	2	0	0	8	2
3	50 µg/ml	23	2	0	0	8	2
4	100 µg/ml	22	3	0	0	12	3
5	250 µg/ml	22	2	1	0	12	4
6	500 µg/ml	19	3	3	0	24	9*
7	1000 µg/ml	16	2	7	1	40	19*
8	2000 µg/ml	14	2	7	2	44	22*
9	4000 µg/ml	12	2	8	3	52	27*
10	8000 µg/ml	9	1	11	4	64	35*

*=significant difference (p<0.01) as compared to negative control analyzed by SPSS Windows Version 16 Tukey's Test.

Table No.3: DNA Damage induced by different concentration of Combination of ASP: MET in lymphocytes evidenced from Comet assay.

Sr. No.	Conc.	Class 0	Class 1	Class 2	Class 3	Fragmentation %	Damage Index
A	DMSO 20%	2	2	6	15	92	59
B	-ve Control	24	1	0	0	4	1
1	12.5:10µg/ml	24	1	0	0	4	1
2	25:20 µg/ml	23	2	0	0	8	2
3	50:80 µg/ml	23	1	1	0	8	3
4	100:100 µg/ml	23	1	1	0	8	3
5	250:150 µg/ml	22	2	1	0	12	4
6	500:200 µg/ml	15	4	3	3	56	19*
7	1000:250 µg/ml	10	4	9	2	60	28*
8	2000:300µg/ml	8	3	10	4	68	35*
9	4000:350 µg/ml	6	2	12	5	76	41*
10	8000:400 µg/ml	4	2	14	5	84	45*

*=significant difference (p<0.01) as compared to negative control analyzed by SPSS Windows Version 16 Tukey's Test.

When the all the three results were analyzed statistically for multiple comparison by applying Analysis of Variance (ANOVA) Post Hoc Test LSD by Statistical

Package of Social Sciences SPSS for windows (version 16; SPSS Inc; Chicago IL; USA) it was revealed that combination doses were significantly (p < 0.05) highly

genotoxic as compared to metformin. However the results of combination doses were not significantly ($p < 0.05$) different as compared to aspartame individually.

DISCUSSION

The prime objective of therapy for type 2 diabetes mellitus is to obtain and sustain good glycemic control, and to reduce the risk of secondary complications associated with DM. Metformin is considered a gold standard treatment of DM along with certain interventions in lifestyle of patients. Metformin also have efficacy against polycystic ovary syndrome and various neoplasms¹⁴.

The antidiabetic drug has been reported to cause a decline in the occurrence of mammary carcinomas in hamsters when administered in therapeutic doses. Most probably it would have damaged the genetic material of the carcinoma cells to reduce chances of cancer prevalence in mammary cells of hamster⁶. The results of comet assay on various concentrations of metformin exhibited dose dependent rise in its potential to damage DNA. Percentage fragmentation of DNA and damage index increases as the concentration of metformin increases reaching a maximum value at 400 μ g/ml. The results of this study are in accordance with the fact that prolonged exposure of metformin may become a potential threat of genotoxicity. A study was conducted to check the genotoxic potential of metformin in Chinese Hamster Ovary cells and DNA damage was checked by Chromosomal Aberration Assay and single cell gel alkaline electrophoresis/comet assay. Results showed significant damage to the DNA by metformin¹⁵. However data is available which supports that metformin is neither cytotoxic nor genotoxic when various concentrations were administered in vivo condition to diabetic and non diabetic rats¹⁶. Another study was conducted to evaluate the prevention of DNA damage in human lymphocytes by metformin. Cells were exposed to various concentrations of metformin and subsequently they were incubated with cumene hydroperoxide a known DNA damaging substance. The results were evaluated by comet assay revealing that metformin is unable to prevent DNA damage by any chemical causing oxidative stress to the cells⁸. Metformin kills cancer stem cells in genetically different type of breast cancer so combination therapy of metformin and doxorubicin is used to reduce tumor mass and delays relapse more efficiently than metformin and doxorubicin can do alone⁷.

The underlying mechanism responsible for DNA damage by metformin may lie in the fact that metformin may inhibit mitochondrial respiration cells and ultimately there is rapid rise in the superoxide level because of inhibition of cellular respiration due to insult to the mitochondria¹⁷. According to Warburg theory of cancer, the key reason for development of tumor is an inadequate cellular respiration due to insult to mitochondria¹⁸.

The use of sweetening agent by diabetic individuals is common. A survey of our diabetic clinic population showed that 65% regularly use these products¹⁹. It is

widely used by the diabetic population for the sweet taste avoiding high calories through sugar consumption²⁰. The results of comet assay revealed that aspartame exhibited significant potential of genotoxicity when different concentrations of the sweetener were exposed to the lymphocytes. Damage Index of DNA revealed that aspartame was causing more damage to the DNA of peripheral blood lymphocytes as compared to metformin when compared with the negative control. The results of comet assay are in agreement with a study exhibiting significantly high ($p < 0.01$) carcinogenic potential on prolonged use, demonstrating that these artificial sweeteners are not entirely safe although they are FDA approved²¹.

Results also state that there is dose dependant rise in the DNA damaging potential of aspartame endorsing the statement that aspartame can cause chromosomal aberrations at all concentrations (500, 1000 and 2000 μ g/ml) and treatment periods, in human lymphocytes, in a dose dependant manner²². The underlying mechanism of DNA damage caused by aspartame may lie in the fact that prolonged exposure of aspartame may result in detectable amount of methanol in blood²³. As aspartame consists of 3 components aspartic acid, phenylalanine and methanol which is most dangerous of all²⁴. Various studies revealed the data that aspartame is responsible for increased frequency of lymphomas and leukemias and is also responsible in significant rise in prevalence of transitional cell carcinomas of renal pelvis at doses approximated with the ADI of aspartame for humans. These results indicate that aspartame proves to be the multipotential carcinogen greatly affecting the quality of life²⁵.

As far as results of the combination doses are concerned they cause severe damage to DNA when exposed to the lymphocytes and cells were quantified using comet assay. %age fragmentation and DNA damage index were significantly high ($p < 0.05$) as compared to individual results of metformin and aspartame. The data advocates the same threshold level of genotoxicity but the intensity of the genotoxic effect was relatively high in case of combination as compared to the individual drugs. The additive effect of both aspartame and metformin on DNA damage may be accredited to the fact that aspartame is responsible for increased oxidative stress to the cells¹⁰. Along with that metformin is associated with production of reactive nitrogen species from mitochondria⁴ which ultimately hinder the cellular respiration leading to cell damage.

CONCLUSION

It can be concluded from the present study that aspartame is posing great genotoxic threat to the cells as compared to metformin. When combination of aspartame and metformin were exposed to the peripheral blood lymphocytes the results showed significantly high ($p < 0.05$) genotoxicity as compared to metformin and aspartame individually. Most of the diabetic patients utilize aspartame as an artificial sweetener along with their daily regimen of antidiabetic drug metformin. So caution must be taken while using

both these products together as it may cause significant damage to the cells of body.

REFERENCES

1. Arnalich F, Hernanz A, Lopez-Maderuelo D, De la Fuente M, Arnalich FM, Andres-Mateos E, Fernandez-Capitan C, Montiel C. Intracellular glutathione deficiency is associated with enhanced nuclear factor kappa B activation in older non-insulin dependent diabetic patients. *Free Radic Res* 2001;35(6): 873-884.
2. Kefas BA, Cai Y, Kerckhofs K, Ling Z, Marten G, Heimberg H, Pipeleers D, Van de Castele M. Metformin induced stimulation of AMP-activated protein kinase in beta-cells impairs their glucose responsiveness and can lead to apoptosis. *Biochem Pharmacol* 2004; 68: 409-416.
3. Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA. Inhibition of AMP activated protein kinase protects pancreatic β -cells from cytokine-mediated apoptosis and CD8 T-Cell-Induced cytotoxicity. *Am Diab Assoc* 2008;57(2): 415-23.
4. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. *J Biol Chem* 2004; 279(42): 43940-43951.
5. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res* 2007;67(14): 6745-6752.
6. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. *Exp Gerontol* 2005; 40(8-9): 685-693.
7. Hirsch HA, Iliopoulos D, Tsihli PN, Struhl K. Metformin selectively targets cancer stem cells and acts together with chemotherapy to block tumor growth and prolong remission. *Cancer Res* 2009;69: 7507-7511.
8. Onaran I, Guven GS, Ozdas SB, Kanigur G, Vehid S. Metformin does not prevent DNA damage in lymphocytes despite its antioxidant properties against cumene hydroperoxide-induced oxidative stress. *Mutat Res* 2006; 611: 1-8.
9. Humphries P, Pretorius E, Naude H. Direct and indirect cellular effects of aspartame on the brain. *Eur J Clin Nutr* 2008;62(4):451-462.
10. Abdel-Salam OM, Salem NA, Hussein JS. Effect of aspartame on oxidative stress and monoamine neurotransmitter levels in lipopolysaccharide-treated mice. *Neurotox Res* 2012; 21(3): 245-55.
11. Dhawan A, Bajpayee M, Pandey AK, Parmar D. 2009. Protocol for the single cell gel Electrophoresis / comet assay for rapid Genotoxicity assessment. ITRC.
12. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, et al. The single cell gel/comet assay: Guidelines for in vitro and in vivo genetic toxicology testing. *Environ Mol Mutagen* 2000;35(3): 206-221.
13. Valencia-Quintana R, Gómez-Arroyo S, Marian Waliszewski S, Sánchez-Alarcón J, Gómez-Olivares JL, Flores-Márquez AR, et al. Evaluation of the genotoxic potential of dimethyl sulfoxide (DMSO) in meristematic cells of the root of *Vicia faba*. *Toxicol Environ Health Sci* 2012;4(3): 154-160.
14. Marić A. Metformin – more than ‘gold standard’ in the treatment of type 2 diabetes mellitus. *Diabetol Croat* 2010;39-3.
15. Amador RR, Longo JP, Lacava ZG, Dórea JG, Almeida Santos Mde F. Metformin (dimethylbiguanide) induced DNA damage in mammalian cells. *Genet Mol Biol* 2011;35(1): 153-158.
16. Attia SM, Helal GK, Alhaider AA. Assessment of genomic instability in normal and diabetic rats treated with metformin. *Chem Biol Interact* 2009; 180: 296-304.
17. González-Barroso MM, Anedda A, Gallardo-Vara E, Redondo-Horcajo M, Rodríguez-Sánchez L, Rial E. Fatty acids revert the inhibition of respiration caused by the antidiabetic drug metformin to facilitate their mitochondrial β -oxidation. *Biochim Biophys Acta* 2012; 1817(10): 1768-75.
18. Verschoor ML, Ungard R, Harbottle A, Jakupciak JP, Parr RL, Singh G. Mitochondria and Cancer: Past, Present, and Future. *Bio Med Res Int* 2013; 1-10.
19. Coulston AM, Hollenbeck CB, Donner CC, Williams R, Chiou YM, Reaven GM. Metabolic effects of added dietary sucrose in individuals with non-insulin dependent diabetes mellitus (NIDDM). *Metabolism* 1985; 34: 962-6.
20. Nehrling JK, Kobe P, McLane MP, Olson RE, Kamath S, Horwitz DL. Aspartame use by persons with diabetes. *Diab Care* 1985;8(41): 5-7.
21. Mukherjee A, Chakrabarti J. In vivo cytogenetic studies on mice exposed to Acesulfame K-a non-nutritive sweetener. *Food Chem Toxicol* 1997;35: 1177-1179.
22. Rencüzoğullari E, Tüylü BA, Topaktaş M, İla HB, Kayraldız A, Arslan M, Diler SB. Genotoxicity of aspartame. *Drug Chem Toxicol* 2004;27(3): 257-268.
23. Iyyaswamy A, Rathinasamy S. Effect of chronic exposure to aspartame on oxidative stress in the brain of albino rats. *J Biosci* 2012; 37(4): 679-88.
24. Lydon C. Could there be evils lurking in aspartame consumption? *Oxygen Magazine*, retrieved October 30, 2008 from <http://www.aspartame.com/lydon.htm>
25. Soffritti M, Belpoggi F, Esposti DD, Lambertini L, Tibaldi E, Rigano A. First experimental demonstration of the multipotential carcinogenic effects of aspartame administered in the feed to sprague-dawley rats. *Environ Health Perspect* 2006;114(3): 379-85.

Study of Type 2 Diabetes Mellitus and its Correalation with Blood Groups

1. Shamsul Arfin Qasmi 2. Aftab Ahmed Khan 3. Hasan Askari 4. Rabiya Pirzada

1. Prof. of Pathology, Mohammad Bin Qasim M&DC, Karachi 2. Asstt. Prof. of Dental Materials Science, Mohammad Bin Qasim M&DC, Karachi 3. Lecturer of Biochemistry, Mohammad Bin Qasim M&DC, Karachi 4. Sindh Medical College (DUHS). Karachi

ABSTRACT

Objectives: To ascertain any relation between T2 Diabetes Mellitus with Blood Groups of the patients coming in the OPD.

Study Design: Experimental / Analytical study

Place and Duration of Study: This study was carried out at Med Path Laboratories and Diagnostic Center Gulshan-e-Iqbal Karachi & KESC Medical center Karachi from August 2012 to December 2012.

Materials and Methods: The present study deals with the distribution of the ABO blood types in patients with diabetes mellitus. 500 samples were collected from Med Path Laborites and Diagnostic Center KESC Medical Center.

Results: The study shows blood group B was prevalent at a high percentage among patients with DM type 2. Blood group O+ were significantly higher among the male diabetics and blood group B+ among female diabetics. People with middle-aged group were seen to be more affected with type 2 diabetes mellitus.

Conclusion: It is highly recommended that this study may proceed further and the affiliation of T2DM can be screened at molecular level to find out the exact mechanism of action for susceptibility to these particular Blood Groups.

Key words: Diabetes Mellitus, Correalation, Blood Groups

INTRODUCTION

Diabetes Mellitus (DM) is a set of related diseases in which the body cannot regulate the amount of sugar (specifically, glucose) in the blood. The blood delivers glucose to provide the body with energy to perform all of a person's daily activities. The liver converts the food a person eats into glucose. In diabetes, glucose in the blood cannot move efficiently into cells, so blood glucose levels remain high. This not only starves all the cells that need the glucose for fuel, but also harms certain organs and tissues exposed to the high glucose levels.¹

Classification of Diabetes Mellitus: Diabetes Type 1 Patients produce no insulin at all. Diabetes Type 2 – Patients don't produce enough insulin, or insulin is not working properly. Gestational Diabetes - develops diabetes just during your pregnancy.

Maturity onset diabetes of the young (Monogenic Diabetes) (MODY)-Refers to any of several hereditary forms of diabetes caused by mutations in an autosomal dominant gene disrupting insulin production.

Type 1 diabetes (T1D): The body stops producing insulin or produces too little insulin to regulate blood glucose level.

Type 1 diabetes involves about 10% of all people with diabetes. Type 1 diabetes is typically diagnosed during childhood or adolescence. It used to be referred to as juvenile-onset diabetes or insulin-dependent diabetes mellitus.²

Causes of Type 1 diabetes: Type 1 diabetes can occur in an older individual due to destruction of the pancreas by alcohol, disease, or removal by surgery. It also results from progressive failure of the pancreatic beta cells, the only cell type that produces significant amounts of insulin.

Type 2 diabetes (T2D): Although the pancreas still secretes insulin, the body of someone with type 2 diabetes is partially or completely unable to use this insulin. This is sometimes referred to as insulin resistance. The pancreas tries to overcome this resistance by secreting more and more insulin.

Causes of Type 2 Diabetes: Type 2 diabetes is thought to be caused by a combination of genetic and environmental factors.

Genetic causes — Many people with type 2 diabetes have a family member with either type 2 diabetes or other medical problems associated with diabetes, such as high cholesterol levels, high blood pressure, or obesity. **Environmental conditions** — Environmental factors such as eating habits and physical activity are, combined with genetic causes, affect the risk of developing type 2 diabetes.³

Gestational Diabetes: A small number (about 3 to 5 percent) of pregnant women develop diabetes during pregnancy, called "gestational diabetes."

Maturity onset diabetes of the young: MODY is a rare form of diabetes which is different from both Type 1 and Type 2 diabetes, and runs strongly in families. MODY is caused by a mutation (or change) in a single gene.

It was reported that DM type 2 is the most common type, accounting for 90-95% of all diabetic cases.⁽⁴⁾ In 1998 it was estimated that there were almost 140 million people with diabetes and the predictions by Hilary King indicate that this figure would rise up to 300 million by the year 2025.⁵

Blood Groups: Blood groups are created by molecules present on the surface of red blood cells (and often on other cells as well). The major human blood group system is ABO. The blood group of a person depends upon the presence or absence of two genes, A and B. The ABO blood groups were the first to be discovered (in 1900) by Karl Landsteiner and are the most important in assuring safe blood transfusions. The Rh blood group system is the second most significant system for blood grouping.

Rh factor refers to Rh D antigen only. Determination of Rh factor along with ABO is essential for defining the Rh +ve or Rh -ve status of the individual. Around 85% of the human population is Rh +ve while 15% is Rh -ve.⁶

The ABO & Rh systems are the most significant blood group systems from the clinical point of view.⁷

Many researchers have made attempts to determine the significance of particular ABO phenotypes for susceptibility to disease. The relationship between the ABO/rhesus (Rh) blood groups and various diseases has generated a great deal of interest⁸. Certain diseases show a strong association with the ABO/Rh blood groups, notably peptic ulcer and gastric cancer⁹. Individuals with blood group O have been found to be at a higher risk of contracting cholera than those with other blood groups. The ratio of this risk of group O to group A individuals has been reported as 1.35:1. Oral candidiasis shows a higher incidence of group O over other ABO groups¹⁰. Small pox virus has been found to carry an A antigen-like structure, so that individuals who possess a naturally occurring anti-A (group O and B individuals) are thought to have an increased resistance to the infection.¹¹

This could be attributed to the inability of the immune system of group A individuals to recognize the A like antigen of the tumor cells as foreign and cannot destroy them, but group O and B individuals do have a naturally occurring anti-A that are most likely to destroy tumor cells.¹²

It has been reported that group O individuals are proportionately more prone to bleeding than individuals of the other blood groups; and group A individuals with highest incidence of thrombosis than in any other group.¹³

The blood groups of diabetics have been extensively studied since McConnell's suggestion in 1955 of an increased frequency of blood group A among these patients.¹⁴ In Copenhagen, an excess of blood group O was found in male diabetics.¹⁵

No diseases are known to result from the lack of

expression of ABO blood group antigens, but the susceptibility to a number of diseases has been interrelated to a person's ABO phenotype.¹⁶ Such correlations remain conflicting and include the observation that gastric cancer is more common in group A individuals, whereas gastric and duodenal ulcers occur more commonly among blood group O individuals.¹⁷ In the present study, an attempt has been made to investigate any association with the ABO blood types and diabetes mellitus type 2.

MATERIALS AND METHODS

The present study was an epidemiological study. A total no of 500 blood samples from patients with Diabetes mellitus (Type 2) were collected from the Med Path Laboratory. Since both gender differentiations are not known to exist in the ABO blood type system, the samples collected from both males and females were pooled for the analyses.

Materials:

- BSL 2 lab
- Gloves
- Lab coat
- Blood typing tiles
- 500 diabetic patients Blood samples
- Synthetic anti-Rh (D) serum
- Synthetic anti-A serum
- Synthetic anti-B serum
- Justors (50 ul)
- Mixing sticks (blue, yellow, and white)

Method:

Blood Sample Collection: For the ABO blood types, standard serological procedures were followed using the anti-A, anti-B and anti-D antisera. A blood sample drawn from a vein in the arm or a finger-prick

Abo Test:

1. Using the justor, place a drop of the blood sample in each demo created area of the blood typing tile. Replace the tip of the jester.
2. Add a drop of synthetic anti-A (blue) to the well labeled A.
3. Add a drop of synthetic anti-B serum (yellow) to the well labeled B.
4. Add a drop of synthetic anti-Rh serum (clear) to the well labeled Rh.
5. Using a different color mixing stick for each well (blue for anti-A, yellow for anti-B, white for anti-Rh), gently stir the synthetic blood and anti-serum drops for 30 seconds. Remember to discard each mixing stick in danger box after a single use to avoid contamination of your samples.
6. Carefully examine the thin films of liquid mixture. If a film remains uniform in appearance, there is no agglutination. If the sample appears granular, agglutination has occurred. Determine the blood type

of the sample. A positive agglutination reaction indicates the blood type.

7. Record the results in the data table.
8. Thoroughly rinse the blood typing tile with a disinfectant, and then repeat steps.
9. The data were entered in Microsoft excel for analysis. Further analysis was carried out using instant graph-pad.

RESULTS

In Table 1 the distribution of the ABO blood types in patients with diabetes mellitus is shown including both male and female.

Table No.1: Correlation of blood groups

Blood Group	Frequency	Percentage
A+	124	24.80%
A-	9	1.80%
B+	150	30.00%
B-	6	1.20%
AB+	63	12.60%
AB-	2	0.40%
O+	131	26.20%
O-	15	3.00%
Total	500	100.00%




Chart: Blood group frequency

Table No.2A: Correlation of blood groups in Male

Blood Group	Frequency	Percentage
A+	71	24.83%
A-	7	2.45%
B+	66	23.08%
B-	3	1.05%
AB+	41	14.34%
AB-	2	0.70%
O+	87	30.42%
O-	9	3.15%
Total	286	100.00%

In our study, the results showed association between ABO blood groups and DM type 2. B+, O+, A+ blood group showed higher incidence of type 2 diabetes mellitus than groups which are Rh-ve signifying the higher incidence in

patients which refers to Rh+ve group. However, significant association was found between DM type 2 and blood groups A (P 24.80%) and O (P 26.20%) The frequency of B blood group (30.00%) was high among patients with DM type 2. AB blood groups showed little association with DM (P 12.60%), which implied that AB blood group patients have less chances of DM type 2. (Table 1)

In Table 2: A and 2: B the distribution of ABO blood groups between genders with diabetes mellitus is shown.




Figure No.2A: Frequency

Table No.2B: Correlation of blood groups in Female

Blood Group	Frequency	Percentage
A+	53	24.77%
A-	2	0.93%
B+	84	39.25%
B-	3	1.40%
AB+	22	10.28%
AB-	0	0.00%
O+	44	20.56%
O-	6	2.80%
Total	214	100.00%




Figure No.2b: Frequency

The distribution of ABO/Rh blood groups between the genders for diabetics is shown in Table II. Blood groups O+ were more dominant in the diabetic group among men (30.42%) than women (20.56%); the type 2 DM in B+

blood groups were more common in women (39.25%) than men (23.08%). (Table 2)

Table No.3A: Correlation of blood group by Age in Male

Blood Group	20 – 40	41 - 60	61 - 80
A+	18	36	17
A-	3	4	0
B+	11	36	19
B-	1	0	2
AB+	8	21	12
AB-	0	2	0
O+	27	47	13
O-	0	4	5
Total	68	150	68




Figure No.3A:

Table No.3B: Correlation of blood group by Age in Female

Blood Group	20 – 40	41 - 60	61 - 80
A+	15	29	9
A-	0	1	1
B+	22	50	12
B-	1	2	0
AB+	7	12	3
AB-	0	0	0
O+	16	22	6
O-	1	4	1
Total	62	120	32




Figure No.3B:

In Table 3: A and 3: B the distribution of diabetic's blood types by age between the genders is shown.

A distinction is also drawn between diabetes in the young and in the middle-aged and in old respectively. It was observed that in middle-aged (40-60) people were more affected by DM type 2 having different blood groups. (Table 3)

DISCUSSION

It was long suggested that the ABO blood group system had evolved under a positive selection pressure in both humans and other primates.¹⁸ This implies that certain ABO groups provide a selected vulnerability to individuals possessing a particular ABO blood group. Diabetes mellitus was observed in all the ABO/Rhesus blood groups. However it was observed that the patients with type 2 diabetes mellitus were at rise in Rh+ve cases of which are A, B and O. This study clearly reveals the importance of blood group in different group of patients based on gender, age and Rh groups. This study suggests that person with Rh+ve are more prone to develop type 2 diabetes mellitus than the person with Rh -ve group.

In this study it was also found out that the following groups were more susceptible to develop type 2 diabetes mellitus in sequence of higher percentage.

Blood group	Percentage	Blood group	Percentage
B+	30.00%	B-	1.20%
O+	26.20%	O-	3.00%
A+	24.80%	A-	1.80%
AB+	12.60%	AB-	0.40%

This comparison certainly reflects that the person having B+ blood group is more likely to develop type 2 diabetes mellitus than person having blood group B.

The association of type 2 DM in male and female is somewhat equal however, in male the incidence was higher in O+ group and female shows high incidence in blood group B+.

This was also evident with regard to age which were divided in to three groups, 20-40, 41-60, 61-80 showing higher incidence in age groups of 41-60 with equal distribution of type 2 DM O+ and B+ blood groups which are more likely to develop type 2 DM in their age group.

The study of Qureshi and Bhatti demonstrated that DM type 2 and ABO blood groups are interrelated; they found that among 70 patients with DM, blood group B was more common and represented 35.71%.¹⁹ It is interesting to note that our study did show a higher percentage of blood group B (30.00%) in the diabetic group, but this failed to achieve statistical significance, and results are in agreement with Qureshi and Bhatti. In addition, there were reports from Italy and Trinidad showing an increased frequency of blood group B among diabetics.²⁰

CONCLUSION

It is concluded that the persons having these blood groups who are more susceptible to develop T2DM should take due care with reference to increased incidence of developing DM and adopt healthy life style in every respect keeping in view the danger zone in which they are living and the information they have with respect to their own blood group. It is highly recommended that this study may proceed further and the affiliation of T2DM can be screened at molecular level to find out the exact mechanism of action for susceptibility to these particular Blood Groups.

REFERENCES

- American Diabetes Association (2008). Diabetes Basics. Available online: <http://www.diabetes.org/diabetes-basics>.
- Van Dam RM, et al. Dietary patterns and risk for type 2 diabetes mellitus in U.S. men. *Annals of Int Med* 2002;136(3):201–209.
- Belmokhtar F, Belmokhtar R. Department of Ecology and Environment, Université Abou Bakr Belkaïd de Tlemcen, 2009.
- King H, Aubert RE, Herman W. Global burden of diabetes 1995–2025. *Diabetes Care* 1998;21:1414–31.
- Harris M, Hadden WC, Knowler WC, Bennett PH. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20–74. 2010.
- Zaoui S, Fingold J, Meguenni K, Chabane Sari D. ABO and rhesus blood groups system in Tlemcen population, West Algerian. *Biologie et Santé* 2007; 7(1):62-71.
- Raj K. The Distribution of the ABO Blood Types in Patients with Diabetes Mellitus (Department of Sports Medicine and Physiotherapy, Guru Nanak Dev University, Amritsar, Punjab, India). *Anthropologist* 2008;10(2):129-132.
- Kamil M, Nagi HA, Al-Jamal, Yusoff NM. Advanced Medical and Dental Institute, University Sains Malaysia, Penang, Malaysia; 2009.
- Buford-Mason AP, Weber JC, Willoughby IM. Oral Carriage of *Candida albicans*, ABO blood group and secretor status in healthy subjects. *J Med Mycol* 26(1):49-56. *Diabetes* 1987;36:523–34.
- Issitt PD, Anstee DJ. *Applied Blood Group Serology*. Fourth Edition Montgomery. Sci Publi 1999;218-246.
- McConnell R, Pyke D, Roberts JAF. Blood groups in diabetes mellitus. *Br Med J* 2006;772 6.
- Koley S. The distribution of the ABO blood types in patients with diabetes mellitus. *Anthropologist* 2008; 10:129–32.
- Der ABO Blutgruppen, *Acta. Gene. Et Statistica Medica* 2010;10:267-294.
- O’huigen C, Sato A, Klein J. Evidence for convergent evolution of A and B blood group antigens in primates. *Hum. Genet* 1997;101:141-148.
- Qureshi M, Bhatti R. Frequency of ABO blood groups among the diabetes mellitus type 2 patients. *J Coll Physician Surg Pak* 2003;8:453-5.
- Tedeschi G, Cavazzuti F. Contributo casistico allo studio dei rapporti tra diabete mellito e gruppi sanguigni. *ABO & Rh Prog Med (Napoli)* 2010;15: 76–82.
- Arid I, Benall H, Roberts J. A relationship between cancer of stomach and the ABO blood groups. *Br Med J* 1953;1:799–801.
- Andersen J, Lauritzen E. Blood groups and diabetes mellitus. *Diabetes* 1960;9:20-4.
- Vogel von F, Pettenkofer HJ, Helmbold W. *Über Die Populations genetics*, 1960.
- Henry MU, Poon-King T. Blood groups and diabetes. *West Ind Med J* 1961;10:156-60.

Address for Corresponding Author:

Dr. Shamsul Arfin Qasmi,
 Professor & HOD, Dept of Pathology,
 Mohammad Bin Qasim Medical & Dental College,
 Bin Qasim Town. Karachi
 e-mail: saqshamsularfin@gmail.com

The Effects of Monosodium Glutamate on the Histology of Fallopian Tube in Female Rats

1. Aftab Ahmed Shaikh 2. Muhammad Bachal Pandhiani 3. Zaheer Ahmed Memon
4. Haji Khan Khoharo

1. Asstt. Prof. of Pharmacology, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad
2. Asstt. Prof. of Anatomy, Al-Tibri Medical College, Karachi 3. Asstt. Prof. of Anatomy, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad 4. Asstt. Prof. of Physiology/Medicine, Faculty of Medicine and Allied Medical Sciences, Isra University, Hyderabad

ABSTRACT

Objective: To investigate the effects of orally administered monosodium glutamate (MSG) on the fallopian tube histology in adult female Wistar rat model.

Study Design: Experimental/Analytical study

Place and Duration of Study: Animal House, Isra University Hyderabad from May to November 2013.

Materials and Methods: Forty adult male Wistar rats were divided into three groups; Group A. controls received 0.9% isotonic saline, Group B. received MSG orally (1.5 mg/kg), and Group C. received MSG orally (3 mg/kg). The animals were sacrificed after six weeks. Fallopian tubes were fixed in 4% formaldehyde, and were embedded in paraffin. Tissue sections of 5 μ thicknesses were subjected to haematoxylin and eosin staining and were assessed by light microscopy.

Results: The fallopian tubes (FT) of the control group A showed normal histological features. The fallopian tubes of the treated groups showed some cellular hypertrophy of the columnar epithelium, distortion of the basement membrane separating the endosalpinx from the myosalpinx. There were degenerative and atrophic changes observed in some parts; these were more pronounced in those that received 3 mg/kg body weight of MSG. There were marked vacuolations and lysed red blood cells, (3 mg/kg body weight treated rats) appearing in the stroma cells

Conclusion: The monosodium glutamate may have deleterious effects on the fallopian tube histology in adult female Wistar rats particularly in high dose. Therefore caution must be taken for its frequent use in female because of possibility of female infertility.

Key words: Histology, Fallopian Tube, Monosodium Glutamate, Female Rat.

INTRODUCTION

The Fallopian tubes are paired, tubular, seromuscular organs which run medially from the cornua of the uterus toward the ovary laterally at the upper margins of the broad ligaments between the round and utero ovarian ligaments.¹ Millions of tiny hair-like cilia line the fimbria and interior of the fallopian tubes. The cilia beat in waves hundreds of times a second catching the egg at ovulation and moving it through the tube to the uterine cavity. Other cells in the tube's inner lining or endothelium nourish the egg and lubricate its path during its stay inside the fallopian tube.² The tubal wall consists of three layers: the internal mucosa (endosalpinx), the intermediate muscular layer (myosalpinx), and the outer serosa, which is continuous with the peritoneum of the broad ligament and uterus, the upper margin of which is the mesosalpinx. The endosalpinx is thrown into longitudinal folds, called primary folds, increasing in number toward the fimbria and lined by columnar epithelium of three types: ciliated, secretory, and peg cells. In the ampullary and infundibular sections, secondary folds of the tubal

mucosa also exist, markedly increasing the surface areas of these segments of the tube. The myosalpinx actually consists of an inner circular and an outer longitudinal layer to which a third layer is added in the interstitial portion of the tube. The serosa of the tube is composed of an epithelial layer histologically indistinguishable from peritoneum elsewhere in the abdominal cavity.^{2,3}

Currently many studies have reported deleterious effects of Monosodium glutamate (MSG) on the histology of fallopian tubes in female rats.^{3,4} The MSG is commonly known as AJINOMOTO.⁵ MSG is the sodium salt of a naturally occurring amino acid; the glutamic acid. MSG is commonly marketed as a flavour enhancer and is used as a food additive particularly in West African and Asian dishes.^{6,7} Generally, monosodium glutamate is accepted as a safe food additive that needs no specified average daily intake or an upper limit intake.⁸ An experimental study demonstrated that both subcutaneous injection and oral administration of MSG to immature rats and mice resulted in neuronal losses in the hypothalamus.⁹ The ability of monosodium glutamate to damage nerve cells

of the hypothalamus is a pointer to the fact that it may alter the neural control of reproductive hormone secretion via the hypothalamic-pituitary-gonadal regulatory axis. The effects of such toxicants on male reproduction may be anatomical or only functional, depending on whether they produce structural changes in the reproductive system, or merely affect the functions of the reproductive organs.¹⁰

In the last few years, fear had increased due to the adverse reactions and toxicity of MSG, with few and limited literature regarding the histological studies of the damage in fallopian tubes of animals treated with MSG. Therefore, the present study aimed to investigate some probable histological effects of MSG on the fallopian tube histology in adult female Wistar rats.

MATERIALS AND METHODS

The present experimental study included forty young adult male Wistar rats at animal house of Isra University from May to November 2013. Adult female Wistar rats of 250-300 grams were included, while male rats weighing <250 grams or >300 grams were excluded from the study.

- **Animals:** The Animals were housed in animal house at an optimal room temperature with 55-60% humidity and exposed to 12 hour light-dark cycles. The chaw like fresh alfalfa and clean water are provided freely. The rats were divided into three groups;
 - **Group A. Control Group** (n=10) Rats received 0.9% isotonic saline orally on alternate day for three successive weeks and served as control group,
 - **Group B.** (n=10) Experimental Rats were given 1 mg/kg of monosodium glutamate orally.
 - **Group C.** (n=10) Experimental Rats were given 3mg/kg of monosodium glutamate orally.
- **Chemical:** The chemical used was monosodium glutamate (C₅H₉NO₄-Na⁺). The MSG was purchased from the open market of Hyderabad under the license of Ajinomoto co.INC. Tokyo, Japan. A stock solution was prepared by dissolving 30 and 60 g of MSG crystals in 100 ml of distilled water. The dose schedule was so adjusted that the amount of MSG administration per animal was as per their respective weight. The MSG doses were given for six weeks. The applied doses were selected according to as referenced.¹¹
- **Fallopian tube histology:** At the end of the experimental period, the animals were sacrificed by cervical dislocation and the abdominal cavity was opened up to expose the fallopian tube which were quickly dissected out, and fixed in 10% formal saline for routine histological techniques. The tissues were dehydrated in an ascending grade of

alcohol (ethanol), cleared in xylene and embedded in paraffin wax. Serial sections of 3-4 μm thick were obtained using a rotator microtome. The deparaffinized sections were stained routinely with hematoxylin and eosin. Sections of fallopian tube were examined by light microscope. Photomicrographs of the desired sections were obtained for microscopic details..

RESULTS

The present study was conducted to evaluate the effects of monosodium glutamate (MSG) on the histology of testis in rat model. The MSG was given in different doses in the experimental group animals as mentioned in methodology. The control group revealed normal histology. The fallopian tubes (FT) of the control group A showed normal histological features, illustrating a well defined tubal wall which consists of three layers: the internal mucosa (endosalpinx), the intermediate muscular layer (myosalpinx), and the outer serosa (Fig. 1).

The experimental groups (Groups B and C) were studied separately for the microscopic structure of fallopian tubes. The major derangements were observed in the fallopian tubes of high dose MSG treated rats (3 mg/kg body weight). The histological details of experimental rats are shown in figure 2-3.

The fallopian tubes of the treated groups showed some cellular hypertrophy of the columnar epithelium, distortion of the basement membrane separating the endosalpinx from the myosalpinx. There were degenerative and atrophic changes observed in some parts; these were more pronounced in those that received 3 mg/kg body weight of MSG. There were marked vacuolations and lysed red blood cells, (3 mg/kg body weight treated rats) appearing in the stroma cells (Figs. 2 and 3).




Figure No. 1: Section of testis from rats of control group (Group A) rat showing seminiferous tubules (T) and interstitial spaces (N) showing normal Leydig cells (H & E stains, × 400).




Figure No.2: Section of testis from rats (experimental group B) treated with monosodium glutamate (1mg/kg body weight) showing seminiferous tubule (T) with lots of spermatids, and oedematous interstitial space (N). (H & E stains, $\times 400$).




Figure No.3: Section of testis from rats (experimental group B) treated with monosodium glutamate (2mg/kg body weight) showing seminiferous tubule (T) with only few spermatids and interstitial space (N) with inflammatory exudates. H&E stains, $\times 400$

DISCUSSION

The results of the hematoxylin and eosin staining (H & E) reactions showed some cellular hypertrophy of the columnar epithelium, distortion of the basement membrane separating the endosalpinx from the myosalpinx. Degenerative and atrophic changes were observed in some parts; these were more pronounced in those that received 3 mg/kg of MSG. There were marked vacuolations and lysed red blood cells (3 mg/kg treated rats) appearing in the stroma cells.

The increase in cellular hypertrophy of the columnar epithelium in the treatment groups as reported in this study may have been as a result of cellular proliferation caused by the improved intake of food which MSG influences.^{12,13,14} The vacuolations observed in the stroma of the fallopian tubes in this experiment may be due to MSG interference. Degenerative and atrophic changes and lysed red blood cell which were observed were more pronounced in the groups treated with higher dose (3 mg/kg) of MSG.

As a result of the distortion and disruption in the lumen of the fallopian tubes, the ciliary action and other functions of the fallopian tubes may have been highly affected as a result of probable toxic effect of MSG. It may be inferred from the present results that higher dose and prolonged administration of MSG resulted in degenerative and atrophic changes observed in the fallopian tubes. The actual mechanism by which MSG induced cellular degeneration observed in this experiment needs further investigation.

Degenerative changes have been reported to result in cell death, which is of two types, namely apoptotic and necrotic cell death. These two types differ morphologically and biochemically.¹⁵ Pathological or accidental cell death is regarded as necrotic and could result from extrinsic insults to the cell such as osmotic, thermal, toxic and traumatic effects.¹⁶ In this experiment MSG could have acted as toxins to the epithelial cells of the fallopian tubes. The process of cellular necrosis involves disruption of membrane's structural and functional integrity which was also a landmark of this experiment.

Cell death in response to toxins occurs as a controlled event involving a genetic programme in which caspase enzymes are activated.¹⁷

CONCLUSION

The monosodium glutamate may have deleterious effects on the fallopian tube histology in adult female Wistar rats particularly in high dose. Therefore caution must be taken for its frequent use in female because of possibility of female infertility.

REFERENCES

1. Hershlag A, Diamond MP, DeCherney AH. Tubal physiology: An appraisal J Gynecol Surg 1989; (5) 2-25.
2. Berger G. Tubal reversal ligation: Chapel Hill Tubal reversal center. (Accessed December 6, 2009, at <http://www.tubal-reversal.net/fallopian-tubes>).
3. Eweka A O, Eweka A, Om'Iniabo FAE. Histological studies of the effects of monosodium glutamate of the fallopian tubes of adult female Wistar rats. North Am J Med Sci 2010; 2 (3): 146-9.

4. Berger G. Tubal reversal ligation: Chapel Hill Tubal reversal center. (Accessed December 6, 2009, at <http://www.tubal-reversal.net/fallopian-tubes>).
5. Eweka O. Histological studies of the effects of monosodium glutamate on the kidney of adult Wistar rats. *Internet J Health* 2007; 6:2.
6. Igwebuike UM, Ochiogu IS, Ihedinihu BC, Ikokide JE, Idika IK. The effects of oral administration of monosodium glutamate (MSG) on the testicular morphology and cauda epididymal sperm reserves of young and adult male rats. *Veterinarski Arhiv* 2011; 81 (4): 525-34.
7. Farombi EO, Onyema OO. Monosodium glutamate-induced oxidative damage and genotoxicity in the rat: modulatory role of vitamin C, vitamin E and guercetin. *Human Experimental Toxicol* 2006; 125: 251-259.
8. Samuels S. The toxicity/safety of MSG: a study in suppression of information. *Account Res* 1999; 6(4):259-310.
9. Burde RM, Schainker MB, Kayes J. Acute effect of oral and subcutaneous administration of monosodium glutamate on the arcuate nucleus of the hypothalamus in mice and rats. *Nature* 1971; 233, 58-60.
10. Witorsch RJ. *Reproductive toxicology*, 2nd ed. Raven press, new york. 1995.
11. Tyl R, Friedman M. Effects of acrylamide on rodents reproductive performance. *Reprod Toxicol* 2003; 17(1):1-13.
12. Rogers PP, Blundell JE. Umani and appetite. Effects of monosodium glutamate on hunger and food intake in human subjects. *Physiol Behav* 1990; 48(6): 801-4.
13. Iwase M, Yamamoto M, Iino K, Ichikawa K, Shinohara N, Yoshinari F. Obesity induced by neonatal monosodium glutamate treatment in spontaneously hypertensive rats: an animal model of multiple risk factors'. *Hypertens Res* 1998; 43: 62-8.
14. Gobatto CA, Mello MA, Souza CT, Ribeiro IA. The monosodium glutamate (MSG) obese rat as a model for the study of exercise in obesity. *Res Commun Mol Pathol Pharmacol* 2002; (2): 116-28.
15. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature, London*, 1980; 284: 555-6.
16. Farber JL, Chein KR, Mittnacht S. The pathogenesis of irreversible cell injury in ischemia. *Am J Pathol* 1981; 102:271-81.
17. Waters CM, Walkinshaw G, Moser B, Mitchell IJ. Death of neurons in the neonatal rodent globus pallidus occurs as a mechanism of apoptosis. *Neuroscience* 1994; 63: 881-894.

Address for Corresponding Author:**Dr. Haji Khan Khoharo,**

Assistant Professor of Physiology/Medicine
Faculty of Medicine and Allied Medical Sciences
Isra University, Hyderabad.
Tel: 0331-2662500

Electronic Copy

Incidence of Malignant Lymphomas in Balochistan

1. Zahid Mehmood 2. M.Hanif Mengal 3. Haroon ur Rasheed

4. Hafiz Khush Naseeb Ahmed

1. Asstt. Prof., Dept. of Radiotherapy & Oncology, BMCH, Quetta 2. Asstt. Prof., Haematology Section, BMCH, Quetta 3. Ex- Asstt. Prof., Dept. of Radiotherapy & Oncology, BMCH, Quetta 4. Director CENAR, Quetta.

ABSTRACT

Background: Traditionally lymphomas are classified into Hodgkin's disease (HD) and Non Hodgkin's lymphoma (NHL) depending upon histo-pathological evidence on biopsy taken from an enlarged lymph node. Delayed diagnosis in lymphoma deteriorates the health eminence resulting in poor outcome.

Objectives: The aim of the study is to estimate the incidence and clinical presentation of malignant lymphomas in Balochistan.

Study Design: Prospective Study

Place and Duration of Study: This study was carried in the Department of Radiotherapy & Oncology, Bolan Medical Complex Hospital, Quetta from June, 2006 to May, 2012

Materials and Methods: A total of 263 newly diagnosed patients of both types of lymphoma from different parts of Balochistan were registered in Bolan Medical Complex Hospital in Department of Radiotherapy & Oncology. Followed by histopathology, WHO classification and Ann Arbor staging was done to assign subtype and extent of disease.

Results: It was found that the incidence of Non Hodgkin's lymphoma a (64.7%) was greater than Hodgkin's disease (35.2%) and both present bimodal distribution in age. Male patients dominate female patients in both cases (2.5:1). Lymph-adenopathy of cervical region was primary site in 44 % of cases while 27.6 % were extra nodal. Histopathology shows 57.4 % mixed cellularity variant in Hodgkin's lymphoma and 25.5% diffuse B cell pattern in Non Hodgkin's lymphoma. Ann Arbor staging reveals that 3.4% cases present with stage I and 64.5% show stage IV.

Conclusion: To conclude Non Hodgkin's lymphoma is two times more frequent than Hodgkin's lymphoma with greater male contribution. Due to delayed diagnosis resulted in late stage presentation ,health awareness is needed for physicians and general population for availability of patients at a due time for management.

Key Words: Hodgkin's lymphoma, Non Hodgkin's lymphoma, Lymph-adenopathy.

INTRODUCTION

Lymphomas are group of disorders caused by malignant lymphocytes that accumulates in lymph nodes and cause the characteristic feature of lymph-adenopathy. Occasionally, they may spill over in blood or infiltrate organs outside the lymphoid tissue ^[1]. Lymphatic organs play an important part in the immune system, having a considerable overlap with the lymphoid system. Lymphoid tissue is found in many organs, particularly the lymph nodes, and in the lymphoid follicles associated with the digestive system. Lymphoid tissues contain lymphocytes, but they also contain other types of cells for support ^[2]. The system also includes all the structures dedicated to the circulation and production of lymphocytes, which includes the spleen, thymus, bone marrow, and the lymphoid tissue associated with the digestive system^[3]. The Primary lymphoid tissues generate two major types of cells, B lymphocytes and T lymphocytes. Lymphoma is a group of cancers that affect these lymphocytes. It is malignant transformation of either B cell or T cell or their subtypes, these abnormal lymphocytes may travel from one lymph node to another and some time to

remote organs via lymphatic system. Care should be taken to assign the primary site of origin as it strappingly affects treatment modality. The primary site may be nodal when malignant cells originate from lymph nodes and is extra nodal when develop from the organs other than lymphatic system such as gastrointestinal tract, hypochondrium, Para-nasal sinuses, central nervous system . Lymphoma may invade the nearby organs involving extra nodal sites and vice versa ^[4].

Traditionally lymphomas are classified into Hodgkin's disease (HD) and Non Hodgkin's lymphoma (NHL) depending upon histo-pathological evidence on biopsy taken from an enlarged lymph node. Hodgkin's lymphoma develops from a specific abnormal B lymphocyte lineage and has characteristics Reed Sternberg cells having large, abundant cytoplasm, double or multiple nuclei with its distinctive clinical features ^[5]. Since there are so many different types of lymphomas, its classification is very complicated ^[6]. Many of these subtypes look similar but they are functionally quite different and respond to different types of therapies with different probability of cure ^[7].

Diffuse large B cell Lymphoma is most common and is potentially curable while mantle cell lymphoma is unique subtypes B cell lymphoma and is potentially incurable^[4,8,9]. Due to the varied clinical picture, many patients are misdiagnosed and treated for diseases like tuberculosis^[10]. Sometimes, Benign disorders including ordinary infections, sebaceous cysts and other non-neoplastic conditions may be interpreted as malignant lymphoma and unnecessarily subjected to surgery and/or chemotherapy^[11]. The first sign of lymphoma is painless enlarged lymph nodes accompanying fever for more than 3 days. Usually patient presents with low grade intermittent fever, unexplained weight loss and drenching night sweats. Confirmed diagnosis is established on the basis of histopathology findings followed by fine needle aspiration or biopsy of relevant site. Histopathology clearly marks the morphology of cells, their subtypes and resemblance to the normal cells. Clinically Non Hodgkin's lymphoma is dividing into low grade, intermediate and high grade. High grade lymphoma has cells and multiply rapidly hence aggressive in nature while low grade lymphoma cells look much similar to normal cells, multiply slowly and are indolent. Lymphomas are also categorized on the basis of tumor burden for appropriate treatment. The Ann arbor staging system is the most popular system for classifying lymphoma in different stages on the basis of number of tumor sites involved (nodal and extra nodal), location, and the presence or absence of B symptoms^[5].

The aim of this study is to evaluate the incidence of malignant lymphomas and its extent at the time of presentation and to promote health awareness in population.

MATERIALS AND METHODS

In this prospective study, 263 newly diagnosed patients of both types of lymphoma from different parts of Balochistan, were registered in Bolan Medical Complex Hospital, Quetta, in Department of Radiotherapy & Oncology, from June, 2006 to May 2012. The study includes patients of all ages and sexes. Exclusion criteria from the study were the patients having chronic lymphocytic leukemia and patients with viral hepatitis. Informed consent was obtained from individual patients for collecting demographic and disease data on pre-designed questionnaire. Initial laboratory evaluation included complete blood count, erythrocyte sedimentation rate, serum electrolytes and urine analysis. Further investigation includes biochemical tests like renal function test, liver function test, total proteins and blood urea, serum creatinin, specific tests such as lactate dehydrogenate and B₂ micro globulin also performed. Final diagnosis was established by fine needle aspiration and excision biopsy of enlarged lymph node. Some cases were diagnosed by bone marrow biopsy. Histopathology confirms the specific

subtype and grade of lymphoma. With the help of radiology imaging such as ultra sonogram, magnetic resonance imaging, computer tomography scan etc. staging and extent of disease assigned by using American Joint Commission on Cancer (AJCC) staging manual and Surveillance Epidemiology End Result (SEER) summary stage, respectively.

RESULTS

Two hundred and sixty nine diagnosed cases of lymphomas were included in this prospective study, out of which 169(71%) cases belonged to NHL with male to female ratio 1.5:1 while 94 (29%) cases were diagnosed having HD with male to female ratio 2:1. Demographics (Table.1) showed that in HL group 56 (60%) were males and 38 (40.4%) patients were females. The patients were divided in two groups, age<40 years consist of 62 (65.9%) patients and age ≥ 40 years consist of 32 (34%) patients. In NHL group, out of 169 (64.9%) patients, 32 (34%) patients were ≥ 40 years. In NHL group, out of 169(64.2) patients, the 123 (172.7) patients were male and 46 (27.2) patients were female. Graphical representation of frequency of age exhibited bimodal distribution, where the first peak appears between 20-29 years, both HD and NHL whereas in NHL the second larger peak stuck between 50-59 years. On general examination, lymphadenopathy was the commonest finding and 100% patients presented with enlarged lymph node of any size. The most frequent primary sites were cervical lymph nodes (41%). It was also observed that incidence of malignant site was also very high (28%), so was the abnormal lymphocyte growth outside the lymphatic system (Fig.1). All extra nodal cases were Non Hodgkin lymphomas. Accompanied with lymphadenopathy, patient usually complained low grade fever, fatigue, weight loss and abdominal fullness. Physical and clinical findings clearly demonstrated the situation of patient at the time of presentation and it was obvious that most of the victims were suffering from B symptoms (Table.1). Fine needle aspiration cytology established the initial diagnosis and surgical resection of lymph node finally confirmed the subtype and cell surface marker by histopathology and immunohistochemistry analysis. Among HD, rate of occurrence of mixed cellularity was highest with 77.5%, and only 18 cases of nodular sclerosis (22.5%) were indentified. In NHL, diffuse large B cell pattern was widespread with 45% cases whereas B cell Non Hodgkin's lymphoma exhibited by 23 patients (13%),seventeen patients each of follicular lymphoma and small lymphocytic lymphoma (SLL) ,7 % each were reported (Table.2). Other less common variant included anaplastic large cell lymphoma, lymphoblastic lymphoma and large cell lymphoma.

In some cases, histopathology mentioned WHO grade but most of the cases were without grading so cell nature became ambiguous and was difficult to assess whether it was aggressive or indolent. Further work up, including computerized tomography (CT) scan,

magnetic resonance imaging (MRI), bone marrow biopsy, was performed to formulate the staging and extent of disease. Eight (8.5%) cases of HL presented with stage I while 12 (12.7%) in stage II and 16 (17%) patients were in stage III and 58 (61.7%) patients were in stage IV, respectively. Stage IV had higher frequency as 61.7% cases were identified with stage IV. One the other, in NHL, 6 (3.5%) cases were stage I disease whereas 19(11.2%) and 45(26.6%) cases presented with stage II and III respectively. Stage IV was dominant in NHL with 109 (64.4%) cases. The comparison between different stages of HL and NHL showed that stage III was dominant in HL and stage IV in NHL. Stage I lied side by side in both types (Fig.2), according to SEER summary stage, stage I and II represent local and regional disease respectively while stage III and IV symbolized for distant metastasis..

Table No. 1: Characteristics of 263 patients Presenting with(HL 94 cases and NHL 169 cases).

Characteristics	HL		NHL	
	No	(%)	No	(%)
Sex				
Male	56	60	123	72.7
Female	38	40.4	46	27.2
Age				
≤4 yr	62	65.9	61	36
≥4 yr	32	34	108	63.9
Ann Arbor Stage				
I	08	8.5	06	3.5
II	12	12.7	19	11.2
III	42	24.8	45	26.6
IV	32	34	109	64.4
Presentation				
Nodal	68	72.3	128	75.7
Extra nodal	26	27.6	41	24.2
Symptoms				
Fever	78	82.9	134	79.2
Weight loss	69	73.4	112	66.2
Lymphomatous involvement				
Spleen	72	76.5	104	61.5
Bone Marrow	31	32.9	42	24.8
Liver	48	51	71	42.0
GIT	26	27.6	36	21.3
CNS	02	2.1	03	1.7
Pleural effusion	08	8.5	11	6.5
Asities	10	10.6	16	9.4
LDH				
1. Normal	30	31.9	42	24.8
2. Abnormal	58	61.7	113	66.8
3. Not known	06	3.5	12	7.1
Extranodal involvement				
1 Site	36	21.3	45	26.6
2 or > 2 sites	51	30.1	109	64.4
Not known	7	4.1	13	7.6

Table No. 2: Different types of NHL cases

Type	WHO classification	Cases	%age
HL	Mixed callularity	54	57.4
	Nodulr sclerosis	24	25.5
	Nodular lymphocyte Predominanat	10	10.6
	Lymphocyte rich	06	6.3
NHL	Diffuse large B cell Lymphoma	85	37.8
	Small Lymphocytic Lymphoma	40	17.2
	Follicular Lymphoma	15	8.8
	Mantle cell Lymphoma	13	7.6
	Anaplastic large T-cell Lymphoma	10	5.9
	Lymhoblastic Lymphoma	8	4.7
	Peripheral T-Cell Lymphoma	5	2.9




Figure No.1: Distribution of Malignant lymph nodes in NHL.




Figure No.2: Staging in HL and NHL.

DISCUSSION

Lymphoma is the most common form of hematological malignancy in the developed world. With addition of life style, malignant lymphoma is increasing in developing countries. Malignant lymphomas accounts for 5.3% and 55.6% of all blood cancers. According to the National Institute of Child Health, lymphomas account for about five percent of all cases of cancer in the United States, and Hodgkin's lymphoma in

particular accounts for less than one percent of all cases of cancer in the United States.

The patients present in the study belong to different geographic and ethnic groups and show evidence of different kinds of lymphoma. The present study shows the incidence of NHL greater than HL with approximate 2.5:1. This frequency is also affected by age as the study shows that people who develop HL are between 30-40 years of age. On the contrary, victims of NHL are young as well as aged people. Moreover, males are more susceptible than female. This pattern is validated by the previous study but no reason was yet established. Age distribution demonstrates a bimodal pattern in NHL where the first peak lies 30-40 years and the second peak involves 41-70 years. HL shows the same pattern with one peak at 3-40 years and a second at 41-49 years. These findings are consistent with previous studies^[12,13]. The process of aging which contributes to health deterioration may explain this type of distribution. Lymphoma occurs when genes associated with programmed cell death (apoptosis) are irregular and the lymphocyte apoptosis response is interrupted. Consequently, the lymphocytes do not die but rather continue to proliferate and circulate causing disease and possible death. The clinical presentation of NHL and HL is also very typical. Lymphadenopathy is a common sign of beginning of malignant disorders^[14]. All HL patients present with a single chain of cervical lymph node with no dissemination or involvement of other lymph nodes but rather directly engross the bone marrow. On the contrary, NHL cases present with cervical, intra-abdominal and extra-nodal sites as well. Most of the cases present with more than one nodal site, diffuse extra-nodal association and in 20% cases extra-nodal sites are primary sites involving lymph nodes as secondary sites. Ascites, pleural effusion and focal defects in spleen and GIT involvement are also frequent. These findings affect the staging and extent of disease. In our country the trend to go for regular check-up is very low and usually self-medication prevents people from going for proper examination, so most of the patients are diagnosed when they develop metastasis in more than one secondary site. Hence 45% under study were diagnosed with stage III and IV in HL and NHL respectively where prognosis is very poor and the rate of survival is low because in late age the immunity continues to decrease and the body rapidly progresses to an advanced stage. As in an advanced stage, the response to treatment is poor and the chances of survival decline so it burdens the health budget.

According to WHO, morphological diagnosis of NHL relies on cytological details, although the development of new technologies has helped to define several NHLs that tend to be sclerotic and diagnosis is possible only with excisional biopsy^[15,16]. Fine needle aspiration cytology (FNAC) though minimally invasive, produces suboptimal material and reveals scanty neoplastic cells.

Presence of lymphoid cells in FNAC are usually considered to be associated with the diagnosis of lymphoma. However, there are other types of lymphoid infiltrates that may be misleading, e.g. granulomatous infiltrates like tuberculosis, lymphoid infiltrates in extra-nodal sites, and neoplasm containing lymphocytes^[17].

Recent advances attempting to increase the specificity of FNAC by combining it with immune flow cytometry (IFC) and immune-histochemistry (IHC), have proven unsuccessful for certain lymphomas and excisional biopsy is still generally recommended^[18]. Histopathology, cytology and immuno-histochemistry analysis set the morphological variations in lymphoma. Our study reveals the most common variant lymphoma, Diffuse Large B Cell Lymphoma (DLBCL) (38%), since DLBCL is heterogeneous, CNS prophylaxis by adding rituximab in chemotherapy is promising^[19,20], while mixed cellularity is the dominant entity in HL rather than Nodular sclerosis. An important finding is that 12% cases of NHL and 10% cases of HL have no further specification of type and are designated as not otherwise specified.

Stage III and IV are dominating in patients diagnosed with HL and NHL, respectively. This delayed diagnosis reveals the unawareness of the importance of regular medical check-up in the general public. Patients presenting with late stage diagnosis too have a poor prognosis that may have economic and social impacts by increasing the burden on the health care budget and their families. Health awareness, both for physicians and the general population, is required on a priority basis.

CONCLUSION

To conclude, Non-Hodgkin's lymphoma is two times more frequent than Hodgkin's lymphoma with a greater male contribution. Due to delayed diagnosis, health awareness is needed for physicians and the general population for the availability of patients at a due time for management.

REFERENCES

1. Haffbrand AV, Moss PA. Hodgkin's lymphoma. *Essentials of Haematology*. 6th ed. Wiley Blackwell Science: London; 2011.p.246-52.
2. Roger W, Williams PL. *Angiology*. Gray's anatomy. Illustrated by Richard E.M. Longman. Moore. 40th ed. London;2008.p.588-785.
3. Tak W, Mak ME, Saunders ME. *Primer to the immune response*. Academic Press 2008, 28-34.
4. Abramson JS, Ship MA. Advances in the biology and therapy of diffuse large B-cell lymphoma; moving toward a molecularly targeted approach. *Blood* 2005;106:1164- 74.
5. Armitage JO. Staging Non-Hodgkin lymphoma. *Clin Cancer J* 2005;55:368-376.
6. Jaffe ES, Pittaluga S. The pathologic basis for the classification of Non-Hodgkin's Lymphoma.

- Haematology. Basic principles and practice. 4th ed. Elsevier: Philadelphia; 2005.p.1369-1379.
7. Gribben JG, Lacase AS. Clinical manifestation, staging and treatment of Non Hodgkin's Lymphoma. Haematology. Basic principles and practice. 4th ed. Elsevier: Philadelphia;2005.p. 1397-1419.
 8. Ghobrial IM, McCormick DJ, Kanfmann SH, Leontovich AA. Proteomic analysis of Mantle cell lymphoma by protein microarray. Blood 2005;1 (105):3722-30.
 9. WU G, Keating A. Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma. Cancer 2006;106:247-57.
 10. Al-Mobeireek AF, Araffah M, Siddiqui N. An African male with cough, hemoptysis, weight loss and hypercalcemia: TB or no TB?, Eur Ruerpir J 2007;20:1060-63.
 11. Phelan E, Lang E, Gormley P, Lang J. Kickuchi-Fujimoto disease; a report of 3 cases. Ear Nose Throat J 2007;86:412-13.
 12. Horner MJ, Ries LAG, Krapcho M, Neyman N. Neyman N. Seer Cancer Statistics Review 1975-2006, National Cancer Institute. Bethesda 2007.
 13. Yahalom J, Straus D. Hodgkin's Lymphoma. In cancer management: A multidisciplinary approach. 11th ed. CMP Medical Album. Lawrence; 2008.p.697-17.
 14. Olu-eddo NN, Ohanaka CE. Perreiphral lymphadenopathy in Nigerian adults. JPMA 2006; 56:405-408.
 15. Song JY, Cheong HJ, Kee SY, Lee J. Disease spectrum of cervical lymphadenitis: analysis based on ultrasound guided core needle gum biopsy. J Infect 2007;55:310-16.
 16. Mayall F, Darlington A, Harrison B. Fine needle aspiration cytology in the diagnosis of uncommon types of lymphoma. J Clin Pathol 2003;821-25.
 17. Rosen ST, Winter JN Gordon LI. Non Hodgkin's Lymphoma. In Cancer management: A multidiscip: approach. 11th ed. CMP Med. Lawrence KS; 2008.p.719-74.
 18. Frederick JW, Mauch PM. American Joint committee on cancer, American cancer society. AJCC staging manual. 6th ed. 2002.
 19. Dunleavy K, Pittaluga S, Maeda LS. Dose adjusted EPOCH- Ritoximab therapy in primary Mediastinal B-cell lymphoma. N Eng J Med 2013; 368:1408-16.
 20. Mori J, Takashashi Y, Tsubokura M. CNS Prophylaxis in Diffuse Large B Cell Lymphoma. Lancet 2012;379:1486-87.

Address for Corresponding Author:**Dr. Zahid Mahmood,**

Assistant Professor,

Dept. of Radiotherapy & Oncology,

Rolan Medical Complex Hospital, Quetta.

Electronic Copy

Adjuvant Therapy for Old Age Glioblastoma Patients

Salman A. Jaffery

Assoc. Prof. of Neurosurgery, Women Medical College, Abbottabad.

ABSTRACT

Objective: Since the advent of Temozolomide (TMZ), optimum management for elderly patients with newly diagnosed Glioblastoma (GBM) is still elusive. The object of this study was to clarify outcomes of present management.

Study Design: Long term prospective study

Place and Duration of Study: This study was carried out on patients who were treated at the Aseer Central Hospital Abha KSA, Frontier Medical College Abbottabad, Women Medical College Abbottabad and those operated privately between August 2001 and August 2013.

Material and Methods: This is a long term study of 41 consecutive cases involving patients aged 55 years or more with newly diagnosed GBM. The patients' median age was 61 years (range 55-87 years). Twenty nine patients underwent resection and rest underwent biopsy. Patients with deep-seated lesions and multifocal lesions (12 patients= 29.26%) were preferably biopsied than gross total resection. Eighteen patients (43.90%) were treated with chemotherapy (mostly TMZ) with radiation therapy (RT) and Six (14.63%) with RT alone. Three patients (7.31%) received only palliative care after surgery.

Results: New neurological deficits developed in 5 patients (12.19%). Postoperative hemorrhage occurred in 8 patients (19.51%), all of whom underwent biopsy. Chemotherapy complications occurred in 19.51% (Advanced hematological complications in 14.63%).

The overall median values for progression-free survival and overall survival were 4.5 and 6 months respectively. Younger age, single lesion resection and adjuvant treatment were associated with better overall survival. Only adjuvant treatment was significantly associated with prolonged progression-free survival. With combined therapy containing resection, RT, and chemotherapy, the median progression-free survival and overall survival were 7.5 and 11 months, respectively.

Conclusions: The prognosis for GBM worsens with increasing age in elderly patients. When high risk factors are present, resection with adjuvant treatment are associated with prolonged survival but are with associated risks. Advanced age alone should not preclude optimal resection followed by adjuvant radio-chemotherapy.

Key Words: Glioblastoma, Old Patients, Adjuvant Therapy, Overall Survival, Progression Free Survival.

INTRODUCTION

Glioblastoma (GBM) is the second most common primary brain tumor after meningioma, accounting for 17.6% of all CNS tumors, and it is by far the most common malignant primary brain tumor.¹ The prognosis of GBM remains dismal with median survival of approximately 1 year despite advances in surgery, radiation and chemotherapy.² Current standard treatment consists of maximal safe resection followed by RT and concomitant and adjuvant chemotherapy with TMZ(3) (47), which results in a median overall survival of approximately 15 months or longer in appropriately selected patients.⁴

Advanced age has been reported as the most significant unfavorable prognostic factor for patients with GBM.⁶ GBM peaks in incidence at 5-74 of age and affects more than 10 per 100,000 people older than 65. (23) In the Pakistani setting an age of 55 is considered to be old, relating to socio-economic standards and health awareness level. Older patients with GBM tend to be offered less aggressive treatment, such as biopsy or

even palliative care, for fear of their possible intolerance of standard treatment.

However, the best treatment regimen for these patients is yet to be fully determined. Stupp et al³ proved the efficacy of TMZ in patients with newly diagnosed GBM, but did not target individuals over the age of 70 years. Therefore, GBM therapy in this population is a difficult decision making resulting in the paucity of evidence. In an attempt to shed light on this situation, we analyzed the outcome in our series of elderly patients with newly diagnosed GBM treated at the Asir central Hospital Abha Saudi Arabia and in Pakistani settings.

MATERIALS AND METHODS

Patients aged 55 or older who underwent surgery in the Department of Neurosurgery Assir Central Hospital Abha, Saudi Arabia, Frontier Medical College Abbottabad, Women Medical College Abbottabad and those operated privately between 2001 and 2013 leading to a new diagnosis of GBM were recruited in this study. Patients with progression from previously diagnosed lower grade glioma were excluded. A total of

41 patients were studied. The patients median age was 61 years (range 56-76 years). Twenty nine patients underwent resection and 12 underwent biopsy. Patients with deep-seated lesions and multifocal lesions) were preferably biopsied than gross total resection. Eighteen patients (43.90%) were treated with chemotherapy (mostly TMZ) with radiation therapy (RT), and six (14.63%) with RT alone. Three patients (7.31%) received only palliative care after surgery.

RESULTS

Patients Data is presented in Table 1. Twenty nine patients (70.73%) presented with focal deficits including cognitive dysfunction (37%) and motor deficit (33%). Nineteen patients (46.34%) experienced seizures before surgery. Seven patients (17.07%) presented with headache and vomiting with or without decreased level of consciousness. Intra-tumoral bleeding was noted at time of presentation in 4 patients (9.75%). Associated medical conditions were common, including cancer in 6 patients (14.63%), coronary artery disease in 5 patients (12.19%), and hypertension in 14 patients(34.14%). The median maximum tumor diameter was 38 mm (range 23-76). Lesions were located most frequently in the Temporal lobe (31%). Multifocal lesions defined as multiple separate enhancing lesions with or without connection when visualized on fluid-attenuated inversion recovery sequences of MRI, were frequently seen (29%).

Surgical outcome: For most patients undergoing resection or open biopsy and for all patients undergoing frameless stereotactic biopsy, MRI or CT scan was obtained prior to surgery for stereotactic purposes. The images were transferred into Neuro-navigation system, a facility only available in Saudi Arabia, and were used during craniotomy as well as tumor resection or biopsy. For patients undergoing frame-based stereotactic biopsy, MRI or CT scan was obtained after frame placement under general anesthesia.

Table No.1:Location of the Glioblastoma in Our series

Location	No. of Patients
Frontal	12
Temporal	15
Parietal	8
Occipital	4
basal ganglia & thalamus	2
corpus callosum	2
Cerebellum	8
deep lesion	6
Bilateral Lesion	13
Multifocal Lesion	9
Eloquent Lesion	7
	23

Table No.2: Patients Data

Variable	Total (n=41)	Group	
		Resection (n=29)	Biopsy (n=12)
Age (yrs)			
Mean	64.1+5.3	64.3+5.5	65.8+5.1
Range	55-87	55-87	55-86
Sex			
Male	25	15	10
Female	16	09	07
Preop focal deficit	28	18	10
Preop Sz	33	12	07
Increased ICP Syndrome	16	07	09
tumor size (mm)			
Mean	44.9+17.0	46.6.1+11.5	41.1+16.4
Range	15-74	18-72	16-71

Table No.3: Patients in Treatment Groups

	Total (n-41)	Treatment Group	
		Resection (n-29)	Biopsy (n -12)
adjuvant treatment			
chemo & RT	21	18	03
RT alone	11	08	03
chemo alone	01	0	01
palliative	08	03	05

Table No.4: Complications during our Study

Type of Complication	Total (n=37)	Treatment Group	
		Resection (n = 25)	Biopsy (n = 12)
any complication	17	11	6
hematological complication	8	7	1
systemic complication†	8	6	2
dermatological complication	3	1	2
psychiatric	1	0	1




Figure No.1: Right Frontal Glioblastoma with mass effect

Target and trajectory for stereotactic biopsy were determined using the software program. The patients with pacemakers underwent CT scan instead of MRI.

Twenty nine (70.73%) patients underwent resection and 12 patients (29.27%) underwent biopsy. The resection group included 5 patients who had previously undergoing biopsy for diagnostic purposes prior to resection. There were no statistically significant differences between the biopsy and resection groups regarding age, sex, morbidities, or tumor size. Resection group presented more frequently with increased ICP and had a higher dexamethazone dose than the biopsy group.

Lesions were located more often in the temporal lobe in the resection group and less often in the parietal lobe, the basal ganglia, and the corpus callosum (Deep Lesion) in the biopsy group.

Surgical complications were divided into 3 groups as suggested by the Glioma Outcome Project. The overall complication rate was 24.8%. Neurological complications were seen in 17 patients (41.46%).

The neurological complication rate did not differ significantly between the resection group and the biopsy group. Regional complications affected 13 patients (31.70%) including hemorrhage in 6 patients (14.63%). All hemorrhagic events occurred in the biopsy group. Systemic complications occurred in 7 patients (17.07%), including thrombo-embolic events in 4 patients (9.7%).

The perioperative mortality (death within 30 days of surgery) rate was 9.7% (3 patients undergoing biopsy and one from resection group).

Outcomes for Adjuvant Treatment: Five patients (12.08%) received palliative care only without any active tumor treatment. All remaining received RT with a completion rate of 100%. The median radiation dose delivered was 51.0 Gy (range 10.0-68.0 Gy). More patients in the biopsy group received only palliative care postoperatively than the resection group of patients with hematological complications (myelosuppression), 2 required dose reduction and 3 needed to discontinue chemotherapy. One of those patients receiving TMZ required platelets. Systemic complications occurred in 6 patients Frontal, Temporal, corpus callosum Eloquent Lesion and included deep venous thrombosis (3 patients) and pulmonary embolism (1 patient), complications included rash, stomatitis, and depression. Among 64 patients who received RT, 8 patients (19.5%) were not able to complete the prescribed treatment. Five patients experienced clinical deterioration during RT.

Significant differences were noted between patients receiving palliative care and patients receiving adjuvant treatment. Patients receiving RT alone were older than those receiving RT and chemotherapy, were more likely to have presented with increased ICP (39% vs 15%), and had a higher mean Dexamethazone dose.

Progression Free Survival (PFs) and overall survival Median PFS, calculate from date of surgery, was 4.5 months. Factors significantly associated with poor PFS

included deep lesion, multifocal lesions biopsy only, new persistent postoperative focal deficit, and palliative care (that is lack of adjuvant treatment). The median PFS for patients undergoing adjuvant treatment was 5.5 months, whereas that for patients who had palliative care only was 0.5 months. Patients receiving chemotherapy along with RT had achieved significantly longer PFS compared with those with RT alone.

The median Overall Survival differed strikingly among the age groups: 1. Months for patients younger than 70 years, but merely 4.5 months for patients aged over 70 years. Favorable survival effects of resection and adjuvant treatment in this study mainly result from relatively younger patients (< 65 years) among our elderly patient adjuvant treatment lived substantially longer if they had undergone resection compared with biopsy (median OS 11.5 months vs 6.5 months). With maximal safe resection followed by the combination of RT and chemotherapy, which is the standard treatment for unselected GBM patients, the median PFS and OS among our elderly patients with GBM were 8 months and 12.5 months, respectively. When limited to patients who were 70 years of age or older, they were 6 months and 10.0 months, respectively.

DISCUSSION

Gross total (safe) surgical resection followed by adjuvant treatment including RT and chemotherapy with TMZ has become the standard of care for patients with newly diagnosed GBM since the landmark study from Stupp and colleagues^{3,21}.

But patients older than 70 years were excluded from this study which is relatively common.^{8,17} In clinical practice, physicians and surgeons are frequently reluctant to offer aggressive treatment to elderly patients because of concerns that it may not be tolerated due to advanced age, co-morbidities and an underlying propensity to complications. Therefore, although the age-adjusted incidence of GBM is greatest among patients older than 65 years, the best treatment strategy for these patients is not as well defined as in younger patients, the very reason this study was carried out.

Impact of Resection versus Biopsy on Survival in Elderly Patients have been performed evaluating the impact of the prospective studies^{9,25} have been more definitive, demonstrating an association Sanai et al,^{10,14} and between resection and survival specially in younger patient impact of extent of resection (determined with or without computer-assisted volumetric assessment) on survival and concluded that the majority supported extent of resection as a prognostic factor for prolonged survival. Some authors have reported increased extent of GBM resection and prolonged PFS in patients undergoing fluorescence-guided surgery using 5-aminolevulinic acid (5-ALA) in a prospective, randomized controlled trial^{12,20} Older patients are often believed to take longer to recover from an aggressive

surgery and carry a higher risk of peri-operative complications. Thus, biopsy is often resection for these patients.^{13,1} A retrospective study from the independent predictor of survival and was associated with favorable OS among patients along with age and performance status.^{14,13} However, this benefit was only evident for patients who went on to receive adjuvant treatment (median survival for resection vs biopsy: 11.5 vs 6.5 months).

Surgical Complications in Elderly Patients: High complication rates in elderly patients like new neurological deficits are associated with decreased survival, not just decreased quality of life.^{15,16} Our overall complication rate of 24.8% for elderly patients compares favorably to other authors and true for patients undergoing resection in our series. The overall complication rate in these patients was 18.9%. By comparison, patients with newly diagnosed malignant glioma undergoing first craniotomy in the Glioma Outcome project had an overall complication rate of 24.2% including 8.1% permanent neurological worsening, 10% regional complications, 9.2% systemic complications, and 1.5% mortality.

Similarly, Sawaya et al reported their experience at MD Anderson Cancer Center with 400 craniotomies for intra-axial tumors (206 gliomas, 194 metastases). The overall complication rate was 32% (including 8.5% permanent neurological worsening, 7% regional complications, 7.8% systemic complications and 1.7% mortality) those undergoing resection (30.8% vs. 18.9%) although the difference did not reach statistical significance. complication rates for stereotactic biopsy in our series of elderly patients with GBM are higher than those reported in large unselected mortality rates range from 0.6% to 2.8%.^{3,9,16,25}

Impact of Adjuvant Treatment on Survival in Elderly Patients: Radiation therapy has an established role in GBM therapy. RT has a significant survival benefit and appears to hold true for elderly patients.^{13,14,15,17} Superiority of an abbreviated RT course (40 Gy in 15 fractions over 3 weeks) in elderly patients has been successfully proved by a prospective randomized clinical trial by Roa and colleagues.¹⁸

Like RT, chemotherapy has an established role in GBM treatment. For many years nitrosoureas such as BCNU or lomustine (CCNU) were the mainstay of chemotherapy for GBM patients and 2 meta-analyses consistently confirmed their efficacy for longer survival.^{19,10} However, the benefits of nitrosoureas for old patients was questioned (similar to RT) especially given the higher incidence chemotherapy-related neurotoxicity and myelosuppression in this population. The changed the standard of care for patients with newly paper by Stupp et al changed the standard of care for the patients with newly diagnosed GBM by demonstrating increased survival for patients receiving RT with concurrent TMZ followed by adjuvant TMZ

compared with RT alone (median survival 14.6 months vs 12.1 months), excluding 70 plus patients. Some recent papers have reported favorable survival for elderly patients with GBM receiving RT and TMZ, such as 10.6 months with the Stupp regimen for 2 patients aged 70 or older or 11 months with adjuvant RT and reduced dose of TMZ.^{9,21}

Adjuvant Treatment Toxicity in Elderly Patients: Adjuvant treatment including RT and TMZ was feasible for elderly patients and was allocated with a modest complication rate.^{4,5,6,9,11,12,24,25}

Most of the major complications did not seem to be directly associated with RT except for an infarct of the ipsilateral corona radiata 2 years after RT for a temporal tumor. In addition to resection and adjuvant treatment, other factors reported to favorably influence survival in unselected GBM patients include young age, good performance status, good mental status, seizure presentation, frontal lesion, superficial 3.1780.11) Younger single lesion, and the absence of postoperative complications age has consistently been one of the strongest favorable prognostic factors across many studies. It is interesting that our data suggest that this holds true even among the elderly population (age-65 years). Several hypotheses have been proposed to explain the poor clinical outcome of GBM in older patients, including the presence of comorbidities, resistance to cancer therapy, genetic aberrations, different histology, neurodegeneration and age discrimination.^{2,4,19,22,23,26}

CONCLUSION

This study demonstrates that aggressive treatment with resection and adjuvant treatment is associated with significantly longer survival for patients 65 years of age or older with newly diagnosed GBM. This finding must be interpreted with caution given that this study not randomized and patient biopsy and/or palliative care were significantly different (had tumors in deeper, more eloquent locations poorer performance status, increased dexamethasone dose) from those receiving resection and or adjuvant treatment. Nevertheless, resection and adjuvant treatment remained significant prognostic factors in a multivariate analysis and were generally well tolerated in this group of elderly patients. Although advanced age is an independent unfavorable factor, this alone should not disqualify patients from being treated with optimal tumor resection followed by.

REFERENCES

1. Central Brain Tumor Registry of the United States: Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2005 [Accessed October 22, 2012]

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987–996.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 2005;352:987–996.
4. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al.: Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. *Clin Cancer Res* 2010;16:2443–2449.
5. Buckner JC. Factors influencing survival in high-grade gliomas. *Semin Oncol* 2003;30:6(Suppl): 1910–14.
6. Tilgner J, Herr M, Ostertag C, Volk B. Validation of intraoperative diagnoses using smear preparations from stereotactic brain biopsies: intraoperative versus final diagnosis—influence of clinical factors. *Neurosurg* 2005;56:257–265.
7. Chang SM, Parney IF, McDermott M, Barker FG, Schmidt MH, Huang W, et al. Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. *J Neurosurg* 2003;98:1175–1181.
8. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al.: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. *J Clin Oncol* 2006;24:2563–2569.
9. Devaux BC, O'Fallon JR, Kelly PJ: Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy and outcome. *J Neurosurg* 1993;78: 767–775.
10. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. *J Neurosurg* 2001;95:190–198.
11. Sanai N, Berger MS: Glioma extent of resection and its impact on patient outcome. *Neurosurg* 2008;62:753–764.
12. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ: Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. *Lancet Oncol* 2006; 7:392–401.
13. Barnholtz Sloan JS, Williams VL, Maldonado JL, Shahani D, Stockwell HG, Chamberlain M, et al. Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. *J Neurosurg* 2008;108:642–648.
14. Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. *N Engl J Med* 2007;356:1527–1535.
15. McGirt MJ, Mukherjee D, Chaichana KL, Than K D, Weingart JD, Quinones-Hinojosa A. Association of surgically acquired motor and language deficits on overall survival after resection of glioblastoma multiforme. *Neurosurg* 2009;65:463–470.
16. Bernstein M, Parrent AG. Complications of CT-guided stereotactic biopsy of intra-axial brain lesions. *J Neurosurg* 1994;81:165–168.
17. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. *Radiother Oncol* 2002;64: 259–273.
18. Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. *J Clin Oncol* 2004;22:1583–1588.
19. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. *Cancer* 1993; 71:2585–2597.
20. Brandes AA, Vastola F, Basso U, Berti F, Pinna G, Rotilio A, et al. A prospective study on glioblastoma in the elderly. *Cancer* 2003;97:657–662.
21. Combs SE, Wagner J, Bischof M, Welzel T, Wagner F, Debus J, et al. Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. *Int J Radiat Oncol Biol Phys* 2008; 70:987–992.
22. Kelly PJ, Hunt C: The limited value of cytoreductive surgery in elderly patients with malignant gliomas. *Neurosurg* 1994;34:62–67.
23. Rosenblum ML, Gerosa M, Dougherty DV, Reese C, Barger GR, Davis RL, et al. Age-related chemosensitivity of stem cells from human malignant brain tumours. *Lancet* 1982;1:885–887.
24. Brandes AA, Monfardini S: The treatment of elderly patients with high-grade gliomas. *Semin Oncol* 2003;30(6 Suppl):1958–62.
25. Fiorica F, Berretta M, Colosimo C, Stefanelli A, Ursino S, Zanet E, et al.: Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with concomitant temozolomide. *Arch Gerontol Geriatr* 2010;51:31–35
26. Batchelor TT, Betensky RA, Esposito JM, Pham L D, Dorfman MV, Piscatelli N, et al. Age-dependent prognostic effects of genetic alterations in glioblastoma. *Clin Cancer Res* 2004;10: 228–233.

Address for Corresponding Author:

Dr. Salman A. Jaffery

Cell #: +92 301 7516514

Comparative Study on Neem Leaf Extract and Nimolicin (NC) on Gastric Mucosa of Albino Rats

1. Qamar Aziz Siddiqui 2. Syed Ijaz Hussain Zaidi 3. Asghar Hussain 4. Muhammad Omar Shamim 5. Nazar Hussain 6. Syed Naimul Hassan Naqvi 7. Mohammed Arshad 8. Rajput Muhammad Tariq 9. Mazhar Hijazi

1. Prof. of Physiology, IM&DC, Sialkot 2. Asstt. Prof. of Pharmacology, Al Tibri Medical College, Karachi 3. Asstt. Prof. of Physiology, Quetta Institute of Medical Sciences, CMH, Quetta 4. Asstt. Prof. of Physiology, IM&DC, Sialkot 5. Prof. of Pathology, BMU, Karachi 6. Prof. of Pharmacology, BIPS, Karachi 7. Asstt. Prof. of Pharmaceutics, Baqai Institute of Pharmacy, Karachi 8. M.AH, Qadri Biological Research Centre, Karachi University, Karachi 9. Prof. of Anatomy, BMU, Karachi

ABSTRACT

Objective: Compare the anti ulcer effect of Methanolic Neem (*Azadirachta indica*, A Juss, Meliaceae) Leaf Extract (NLE) and Neem compound Nimolicin on gastric mucosa of albino rats.

Azadiradione also called Nimolicine coded as NC has been studied for its anti insect effect but anti ulcer effect has never been studied.

Study Design: Experimental study

Place and Duration of Study: This study was carried out at the Pharmacy and Physiology Department of Baqai Medical College for duration of two years.

Materials and Methods: Gastric ulcers in albino rats were induced in group-1 (check group) by a single oral dose of 1 ml 100% ethanol. After 24 hours the treatment was started. Group-2 was treated with oral administration of peanut oil 1ml/day for 5 days (control of the treated group). Group-3 was treated with NLE (1ml/day for 5 days) and Group-4 with NC 1% (1ml/day for 5 days). The healing effects of neem were compared to oral administration of anti ulcer drugs ranitidine (50mg/kg daily for 5 days) and omeperazole (2.5 mg/kg daily for 10 days). Histopathology of the stomach was performed to confirm the presence or healing of ulcers. Ulcers were scored and indexed on the basis of histopathology.

Results: Ranitidine had the highest ulcer inhibition of 84%. NLE proved to be better than omeperazole by showing an ulcer inhibition of 82 % compared to 73% ulcer inhibition of omeperazole. NC showed least anti ulcer activity with an ulcer inhibition of only 69%. HPLC was performed to show the tissue concentration of NC, omeperazole and ranitidine showing their retention time, area and concentration compared to their controls.

Conclusion: It is concluded that NLE proved to be better anti ulcer agent as compared to NC and can be used as an anti ulcer drug after clinical trials.

Key Words: Gastric ulcer, neem (*Azadirachta indica*, A Juss, Meliaceae) leaf extract, azadiradione, nimolicin, ranitidine, omeperazole, ulcer inhibition.

INTRODUCTION

Neem (*Azadirachta indica* A. Juss) has been known for its medical values for the last 2000 years. Even today neem has been the centre of attraction especially for workers of medical field. All parts of neem are important particularly the leaves which is "storehouse of organic compounds"¹. The leaves are easily available through out the year and preparation of extracts is easy. Thus they have been used extensively for medicinal applications².

More than 300 different compounds of neem have been isolated from different parts of tree about one third are tetranortriterpinoids (Liminoids).³ Nimolicine coded as NC is a known neem compound. The neem fruit is divided into two parts. Fleshy outer part pericarp and mesocarp and inner part seed coat and kernel. The active ingredient of seed coat and kernel is Azadirachtin

(AZ).⁴ NC (Azadiradione) was isolated from fresh fruit coatings (after separation of seeds from fruits). Thus in the present study the anti ulcer effects of neem leaf extract were studied and compared with NC. The potent anti ulcer and anti secretory effect of neem leaf extract has been attributed to a glycoside.⁵ Plant glycosides are known to inhibit chloride transport in gastric juice reducing gastric acidity.⁶ The mechanism of action of NLE in healing of gastric ulcers is possibly because of its antioxidant effect which is independent of acid suppression.⁷ This effect may be similar to the effects of omeperazole providing gastroprotection due to its antioxidant and anti apoptotic role.⁵

This study shows a comparison of anti ulcer effects of methanolic extract of neem leaves with neem compound NC showing the healing effects by histopathology.

MATERIALS AND METHODS

Wistar strain of rats were purchased from HEJ Institute of Chemistry, Karachi University and kept under optimum conditions in the animal house of Baqai Medical University. The animals were acclimatized and had free access to food and tap water ad libitum. Principals of laboratory animal care (NIH publication no.82-83, revised 1985) guidelines were followed. The animal experimentation approval was obtained from University Animal Ethical committee. NLE and NC were obtained from HEJ Institute of Chemistry, Karachi.

A total of 60 albino rats weighing 180Gm to 200Gm were divided into six groups. In each group 5 male and 5 female rats were included. Group-1 was the check group which was given 1 ml of 100% ethanol orally and sacrificed after 24 hrs to check for ulcers. Macroscopic and microscopic examination for the confirmation of ulcers was done. Once it was established that oral administration of ethanol caused gastric ulceration in rats, the next part of the study was undertaken. All the other groups were first given oral ethanol for ulcer production and then treated orally after 24 hours accordingly and then sacrificed. Group no 2 (control of the treated group) was treated with 1 ml of peanut oil daily for 5-7 days. Group-3 (test group) was treated with 1ml NLE daily for 5 days. The rats of fourth group (test group) were treated with 1% NC daily for 5 days. The fifth group (comparison group) of rats was treated with ranitidine (purity 50%) 50mg/Kg daily for 5 days. The rats of the 6th group were treated with Omeperazole (purity 83.33%) 2.5 mg/kg daily for 10 days. After completion of the respective treatment rats of Group-2 to Group-6 were sacrificed and stomach was incised. The gastric ulcer was examined in all the rats by a hand lens (power 10). The gastric tissues were then processed for histopathological examination by staining procedure of⁸. Gastric ulcers were scored on the basis of histopathology and indexed as Ulcers = 3, Heavy infiltration of polymorpho nuclear (PMN) cells = 2, Mild infiltration of (PMN) cells = 1, no ulcers = 0. The ulcer index and ulcer inhibition was determined.^{9,10} The experiments were carried out in the Pharmacology Department of the Baqai Institute of Pharmaceutical Sciences and were repeated three times. The total duration of the study was three years.

High Performance Liquid Chromatography (HPLC): HPLC was performed to demonstrate the concentration of drugs in tissues. This was then compared with the standard solution prepared. One Gm of gastric tissue was homogenized in a homogenizer (OSK 9258) at 500RPM and centrifuged at 3500RPM (Labofuge-200 Heraeus). Soxhalation of the supernatant fluid was done. Sorption was done by passing the solution through Aluminium Oxide and Silica¹¹. Pure methanol was used as a solvent for the mobile phase with a flow rate of 1 ml/min. A UV detector was used at a wavelength of 214 nm, pressure 200 kg/cm² and absorbance 0.08 with chart speed 2.5mm/min. Standard samples were prepared and run for comparison. The samples were filtered by Swiney syringe a micro filter pore diameter of 0.42 nm (Millipore Corporation Bedford MA01730). 20μL of the sample were injected by a special 25μL chromatographic syringe via the injector pore. HPLC apparatus Shimadzu (Japan) SPD-10A UV spectrophotometer with Merck reverse phase column (RP-C₁₈, 25cm X 0.46mm) was used. The chromatographic data were processed with Class LC-10 software (Shimadzu, Japan) and CBM (communication bus model) to the monitor. Peaks were recorded by software programme Real Time Analysis. The peaks were compared on the basis of retention time (RT) with the standard peaks. The area of each peak was noted to quantify the different compound residues in the samples.

RESULTS

In normal healthy rats ulcers were induced by giving 100% ethanol in the check group. This group had the highest ulcer score as shown in table-1 seen on naked eye and later confirmed on microscopic examination (Fig.2). There was no ulcer inhibition because no treatment was given to this group. The remaining 5 groups were treated with pea nut oil, neem, omeperazole or ranitidine after the induction of ulcers. The comparison of anti ulcer effects of neem with anti ulcer drugs on gastric tissue of rats have been shown in table-1 and figures 1-7.

Table No.1: Comparison of ulcer inhibition of NLE, NC, Omeperazole and Ranitidine with the control.

	Ethanol (Check Group) n=17	PNO (Control Group) n=17	NC (Test Group) n=7	NLE (Test Group) n=9	OMP (Known Antiulcer Group) n=6	Ranitidine (Known Antiulcer Group) n=7
Ulcer Score	31	31	4	3	3	2
Ulcer Index	1.82	1.82	0.57	0.33	0.5	0.29
Ulcer Inhibition	Nil	Nil	69%	82%	73%	84%

Table No.2: Shows concentration of NC, omeperazole and ranitidine in gastric tissue compared to the control by HPLC (Schimadzu)

	NC	Ranitidine	Omeprazole
Gastric tissue Conc (µg/20 µl)	3.37	3.62	7.11
Control Conc. (µg/20 µl)	7.08	14.64	9.22




Figure No. 1: H & E stained, 5 micron thick paraffin section of stomach in an adult female rat untreated showing normal gastric mucosa. (Photomicrograph H&Ex10)




Figure No.2: H & E stained, 5 micron thick paraffin section of stomach in an adult female rat given oral Ethanol 100% showing massive erosions (A). The section reveals ulceration of mucous membrane with infiltration of the base with neutrophils (B & C) and dilatation and congestion of blood vessels. (Photomicrograph H&E x 10)

The normal gastric tissue Fig.1 has been compared with ulcerated gastric epithelium in Fig.2. Treated gastric epithelium has been shown in Fig.3-7. Pea nut oil used as control of treatment group has not caused a healing effect and the persistence of ulcers has been demonstrated in Fig.3. The healing effect of neem has been shown in Fig.4 & Fig.7 and this gastric tissue can be compared to the normal gastric mucosa fig.1 and

healing effect of ranitidine and omeperazole Fig 6 & Fig 7. Table-1 shows that ranitidine had the highest ulcer inhibition of 84%. The ulcer inhibition of NLE was better than omeperazole by showing an ulcer inhibition of 82% compared to 73% of omeperazole. NC showed least anti ulcer activity with an ulcer inhibition of only 69% (Table-1). The ulcer score of the check group and control is the same. There was no ulcer inhibition with pea nut oil which served as the control of treated group. Tissue concentration of NC, ranitidine and omeperazole on HPLC has been shown in table -2 compared to their controls.




Figure No.3: H & E stained 5 micron thick paraffin section of stomach in an adult female rat treated with Pea nut oil for 5 days. The section shows the presence of chronic inflammatory cells showing a non healing effect of PNO. Ulcers are seen. A & B. (Photomicrograph H&E x 10)




Figure No.5: Photomicrograph of H & E stained, 5 micron thick paraffin section of stomach in an adult female rat treated with neem compound nimolincin (NC). The section reveals

mild infiltration of mucosa by PMN cells, lymphocytes and occasional plasma cells. No ulcers visible. A & B. (H & EX 10).




Figure No.5: Photomicrograph of H & E stained, 5 micron thick paraffin section of stomach in an adult female rat treated with neem compound nimolicin (NC). The section reveals mild infiltration of mucosa by PMN cells, lymphocytes and occasional plasma cells. No ulcers visible. A & B. (H & EX 10).




Figure No.6: H & E stained, 5 micron thick paraffin section of stomach in an adult female rat treated with ranitidine. The section shows mild focal infiltration by chronic inflammatory cells (A). No ulcers seen (B). (Photomicrograph H & E x 10).




Figure No.7: H & E stained, 5 micron thick paraffin section of stomach from an adult female rat treated with omeperazole. The section shows mild focal infiltration by chronic inflammatory cells. No ulcers seen A & B. (Photomicrograph H & E x 10).

DISCUSSION

In the present study ulcer was induced by oral administration of ethanol which is in contrast with the findings of¹² who used mercaptomethylimidazole compound for the production of ulcer which is less potent in ulcer induction than ethanol. The anti ulcer effect of neem has been demonstrated in the present study by the induction of ulcer first, followed by treatment and confirmation by histopathology which is in contrast with the findings of¹³ who studied the ulcer protective effect by pretreatment followed by ulcer induction without any histological evidence.

The anti ulcer effects of methanolic extract of NLE in the present study has been reported which has been shown to decrease ulcer index, which is similar with the findings of¹⁴ who used aqueous extract of NLE and bark extract of neem respectively.

Hence the present study demonstrates that NLE is more effective as an anti ulcer agent compared to NC possibly because of its cumulative effect. Resistance is difficult to develop with extracts compared to isolated compounds. Clinical trials may further help in supporting our results.

CONCLUSION

It is concluded that NLE proved to be better anti ulcer agent as compared to NC and can be used as an anti ulcer drug after clinical trials.

Acknowledgements: We gratefully acknowledge the contribution of Professor Dr Beena Siddiqui of HEJ institute of Chemistry, Karachi University for providing us neem leaf extract and neem compound NC. We are also highly indebted to Madam Zehra Yaqeen, Dr Nudrat Fatima and Dr Lubna of the PCSIR laboratories Karachi for their cooperation and support during the project. We are very thankful to Dr Mirza MF Subhan, Assistant Professor, Department of Physiology, University of Kingdom of Bahrain for his expert guidance in editing this article. A special word of thanks to the department of Baqai Institute of Information Technology specially Syed Rizwan Nisar for their cooperation in computer skills in formatting and processing for publication of this article. We also are greatly indebted to Professor Dr Arshad Azmi of Karachi University for his support during HPLC. Partial financial support from HEC project no. 20-1127/R&D/2008 is gratefully acknowledged.

REFERENCES

1. Subapriya R, Nagini S. Medicinal properties of Neem Leaves: A Review. *Curr Med Chem AntiCancer Agents* 2005;5(2):1-8.
2. Brahmachari G. Neem—An Omnipotent Plant: A Retrospection. *Chem Bio Chem* 2004; 5: 408- 421.

3. Siddiqui BS, Kashif SA, Tariq SA, Naqvi SNH, Tariq RM. Variation of Major Liminoids in *Azadirachta indica* fruits at different ripening stages and toxicity against *Aedes aegypti*. *Natural Product Communications* 2009;4(4): 473-476.
4. Lavie D, Levie E C, Jain M K. *Tetrahedron* 1971; 27: 3927-3939.
5. Biswas K, Chattopadhyay I, Ranajit K, Banerjee, Bandyopadhyay U. Biological activities and medicinal properties of Neem (*Azadirachta indica*). *Current Sci* 2002;82(11): 1336-1345.
6. Machen TF, Forte JG. Gastric secretion. In: Guebischil G, Tasteson DC, Using HH, editors. *Handbook of Transport Organs*. Berlin: Springer; 1979.p.693-747.
7. Saddiqui QA, Feisal S, Naqvi SNH. The effect of neem (*Azadirachta indica*) leaf extract and neem compound Nimolicine on gastric acidity. *Med Forum* 2011;22(3):30-34.
8. Bancroft JD, Stevens A. *Theory and Practice of Histological Techniques*. 3rd ed. Edinburgh (London): Churchill Living Stone;1990.p.42-43,107-110, 186-189.
9. Bandyopadhyay U, Biswas K, Sengupta A, Moitra P, Dutta P, Sarkar D, et al. Clinical studies on the effect of Neem (*Azadirachta indica*) bark extract on gastric secretion and gastroduodenal ulcer. *Life Sci*2004.75(24): 2867-2878.
10. Nijar VCO, Adesonwo JK, Raji Y. Methyl Angolensate: The antiulcer agent of the stem bark of *Entandrophragma angolense*. *Planta Medica* 1995; 61: 91-92.
11. Holden AV, Marsdon M. Single stage clean up of animal tissue extract for Organochlorine's residue analysis. *J Chromatograph* 1969;44: 481.
12. Bandyopadhyay U, Biswas K, Chatterjee R, Bandyopadhyay D, Chattopadhyay I, Ganguly CK, et al. Gastroprotective effect of Neem (*Azadirachta indica*) bark extract: Possible involvement of H⁺-K⁺-ATPase inhibition and scavenging of hydroxyl radical. *Life Sci* 2002;71; 2845-2865.
13. Yoshikawa M, Youtana P, Matsuda H, Morikawa T, Yasunobu A. Protective effects of Polygoidal on gastric mucosal lesions induced by necrotizing agents in rats and the possible mechanisms of action. *Biol Pharm Bull* 2003;26(5): 651-657.
14. Garg GP, Nigam SK, Ogle CW. The gastric antiulcer effects of the leaves of the neem tree. *Planta Med* 1993;59(3):215-217.

Address for Corresponding Author:**Dr. Qamer Aziz Siddiqui,**Professor & Head Department of Physiology,
Islam Medical & Dental College, Pasroor Road,
Sialkot, Pakistan.

Cell No.: 092-3333145734

Residence No.:092-21-34657855

Tel: 092-52-3610001

Fax: 092-52-3610009

email: drqamer1@hotmail.com

Electronic
Copyright

Subjects Index January to December 2013**Azhar Masud Bhatti**

Editor in Chief

Vol. 24, No. 1, January, 2013**ANATOMY****Page No.**

Morphological Changes after Chronic Heat Exposure on Zona Fasciculata of Adrenal Gland of Albino Rats (Sarwat S, et al) 2

Morphological Study of Native Foramina Transversaria in the Cervical Spine (Maqbool A, et al) 33

BIO CHEMISTRY

Effect of Concept Maps on Knowledge Retention in Dental Students (Khan I, et al) 7

SURGERY

Procedure for Prolapsed Haemorrhoids versus Excisional Haemorrhoidectomy - A Systematic Review and Meta-Analysis (Shahid ZA, et al) 12

Acute Abdomen, Causes and Outcome - Experience at DHQ Hospital Abbottabad (Saeed A, et al) 38

Determinants of Upper Limb Amputations in a Tertiary Care Center, Pakistan (Soomro N, et al) 60

MEDICINE

Incidence of Thyroid IMA Artery in our Population (Ullah S, et al) 17

Vitamin D Levels in OPD Patients in Teaching Hospital, Sukkur (Soomro AA, et al) 26

Experience of Acute Systemic Lupus Erythematosus in Indoor and Outdoor Patients (Ansari IA, et al) 29

Effects of Combined Interferon Alpha and Ribavirin Therapy on Thyroid Function in Patients with Chronic Hepatitis C, Attending Hepatitis Centre Ghulam Mohammad Medical College Hospital, Sukkur (Phulpoto JA, et al) 44

GYNAE & OBS

Frequency, Risk Factors and Complications in Pregnancies Associated with Placenta Praevia (Hafeez R, et al) 21

PATHOLOGY

Histopathological spectrum of Gastric biopsies in a tertiary care hospital (Hasan SM, et al) 41

Histopathological Study of 209 Cases of Early Abortions (Hashim Y, et al) 55

OPERATIVE DENTISTRY**Page No.**

Evaluation of Post Operative Pain in Single and Multi Visit Endodontic Therapy with Rotary Instruments (Shaikh AG, et al) 49

Determination of Number of Apical Foramina in Mesial Root of Mandibular First Molar - Ex Vivo (Dall AQ, et al) 70

COMMUNITY MEDICINE

Effects L-Arginine on the Gastric Mucosal Cell count when given with Ibuprofen in Albino Rats under light Microscope (Kumar S, et al) 64

Vol. 24, No. 2, February, 2013**PHYSICAL MEDICINE**

Diabetes Mellitus and Limb loss: An analysis from a Tertiary Care Center (Soomro N, et al) 2

ANATOMY

Immunohistochemical Determination of Effects of Withania Somnifera Root Extract on Noise Stress Induced Adenohypophysis in Albino Rats (Naqvi, et al) 6

NEUROLOGY

Frequency of Demyelinating Pattern on Electrophysiological Study in Patients with Diabetic Peripheral Polyneuropathy (Iqbal J, et al) 10

GYNAE & OBS

Histopathological findings of abdominal hysterectomies in patients presenting with heavy menstrual bleeding (HMB) (Jaffar Y, et al) 14

Adolescent Menorrhagia: Causes and Evaluation (Bokhari NA, et al) 22

Role of Foleys Catheter for Pre-Induction Ripening of Cervix (Bhatti K, et al) 39

Histomorphological Features of Placentae in Pregnancies Complicated with Intrauterine Growth Restriction (Rehman MZ, et al) 42

A Randomized Clinical Trial of 200 Patients of Oral Vs Vaginal Misoprostol in Second Trimester Pregnancy Termination (Usmani I, et al) 55

MEDICINE

Outcome with and without Aspiration of the Amoebic Liver Abscess at Civil Hospital, Karachi (Alam MT, et al) 17

Occupational Exposure to Blood and Body Fluids amongst Health Care Workers in a Teaching Hospital of the Sukkur, Sindh (Phulpoto JA, et al) 26

The IT IT Study (The Incubation Time in Tetanus Study) (Khan BA, et al) 52

PHARMACOLOGY

Studies on Effectiveness of DOTs and weekly three times Treatment of Sputum Positive Tuberculosis Patients (Bhurgri GR, et al) 30

ANTHROPOLOGY

Role of Traditional Birth-practices causing Maternal and Neonatal Mortality in Faisalabad. An

Anthropological Approach of Household Decision Making (Ahmed A, et al) 35

ENT

Outcome of Silver Nitrate Cauterization in Controlling Anterior Epistaxis in Children (Khan MI, et al) 48

COMMUNITY MEDICINE

Knowledge and Practices of Basic Life Support amongst the Ambulatory Staff in Karachi (Mehtab K, et al) 58

BIOCHEMISTRY

Lipid profile in Females of Reproductive Age Group Using Injectable Contraceptives (Progestogenonly) (Faryal U, et al) 61

Association of BMI with Elevated Values of CK-MB and cTnT in Acute Myocardial Infarction (Rashid S, et al) 64

Effects of Ibuprofen on Gastric Mucosa of Albino Rats and the Protective Role of L-Arginine. A Morphological Study Under Light Microscope (Kumar S, et al) 68

NEUROSURGERY

Surgical Management of Missile Trauma to Thoraco - Lumbar Spine (Jafferi SA) 74

NEUROLOGY

A study of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Diabetics: Clinical Features, Laboratory findings and Response to Treatment (Javed MA, et al) 79

CARDIAC SURGERY

Right Coronary Artery Aneurysm (Saleem M) 83

Vol. 24, No. 3, March, 2013

GYNAE & OBS

Frequency of Perinatal Mortality at Bolan Medical Complex Hospital Quetta (Usmani I, et al) 2

Eclampsia: Still A Major Cause For Adverse Maternal and Perinatal Outcome (Bhatti K, et al) 15

ANATOMY

Effects of Diclofenac Sodium on Renal Parenchyma and Prevention by Vitamin-E in Adult Albino Rats (Rathore MI, et al) 6

Depletion of Body and Cerebellar Weights after Chronic Lithium Carbonate Ingestion in Albino Rats (Kohari T, et al) 47

A study of Gross Anatomical Observations of Stomach and Changes in Body Weight of Albino Rats after Simultaneous Administration of Ibuprofen and L-Arginine (Kumar S, et al) 55

COMMUNITY MEDICINE

Morbidity Pattern and Health Education for School age Children in Karachi (Kolachi HB, et al) 11

Colored Text Enhances Learning Power of Medical Students "A New Concept of Learning" (Mehtab K, et al) 60

BIOCHEMISTRY

Isolation of E – Coli in UTI cases with malnutrition in children of distant rural area of Sukkur, Sindh (Laghari AH, et al) 18

MEDICINE

The Frequency Causative Organisms and Their Sensitivity to the Commonly used Antibacterial Agents in Cases of Urinary Tract Infections (Alam MT, et al) 22

Glycemic control in type 2 Diabetes mellitus and its association with duration of Diabetes & Glycosylated Hemoglobin (Memon A, et al) 28

Hypertension in Working and Non working Women Attending OPD of A Tertiary Care Private Sector Hospital in Karachi (Shafi S, et al) 51

MEDICAL EDUCATION

Teaching Anatomy at Undergraduate Level -- A Survey amongst Students Comparing use of Powerpoint and Blackboard (Ali S, et al) 32

NEUROLOGY

Clinical Features, Role of Mobile Plasmapheresis Unit and Outcome in Patients with Acute Inflammatory Demyelinating Polyradiculoneuropathy (Guillain-Barré Syndrome) (Javed MA, et al) 38

DENTISTRY

Gingivitis & Dental Caries Status among the School Going Children of Jamshoro City (Banglani MA, et al) 43

MAXILLOFACIAL SURGERY

Management of Mandibular Fracture in Paediatric Patients at L.U.H Hyderabad (Hassan SG, et al) 63

Vol. 24, No. 4, April, 2013

ORTHOPAEDIC

Effectiveness of Local Corticosteroids in Carpal Tunnel Syndrome (Jan R, et al) 2

PATHOLOGY

Screening for Dengue Virus Infection at GMMMC Hospital, Sukkur (Qureshi KA, et al) 6

The Significance of C-Reactive Protein in Adult Obese and Centrally Obese Group (Azhar S, et al) 19

MAXILLOFACIAL SURGERY

Risk Factors in Spreading Odontogenic Infection (Ali S, et al) 9

Maxillofacial Fractures in Hyderabad City: A 1-year Study of 448 Patients (Punjabi SK, et al) 58

Public Awareness Assessment: regarding Qualified and Unqualified Dental Practitioners. What difference does it makes in Treatment Outcome (Mirza A, et al) 62

Comparison of Analgesic Effects of Oral Carbamazepine with Pregablin in Idiopathic Trigeminal Neuralgia (Hassan SG, et al) 66

DENTISTRY

- Single Arch Treatment in Class II Div 1 Malocclusion (Moazzam M, et al) 14
- Reasons of Tooth Extraction at L.U.M.H.S Civil Hospital Hyderabad Sindh (Shahzad M, et al) 51

MEDICINE

- Methylglyoxal Level in Type-2 Diabetes Mellitus Patients: A Prospective, Randomized and Case Control Study at Tertiary Care Hospitals, Hyderabad, Pakistan (Qureshi MA, et al) 22
- Frequency of Culture Positive Tuberculosis in Exudative Pericardial Effusion (Alam MT, et al) 38
- Role of Pregablin in Neuropathic Pain (Alvi H, et al) 54
- Efficacy of Telbivudine in the Treatment of Chronic Hepatitis B Infection in Population of Peshawar, Pakistan (Meher T, et al) 73

ANATOMY

- Histomorphological Patterns of Testicular Biopsies in Azoospermic Infertile Males From a Tertiary Care Unit of Pakistan (Qazi S, et al) 26
- Histological Changes in Human Gallbladder Mucosa due to Cholelithiasis (Saqib A, et al) 34

GYNAE & OBS

- Manual Vacuum Aspiration: A Safe Alternative for Surgical Management of Early Pregnancy Loss (Bhatti K, et al) 31
- Placenta Previa Major Degree; Obstetrical Risk Factors and Maternal Outcome (Sarfraz N, et al) 47

PATHOLOGY

- Miscellaneous Liver Diseases in Infancy & Childhood in Several Hospitals (Fatima I, et al) 42

SURGERY

- Surgery as a Preferred Modality of Treatment for the Patients of Chronic Anal Fissure with Sentinel Piles (Qadeer A, et al) 70

Vol. 24, No. 5, May, 2013**PATHOLOGY**

- Spectrum of Gall Bladder Diseases Diagnosed at Dow Diagnostic Reference and Research Laboratory, Dow University of Health Sciences (Butt SA, et al) 2
- Study of Changing Pattern of Bacterial Isolates in Neonatal Sepsis (Sami F, et al) 17
- Disease Trends in Appendix in Relation to Age, Gender and Month of the Year (Saeed N, et al) 26
- Frequency of Endometrial Hyperplasia and Endometrial Cancer in Women from Different Hospital of Karachi (Fatima IF, et al) 37
- Prevalence of Cutaneous Leishmaniasis in urban and semi-urban areas of Karachi (Soomro AA, et al) 55

ORTHOPAEDIC SURGERY

- Incidence and Subsequent Mortality after Hip Fracture in Sindh and KPK Population (Hussain A, et al) 6
- Postoperative Complications and Mortality in Elderly Patients with Acute Hip Fracture (Vohra S, et al) 9

BIOCHEMISTRY

- Methylglyoxal Level In Type 2 Diabetes with Acute Myocardial Infarction and its Association with Systemic Hypertension (Soomro N, et al) 12
- Evaluation of Efficacy & Biochemical effects of Pharmaceutical Optimized Amlodipine 5mg (F-5) with Essential Hypertension (Asnad, et al) 64

GYNAE & OBS

- Maternal and Perinatal Outcome in Women With Threatened Miscarriage in the First Trimester (Maqsood SM, et al) 21

DENTISTRY

- Prevalence of Dental Fluorosis among School Going Students of District Khairpur (Memon AB, et al) 32

ANATOMY

- A comparative Study of Evaluating Healing Effect of Nigella Sativa on Experimentally Induced Skin Wounds in Rabbit Model (Memon S, et al) 41

FORENSIC MEDICINE

- Pakistani Society and Autopsy Practices (Jawaad I, et al) 45
- Hanging: The Commonest Cause of Suicide in All the Fatal Compressive Traumas to the Neck in Lahore (Iqbal M, et al) 78

SURGERY

- Effect of Obesity on Outcome of Ventral Hernia Mesh Repair (Shaikh B, et al) 51
- Incidence of Carcinoma in Gall Stone Disease and its Effect on People (Mirani SH, et al) 64
- Removal of Mesh; a Prerequisite to Resolve the Infection of Inguinal Hernia Repair (Qadeer A, et al) 82

MEDICINE

- Orthostatic Hypertension in Patients with Type 2 Diabetes (Shafi S, et al) 60
- Cutaneous Manifestations in Diabetes Mellitus Patients "Ignored Issue Dangerous Outcome" (Mehtab K, et al)

PHYSIOLOGY

- Incidence of ABO Blood Groups in Patients with Stroke (Akhund IA, et al) 71

MAXILLOFACIAL SURGERY

- Analysis of Jaw Lesions at Liaquat University Hospital Hyderabad (Shahzad M, et al) 85
- Patterns of Orbital Fracture and Association with Other Mid Face Fractures: A Retrospective Study (Hassan SG, et al) 89

Vol. 24, No. 6, June, 2013**GYNAE & OBS**

- A study of Vesicovaginal fistula repaired by vaginal route at fistula centre Lady Willington Hospital Lahore (Nadeem S, et al) 2
- Primary Post Partum Hemorrhage An Obstetric Catastrophe A Review of 270 Cases (Usmani I, et al)

ANAESTHESIOLOGY

- To Evaluate Clinical Efficacy of Intravenous Midazolam alone and along with Propofol for Sedation in Patient Management during Interventional Endoscopic Procedures (Maqbool MI, et al) 6
- Comparison of Hemodynamic Responses of Intrathecally Placed Hyperbaric 0.75% Bupivacaine Hydrochloride in Different Height Groups of Patients Undergoing Caesarean Section (Sabbar S, et al) 18

PAEDIATRICS

- Stunting Among Children in District East Karachi, Pakistan (Tajudin M, et al) 11

MEDICINE

- Diagnostic Accuracy of Magnetic Resonance Cholangiopancreatography in Diagnosis of Obstructive Jaundice (Arif U, et al) 14
- Evaluation of Various Causes and Treatment of Obstructive Jaundice at Liaquat University Hospital (Dalwani AG, et al) 60

PATHOLOGY

- Magnitude of Breast Diseases in OJHA Histopathology Department (Vakil M, et al) 21

COMMUNITY MEDICINE

- Indus water related Mortality and Morbidity due to Water Borne Diseases Outbreak in Hyderabad (Kolachi HB, et al) 26
- Eating Habits and Body Mass Index of Medical Students of Shaheed Mohtarma Benazir Bhutto Medical University, Larkana (Memo MN, et al) 39

DENTISTRY

- Prevalence of Fluorosis among Children aged 12 Years, Living in Urban and Peri-Urban Areas of Quetta District, Balochistan (Baloch HN, et al) 30
- Differences in Tooth Size Ratio between Male and Female Patients Reporting to OPD of Orthodontic Department L.U.M.H.S Hyderabad/ Jamshoro (Memon QN, et al) 65
- Freeway Space Measurement by Willis Gauge and Sprung Divider (Samejo I, et al) 73

SURGERY

- Terminal Ileal Perforation due to Various Etiologies and their Treatment Modalities (Hussain S, et al) 34

OPHTHALMOLOGY

- Management of Congenital Nasolacrimal Duct Obstruction with Massaging and Probing Without General Anaesthesia (Ahmad M, et al) 43
- In Vitro Comparison of the Apical Microleakage of Mineral Trioxide Aggregate (MTA) with Amalgam as a Retrograde Filling Material (Bhangar F, et al) 69 51

BIOCHEMISTRY

- Comparative Efficacy Evaluation of Amlodipine/ Ramipril Combination with Essential Hypertension (Asnad, et al) 45
- Efficacy Evaluation of Pharmaceutical Optimized Ramipril 1.25mg (F-4) with Essential Hypertension (Qavi A, et al) 48
- Frequency of ABO, and Rh (D) blood groups at Hyderabad, Sind and its territory (Soomro RA, et al) 88

MAXILLOFACIAL SURGERY

- Level of Awareness and Knowledge among General Dental Surgeon Regarding Oral Cancer (Hassan SG, et al) 56
- Pattern of Mandibular Fractures Reported at Liaquat University Hospital Hyderabad (Shahzad M, et al) 91

ANATOMY

- Evaluation of Chick in Ovo Culture as Screening Method for Detection of Teratogens (Memon S, et al) 78
- A Guide for Bucco-lingual Position of Posterior Teeth Arrangement in Complete Dentures (Butt AM, et al) 84
- L-Arginine as a Protective Adjuvant in the Treatment of Bipolar Disorders with Hepatotoxic agent Lithium (Bhutto SA, et al) 95

Vol. 24, No. 7, July, 2013**ORTHOPAEDIC**

- Results of Fluoroscopic Guided Percutaneous Needle Biopsy of Vertebral Pathologies in our Teaching Hospital (Shah ZA, et al) 2
- Outcome of Caudal Epidural Steroid Injection in Chronic Low Back Pain (Ahmed GS) 78

MEDICINE

- To Evaluate Different Features of Pyogenic Liver Abscess (Alvi H, et al) 6

HAEMODIALYSIS

- Haemodialysis Vascular Access Practice Patterns in North Pakistan (Bhatti AM, et al) 10

GESTATIONAL DIABETES

- Consequences of Gestational Diabetes Mellitus on Placentae in Rural Area of Sindh (Qureshi MA, et al) 15

FORENSIC MEDICINE

Determine the Prevalence and pattern of killings in Quetta, Balochistan (Rehman S, et al) 20

Third Decade of Life: The Most Vulnerable Age in Homicidal Fire-Arms Deaths in Lahore (Jawad I, et al) 51

DIABETIC FOOT ULCER

Management of Diabetic Foot Ulcers (Latif A, et al) 23

PATHOLOGY

A Review of Uterine Cancers (Zafar MN, et al) 27

Detection of Beta-Lactamase and Extended Spectrum Beta-Lactamase from Bacteria Causing Neonatal Sepsis (Sami F, et al) 85

GYNAE & OBS

Comparison of Efficacy of Cervical Foleys Catheter and Prostaglandin E2 for Induction of Labour (Bhatti K, et al) 31

Internal Podalic Version Still Has a Role in the Management of Transverse Lie (Gul K, et al) 59

MEDICINE/HIV

Radiographic Patterns in HIV Associated Pulmonary Tuberculosis (Siddiqui MH, et al) 35

ANESTHESIA

To Compare the Efficacy of Rocuronium Bromide and Succinylcholine in Elective Surgery for Endotracheal Tube (Iqbal M, et al) 38

ANATOMY

Protective Effect of Vitamin E (A Tocopherol Acetate) on Gentamicin-induced Nephrotoxicity in Adult Albino Rats (Rathore MI, et al) 42

Effect of Nigella sativa extract oil on granulation tissue in cutaneous wound: An experimental study in a Rabbit Model (Shahani MY, et al) 72

Ethanol induced developmental defects can be prevented with supplementation of vitamin E (Memon S, et al) 89

A Morphological Study of the Effects of X-Rays on the Melanocytes of the Skin, Under Light Microscope (Memon FM, et al) 99

COMMUNITY MEDICINE

Body Mass Index (BMI) of International Medical Student in OJHA Campus Karachi, Pakistan (Maqsood SM, et al) 47

Maternal Age & Parity as Risk Factors for Preterm Births & Low Birth Weight among New-bornes Delivered In Outskirts of District Mirpurkhas (Memon KN, et al) 68

Psychological Effects among Internally Displaced Persons (IDPS) Residing in two Districts of Sindh (Rehman AT, et al) 82

Neonatal Sepsis - its Determinants & Outcome among Newborns admitted in Neonatal Intensive Care Unit (NICU), Liaquat University Hospital Hyderabad (Siddique M, et al) 94

ORTHODONTICS

Comparison of Cephalometric Norms of Pleasing Faces Reporting to OPD of Orthodontic Department L.U.M.H.S Jamshoro / Hyderabad (Memon QN, et al) 55

PHYSIOLOGY

Comparison of Effects of Short Term (12 Weeks) Low, Moderate and High Intensity Exercises on Lipids and Lipoproteins Levels in Young Hyperlipidemic Adults (Khan GM, et al) 63

DENTISTRY

Dental Caries Status among Children aged 12-14 Years in Urban and Rural Areas of Lasbella District, Balochistan (Khail AAK, et al) 103

Vol. 24, No. 8, August, 2013**GYNAE & OBS**

Role of PH and Leukocyte Count in Prediction of Preterm Labour (Masood H, et al) 2

Feto-maternal Outcomes in Women with Congenital Heart Disease (Shaikh MM, et al) 5

Obstetrics Determinants of Cerebral Palsy in Children from Birth to Five Years (Soomro N, et al) 47

Threatened Miscarriage as a Predictor of Obstetric Outcome (Waheed S, et al) 51

ORTHOPAEDIC

Cannulated Screw Fixation of Fracture Neck of Femur (Mehmood SQ, et al) 10

MEDICINE

Diagnostic Yield of Lymphocyte Rich Exudative Pleural Effusion (Khan BA, et al) 13

Sensitivity Pattern of Causative Microorganisms in Septicemia (Bashir B, et al) 16

Various Clinical Presentations of Falciparum Malaria and Outcome: A study of 100 Patients (Fazel PA, et al) 35

Incidence of Hepatitis A, B & C with Relation to Age, Sex, Occupation, Socio-Economic Status, & Urban or Rural Area of Hazara Division & District Sialkot (Haq QM, et al) 43

Management of Hypertension and Diabetes Mellitus at Primary Health Care Settings in Pakistan; Clinician's Perspective (Saleem S, et al) 98

BIOCHEMISTRY

To Study Biochemical Effects of Optimized Product Ramipril 1.25mg Tablet with Essential Hypertension (Latif A, et al) 20

Biochemical Evaluation of Amlodipne / Ramipril in Combination with Essential Hypertension (Asnad, et al) 76

PATHOLOGY

Estrogen and Progesterone Receptor Status and Her-2/Neu Over expression in Breast Carcinoma with Relation to Age (Shaikh TA, et al) 24

Role of Amaltas and Dandasa in Controlling Biofilm Formation of Streptococcus Mutans and Pseudomonas (Faraz N, et al) 39

Pancytopenia: A Clinico-Haematologic Analysis of 100 Cases At Tertiary Care Hospital (Memon F, et al) 80

SURGERY

Incidence of Inguinal Hernia with relation to Age, Sex, Occupation, Socio-Economic Status, Dietary Habits & Urban or Rural Area of District Sialkot (Sheikh TH, et al) 27

Incidence of Tuberculosis with Relation to Age, Sex, Occupation, Socio-Economic Status & Urban or Rural Area of Hazara Division & District Sialkot (Ahmad N, et al) 55

Adult Intussusception –Temple of Surprise 7 Year Experience in Sialkot (Hussain S, et al) 71

FORENSIC MEDICINE

Chest: The Most Targeted Area in Homicidal Firearms Fatalities in Lahore (Khokhar JI, et al) 31

ZOOLOGY

Study of Histological Changes in Liver, Lungs and Testes of Dermal Nicotine Treated Albino Mice (Latif AA, et al) 59

FIRE BURN

To Compare the Rate of Mortality among Fire Burn Inhalational and Non Inhalational injuries in admitted Patients at Burns Centre Civil Hospital Karachi (Ibran E, et al) 64

REHABILITATION MEDICINE

Causes of Hand Impairment (Aasi MH, et al) 67

ANATOMY

Histochemical and Serological Parameters of Hepatic Lithium Toxicity Ameliorated by L-Arginine Supplementation (Makhija PM, et al) 84

PULMONOLOGY

Diagnostic yield of Fine Needle Aspiration Cytology and Biopsy (FNAC/FNAB) in Thoracic Mass Lesions (Mushtaq MA, et al) 90

COMMUNITY MEDICINE

Frequency of Hypertension in Male and Female Medical students of Public Sector University of Jamshoro in Hilly Region (Memon MN, et al) 93

Vol. 24, No. 9, September, 2013

ANATOMY

Comparative Study of Hepatic Serum Enzymes in Albino Rats after Treatment with Tamoxifen and Taurine (Ali A, et al) 2

NEUROSURGERY

Surgical Outcome of Thoracic and Thoraco-lumbar Injuries of the Spine: A Case For Posterior Instrumentation (Jaffery SA) 7

MEDICINE

Prevalence of Metabolic Syndrome in patients present with Unstable Angina (Baloch AA, et al) 13

Serum Prolactin: A diagnostic marker in Fertile Female Suffering from Rheumatoid Arthritis (Iqbal T, et al) 25

GYNAE & OBS

Efficacy of Umbilical Artery Doppler in Detection and Management of Intrauterine Growth Retardation (Parveen R, et al) 18

PATHOLOGY

Significance of Platelet Count and D-Dimers Level in Carcinoma Prostate (Shaikh SS, et al) 22

SURGERY

Altered lipid profile in patients with gallstones admitted for cholecystectomy (Moosa FA, et al) 29

Evaluation of Risk Factors for Perforation in Acute Appendicitis (Javed M, et al) 79

PHYSIOLOGY

Measurement of Plasma Fibrinogen Level in Healthy Smokers to Predict the Risk of Cardio-vascular Disease (Aslam N, et al) 32

LITHOTRIPSY

A prospective study of Extracorporeal Shock Wave Lithotripsy (ESWL) Induced Hypertension, in Lahore Division, Pakistan (Qadir MI, et al) 37

OSTEOPOROSIS

Cortical Changes in Orthopantomogram (OPG) of Human Mandible as Early Detector of Osteoporosis (Rehman DS, et al) 41

RADIOLOGY

Disk Degeneration in Adolescence and Young Adults: A Cross-Sectional Magnetic Resonance Imaging Study (Sattar A, et al) 45

ORTHOPAEDICS

Effectiveness of Platelete Rich Plasma (PRP) Injections in Patients with Plantar Fasciitis (Jan R, et al) 49

CARDIOLOGY

Early Assessment of Outcome by ST Segment Elevation after Acute Myocardial Infarction (Haq QM, et al) 53

DIABETES MELLITUS

To Correlate the Serum Levels of Adiponectin with Fasting and Random Blood Sugars in Diabetes Mellitus and Healthy Individuals (Ghori HN, et al) 57

OPERATIVE DENTISTRY

Assessment of Microleakage of Three Restorative Materials in Class V Cavities. An in Vitro Study (Naz F, et al) 60

COPD

Bronchoalveolar lavage fluid (BALF) differential leucocyte count in Patients with Chronic Obstructive Pulmonary Diseases (Rashid MN, et al) 65

COMMUNITY MEDICINE

Self Medication Practices among Residents of Slum Areas of Qasimabad, Hyderabad (Memon KN, et al) 70

BURN

To Evaluate the Presence and Spread of Environmental Pathogens and their Sensitability. An Epidemiological Survey of the Microbiological Monitoring at Burns Ward Civil Hospital Karachi (Ibran E, et al) 74

NEUROSURGERY

Translation and Validation Study of the First Modified Pakistani Version of the Neck Disability Index and its Revalidation (Ahmed M, et al) 82

PULMONARY TB

Radiographic Patterns in HIV Associated Pulmonary Tuberculosis (Siddiqui MH, et al) 87

Vol. 24, No. 10, October, 2013**DYSPEPSIA**

To See the Synergistic Effect of PPI and Propride in Functional Dyspepsia (Alvi H, et al) 2

PRE AND POST MENOPAUSAL WOMEN

Study to Compare Serum Beta Crosslaps Levels Between Premenopausal and Postmenopausal Women (Nihal S, et al) 6

ANATOMY

Morphological Study of Superior Articular Facets of Atlas Vertebrae (Hameed O, et al) 11

Cytoprotection of Heat – Induced Splenic Tissue by Cyanocobalamin in Albino Rats (Hafeez A, et al) 67

Anti-stress Role of Cyanocobalamin in Heat- induced Weight Loss in Albino Rats (Kumar A, et al) 91

BACTERIA RESISTANCE

Incidence of Bacteria Resistance to Antibiotics in Hospitals (Ijaz A, et al) 16

DENTAL CARIES

Socio-economic Gradient & its Impact on Dental Caries among School Children of Primary and Early Mixed Dentition (Baig QA, et al) 20

SAFE INJECTION PRACTICES

Assessment of the Knowledge and Factors Affecting safe Injection Practices among Health Care Providers in Public and Private Sector Health Facilities of Tehsil Gujarkhan Rawalpindi Pakistan (Arshad A, et al) 25

BACTERIAL VAGINOSIS

Wet Mount Microscopy A Better Diagnostic Tool for Bacterial Vaginosis Screening than Gram Staining (Rizvi S, et al) 30

DIABETES MELLITUS

Burden of Diabetes Mellitus in the Families of Medical Students of Lower Sindh (Ilyas M, et al) 35

PATHOLOGY

Sensitivity and Specificity of Phenotypic and Genotypic tests for Detection of Methicillin-Resistant Staphylococcus aureus in Clinical Isolates (Taj Y, et al) 38

HYPOLYCAEMIC EFFECT OF DRUGS

To Compare the Hypoglycaemic Effect of Sitagliptin / Metformin Combination versus Glimiperide in Type II Diabetes Patients during Ramadan (Abid R, et al) 43

PRETERM LABOUR

Increased Risk of Preterm Labour in Younger Pregnant Females (Javed M, et al) 47

IODINE STATUS

Evaluation of Impact of Dietary Pattern on Iodine and Thyroid Status of Adolescent Girls in Lahore (Imdad S, et al) 49

CAESAREAN SECTION

Frequency and indications of Caesarean section at Department of Obstetrics and Gynaecology Unit-III, Civil Hospital Quetta (Jaffar Y, et al) 55

IMPAIRED GLUCOSE

Frequency of Impaired Glucose Tolerance in Patients of Essential Hypertension in Tertiary Care Hospital, Larkana (Soomro MA, et al) 58

HEPATITIS B

Prevalence of Hepatitis-D Virus Infection in Hepatitis B Surface Antigen-Positive Children in Southern Punjab (Ahmad M, et al) 64

ORTHOPAEDIC

External Fixation: Daily Versus Weekly Pin Site Care (Jan R, et al) 72

RADIATION AND GROWTH HORMONE

Radioprotective Effect of Growth Hormone (Somatotrophin) on Irradiated Long Bones of Young Albino Rats (Panwhar AL, et al) 77

GYN&E & OBS

Three Monthly Intravenous Injections of Ibandronate in the Treatment of Postmenopausal Osteoporosis (Akhtar S, et al) 82

HOMICIDAL FIREARMS

Predominance of Homicidal Fire-Arms Deaths in Medico-Legal Autopsies in Lahore (Khokhar JI, et al) 86

SUBDURAL EMPYEMA

Subdural Empyema: How Effective is The Burr Hole Drainage? (Jaffery SA) 95

PROSTATE LESIONS

Spectrum of Prostate Lesions: A Decade Experience (Sheikh NA, et al) 100

ISCHEMIC STROKE

Integrated Care of Modifiable Risk Factors in Patients with Ischemic Stroke can Improve the Reproductivity of State Rehman B, et al) 103

Vol. 24, No. 11, November, 2013**PHARMACOLOGY**

Prevention of Insulin Induced Airway Hyper-Reactivity with Montelukast on Isolated Tracheal Muscle of Guinea Pig (Sharif M, et al) 2

JUNES FRACTURE

Conservative Management of Proximal Fifth Metatarsal Fractures (Jones fracture) (Jan R, et al) 6

APPENDICITIS

Incidence of Appendicitis with relation to Age, Sex, Occupation, Socio-Economic Status, Dietary Habits & Urban or Rural Area of District Sialkot (Sheikh TH, et al) 10

HEPATITIS A

Frequency of hepatitis A in patients with acute hepatitis in Abbottabad (Haq QM, et al) 13

BACKACHE

To Determine the Frequency of Chronic Back ache in the Nursing Staff of a Tertiary Care Hospital (Jatoi S, et al) 16

INFERIOR WALL M1

To Know the Frequency of Right Ventricular Infarction in Patients Presenting with Inferior Wall Myocardial Infarction (Alam MT, et al) 20

ABDOMINAL TB

Various Presentation of Abdominal Tuberculosis in Surgical Patients (Jawed M, et al) 25

CHEMICAL BURN

Frequency of Chemical Burn and Mortality Rate in Admitted Patients at a Tertiary Care Hospital of Karachi (Ibran E, et al) 30

DRONE ATTACKS

Increasing Trend of Homicidal Drone Attacks in Pakistan (Hanif M, et al) 33

MAXILLOFACIAL SURGERY

Dry Socket following Extraction of Permanent Teeth. A Study (Shahzad M, et al) 37

MAXILLOFACIAL SURGERY

Pattern, Etiology and Risk Factors for Tooth Extraction in Adult Population of Larkana City (Sheikh Q, et al) 41

NOISE STRESS

The Effects of Acute and Chronic Noise Stress on the Body Weight of Male Albino Rats (Iftekhar SM, et al) 45

ACUTE MI

Predictors of In-Hospital Mortality in Acute Myocardial Infarction (Rathore JA) 49

VIOLENCE WITH WOMEN

Increasing Trend of Domestic Violence with women in Pakistan (Bhatti A, et al) 54

PRETERM LABOUR

Increased Risk of Preterm Birth in Anemic Pregnants (Javed M, et al) 58

LIPID PROFILE DURING PREGNANCY

Evaluation of Serum Lipid Profile During The Trimesters of Pregnancy (Kumar A, et al) 60

MAXILLOFACIAL SURGERY

Maxillofacial Trauma and Associated Brain Injuries (Islam T, et al) 64

LYMPH NODE BIOPSY

A 4-Year Study of Lymph Node Biopsy in the Patients Belonging to the Labour Class (Noorani SM, et al) 67

SACROILIAC JOINT SYNDROME

Sacroiliac Joint Syndrome in the Differential Diagnosis of Low Back Pain and Sciatica (Jaffery SA) 71

RESPIRATORY DISEASES WITH CEMENT

Pattern of Respiratory Diseases & Associated Socio-Demographic Factors among Workers of Zeal Pak Cement Factory, site area, Hyderabad (Shaikh K, et al) 76

ACUTE POISONING

Current Trends of Acute Poisoning Reporting at Private Medical Center of Rural Sindh (Khocharo HK, et al) 80

CARPAL TUNNEL SYNDROME

Carpal Tunnel Syndrome in Pregnancy (Akhtar S, et al) 84

BIOCHEMICAL EFFECTS OF DRUGS WITH HYPERTENSION

Evaluation of Efficacy & Biochemical Effects of Amlodipine / Atorvastatin with Essential Hypertension (Asnad, et al) 88

OSTEOARTHRITIS

Efficacy of Piroxicam in Osteoarthritis Khokhar GN, et al) 91

OPHTHALMOLOGY

Comparison of the Effect of Ringer's Lactate and Balanced Salt Solution on Postoperative Endothelial Cell Count after Phacoemulcification? (Hussain SA, et al) 94

Vol. 24, No. 12, December, 2013**ERB'S PALSY**

Birth related Erb's Palsy: Obstetrical correlates and Outcome (Jan R, et al) 2

FETAL BIOMETRY

Fetal Biometry in Correlation with Ultrasonographic Appearance and Measurement of Epiphyseal Ossification Centres of Fetal Peripheral Long Bones for Assessment of Gestation age in the third Trimester (Channar MI, et al) 6

CHILD PUGH CLASS

Frequency of Different Child Pugh Class Presentation in Patients of Chronic Hepatitis-C and diabetes mellitus based on HBA1c (Shah MU, et al) 11

BETA THALASSAEMIA

Evaluation of Patterns of Beta Thalassaemia in Children with Microcytic Hypochromic Anemia (Khoja S, et al) 15

ACUTE APPENDICITIS

Pattern of Microbes Associate to Acute Appendicitis at Liaquat University Hospital (Yousif S, et al) 20

DIAGNOSIS BRONCHOSCOPY

The Role of Fiberoptic Bronchoscopy in the Diagnosis of Unsuspected Pulmonary Disease Presenting with Hemoptysis (Ashfaq M, et al) 24

WISDOM TOOTH

Wisdom Tooth Removal: Are We Following any Guidelines in Pakistan (Hassan SG, et al) 27

OTITIS MEDIA

Prevalence of Bacteria and Their Sensitivity to Various Antibiotics in Chronic Suppurative Otitis Media (Nisa Z, et al) 31

MEDICAL EDUCATION

Students' Perspective of an Innovative Assessment Strategy of Anatomy (Zareen N, et al) 34

FATTY DIET

In-House Prepared High Fat Diet (HFD) can Cause an Increase in Body Weights of Male Albino Wistar Rats in a Short Period of 2-3 Weeks (Mubeen S, et al) 38

TARGET KILLING

Increasing Tendency of "Target Killing" in Pakistan (Hanif F, et al) 42

GIT TUMOUR

Pattern of Gastrointestinal (GIT) Cancer in CENAR, Quetta Balochistan Pakistan: 10 Year Review (2001-2010) (Manzoor H, et al) 46

PULMONARY NOCARDIOSIS

Pulmonary Infections caused by Nocardia Species in Patients with Chronic Obstructive Pulmonary Diseases (Rashid MN, et al) 52

ENZYMES IN CHRONIC DIABETIC

Correlation of Advanced Glycation End Products (AGEs) with the Level of Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST) Enzymes in Chronic Diabetic Patients (Malik RM, et al) 57

INGROWN TOE NAIL

Early Stage Ingrown Toe Nail & role of conservative treatment- An experience at Sukkur (Shah AA, et al) 61

FETAL BIOMETRY

Fetal Biometry in the Third Trimester; Local Perspective (Suhag AH, et al) 64

ASSESSMENT OF GESTATION AGE

Ultrasonographic Appearance and Measurement of Epiphyseal Ossification Centres of Fetal Peripheral Long Bones for Assessment of Gestation Age (Suhail S, et al) 69

VESICOVAGINAL FISTULA

Simultaneous Repair for Complicated/Complex Vesicovaginal Fistula (Suhail MA, et al) 74

LIVER ABSCESS

Frequency of Clinical Manifestations, in Cases of Liver Abscess in Hospital Based Study (Shah SK, et al) 78

LOWER BACK PAIN

Effectiveness of Core Stabilization Exercises versus Mckenzie's Exercises in Chronic Lower Back Pain (Ali S, et al) 82

HYPERCHOLESTEROLEMIA

Significance of Hypercholesterolemia in Hypothyroid Patients (Qavi A, et al) 86

RELIGION & DEPRESSION

Relationship Between Religious Orientation and Depression (Akram H, et al) 89

BRONCHOGENIC CARCINOMA

Frequency of Bronchogenic Carcinoma in Smoker Patients with Hemoptysis Undergoing Fiberoptic Bronchoscopy (Muhammad S, et al) 92

VIT. D MENOPAUSAL

Prevalence of Vitamin D Inadequacy among Postmenopausal Women (Akhtar S, et al) 96

Authors Index January to December 2013

Azhar Masud Bhatti

Editor in Chief

Vol. 24, No. 1, January, 2013

Names	Page No.
1. Bhatti AM	1
2. Sarwat S, Rafique M, Ahmed R	2
3. Khan I, Qadir F, Fareed A, Ain Q	7
4. Shahid ZA, Qureshi KH, Zulfiqar L	12
5. Ullah S, Nizami SM, Anjum I	17
6. Hafeez R, Memon SR, Bhatti K	21
7. Soomro AA, Soomro ZA, Channa SM, Chand H, Jamro BD	26
8. Ansari IA, Shah SAH, Lal S, Yasin G	29
9. Maqbool A, Hameed O, Athar Z, Rafi A	33
10. Saeed A, Mehmood SM, Awan AN	38
11. Hasan SM, Siddiqui KJ, Hasan SM, Khan TN, Zaidi SAH	41
12. Phulpoto JA, Bhatti ZA	44
13. Shaikh AG, Kalhoro FA, Dall AQ	49
14. Hashim Y, Rizvi S, Muhammad D, Aftab R, Hasan M	55
15. Soomro N, Khan M, Ahmed SI, Hanafi M, Anwar K, Minhas MA, Siddiqui KY	60
16. Kumar S, Kolachi GM, Usman G	64
17. Dall AQ, Siyal ZH, Butt m	70

Vol. 24, No. 2, February, 2013

Names	Page No.
1. Bhatti AM	1
2. Soomro N, Khan M, Ahmed SI	2
3. Naqvi A, Shoro AA, Farooq AD	6
4. Iqbal J, Anjum MS, Rashid A, Tahin GA, Hussain T, Hameed A	10
5. Jaffar Y, Ehsan N, Nosheen	14
6. Alam MT, Ahmed S, Salekeen MS, Siddiqui AS, Nasir S	17
7. Bokhari NA, Irshad S, Akhtar S, Neelam S	22
8. Phulpoto JA, Bhatti ZA	26
9. Bhurgri GR, Samon NA, Baig F	30
10. Ahmed A, Chaudhry AG, Ali N, Hussain S, Afzal MI, Irshad MK	35
11. Bhatti K, Hafeez R, Shaikh F	39
12. Rehman MZ, Habib S, Ullah S, Ullah E, Malik ZI	42
13. Khan MI, Khan W, Ashraf M, Muhammad	48
14. Khan BA, Ahmad A, Ahad A	52
15. Usmani I	55
16. Mehtab K, Kumar S, Ahmed R, Ahmed W, Bhura S	58
17. Faryal U, Rashid S, Fayyaz I	61

18. Rashid S, Faryal U, Fayyaz I	64
19. Kumar S, Kolachi GM, Mehtab K	68
20. Jafferi SA	74
21. Javed MA, Ahmad F, Gill AH	79
22. Saleem M	83

Vol. 24, No. 3, March, 2013

Names	Page No.
1. Jan MM	1
2. Usmani I, Kamal Z, Ashraf T	2
3. Rathore MI, Sultana K, Bhurgri GR, Qazi MA	6
4. Kolachi HB, Tajuddin M, Maqsood SM, Shaikh MA	11
5. Bhatti K, Lashari AA, Shaikh F, Hafeez R	15
6. Laghari AH, Samoo AH, Qureshi KA, Shaikh GS, Shah AM	18
7. Alam MT, Faraz A, Ahmed S, Siddiqui AS, Siddiqui SS, Nasir S	22
8. Memon A, Laghari M, Talpur AH, Shah Q, Koharo HK	28
9. Ali S, Niazi S, Tariq NA, Hameed W, Tareen, Qamar K	32
10. Javed MA, Furqan A, Ali S	38
11. Banglani MA, Punjabi SK, Khoso NA	43
12. Kohari T, Rizvi MIH	47
13. Shafi S, Rao MH, Rehman A	51
14. Kumar S, Mehab K, Kolachi GM, Rajput AR	55
15. Mehtab K, Nisar N, Kumar S, Nihal S, Zaheer S, Aman H	60
16. Hassan SG, Shahzad M, Butt AM, Shams S, Ali N	63

Vol. 24, No. 4, April, 2013

Names	Page No.
1. Jan MM	1
2. Jan R, Askar Z, Iqbal J	2
3. Qureshi KA, Laghari AH, Samoo AH	6
4. Ali S, Hassan Q, Channar KA, Kumar S, Memon AB, Dahri WM	9
5. Moazzam M, Hameed W, Khan RMS, Khan AS, Rahber I, Masood MO	14
6. Azhar S, Shafiq M, Farrukh A	19
7. Qureshi MA, Soomro N, Talpur GM	22
8. Qazi S, Mazhar A, Sarwat S	26
9. Bhatti K, Shaikh D, Hafeez R	31
10. Saqib A, Fatima S, Bhugri AN, Ansari AK	34

11. Alam MT, Lashari MN, Ahmed S, Siddiqui AS, Aslam M	38	3. Maqbool MS, Draz MU, Shahani AS, Iqbal M	6
12. Fatima I, Sheikh NA, Khan MKH	42	4. Tajuddin M, Maqsood SM, Kolachi HB, Khan RTY, Kamdar HA	11
13. Sarfraz N, Anjum S, Masood MS	47	5. Arif U, Shah ZA, Khan MNB	14
14. Shahzad M, Hassan SG, Arain GH, Shams S	51	6. Sabbar S, Siddiqui MH, Bashir B, Turab SM, Majid U, Salam J, Baloch AA	18
15. Alvi H, Arain MA	54	7. Wakil M, Mustanser T, Shaikh NA, Rasool S, Mirza T, Ali A	21
16. Punjabi SK, Hassan Q, Nisa Z, Ali S	58	8. Kolachi HB, Memon MN, Siddiqui MI	26
17. Mirza A, Hassan SG, Shahzad M, Arain GH	62	9. Baloch HN, Mengal N, Khail AAK, Kurd SA, Alizai KA	30
18. Hassan SG, Dall AD, Shahzad M, Shams S, Baig MA, Ali N	66	10. Hussain S, Sajjad A, Farooq A	34
19. Qadeer A, Usmani MS, Kumar S, Rajput AR	70	11. Memon MN, Memon AH, Abro A	39
20. Meher T, Iman N, Maheshwary N, Ishtiaq S, Siddiqi A	73	12. Ahmad M, Fida R, Khattak NN, Akhund IA	43

Vol. 24, No. 5, April, 2013

Names	Page No.	Names	Page No.
1. Jan MM	1	16. Hassan SG, Shahzad M, Hassan Q, Shams S, Ijaz P	56
2. Butt SA, Raja TM, Shaikh NA	2	17. Dalwani AG, Shaikh AR, Devanand	60
3. Hussain A, Vohra S, Abid S	6	18. Memon MN, Alizai KA	65
4. Vohra S, Hussain A, Ali R	9	19. Usmani I, Bashir FM	69
5. Soomro N, Qureshi MA, Talpur GM	12	20. Sanejo I, Dall AQ, Channar KA, Shaikh IA	73
6. Sami F, Hashim Y, Barakzai R, Aftab R, Zafar N	17	21. Memon S, Bano U, Shahani MY, Shahani SB	78
7. Maqsood SM, Tajuddin M, Matloob A	21	22. Butt AM, Punjabi SK, Channar KA	84
8. Saeed N, Mustansar T, Sheikh NA, Khanzada MS, Rasool S, Mirza T	26	23. Soomro RA, Shaikh TA, Memon MN, Qazi N, Pathan NA, Abro A	88
9. Memon AB, Channar KA, Kalhor FA, Mirani SA	32	24. Shahzad M, Hassan SG, Nisa Z, Shams S, Aijaz P, Habib G	91
10. Fatima I, Taj Y, Khan MKH, Kamal M, Fraz TR	37	25. Bhutto SA, Makhija PM, Chang AH, Naqvi A	95
11. Memon S, Shahani SB, Shahani MY, Bano U	41		
12. Jawaad I, Mughal MI, Ehsan N	45		
13. Shaikh B, Shaikh SA, Shah AA, Sohu KM, Soomro SH	51		
14. Soomro AA, Taj Y, Mirjat KA, Parveen A, Ali SW	55		
15. Shafi S, Rao MH, Rehman S	60		
16. Mirani SH, Sohu KM, Shah AA	64		
17. Mehtab K, Salat MY, Shaikh S, Chughtai S, Abid S, Khalid S, Hameed H	68		
18. Akhund IA, Abid S, Vohra MS	71		
19. Asnad, Vohra MS, Abid S	74		
20. Iqbal M, Khokhar JI, Jawad I, Nadir S	78		
21. Qadeer A, Noonari SM, Kumar S	82		
22. Shahzad M, Hassan SG, Abbas Z, Shams S, Aijaz P, Kumar M	85		
23. Hassan SG, Israr M, Shahzad M, Shams S, Aijaz P	89		

Vol. 24, No. 6, June, 2013

Names	Page No.
1. Jan MM	1
2. Shahzad N, Malik A, Hanif A	2

Vol. 24, No. 7, July, 2013

Names	Page No.
1. Hameed N	1
2. Shah ZA, Arif U, Bilal A	2
3. Alvi H, Arain MA	6
4. Bhatti AM, Mansoor J, Ahsin S, Salim B, Humayun J, Anwar I, Mir M, Aslam M, Mallick T	10
5. Qureshi MA, Bhurgri GR, Shah MR	15
6. Rehman S, Khan Z, Agha SA, Khetran AK, Baloch MR	20
7. Latif A, Ansar A, Waheed S, Hamid A	23
8. Zafar MN, Barakzai R, Hashim Y, Muhammad D, Rizvi S, Akram S	27
9. Bhatti K, Mahar T, Hafeez R	31
10. Siddiqui MH, Majid U, Salam J, Bashir B, Turab SM, Baloch AA, Qasim A	35
11. Iqbal M, Turab SM, Siddiqui MH, Salam J, Majid U, Baloch AA, Bashir B	38
12. Rathore MI, Khooharo Y, Ali SMM	42

13. Maqsood SM, Tajuddin M, Rahman AA, Kolachi HB, Shaikh MA	47
14. Jawad I, Khokhar JI, Iqbal M	51
15. Memon QN, Alizai KA, Ahmed S	55
16. Gul K, Bibi S, Gul Z, Gul P	59
17. Khan GM, Memon AS, Khan D	63
18. Memon KN, Memon S	68
19. Shahani MY, Memon S, Shahani SB, Bano U, Arain SN	72
20. Ahmed GS	78
21. Rahman AA, Akhtar P, Siddiqui MI	82
22. Sami F, Rizvi S, Barakzai R, Hashim Y, Farrukh, Shah T	85
23. Memon S, Shahani MY, Bano U, Shahani SB	89
24. Siddique M, Memon KN, Sulehri MA	94
25. Memon FM, Kolachi GM, Kumar S	99
26. Khail AAK, Baloch HN, Hammad J, Kurd SA, Baloch MR	103

Vol. 24, No. 8, August, 2013

Names	Page No.
1. Hameed N	1
2. Masood H, Ashraf S, Siddique H, Masood M, Masood MS	2
3. Shaikh MM, Bano K, Mujtaba S	5
4. Mehmood SQ, Ahmed S, Duha M, Latifs R	10
5. Khan BA, Ahmad A, Aziz MI	13
6. Bashir B, Baloch AA, Fazel PA, Siddiqui MH, Salam J, Majid U, Masroor M, Turab SM	16
7. Latif A, Asnad, Karim A, Ishaq M, Akhund IA	20
8. Shaikh TA, Memon F, Pathan NA, Soomro RA	24
9. Sheikh TH, Azeem K, Khan MA, Hamid A, Sabir M, Hamid M	27
10. Khokhar JI, Nadir S, Iqbal M	31
11. Fazel PA, Bashir B, Baloch AA, Siddiqui MH, Tahir M, Turab SM, Salam J, Majid U	35
12. Faraz N, Abbas S, Murad R, Sehrish	39
13. Haq QM, Ahmad N, Ijaz A, Hamid A, Sabir M, Hamid M	43
14. Soomro N, Khan M, Ahmed SI	47
15. Waheed S, Ansar A, Meraj B	51
16. Ahmad N, Haq QM, Ijaz A, Hamid A, Sabir M, Hamid M	55
17. Latif AA, Mansha M, Sharif S, Saeed S, Gill T, Saif K, Farasat T	59
18. Ibran E, Rao MH, Ali S, Raza A, Khanum A, Malik R	64
19. Aasi MH, Malik TM, Malik NI	67
20. Hussain S, Din IH, Farooq A	71
21. Asnad, Muhammad S, Fida R, Ishaq M, Akhund IA	76

22. Memon F, Shaikh TA, Memon JH, Soomro RA	80
23. Bhutto SA, Shoro AA, Makhija PM, Arif M, Chang AH, Mangi MM	84
24. Mushtaq MA, Ayaz S, Khan SA	90
25. Memon MN, Siddiqui MI, Soomro RA, Abro A, Kolachi HB	93
26. Saleem S, Qaiser N, Tahir A, Mahmood H	98

Vol. 24, No. 9, September, 2013

Names	Page No.
1. Jan MM	1
2. Ali A, Tasneem K, Naikzada, Inayat Q	2
3. Jaffery SA	7
4. Baloch AA, Bashir B, Siddiqui MH, Qasim A, Majid U, Salam J, Turab SM, Masroor M	13
5. Parveen R, Khakwani M, Masood MS	18
6. Shaikh SS, Saqib A, Memon RA, Shaikh NS, Shaikh SS, Shaikh KR	22
7. Iqbal T, Zuberi NA, Niger S	25
8. Moosa FA, Bakhtiar N, Khalique A, Jawaid M	29
9. Aslam M, Khalid M, Qureshi H, Khan R	32
10. Qadir MI, Mobeen A, Khan MM, Iqbal A	37
11. Rehman DS, Rafique M, Hussain M	41
12. Sattar A, Shahzad A, Anjum S, Jalal LA	45
13. Jan R, Akhtar S, Khan MS, Karam F, Iqbal J	49
14. Haq QM, Ahmed N, Ali J, Ijaz A, Hamid A, Sabir M, Hamid M	53
15. Ghorri HN, Akram SF, Ashraf F, Masood SH	57
16. Naz F, Amin M, Ahmed A, Rahman M	60
17. Rashid MN, Memon MA, Ismail MO, Noman B	65
18. Memon KN, Memon S, Shaikh K	70
19. Ibran E, Hassan M, Farooq Z, Rao MH, Khan M	74
20. Javed M, Shaima A, Mubeen A	79
21. Ahmed M, Jaffery SA	82
22. Siddiqui MH, Baloch AA, Bashir B, Salam J, Qasim A, Masroor M, Javed A, Wahab S, Mehmood A	87

Vol. 24, No. 10, October, 2013

Names	Page No.
1. Jan MM	1
2. Alvi H, Arian MA	2
3. Nihal S, Masood SH, Memon AS, Zuberi NA, Fatima SS	6
4. Hameed O, Athar Z, Maqbool A	11

5. Ijaz A, Haq QM, Ahmad N, Hamid A, Sabir M, Hamid M	16
6. Baig QA, Afaq A, Nasir M, Qureshi M	20
7. Arshad A, Sikander S, Arshad T, Habib H, Asghar MI, Rana SM	25
8. Rizvi S, Sami F, Hashim Y, Zafar MN, Shah T, Muhammad D	30
9. Siddiqui MI, Shaikh TA, Soomro RA, Memon MN, Kolachi HB, Nizamani WM, Abro S	35
10. Taj Y, Soomro AA, Ali SW, Parveen A, Kazmi SU	38
11. Abid R, Zahid M	43
12. Javed M, Mubeen A, Javed N	47
13. Imdad S, Muzaffar R, Shoukat MS	49
14. Jaffar Y, Sikander N	55
15. Soomro MA, Abro GY, Ansari IA, Shah SAA, Shah SSR	58
16. Ahmad M, Irshad H, Khan ZA	64
17. Hafeez A, Kumar A, Jokhio AL	67
18. Jan R, Akhtar S, Khan MA	72
19. Panwhar AL, Kumar H, Gohar N, Ansari AG	77
20. Akhtar S, Jan R	82
21. Khokhar JI, Iqbal M, Nadar S	86
22. Kumar A, Hafeez A, Ansari AG	91
23. Jaffery SA	95
24. Sheikh NA, Butt SA, Raja TM, Zaheer S	100
25. Rehman B, Qidwai A, Ahmed S, Hussain T	103

Vol. 24, No. 11, November, 2013

Names	Page No.
1. Jan MM	1
2. Sharif M, Khan BT, Sharif A	2
3. Jan R, Akhtar S, Askar G	6
4. Sheikh TH, Azeem K, Khan MA, Hamid A, Sabir M, Hamid M	10
5. Haq QM, Ahmed N, Ejaz A	13
6. Jatoi S, Alam MT, Nisa Q, Arvind, Naila, Nasir S	16
7. Alam MT, Lashari MN, Murtaza M, Moin F, Sadiq M, salkeen S	20
8. Jawed M, Khan MLZ, Qureshi MA, Shaikh U, Akhater N	25
9. Ibran E, Rao MH, Khan M, Yasin I	30
10. Hanif M, Ahmad A, Masood R, Din SZ, Hamid A, Najeeb	33
11. Shahzad M, Hassan SG, Sheikh Q, Shams S, Aijaz P	37
12. Sheikh Q, Hassan SG, Shahzad M, Shams S, Aijaz P	41
13. Iftahkar SM, Ilyas A, Mubeen S	45
14. Rathore JA	49
15. Bhatti A, Din SZ, Hamid A, Hanif F	54

16. Javed M, Mubeen A, Javed N	58
17. Kumar A, Baloch S, Shahani RA, Lata	60
18. Islam T, Lakhani MJ, Mehdi H, Zubairi A	64
19. Noonari SM, Qadeer A, Soomro AQ, Sajjad K	67
20. Jaffery SA	71
21. Shaikh K, Memon MA, Memon KN, Sarah B, Ahmadani R	75
22. Khoharo HK, Kazi SAF, Rehman S, Shah Q	80
23. Akhtar S, Jan R	84
24. Asnad, Ansari AL, Fida R, Ishaq M, Akund IA	88
25. Khokhar GN, Khalid M, Ansari AL, Alvi IA, Akhund IA	91
26. Hussain SA, Imran M	94

Vol. 23, No. 12, December, 2012

Names	Page No.
1. Jan MM	1
2. Jan R, Akhtar S	2
3. Channar MI, Lakho AR, Suhag AH	6
4. Shah M, Shah K, Zarkoon AK	11
5. Khoja S, Fahim A, Ahmed N, Azmi MA, Kazi SA	15
6. Yousif S, Ahuja P, Bashir J, Arain MA	20
7. Ashfaq M, Ullah I, Zahoor A, Ishaq M, Akhund IA	24
8. Hassan SG, Shahzad M, Mirza D, Shams S, Aijaz P	27
9. Nisa Z, Hassan Q, Hassan SG, Shams S	31
10. Zareen N	34
11. Mubeen S, Waggan IA, Nigar S	38
12. Hanif F, Din SZ, Bhatti MA, Hamid A	42
13. Manzoor H, Shuja J, Mahmood Z, Ahmad HK, Mustafa KA	46
14. Rashid MN, Memon MA, Shakoore S, Noman B	52
15. Malik RM, Bano S, Ahmed R	57
16. Shah AA, Sohu KM, Mirani SH, Shaikh B	61
17. Suhag AH, Channar MU, Lakho AR	64
18. Suhail S, Channar MI, Shaikh AH, Lakho AR, Suhag AH	69
19. Suhail MA, Shaikh AR, Kashif F	74
20. Shah SK, Kakar AK, Zarkoon AK	78
21. Ali S, Ali SM, Memon KN	82
22. Qavi A, Khokhar GN, Zahoor A, Akhund IA, Ishaq M	86
23. Akram H, Bano S, Ahmed R	89
24. Muhammad S, Ullah I, Ashfaq M, Ishaq M, Akhund IA	92
25. Akhtar S, Jan R	98

Electronic Copy